AU2011290261B2 - Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity - Google Patents

Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity Download PDF

Info

Publication number
AU2011290261B2
AU2011290261B2 AU2011290261A AU2011290261A AU2011290261B2 AU 2011290261 B2 AU2011290261 B2 AU 2011290261B2 AU 2011290261 A AU2011290261 A AU 2011290261A AU 2011290261 A AU2011290261 A AU 2011290261A AU 2011290261 B2 AU2011290261 B2 AU 2011290261B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
ring
alkyl
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011290261A
Other versions
AU2011290261A1 (en
Inventor
Kentaro Asahi
Takeshi Endoh
Yasuhiko Fujii
Tsuyoshi Hasegawa
Tohru Horiguchi
Akira Iida
Hiroyuki Kai
Takayuki Kameyama
Toshikatsu Maki
Sae Matsumoto
Ken'ichiroh Nakamura
Miho Oohara
Takuya Shintani
Yukio Tada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2011290261A1 publication Critical patent/AU2011290261A1/en
Application granted granted Critical
Publication of AU2011290261B2 publication Critical patent/AU2011290261B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed is a novel compound that acts as an antagonist for P2X

Description

Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same [Technical field] [0001] The invention relates to a compound useful for the treatment of diseases or conditions associated with P2X receptor, specifically to P2X3 and/or P2X2/3 receptor, and a pharmaceutical composition having an analgesic effect, an improving effect on a urination disorder comprising such compound. [Background Art] [0002] Adenosine triphosphate (ATP) is known to serve as a source of energy in cells and a substrate of phosphorylation, as well as an extracellular messenger. It is known that ATP is released from a cell by various stimulation such as cellular injury, inflammation, nociceptive stimulus, reduced blood oxygen level, and also known to be released together with another messenger from a primary sensory nerve terminal. ATP thus released mediates various extracellular signal transductions through an ATP receptor (Non-Patent Document 4, Non-Patent Document 5). [0003] ATP receptor is categorized into ionotropic P2X family and G protein-coupled P2Y family. For P2X family, seven subtypes have been reported, and a member of this family forms a homo-trimeric structure or a hetero-trimeric structure together with another member of this subtype and functions as a non-specific cation channel (Non-Patent Document 6). [0004] ATP is known to cause pain, and studies with P2X3 knockout and knockdown methodologies have shown that P2X3 receptor mediates transmission of chronic pain. P2X3 receptors are expressed in a specific manner on peripheral sensory nerve to form a homo-complex or hetero-complex with P2X2 (P2X2/3) (Non-Patent Document 1). [0005] Later, the compound A-317491 was reported as a specific antagonist to P2X3 and P2X2/3 receptors. A-317491 is tri-substituted-N-[(iS)-1,2,3,4-tetrahydro-1 naphthalenyl]benzamide derivative represented by the formula: [Chemical Formula 1] HO 0 O O 0 N 0 (Patent Document 1). It was reported to exhibit an antagonist activity to P2X3 and P2X2/3 receptors and analgesic action in neuropathic pain model and inflammatory pain model (Non-Patent Document 7). This indicates that pain sensation is 1 transmitted via P2X 3 or P2X 2
/
3 receptor and that a compound having a P2X 3 or P2X 2 /3 receptor antagonistic effect is useful as an analgesic. Also, compounds that exhibit P2X 3 or P2X 2
/
3 receptor antagonistic effect are described in Patent Documents 2-7. [0006] Additionally, it was recently reported that vesical reflex was strongly reduced in P2X 3 knockout mouse (Non-Patent Document 2), suggesting that a compound having P2X 3 antagonistic effect is useful in the treatment of diseases caused by overactive bladder. Patent Documents 8, 9, 10 and 11 disclose compounds having similar structure to the compounds of the present invention but they do not disclose analgesic effect and P2X 3 or P2X 2
/
3 receptor antagonistic effect. Non-Patent Document 8 discloses compounds having similar structure to the compounds of the present invention and having analgesic effect, but it does not discloses P2X 3 or P2X 2 /3 receptor antagonistic effect. Patent Document 12 discloses compounds having P2X 3 receptor antagonistic effect but the structures are different with those of the compounds of the present invention. Patent Document 13 discloses compounds having P2X 3 or P2X 2
/
3 receptor antagonistic effect with a triazine structure but in case that a ring corresponding to ring B of the present application is a cyclopentane ring, a benzene ring, a tetrahydropyrane ring or a piperizine ring, then the ring is unsubstituted, and therefore, the structures are different with those of the present invention. Patent Document 14 discloses compounds having a pyrazolyl-substituted triazine ring but the structures are different with those of the compound of the formula (XII) of the present invention. Patent Document 14 does not disclose a process for converting a pyrazolyl group on a triazine ring into an anilino group by using a pyrazolyl group as a leaving group. Non-Patent Documents 9, 10, 11 and 12 disclose a process for converting a pyrazolyl group to an anilino group by using a pyrazolyl group as a leaving group, but do not disclose a process for converting a pyrazolyl group on a triazine ring into an anilino group. [Prior Art] [Patent Document] [0007] [Patent Document 1] W002/094767 [Patent Document 2] W02005/095359 [Patent Document 3] US20070037974 [Patent Document 4] US20070049758 [Patent Document 5] US20070049610 [Patent Document 6] US20070049609 [Patent Document 7] US20070049534 [Patent Document 8] JP12-072757A [Patent Document 9] W02006/104713 [Patent Document 10] W02006/104715 [Patent Document 11] W02006/102112 [Patent Document 12] W02010/051188 [Patent Document 13] W02010/092966 [Patent Document 14] EP547461A [Non-patent Document] 2 [0008] [Non-Patent Document 1] Neuroscientist 11 (2005) pp.
3 4 5
-
3 5 6 [Non-Patent Document 2] J. Physiol. 567.2 (2005) pp.
6 2 1
-
6 3 9 [Non-Patent Document 3] Expert Opin. Ther. Patens (2006) 16(8), p.
1 1 3
-
1 12 7 [Non-Patent Document 4] J. Physiology (2003), 554(2), p.
3 0 1
-
3 0 8 [Non-Patent Document 5] J. Physiology (2003), 553(3), p.
6 8 3
-
6 9 4 [Non-Patent Document 6] Pflungers Arch Eur J physiol (2006), p.452, 513 537 [Non-Patent Document 7] PNAS (2002), 99(26), p.
1 7 1 7 9
-
1 7 18 4 [Non-Patent Document 8] Journal of Medicinal Chemistry (2008), 51(23), p.7635-7639 [Non-Patent Document 9] J. Org. Chem. (1992), 57, p.
2 4 9 7
-
2 5 0 2 [Non-Patent Document 10] Tetrahedron Lett. (2007), 48, p.
2 3 5 7
-
2 3 5 9 [Non-Patent Document II] Tetrahedron Lett. (2002), 43, p.
1 4 0 1
-
1 4 0 3 [Non-Patent Document 12] Bioorganic & Medicinal Chemistry Letters (2010), 20(23), p.
6 8 9 5
-
6 8 9 8 [Summary of the invention] [0009] The present invention provides a novel compound having a P2X3 and/or P2X2/3 receptor antagonistic effect. It also provides a pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect and having an analgesic effect or an improving effect on a urination disorder. Furthermore, it provides methods of producing the above-mentioned compound or pharmaceutical composition and important intermediates for the producing methods. [0010] Through their extensive research, the inventors have found novel compounds that bind specifically to P2X3 and/or P2X2/3 receptor and exhibit an antagonistic effect, and novel compounds that bind specifically to P2X3 and/or P2X2/3 receptor. Additionally, they have discovered pharmaceutical compositions that have P2X3 and/or P2X2/3 antagonistic effect and having an analgesic effect or an improving effect on a urination disorder. Furthermore, they have found methods for producing the above-mentioned compound or pharmaceutical composition and important intermediates for the producing methods. The compounds and pharmaceutical compositions encompassed by the present invention produced excellent results of P2X3 receptor inhibitory effect, P2X3 receptor inhibitory effect in the presence of rat serum albumin (hereinafter referred to as RSA) and the like. The compounds encompassed by the present invention or the pharmaceutical compositions encompassed by the present invention also produced excellent results in CYP enzyme inhibition assay, FAT assay, solubility assay, metabolic stability assay, hERG inhibitory activity assay, bioavailability assay and/or protein binding assay and the like. The compounds encompassed by the present invention or the pharmaceutical composition encompassed by the present invention showed potent analgesic effect or improving effect on a urination disorder. This invention relates to 3 [0011] (1) A compound of the formula (VIII): [Chemical Formula 2]
(R
9 )s Z 1
(R
9 ')s' La N Re B C N N' bD X N Z 2 (VIII)
(CR
4 aR 4 bf R2 wherein
Z
1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Re is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R4a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R5)- or -(CR5aR5b)-; -L- is -0-, -S-, -N(R5')- or -(CR5a'R5b')-;
R
5 and R' are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R5a, R5b, R5a' and R5b' are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy or substituted or unsubstituted alkenyloxy; ring D is a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; carbon atom a and carbon atom b are carbon atoms which constitute ring D; ring B is an aromatic carbocyclic ring, a non-aromatic carbocyclic ring, an aromatic heterocyclic ring or a non-aromatic heterocyclic ring; s and s' are each independently an integer of 0 to 3; and
R
9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted 4 or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy; provided that s' is an integer of 1 to 3 when ring B is a cyclopentane ring, a benzene ring, a tetrahydropyran ring or a piperidine ring, or its pharmaceutically acceptable salt or a solvate thereof. [0012] (2) The compound according to the above (1), wherein -L- is -0-, or its pharmaceutically acceptable salt or a solvate thereof. (3) The compound according to the above (1) or (2), wherein ring B is an aromatic heterocyclic ring, or its pharmaceutically acceptable salt or a solvate thereof. (4) The compound according to any one of the above (1) to (3), wherein ring B is a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a pyrazole ring, an imidazole ring, a triazole ring, a furan ring, a thiophene ring, a thiadiazole ring, an oxadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a triazine ring or a benzoxazole ring, or its pharmaceutically acceptable salt or a solvate thereof. (5) The compound according to any one of the above (1) to (4), wherein ring B is a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a thiadiazole ring, an oxadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, or its pharmaceutically acceptable salt or a solvate thereof. (6) The compound according to any one of the above (1) to (5), wherein s' is an integer of 1 to 2, and at least one of R 9 ' is hydroxy, carboxy, cyano, substituted alkyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof. (7) The compound according to any one of the above (1) to (6), wherein s' is 1, and R 9 ' is carboxy or substituted or unsubstituted carbamoyl, or its pharmaceutically acceptable salt or a solvate thereof. [0013] (8) A compound of the formula (IX): 5 [Chemical Formula 3]
(R
9 ')s'
(R
9 )S 1 E ON N 'R .- , C- N N'
R
13 a R1 3 b D X I" N Z2 (IX)
(CR
4 aR 4 bf R 2 wherein
Z
1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Re is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R4a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R5)- or -(CR5aR5b)-;
R
5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R5a and R5b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; ring D is a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; carbon atom a and carbon atom b are carbon atoms which constitute ring D; Rl 3 a and R13b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy, or Rl3a and R13b attached to the same carbon atom are taken together to form oxo or thioxo; ring E is a cycloalkane ring or a cycloalkene ring; s and s' are each independently an integer of 0 to 3; and 6
R
9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof. [0014] (9) The compound according to the above (8), wherein Rl3a and R13b are both hydrogen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (10) The compound according to the above (8) or (9), wherein ring E is a cyclopropane ring, or its pharmaceutically acceptable salt or a solvate thereof. (11) The compound according to any one of the above (1) to (10), wherein ring D is a benzene ring, or its pharmaceutically acceptable salt or a solvate thereof. (12) The compound according to any one of the above (1) to (11), wherein carbon atom a is positioned on ring D in a 1,4 relationship with respect to carbon atom b, or its pharmaceutically acceptable salt or a solvate thereof. (13) The compound according to any one of the above (1) to (12), wherein s and s' are each independently an integer of 0 to 2; and R 9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof. [0015] (14) A compound of the formula (VII): 7 [Chemical Formula 4] Zi
(R
9 )s _ 1 S X N Z2 (VII)
(CR
4 aR 4 b)f
R
2 wherein
Z
1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Re is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R4a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R5)- or -(CR5aR5b)-;
R
5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R5a and R5b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; s is an integer of 0 to 3; and
R
9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted 8 non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof. [0016] (15) The compound according to the above (14), wherein s is an integer of 0 to 2; and R 9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof. (16) The compound according to any one of the above (1) to (15), wherein Z1 and Z 2 are both oxygen atoms or both sulfur atoms, or its pharmaceutically acceptable salt or a solvate thereof. (17) The compound according to any one of the above (1) to (16), wherein Z' and Z 2 are both oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (18) The compound according to any one of the above (1) to (17), wherein Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group A, unsubstituted alkynyl or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof. [0017] (19) The compound according to any one of the above (1) to (18), wherein Re 9 is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group B" (Substituent Group B": hydroxy, carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group B", unsubstituted alkynyl or alkynyl substituted with one or more substituents selected from Substituent Group B", or its pharmaceutically acceptable salt or a solvate thereof. (20) The compound according to any one of the above (1) to (19), wherein Re is unsubstituted alkyl, or its pharmaceutically acceptable salt or a solvate thereof. (21) The compound according to any one of the above (1) to (19), wherein Re is -(CR11aR11b)m-OH; R11a and R11b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R11a and R11b together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non aromatic heterocyclic ring; and m is an integer of 2 to 4, or its pharmaceutically acceptable salt or a solvate thereof. (22) The compound according to any one of the above (1) to (19) and (21), wherein Re is -(CR11aR11b)m-OH; R11a is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R11b is -(CR12aR12b)u-OH; R12a and R12b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; u is an integer of 0 to 2; and m is an integer of 2 to 4, or its pharmaceutically acceptable salt or a solvate thereof. [0018] (23) The compound according to any one of the above (1) to (19), (21) and (22), wherein Re is a group of the formula: [Chemical Formula 5] OH OH OH OH OH OH OH OH OH OH OH OH OH H HOH OH OH 5 OH OH OH or OH or or its pharmaceutically acceptable salt or a solvate thereof. (24) The compound according to any one of the above (1) to (19), wherein Re 10 is -(CR14aR14b)t-N(R15a)(R15b); R14a and R14b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R14a and R14b together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non aromatic heterocyclic ring; t is an integer of 2 to 4; and Rl 5 a and R15b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl; or -(CR14a'R14b')t'-C(=O)N(R5a')(R5b'); R1 4 a' and R14b' are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl or R1 4 a' and R14b' together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non aromatic heterocyclic ring; t' is an integer of 1 to 4; and Rl 5 a' and R15b' are each independently a hydrogen atom, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof. [0019] (25) The compound according to any one of the above (1) to (19), and (24), wherein Re is a group of the formula: [Chemical Formula 6] z N (R 15b N(R 15a)(R 15b ,,N(R1 5 a)(R 5 b5b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R15a)(R15b (R1
N
(R15 1 5 b) N(R1 5 a)(R1 5 b) 0 0 N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b') 0 0 5a 5)N (Rl1 5 a) (R 1 5 b) -yN(Rl 5 a)(Rl 5 b) L N(R15a)(R15bt 0 0 or 0 N(R1 5 a)(R1 5 b) wherein Rl 5 a, R15b, R1 5 a' and R15b' are as defined in the above (24), or its pharmaceutically acceptable salt or a solvate thereof. (26) The compound according to any one of the above (1) to (25), wherein n is 11 1, or its pharmaceutically acceptable salt or a solvate thereof. (27) The compound according to any one of the above (1) to (26), wherein R 4 a and R4b are both hydrogen atoms, or R4a and R4b attached to the same carbon atom are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof. (28) The compound according to any one of the above (1) to (27), wherein n is 1, and R4a and R4b are both hydrogen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (29) The compound according to any one of the above (1) to (28), wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. [0020] (30) The compound according to any one of the above (1) to (29), wherein R 2 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. (31) The compound according to any one of the above (1) to (30), wherein -X is -N(R5)-, and R 5 is as defined in the above (1), or its pharmaceutically acceptable salt or a solvate thereof. (32) The compound according to any one of the above (1) to (31), wherein -X is -NH-, or its pharmaceutically acceptable salt or a solvate thereof. [0021] (33) A compound of the formula (IV): [Chemical Formula 7] CR4aR4b Z1 c1 R 6 - N N 1R
Z
3 N
Z
2 (IV) C R 4 aR 4 b wherein Z1, Z 2 and Z 3 are each independently an oxygen atom or a sulfur atom; Re' is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B (Substituent Group B: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or 12 unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, and nitro), alkenyl substituted with one or more substituents selected from Substituent Group B, alkynyl substituted with one or more substituents selected from Substituent Group B;
R
4 a is a hydrogen atom or substituted or unsubstituted alkyl; R4b is a hydrogen atom;
R
6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R
4 a' is a hydrogen atom or substituted or unsubstituted alkyl; R4b' is a hydrogen atom; and R' is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; provided that 1) a compound wherein Re' is ethyl substituted with substituted or unsubstituted amino, or propyl substituted with substituted or unsubstituted amino, and R 6 and R 6 ' are both substituted or unsubstituted phenyl, and 2) a compound wherein Re' is unsubstituted oxirane, substituted or unsubstituted phenyl, or alkyl substituted with unsubstituted acetyl, are excluded, or its pharmaceutically acceptable salt or a solvate thereof. (34) The compound according to the above (33), wherein Z1, Z 2 and Z 3 are oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (35) The compound according to the above (33) or (34), wherein R 6 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. (36) The compound according to any one of the above (33) to (35), wherein R' is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non-aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof. [0022] 13 (37) A pharmaceutical composition comprising the compound according to any one of the above (1) to (36), or its pharmaceutically acceptable salt, or a solvate thereof. (38) The pharmaceutical composition according to the above (37), wherein the composition has a P2X3 and/or P2X2/3 receptor antagonistic effect. (39) Use of a compound according to any one of the above (1) to (36), or its pharmaceutically acceptable salt, or a solvate thereof in the manufacture of a medicament for the treatment or prevention of a disease related to P2X3 and/or P2X2/3 receptor. (40) A method for treating and/or preventing a disease related to P2X3 and/or P2X2/3 receptor comprising administering the compound according to any one of the above (1) to (36), or its pharmaceutically acceptable salt, or a solvate thereof. (41) A pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder comprising a compound of the formula (I): [Chemical Formula 8] Ra Rb REIN N I., Rh 'N Rd R9 i Re Rf wherein (i) Rh and Ri are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo, thioxo or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Rf is -(CR 4 aR 4 b)n-R 2 ;
R
4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -R9 is -X-R 3 ; -X- is -0-, -S-, -N(R5)-or -(CR5aR5b)-;
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; 14
R
5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or 14A unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; and R5a and R5b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; or [0024] (ii) Rh and Ri are taken together to form a bond; Ra is a group of -Y-Rla; Ria is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Y- is -0-, -S-, -N(R7)- or -C(R8aR8b)-;
R
7 is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted acyl; R8a and R8b are each independently a hydrogen atom, halogen or substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rb and Re are taken together to form a bond; Rd and Re are taken together to form oxo or thioxo; and RI and R9 are as defined in the above (i); or [0025] (iii) Ra and Rb, Rd and Re, and/or R9 and Rh are taken together to form oxo or thioxo; Re is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B (Substituent Group B: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, and nitro ), alkenyl substituted with one or more substituents selected from Substituent Group B, or alkynyl substituted with one 15 or more substituents selected from Substituent Group B; RI is -(CR4aR4b)-R6; Ri is -(CR4a'R4b')-R6';
R
6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R
6 ' is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R4a, R4b, R4a' and R4b' are each independently a hydrogen atom, or substituted or unsubstituted alkyl; or [0026] (iv) Ri and Rb are taken together to form a bond; Ra is a group of -Y-Rla; -Y- is -0-, -S-, -N(R7)- or -C(R8aR8b)-; Ria is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Re is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rd and Re are taken together to form oxo, thioxo or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Rf is -(CR4aR4b)n-R2; R4a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R9 and Rh are taken together to form =N-R 3 ; and
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that 1) a compound wherein, in (i), -X- is -NH-, and R 3 is cyclohexyl substituted with guanidyl, and 2) a compound wherein, in (ii), Ra is substituted phenyl, Rd and Re are taken together to form thioxo, R4a and R4b are taken together to form oxo, and R 3 is unsubstituted cyclohexyl, are excluded, 16 or its pharmaceutically acceptable salt or a solvate thereof. [0027] (42) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to the above (41), comprising the compound of the formula (II): [Chemical Formula 9] Zi N NRC RiX N Z2(II)
(CR
4 aR 4 b0f
R
2 wherein Z1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx, R 4 a, R4b, n, R 2 , X, and R 3 are as defined in the above (41); and Rei is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aronmatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. (43) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to the above (42), comprising the compound wherein Z1 and Z 2 are both oxygen atoms or both sulfur atoms, or its pharmaceutically acceptable salt or a solvate thereof. (44) The pharmaceutical composition having an analgesic effect or an improving effect on aurination disorder, according to the above (42) or (43), comprising the compound wherein Z1 and Z 2 are both oxygen atoms or its pharmaceutically acceptable salt or a solvate thereof. (45) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (44), comprising the compound wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aronmatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carb amoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non- aromatic 17 heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof. (46) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (45), comprising the compound wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof. [0028] (47) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to the above (41), comprising the compound of the formula (III): [Chemical Formula 10]
RR
1 a N N RX ),N I Z2 III
(CR
4 aR 4 b) n
R
2 wherein Z 2 is an oxygen atom, a sulfur atom or =N-Rx; and Rx, -Y-, Ria, R 4 a, R4b, n, R 2 , -X- and R 3 are as defined in the above (41), or its pharmaceutically acceptable salt or a solvate thereof. (48) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to the above (47), comprising the compound wherein Z 2 is an oxygen atom or a sulfur atom, or its pharmaceutically acceptable salt or a solvate thereof. (49) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to the above (47) or (48), comprising the compound wherein -Y- is -0-, or its pharmaceutically acceptable salt or a solvate thereof. (50) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (47) to (49), comprising the compound wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or 18 unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocycyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof. [0029] (51) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (47) to (50), comprising the compound wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof. (52) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (51), comprising the compound wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof. (53) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (52), comprising the compound wherein R 4 a and R4b are both hydrogen atoms, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof. (54) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (53), comprising the compound wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. (55) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (54), comprising the compound wherein R 2 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, 19 cycloalkynyl, and alkylsilylalkynyl), aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. (56) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (55), comprising the compound wherein -X- is -N(R5)-, and R 5 is as defined in the above (41), or its pharmaceutically acceptable salt or a solvate thereof. (57) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (56), comprising the compound wherein -X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof. [0030] (58) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (57), comprising the compound wherein R 3 is a group of the formula: [Chemical Formula II]
(R
9 ) S A wherein ring A is an aromatic carbocyclic ring or an aromatic heterocyclic ring; s is an integer of 0 to 3; and
R
9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof. (59) The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of the above (42) to (58), comprising the compound wherein R 3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; 20 hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof. [0031] (60) A method of producing a compound of the formula (XI): [Chemical Formula 12] Zi R3 I'llX 111 11 Z2 (X1) wherein Z 1 and Z 2 are each independently an oxygen atom or a sulfur atom, Rfl is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Re' is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X is -N(R5)-;
R
5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl, or its pharmaceutically acceptable salt or a solvate thereof, characterized by reacting a compound of the formula (X): [Chemical Formula 13] Zi N N Rc1 N, 2 N N Z(X)
(R
27 )n' wherein Z1, Z 2 ,Rfl and Re' are as defined above;
R
2 7 is substituted or unsubstituted alkyl; and n' is an integer of 0 to 3 or its salt, with a compound of the formula: R 3 -X' 21 wherein R 3 is as defined above; -X' is -NH(R5); and
R
5 is as defined above. In the above (60), the following compound of the formula (XII), its pharmaceutically acceptable salt or a solvate thereof can be used instead of the compound of the formula (X), its pharmaceutically acceptable salt or a solvate thereof. [0032] (60') A method of producing a compound of the formula (XVII): [Chemical Formula 14] Z1 N N Rc1 R(XVII)
(CR
4 aR 4 byf R2 wherein Z1, Z2, Re', R4a, R4b, n, R 2 , X and R 3 are as defined in the (62) mentioned below, or its pharmaceutically acceptable salt or a solvate thereof comprising the steps of i) reacting a compound of the formula (XIII); [Chemical Formula 15] NH NLN NH 2 (XIII)
(R
27 ) n wherein R 2 7 and n' are as defined in the above (60) or its salt with a compound of the formula: [Chemical Formula 16] H nN H N c-N N<' -N Ng Rc-NCO Rc Rc-NCS RC [ N 0 or s wherein Re is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl or its salt in the presence of a base to give a compound of the formula (XIV): [Chemical Formula 17] Zi N, H 7N NH 2 (XIV)
(R
27 ) n wherein Z1, Re', R 2 7 and n' are as defined in the above (60) or its salt, ii) reacting the compound of the formula (XIV) or its salt with a carbonylating agent 22 or a thiocarbonylating agent in the presence of a base to give a compound of the formula (XV): [Chemical Formula 18] Z1 Th Rcl N, N N 'NN lzzzZ2 (XV)
(R
27 )n H wherein Z1, Z2, Re', R 2 7 and n' are as defined in the above (60) or its salt, iii) reacting the compound of the formula (XV) with a compound of the formula:
R
2 -(CR4aR4b)n-Y wherein R 2 , R4a, R4b and n are as defined in the (62) mentioned below and Y is a leaving group or its salt in the presence of a base to give a compound of the formula (XVI): [Chemical Formula 19] Z1 N NRc1 NN N z2 (XVI)
(R
27 )n' (CR 4 aR 4 b )n
R
2 wherein Z1, Z2, Re', R4a, R4b, n, R 2 , R 2 7 and n' are as defined in the (62) mentioned below or its salt, and iv) reacting the compound of the formula (XVI) or its salt with a compound of the formula:
R
3 -X' wherein R 3 and -X' are as defined in the above (60) or its salt. [0034] In the above (60'), "to give a compound or its salt" includes a case that the compound or its salt are presence in a reaction system and a case that the compound or its salt are isolated. In the above (60'), a compound of the following formula (XII): [Chemical Formula 20] Z1 N N e1 X1 NAN2
(R
27 )n' wherein Ra 1 is-(CR4aR4b)n-R2 wherein R4a, R4b, n and R 2 are as defined in the (68) mentioned below; Z1, Z2, Re', R 2 7 and n' are as defined in the (66) mentioned below, or its pharmaceutically acceptable salt or a solvate thereof can be used instead of the compound of the formula (XVI) or its pharmaceutically acceptable salt or a solvate 23 thereof. (61) The method according to the above (60) or (60'), wherein Z 1 and Z 2 are oxygen atoms. (62) The method according to any one of the above (60), (60') and (61), wherein Rfl is a group of -(CR4aR4b)n-R2; wherein R4a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; and
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl. (63) The method according to any one of the above (60), (60'), (61) and (62), wherein Re' is substituted or unsubstituted alkyl. (64) The method according to any one of the above (60), (60'), and (61) to (63), wherein R 5 is a hydrogen atom. (65) The method according to any one of the above (60), (61'), and (61) to (64), wherein R 3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl. [0035] (66) A compound of the formula (XII): [Chemical Formula 21] Z1 <NN J1,N e1 (I1 NAN2
(R
2 7 )n' wherein Z 1 and Z 2 are each independently an oxygen atom or a sulfur atom; Rfl is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Re' is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; provided that Re' is not unsubstituted alkyl, unsubstituted alkenyl or unsubstituted cycloalkyl when Rfl is a hydrogen atom;
R
2 7 is substituted or unsubstituted alkyl; and n' is an integer of 0 to 3, or its pharmaceutically acceptable salt or a solvate thereof. (67) The compound according to the above (66), wherein Z 1 and Z 2 are oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (68) The compound according to the above (66) or (67), wherein RfI is a group of -(CR4aR4b)n-R2; 24 wherein R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; and
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. (69) The compound according to any one of the above (66) to (68), wherein Rci is substituted or unsubstituted alkyl, or its pharmaceutically acceptable salt or a solvate thereof. (70) The compound according to any one of the above (66) to (69), wherein R 5 is a hydrogen atom, or its pharmaceutically acceptable salt or a solvate thereof. [0036] Furthermore, the present invention relates to the followings: (1) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising a compound of the formula (I): [Chemical Formula 22] Ra Rb k N Rh Rd Rd RN Re Rf wherein (i) Rh and R are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo, thioxo, or =N-Rx; Rx is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -Rf is -(CR4aR4b)n-R2;
R
4 a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, or
R
4 a and R4b are taken together to form oxo or thioxo; n is an integer of 1-4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; Rg is -X-R 3 ; -X- is -0-, -S-, -N(R5)-, or -(CR5aR5b)-;
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted 25 cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R
5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl; R5a and R5b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; (ii) Rh and Ri are taken together to form a bond; Ra is a group of -Y-Rla; Ria is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -Y- is -0-, -S-, -N(R7)-, or -C(R8aR8b)-;
R
7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl; R8a and R8b are each independently hydrogen, halogen or substituted or unsubstituted alkyl; hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Rb and Re are taken together to form a bond; Rd and Re are taken together to form oxo or thioxo; RI and R9 are as defined in the above (i); (iii) Ra and Rb, Rd and Re, and/or R9 and Rh are taken together to form oxo or thioxo; Re is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B (Substituent Group B: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, and nitro), alkenyl substituted with one or more substituents selected from Substituent Group B, or alkynyl substituted with one or more substituents selected from Substituent Group B; 26 Rf is -(CR4aR4b)-R6; Ri is -(CR4a'R4b')-R6';
R
6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R
6 ' is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4a, R4b, R4a', and R4b' are each independently hydrogen or substituted or unsubstituted alkyl; (iv) Ri and Rb are taken together to form a bond; Ra is a group of -Y-Rla; - Y- is -0-, -S-, -N(R7)-, or -C(R8aR8b)-; Ria is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Re is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Rd and Re are taken together to form oxo, thioxo, or =N-Rx; Rx is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Rf is -(CR4aR4b) n-R2; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, or R4a and R4b are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R9 and Rh are taken together to form =N-R 3 ;
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that 1) a compound wherein, in (i), -X- is -NH-, and R 3 is cyclohexyl substituted with guanidyl, and 2) a compound wherein, in (ii), Ra is substituted phenyl, Rd and Re are taken together to form thioxo, R4a and R4b are taken together to form oxo, and R 3 is unsubstituted cyclohexyl, are excluded, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0037] Furthermore, the present invention relates to the mentioned below. 27 (2) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the formula (II): [Chemical Formula 23] Z1 N NRc R(II)
(CR
4 aR 4 b)
R
2 wherein
Z
1 and/or Z 2 is an oxygen atom, a sulfur atom, or (=)N-Rx; Rx, R 4 a, R4b, n, R 2 , X and R 3 are as defined in the above (1); Rei is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (3B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (2B) wherein Z 1 and/or Z 2 is an oxygen atom or a sulfur atom or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (4B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (2B) or (3B) wherein Z1 and Z 2 are both oxygen atoms, its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (5B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (4B) wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, its 28 pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0038] (6B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (5B) wherein Rci is alkyl substituted with one ore more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (7B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder according to the above (1B) comprising the compound of the formula (III): [Chemical Formula 24] RR3 NN RM1X ilN Z2 NZ III
(CR
4 aR 4 b) n R2 wherein Z 2 is an oxygen atom, a sulfur atom or (=)N-Rx; Rx, -Y-, Ria, R 4 a, R4b, n, R 2 , -X , and R 3 are as defined in the above (1B) or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (8B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (7B) wherein Z 2 is an oxygen atom or a sulfur atom or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (9B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (7B) or (8B) wherein -Y- is -0-, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (10B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (7B) to (9B) wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, 29 substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0039] (11B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (7B) to (10 ) wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (12B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (11B) wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredients. (13B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (12B) wherein R 4 a and R4b are both hydrogen atoms or R 4 a and R4b are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (14B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (13B) wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (15B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (14B) wherein R 2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C or cycloalkyl optionally 30 substituted with one or more substituents selected from Substituent Group C, its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (16B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (15B) wherein -X- is -N(R5)- wherein R 5 is as defined in the above (1), its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0040] (17B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (16B) wherein -X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (18B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (17B) wherein R 3 is a group of the formula: [Chemical Formula 25]
(R
9 ) s A wherein ring A is aryl or heteroaryl; s is an integer of 0 to 3;
R
9 are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (19B) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2B) to (18B) wherein R 3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non-aromatic heterocyclic 31 group; and alkylamino), or heteroaryl optionally substituted with one or more selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0041] (20B) A compound of the formula (IV): [Chemical Formula 26] CR4a R4b Z1 R 6 ' N N R'l1 Z N 1Z2 (IV)
CR
4 aR 4 b wherein Z1, Z2, and/or Z 3 is an oxygen atom or a sulfur atom; Re' is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B (Substituent Group B: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, and nitro), alkenyl substituted with one or more substituents selected from Substituent Group B, or alkynyl substituted with one or more substituents selected from Substituent Group B;
R
4 a is hydrogen or substituted or unsubstituted alkyl; R4b is hydrogen;
R
6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R
4 a' is hydrogen or substituted or unsubstituted alkyl; R4b' is hydrogen;
R
6 ' is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or solvate thereof. (21B) The compound according to the above (20B) wherein Z1, Z 2 and Z 3 are oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (22B) The compound according to the above (20B) or (21B) wherein R 6 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, 32 alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. [0042] (23B) The compound according to any one of the above (20B) to (22B) wherein R' is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non-aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof. (24B) A compound of the formula (II): [Chemical Formula 27] Zi RMX N Z2(II)
(CR
4 aR 4 byf
R
2 wherein
Z
1 and/or Z 2 is an oxygen atom, a sulfur atom, or (=N)-Rx; R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aronaatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Re is hydrogen, alkyl substituted with one or more substituents selected from Substituent Group E (Substituent Group E: sulfo; substituted or unsubstituted sulfamoyl; substituted or unsubstituted imino; substituted or unsubstituted guanidyl; a substituted or unsubstituted non-aromatic heterocyclic group provided that morpholinyl, imidazolidinyl, tetrahydropyranyl and piperidinyl are excluded; substituted or unsubstituted heteroaryl provided that pyridyl is excluded), alkenyl substituted with one or more substituents selected from Substituent Group E, or alkynyl substituted with one or more substituents selected from Substituent Group E; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, or R4a and R4b are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; 33 -X- is -0-, -S-, -N(R5)-, or -(CR5aR5b)-;
R
5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl;
R
5 a and R5b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy;
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. [0043] (25B) The compound according to the above (24B) wherein Z 1 and/or Z 2 is an oxygen atom or a sulfur atom, or its pharmaceutically acceptable salt or a solvate thereof. (26B) The compound according to the above (24B) wherein Z 1 and Z 2 are both oxygen atoms, its pharmaceutically acceptable salt or a solvate thereof. (27B) The compound according to any one of the above (24B) to (26B) wherein Re' is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof. (28B) The compound according to any one of the above (24B) to (27B) wherein Re is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof. 34 (29B) The compound according to any one of the above (24B) to (28B) wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof. [0044] (30B) The compound according to any one of the above (24B) to (29B) wherein R4a and R4b are both hydrogen atoms or R4a and R4b are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof. (31B) The compound according to any one of the above (24B) to (30B) wherein
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. (32B) The compound according to any one of the above (24B) to (31B) wherein
R
2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. (33B) The compound according to any one of the above (24B) to (33B) wherein -X- is -N(R5)- (wherein R 5 is as defined in the above (1B)), or its pharmaceutically acceptable salt or a solvate thereof. (34B) The compound according to any one of the above (24B) to (33B) wherein X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof. (35B) The compound according to any one of the above (24B) to (34B) wherein
R
3 is a group of the formula: [Chemical Formula 28]
(R
9 ) A wherein ring A is aryl or heteroaryl; s is an integer of 0 to 3; and
R
9 are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or 35 substituted or unsubstituted heteroaryloxy), or its pharmaceutically acceptable salt or a solvate thereof. [0045] (36B) The compound according to any one of the above (24B) to (35B) wherein
R
3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non-aromatic heterocyclic group; and alkylamino) (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, aryl or a non aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; aryloxy; heteroaryloxy; a non-aromatic heterocyclic group; and alkylamino) or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof. (37B) A compound of the formula (VII): [Chemical Formula 29] Z1
(R
9 )s N 1 ( ls Xz ( V I I)
(CR
4 aR 4 b)
R
2 wherein
Z
1 and/or Z 2 is oxo, thioxo, or =N-Rx; Rx is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Re is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, or R4a and R4b are taken together to form oxo or thioxo; n is an integer of 1 to 4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, 36 substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R5)-, or -(CR5aR5b)-;
R
5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R5a and R5b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; s is an integer of 0 to 3;
R
9 are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof. [0046] (38B) The compound according to the above (37B) wherein Z 1 and Z 2 are both oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (39B) The compound according to the above (37B) or (38B) wherein Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group A, unsubstituted alkynyl, alkynyl substituted with one or more substituents selected 37 from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof. (40B) The compound according to any one of the above (37B) to (39B) wherein Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group B" (Substituent Group B": hydroxy, carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group B", unsubstituted alkynyl, alkynyl substituted with one or more substituents selected from Substituent Group B", or its pharmaceutically acceptable salt or a solvate thereof. (41B) The compound according to any one of the above (37B) to (40B) wherein n is 1 and R4a and R4b are both hydrogen atoms, or its pharmaceutically acceptable salt or a solvate thereof. [0047] (42B) The compound according to any one of the above (37B) to (41B) wherein
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. (43B) The compound according to any one of the above (37B) to (42B) wherein
R
2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof given in either of the statements to either of the above (37B) (42B). (44B) The compound according to any one of the above (37B) to (43B) wherein -X- is -N(R5)- wherein R 5 is as defined in the above (37B), or its pharmaceutically acceptable salt or a solvate thereof. (45B) The compound according to any one of the above (37B) to (44B) wherein X- is -NH-, its pharmaceutically acceptable salt or a solvate thereof. (46B) The compound according to any one of the above (37B) to (45B) wherein s is an integer of 0 to 2, and R 9 are each independently, halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, and substituted or unsubstituted sulfamoyl), or its pharmaceutically acceptable salt or a solvate thereof. 38 In (46B), a compound wherein s is 0 or 1, or its pharmaceutically acceptable salt or a solvate thereof is preferable. [0048] (47B) A compound of the formula (VIII): [Chemical Formula 30]
(R
9 )s Z 1 (R 9 ')s' 0 X N N 'lRl ~ X "N Z2 (Vill) (C R 4 aR 4 b)
R
2 wherein
Z
1 and/or Z 2 is oxo, thioxo, or =N-Rx; Rx is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Re is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, or R4a and R4b are taken together to form oxo or thioxo; n is an integer of 1-4;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R5)-, or -(CR5aR5b)-; ring B is heteroaryl; s and s' are each independently is an integer of 0 to 3;
R
9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or substituted or unsubstituted heteroaryloxy, 39 or its pharmaceutically acceptable salt or a solvate thereof. (48B) The compound according to the above (47B) wherein Z 1 and Z 2 are both oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. [0049] (49B) The compound according to the above (47B) or (48B) wherein Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group A, unsubstituted alkynyl, alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof. (50B) The compound according to any one of the above (47B) to (49B) wherein Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group B" (Substituent Group B": hydroxy, carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group B", unsubstituted alkynyl, alkynyl substituted with one or more substituents selected from Substituent Group B", or its pharmaceutically acceptable salt or a solvate thereof. (51B) The compound according to any one of the above (47B) to (50B) wherein n is 1 and R4a and R4b are both hydrogen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (52B) The compound according to any one of the above (47B) to (51B) wherein
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof (53B) The compound according to any one of the above (47B) to (52B) wherein
R
2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, 40 alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C , or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. (54B) The compound according to any one of the above (47B) to (53D) wherein X- is -N(R5)- wherein R 5 is as defined in the above (47B), or its pharmaceutically acceptable salt or a solvate thereof. (55B) The compound according to any one of the above (47B) to (54B) wherein X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof. [0050] (56B) The compound according to any one of the above (47B) to (55B) wherein ring B is thiazole, isothiazole, oxazole, isoxazole, pyrazole, imidazole, triazole, furan, thiophene, thiadiazole, oxadiazole, pyridine, pyrimidine, pyrazine, pyridazine, pyridazine, triazine, or benzoxazole, or its pharmaceutically acceptable salt or a solvate thereof. (57B) The compound according to any one of the above (47B) to (56B) wherein s and s' are each independently an integer of 0 to 2, and R 9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, or substituted or unsubstituted sulfamoyl, or its pharmaceutically acceptable salt or a solvate thereof. In (57B), a compound wherein s is 0, s' is 0 or 1, and R 9 ' is halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, or substituted or unsubstituted sulfamoyl, or its pharmaceutically acceptable salt or solvate thereof is preferable. (58B) A pharmaceutical composition comprising a compound according to any one of the above (20B) to (57B), or its pharmaceutically acceptable salt or a solvate thereof. (59B) The pharmaceutical composition according to (58B) wherein the composition has a P2X 3 and/or P2X 2
/
3 receptor antagonistic effect. (60B) A compound according to any one of the above (20B) to (57B) for use in a method for treating and/or preventing a disease related to P2X3 and/or P2X 2 /3 41 receptor, or its pharmaceutically acceptable salt or a solvate thereof. (61B) A compound according to any one of the above (20B) to (57B) for use in a method for treating and/or preventing a disease related to P2X3 and/or P2X2/3 receptor, or its pharmaceutically acceptable salt or a solvate thereof. (62B) A method for treating or preventing a disease related to P2X3 and/or P2X2/3 receptor, comprising administering the compound according to any one of the above (20B) to (57B), or its pharmaceutically acceptable salt or a solvate thereof. [0051] (1A) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the formula (I): [Chemical Formula 31] Ra Rb R)N Re R9 I R Rf wherein (i) Rh and Ri are taken together to form a bond; Ra and Rb, and/or Rd and Re are taken together to form oxo, thioxo, or =N-Rx; Rx is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; - Rf is -(CR 4 aR 4 b) n-R 2 ;
R
4 a and R4b are each independently substituted or unsubstituted alkyl, or R 4 a and R4b are taken together to form oxo or thioxo;
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -R9 is -X-R 3 ; - X- is -O-, -S-, -N(R5)-, or -(CR5aR5b)-;
R
3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R
5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R5a and R5b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy;, [0052] 42 [0052] (ii) Rh and Ri are taken together to form a bond; Ra is a group of -Y-Rla; Ria is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -Y- is -0-, -S-, -N(R7)-, or -C(R8aR8b)-; R7 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted acyl; R8a and R8b are each independently hydrogen, halogen or substituted or unsubstituted alkyl; hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Rb and Re are taken together to form a bond; Rd and Re are taken together to form oxo or thioxo; RI and R9 are as defined in the above (i);, (iii) Ra and Rb, Rd and Re, and/or R9 and Rh are taken together to form oxo or thioxo; Re is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B (Substituent Group B: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl and nitro), alkenyl substituted with one or more substituents selected from Substituent Group B, or alkynyl substituted with one or more substituents selected from Substituent Group B; Rf is -(CR4aR4b)-R6; Ri is -(CR4a'R4b')-R6';
R
6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R
6 ' is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4a, R4b, R4a', and R4b' are each independently hydrogen or substituted or 43 unsubstituted alkyl, provided that 1) a compound wherein, in (i), -X- is -NH-, and R 3 is cyclohexyl substituted with guanidyl, and 2) a compound wherein, in (ii), Ra is substituted phenyl, Rd and Re are taken together to form thioxo, R 4 a and R4b are taken together to form oxo, and R 3 is unsubstituted cyclohexyl, are excluded, or its pharmaceutically acceptable salt or solvate thereof as an active ingredient. [0053] (2A) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the formula (II): [Chemical Formula 32] Z1 N NRc R(II)
(CR
4 aR 4 b) R2 wherein
Z
1 and/or Z 2 is oxo, thioxo, or =N-Rx; Rx, R 4 a, R4b, n, R 2 , X, and R 3 are as defined in the above (1A); Rei is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (3A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (2A) wherein Z 1 and/or Z 2 is oxo or thioxo, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (4A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (2A) or (3A) wherein Z1 and Z 2 are both oxo, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (5A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (4A) wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, 44 substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (6A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (5A) wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0054] (7A) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the formula (III): [Chemical Formula 33]
RR
1 a N N RM1X il N 1 Z2 III (C R 4 aR 4 b) n
R
2 wherein Z 2 is oxo, thioxo, or =N-Rx; Rx, -Y-, Ria, R 4 a, R4b, n, R 2 , -X-, and R 3 are as defined in the above (1A); or its pharmaceutically acceptable salt or solvate thereof as an active ingredient. (8A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (7A) wherein Z 2 is oxo or thioxo or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (9A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (7A) or (8A) wherein -Y- is -0-, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (10A) The pharmaceutical composition having an analgesic effect and/or an 45 improving effect on a urination disorder comprising the compound according to any one of the above (7A) to (9A) wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0055] (11A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (7A) to (10A) wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (12A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (16A) wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (13A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (12A) wherein R 4 a and R4b are both hydrogen, or R 4 a and R4b are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (14A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (13A) wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its 46 pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (15A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (2A) to (14A) wherein R 2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (16A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to the above (2A) to (15A) wherein -X- is -N(R5)- wherein R 5 is as defined in the above (1A), or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (17A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (16A) wherein - X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0056] (18A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (17A) wherein R 3 is a group of the formula: [Chemical Formula 34]
(R
9 ) S A wherein ring A is aryl or heteroaryl; s is an integer of 0 to 3;
R
9 are each independently halogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0057] (18A') The pharmaceutical composition having an analgesic effect and/or an 47 improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (18A) wherein R 3 is a group of the formula: [Chemical Formula 35]
R
9 b wherein R9a is hydrogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted non-aromatic heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryloxy; R9b is halogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (18A") The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (18A) and (18A') wherein R 3 is a group of the formula: [Chemical Formula 36] Rea Ri0 48 wherein R 9 a is as defined in the above (18A'); R 10 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (19A) The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (18A) and (18A') wherein R 3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alky; a non-aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0058] (19A') The pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound according to any one of the above (2A) to (18A) wherein R 3 is a group of the formula(A): [Chemical Formula 37] (A) w wherein =W1-W 2 =W3.W 4 =W5- is any one selected from the following (a) to (h): (a): =C(H)-C(ROa)=C(RiOb)-C(ROc)=C(H) (b): =N- C(R iaa)=C(R10b). C(R iac)=C(H)-; (c): =C(H)-N=C(R10b)- C(R iac)=C(H)-; (d): =C(H)-C(Riaa)=N- C(R iac)=C(H)-; (e): =C(H)-C(Riaa)=C(R iab)-N=C(H)-; (f): =N-C(R iaa)=C(R iab).C(R iac)=N-; (g): =C(H)-C(Riaa) =N-C(Ric) =C(H)-; and (h): =C(H)-N=C(R iab)-N=C(H)-I Riaa, Riab, and RiOc are each independently hydrogen, halogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted 49 cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or substituted or heteroaryloxy; or R1Oa and R1Ob or R10b and R1Oe together with the ring atom to which they are attached form a non aromatic carbocyclic ring, a non-aromatic heterocyclic ring, an aromatic carbocyclic ring or an aromatic heterocyclic ring, ,or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (19A") A compound described in any one of the above (1A) to (19A), (18A'), (18A") and (19A') for use in a method for treating, preventing and/or improving pain and/or urination disorder, or its pharmaceutically acceptable salt or a solvate thereof. (19A.') A method for treating, preventing and/or improving pain and/or urination disorder comprising administering the compound described in any one of the above (1A) to (19A), (18A'),(18A") and (19A'), or its pharmaceutically acceptable salt or a solvate thereof. [0059] (20A) A compound of the formula (IV): [Chemical Formula 38] CR4aR4b Z1 Rc R 6 '- N 1 N R
Z
3 N Z 2 (IV) C R 4 aR 4 b wherein Z1, Z2, and/or Z 3 is an oxygen atom or a sulfur atom; Re' is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B, alkenyl substituted with one or more substituents selected from Substituent Group B, or alkynyl substituted with one or more substituents selected from Substituent Group B;
R
4 a is hydrogen or substituted or unsubstituted alkyl; R4b is hydrogen;
R
6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R
4 a' is hydrogen or substituted or unsubstituted alkyl; R4b' is hydrogen;
R
6 ' is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. (21A) The compound according to the above (20A) wherein Z1, Z2, and Z 3 are oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof. (22A) The compound according to the above (20A) or (22A) wherein R 6 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C, aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically 50 acceptable salt or a solvate thereof. (23A) The compound according to any one of the above (20A) to (22A) wherein
R
6 ' is aryl optionally substituted with one or more substituents selected from Substituent Group D, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof. [0060] (24A) A compound of the formula (II): [Chemical Formula 39] Zi R2 III wherein
Z
1 and/or Z 2 is oxo, thioxo, or =N-Rx; Rx, R4a, R4b, n, R 2 , X and R 3 are as defined in the above (1A); Re' is hydrogen, alkyl substituted with one or more substituents selected from Substituent Group E (Substituent Group E: sulfo; substituted or unsubstituted sulfamoyl; substituted or unsubstituted, imino; substituted or unsubstituted guanidyl; a substituted or unsubstituted non-aromatic heterocyclic group provided that morpholinyl, imidazolidinyl, tetrahydropyranyl and piperidinyl are excluded; and substituted or unsubstituted heteroaryl provided that pyridyl are excluded), alkenyl substituted with one or more substituents selected from Substituent Group E, or alkynyl substituted with one or more substituents selected from Substituent Group E, or its pharmaceutically acceptable salt or a solvate thereof. (25A) The compound according to the above (24A) wherein Z 1 and/or Z 2 is oxo or thioxo, or its pharmaceutically acceptable salt or a solvate thereof. (26A) The compound according to the above (24A) or (25A) wherein Z 1 and Z 2 are both oxo, or its pharmaceutically acceptable salt or a solvate thereof. (27A) The compound according to any one of the above (24A) to (26A) wherein Re' is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof. (28A) The compound according to any one of the above (24A) to (27A) wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof. (29A) The compound according to any one of the above (24A) to (28A) wherein R4a and R4b are both hydrogen atoms or R4a and R4b are taken together to form oxo, or 51 its pharmaceutically acceptable salt or a solvate thereof. (30A) The compound according to any one of the above (24A) to (29A) wherein
R
2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. [0061] (31A) The compound according to any one of the above (24A) to (30A) wherein
R
2 is aryl substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof. (32A) The compound according to any one of the above (24A) to (31A) wherein -X- is -N(R5)- wherein R 5 is as defined in the above (1A), or its pharmaceutically acceptable salt or a solvate thereof. (33A) The compound according to any one of the above (24A) to (32A) wherein X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof. (34A) The compound according to any one of the above (24A) to (33A) wherein
R
3 is a group of the formula: [Chemical Formula 40]
(R
9 ) A wherein ring A is aryl or heteroaryl; s is an integer of 0 to 3; R9 are each independently halogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof according to any one of the above (24A) to (33A). [0062] (34A') The compound according to any one of the above (24A) to (34A) wherein R 3 is a group of the formula: 52 [Chemical Formula 41] RRa R9 wherein R9a is hydrogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy, or substituted or unsubstituted heteroaryloxy; R9b is halogen, hydroxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof. (34A") The compound according to any one of the above (24A) to (34A) and (34A') wherein R 3 is a group of the formula: [Chemical Formula 42] R9 R10 wherein
R
9 is as defined in the above (7A); RIO is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, 53 substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof. [0063] (35A) The compound according to any one of the above (24A) to (34A), (34A') and (34A") wherein R 3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non-aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof. (36A) A compound of the following formula: 54 [Chemical Formula 43] N~HN N OH O~ HN N O 0C , HN O HN N OH O N N N N 0 C I ' C O0 0 z 0 O HN N - OH HN N OH ONOOO NN N O N N O Br 0 0 B Br 0 0 HN N OH 0NOH IN 1 ,N 0
N
H a~j N N -O 0 0 0ci o5 [Chemical Formula 44] CI 0, 0~ HN N' N- H " O N NOO N N O ~CI Br O O CI 0 0 -O H N H N -o CI 0 Cl 0 -,-& H N "N OH -,T - HN~ N ~NOH N N- O 0Nl'-< N -k0 [0064] I N N -O NoN ,or its pharmaceutically acceptable salt or a solvate thereof. [0 064] (36A') A compound of the following formula: 56 [Chemical Formula 45] N~HN N OH O~ HN N O 0C , HN O HN N OH O N N N N 0 C I ' C B O 0 0 O HN N - OH HN N OH ONOOO N NOH O N N O CIC, Br a c 0 0c , o i Br 0 0 H H N 1 N - - - O H 0 N ' ' O 'N'_ N 0 N - 0 0 0 CI o 0 0 N N - OH 0 HNNO INN OHN H a N N O or its pharmaceutically acceptable salt or a solvate thereof. [0065] (36A") A compound of the following formula: 57 [Chemical Formula 46] CI 0 HN ON y N HN 'N"N- O Br 0 C CI 0 0 NO N 9 ON 0 HN N>N NCIN O OH O OHO ICI CI O CI 0 H N OH HN N OH N Nz O 0NA:' N - O o -a CI 0 0CI 0 0 HN-oY''OO HN N N NO N NO or its pharmaceutically acceptable salt or a solvate thereof. [0066] (36A"') A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the following formula: 58 [Chemical Formula 47] O- 000 HN N OH HN N OH HN N-OH HN N OH N NO Oa H NN N O CI ' O 0 0 0 HN N OH 0 HN NO YN N N OH N N O N N- -O CI 0 0 CI 0 00 0 0 0 HN N" -J OH 0N N -OH N N-'O - N 1,N -O H aN 59I [Chemical Formula 48] CI o O 0 O NH - HN N-- J 0~ H N ON-O N N-OO CI , CI Br 0 0 CI 0 NIO ON OH N 4 N"N IN N-N OO CI 0 CI 0 0 -Nr N 1N^ OH- HNN No ,O N N O O N -O CI 0 CI CI N -k0 0I N5 CI 0 0 yO 0 0 O HN N OH HN OH N N '-O N NN- O or or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0067] (37A) A pharmaceutical composition comprising the compound according to any one of the above (20A) to (36A), (35A'), (36A'), (35A") and (36A"), or its pharmaceutically acceptable salt or a solvate thereof. (37A') A pharmaceutical composition comprising the compound according to 60 any one of the above (20A) to (36A), (35A'), (36A'), (35A") and (36A") or its pharmaceutically acceptable salt or a solvate thereof wherein the composition has a P2X 3 and/or P2X 2
/
3 receptor antagonistic effect. (38A) The pharmaceutical composition according to (37A) which has a P2X 3 and/or P2X 2
/
3 receptor antagonistic effect. (39A) A compound according to any one of the above (20A) to (36A), (35A'), (36A'), (35A") and (36A"), or its pharmaceutically acceptable salt or a solvate thereof for use in a method for treating and/or preventing a disease related to P2X 3 and/or P2X 2
/
3 receptor. (40A) A method for treating and/or preventing a disease related to P2X 3 and/or P2X 2
/
3 receptor comprising administering the compound according to (20A) to (36A), (35A'), (36A'), (35A"), (36A") and (36A.'), or its pharmaceutically acceptable salt or a solvate thereof. (41A) A compound according to any one of the above (20A) to (36A), (35A'), (36A'), (35A"), (36A") and (36A"'), or its pharmaceutically acceptable salt or a solvate thereof for use in a method for treating pain and/or urination disorder. (42A) A method for relieving pain and/or treating urination disorder comprising administering the compound according to (20A) to (36A), (35A'), (36A'), (35A"), (36A") and (36A"') or its pharmaceutically acceptable salt or a solvate thereof. 61 [Effect of the Invention] [0068] The compound of the invention has an antagonistic effect on P2X 3 and/or P2X 2 /3 receptor and is useful in the treatment of diseases or conditions associated with a P2X 3 and/or P2X 2
/
3 receptor, especially chronic pain, overactive bladder, etc. [Mode for Carrying Out the Invention] [0069] As used throughout the specification, the following terms have the following meaning unless specifically indicated. [0070] The term "halogen" means fluoro, chloro, bromo and iodo. [0071] The halogen moiety in said "haloalkyl", "haloalkylcarbamoyl" and "haloalkyloxy" is as defined above for "halogen". [0072] The term "alkyl" includes a straight or branched chain monovalent hydrocarbon group of a carbon number of 1 to 15, as one embodiment a carbon number of 1 to 10, and as another embodiment a carbon number of 1 to 6. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl, n-undecanyl, dodecanyl, tridecanyl, and the like. [0073] The alkyl moiety in said "haloalkyl", "hydroxyalkyl", "aminoalkyl", "alkylaminoalkyl", "alkylamino", "alkylimino", "alkylsulfonyl", "alkylsulfamoyl", "alkylcarbamoyl", "arylalkyl", "alkylsilylalkynyl", "alkylsulfonyl", "alkylsulfinyl", "alkylcarbamoyl", "alkylcarbamoylalkyl", "alkylsulfamoyl", "alkylsulfamoylalkyl", "haloalkylcarbamoyl", "hydroxyalkylcarbamoyl", "alkyloxycarbonylalkyl" and "arylalkylamino" is as defined above for "alkyl". [0074] The term "alkyloxy" includes an alkyloxy group of which alkyl moiety is as defined above for "alkyl". For example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, etc are exemplified as alkyloxy. The alkyloxy moiety in said "haloalkyloxy", "arylalkyloxy", "alkyloxycarbonyl", "alkyloxycarbonylalkyl", and "alkyloxyimino" is as defined above for "alkyloxy". [0075] For example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, and the like are exemplified as "alkylthio". [0076] For example, methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, n-pentyloxycarbonyl, and the like are exemplified as "alkyloxycarbonyl". [0077] For example, mono- or di- alkylcarbamoyl, such as methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, n-butylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, and the like 61 are exemplified as "alkylcarbamoyl". [0078] The term "alkenyl" includes linear or branched alkenyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, and as another embodiment a carbon number of 2 to 6 having one or more double bonds at any available position. Examples include vinyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl and the like. [0079] The alkenyl moiety in said "alkenyloxy", "alkenylthio", "alkenylcarbamoyl", "alkenylsulfamoyl" and "alkenyloxycarbonyl" is as defined above for "alkenyl". [0080] The term "alkynyl" includes a linear or branched alkynyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, as another embodiment a carbon number 2 to 6. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. These have one or more triple bonds at any available position and may further a double bond. [0081] The alkynyl moiety in said "alkynyloxy", "alkynylthio" and "alkynyloxycarbonyl" is as defined above for "alkynyl". [0082] The term "acyl" includes a group of the formula R-C(=O)-, wherein R is, for example, "hydrogen", "alkyl", "alkenyl" or "alkynyl" as defined above and "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl" or "heteroaryl" as defined below. [0083] The acyl moiety in "acylamino" and "acylimino" is as defined above for "acyl [0084] The term "cycloalkane" includes a monocyclic or polycyclic saturated cyclic carbocyclic ring containing from 3 to 10 carbons. Monocyclic cycloalkane includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, etc. Polycyclic cycloalkane includes norbornanane, tetrahydronaphthalene, etc. [0085] The term "cycloalkyl" includes a monovalent group derived from "cycloalkane" as defined above. Monocyclic cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, etc. As one embodiment, C3 to C8 cycloalkane is exemplified. As another embodiment, C3 to C7 cycloalkane is exemplified. Polycyclic cycloalkyl includes norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, etc. Examples of "cycloalkyl" for R2 are cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Examples of "cycloalkyl" for R3 are cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. [0086] The cycloalkyl moiety in said "cycloalkyloxycarbonyl" and "cycloalkyloxy" is as defined above for "cycloalkyl". [0087] The term "cycloalkene" includes a non-aromatic monocyclic or polycyclic ring of 3 62 to 10 carbons containing at least one carbon-carbon double bond. As one embodiment C3 to C8 cycloalkene is exemplified. As another embodiment C3 to C7 cycloalkene is exemplified. Monocyclic cycloalkene includes, for example, cyclopentene, cyclohexene, etc. Polycyclic cycloalkene includes norbornene, indene, etc. [0088] The term "cycloalkenyl" includes a monovalent group derived from "cycloalkene" as defined above. Monocyclic cycloalkenyl includes cyclopentenyl, cyclohexenyl, etc. As one embodiment, C3 to C8 cycloalkane is exemplified. As another embodiment, C3 to C7 cycloalkane is exemplified. Polycyclic cycloalkenyl includes norbornenyl, indene-1-yl, indene-2-yl, indene-3-yl, etc. [0089] The cycloalkenyl moiety in said "cycloalkenyloxycarbonyl" and "cyclolalkenyloxy" is as defined above for "cycloalkenyl [0090] The term "aromatic carbocyclic ring" includes an aromatic hydrocarbocyclic ring which is monocyclic or fused-cyclic, such as benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, etc. [0091] The term "aryl" includes a monovalent group derived from "aromatic carbocyclic ring" as defined above. For example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, phenanthryl, etc. are exemplified. Preferable "aryl" for R3 is phenyl. [0092] The aryl moiety in said "aryloxy", "arylthio" and "aryloxycarbonyl" is as defined above for "aryl [0093] The term "heterocyclic ring" includes an aromatic or a non-aromatic monocyclic or fused-cyclic ring, which includes a five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring; a fused ring consisting of two or more said five- to seven-membered rings; or a fused ring consisting of said five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring", "cycloalkane" or "cycloalkene" as defined above. For example, a monocyclic non-aromatic heterocyclic ring such as pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyrane, dihydropyridine, dihydropyridazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazole, tetrahydroisothiazole, etc.; a monocyclic aromatic heterocyclic ring such as pyrrole, pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, tetrazole, triazine, pyridazine, pyrimidine, isoxazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused heterocyclic ring such as indole, isoindole, indazole, indolizine, indoline, isoindoline, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzopyrane, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, benzimidazole, benzodioxane, tetrahydroquinoline, tetrahydrobenzothiophene, etc. are exemplified. [0094] 63 The term "heterocyclic group" includes a monovalent group derived from "heterocyclic ring" as defined above. For example, monocyclic non-aromatic heterocyclic groups such as pyrrolinyl, pyrrolidino, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl, etc.; monocyclic aromatic heterocyclic groups such as pyrrolyl, pyrazinyl, pyrazolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and fused heterocyclic groups such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl, benzodioxanyl, tetrahydroquinoline, tetrahydrobenzothienyl, etc. are exemplified. [0095] The term "non-aromatic carbocyclic ring" includes "cycloalkane" as defined above, "cycloalkene" as defined above, a fused ring consisting of "aromatic carbocyclic ring" as defined above fused to "cycloalkane" or "cycloalkene" as defined above. As a fused ring, indene and the like are exemplified. [0096] The term "non-aromatic carbocyclic group" includes a monovalent group derived from "non-aromatic carbocyclic ring" as defined above. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, norbornenyl, inden-1-yl, inden-2-yl, inden-3-yl and the like are exemplified. [0097] The non-aromatic carbocyclyl moiety in said "non-aromatic carbocyclyloxy" and "non-aromatic carbocyclylalkyloxy" is as defined above for "non-aromatic carbocyclic ring". [0098] The term "aromatic heterocyclic ring" includes aromatic rings of "heterocyclic ring" as defined above. "Aromatic heterocyclic ring" includes a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring; a fused aromatic ring consisting of two or more said rings; and a fused ring consisting of a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" as defined above. For example, a monocyclic aromatic heterocyclic ring such as pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, triazine, pyridazine, pyrimidine, pyrazine, isoxazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused aromatic heterocyclic ring such as indole, isoindole, indazole, indolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, 64 purine, pteridine, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, benzimidazoline, etc. are exemplified. [0099] "Five- or six-membered aromatic heterocyclic ring" includes five- or six-membered rings of "aromatic heterocyclic ring" as defined above. Examples are thiazole, isothiazole, oxazole, isoxazole, thiadiazole, oxadiazole, pyrazole, furan, thiophene, imidazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyridazine, triazine, etc. [0100] "Five membered-aromatic heterocyclic ring" includes 6-membered rings of "aromatic heterocyclic ring" as defined above. Examples are thiazole, isothiazole, oxazole, isoxazole, thiadiazole, oxadiazole, pyrazole, furan, thiophen, imidazole, triazole, tetrazole etc. [0101] "Six-membered aromatic heterocyclic ring" includes six-membered rings of "aromatic heterocyclic ring" as defined above. Examples are pyridine, pyrimidine, pyrazine, pyridazine, triazine, etc. [0102] The term "heteroaryl" includes a monovalent group derived from "aromatic heterocyclic ring" as defined above. "Heteroaryl" includes a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring; a fused aromatic group consisting of two or more said rings; and a fused ring consisting of a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" as defined above. For example, monocyclic heteroaryl such as pyrrolyl, pyrazinyl, pyrazolyl, indolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and fused heteroaryl such as isoindolyl, indazolyl, indolizinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl, etc. are exemplified. [0103] One of examples of "heteroaryl" for R2 is pyridyl. Examples of "heteroaryl" for R 3 are pyridyl, pyrimidyl, benzofuryl, benzothienyl, indolyl, benzisoxazolyl etc. One of examples of "heteroaryl" for R 3 is pyridyl. [0104] The heteroaryl moiety in said "heteroaryloxy" and "heteroaryloxycarbonyl" is as defined above for "heteroaryl [0105] The term "non-aromatic heterocyclic ring" includes non-aromatic rings of 65 "heterocyclic ring" as defined above. "Non-aromatic heterocyclic ring" includes, a four- to seven-membered non-aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring; a fused non-aromatic ring consisting of two or more said rings; a fused ring consisting of a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "cycloalkane" or "cycloalkene" as defined above; and a fused ring consisting of a five- to seven-membered non-aromatic heterocyclic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" or "non-aromatic carbocyclic ring" as defined above. For example, monocyclic non-aromatic heterocyclic ring such as oxetane, thietane, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine, tetrahydropyran, dihydropyridine, dihydropyridazine, dihydropyrazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazoline, tetrahydroisothiazoline etc.; a fused non-aromatic heterocyclic ring such as indoline, isoindoline, benzopyrane, benzodioxane, tetrahydroquinoline, benzo[d]oxazole-2(3H) -one, tetrahydrobenzothiophene etc. are exemplified. [0106] "Non-aromatic heterocyclic group" includes a monovalent group derived from "non-aromatic heterocyclic ring" as defined above. Examples are monocyclic non-aromatic heterocyclic group such as pyrrolinyl, pyrrolidine, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazine, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydrlisothiazolinyl etc. and a fused heterocyclic group such as benzodioxane, tetrahydroquinoline, benzo[d]oxazole-2(3H) -one, tetrahydfobenzothiophene etc. [0107] The non-aromatic heterocyclyl moiety in said "non-aromatic heterocyclyloxy" and "non-aromatic heterocyclyloxycarbonyl" is as defined above for "non-aromatic heterocyclic ring". [0108] The term "nitrogen-containing non-aromatic heterocyclic group" includes a group derived from a four- to seven-membered non-aromatic ring which contains at least one nitrogen atom in the ring and may contain one or more atoms arbitrarily selected from an oxygen atom and an sulfur atom in the ring and a fused ring consisting of two or more said rings. Examples are pyrrolinyl, pyrrolidino, pyrrolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholino etc. [0109] The non-aromatic heterocyclyl moiety in said "non-aromatic heterocyclyloxycarbonyl" is as defined above for "non-aromatic heterocyclic ring [0110] Substituents for "substituted alkyl", "substituted alkenyl", "substituted alkynyl ", "substituted alkyloxy", "substituted alkenyloxy", "substituted alkynyloxy", "substituted 66 alkylthio", "substituted alkenylthio", "substituted alkynylthio", "substituted alkyloxycarbonyl", "substituted alkenyloxycarbonyl" and "substituted alkynyloxycarbonyl" include but are not limited to one or more same or different substituents selected from the group consisting of: hydroxy, carboxy, halogen (F, Cl, Br, I) , haloalkyloxy (e.g., CF 3 0) , cycloalkyl (e.g., cyclopropyl) , cycloalkenyl (e.g., cyclopropenyl) , lower alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.) , alkenyloxy (e.g., vinyloxy, allyloxy, etc.) , alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.) , nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.) , acylamino (e.g., acetylamino, benzoylamino, etc.) , arylalkylamino (e.g., benzylamino, tritylamino) hydroxyamino, alkylsulfonylamino (e.g., methanesulfonylamino) , alkylsulfinylamino (e.g., methanesulfinylamino), imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.) , alkyloxyimino (e.g., methoxyimino, ethoxyimino, etc.) , acylimino (e.g., acetylimino, benzoylimino, etc.) , azido, aryl (e.g., phenyl, etc.) , arylalkyl (e.g., benzyl, phenylethyl etc.) , arylalkyloxy (e.g., benzyloxy) , a non-aromatic heterocyclic group(e.g., pyrrolinyl, piperidyl, piperazinopyrrolidino, pyrrolidinyl, morpholinyl, morpholino etc.) , heteroaryl (e.g., furyl, thienyl, pyridyl, isoxazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, tetrazolyl, indolyl, benzofuryl etc.) heteroarylalkyl (e.g., pyridylmethyl, pyridylethyl etc.) , cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio, etc.) , alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl) , carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, etc.) , sulfamoyl, alkylsulfamoyl, acyl (e.g., formyl, acetyl, etc.) , formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazino, azido, ureido, amidino, guanidino, phthalimido, tri-alkylsilyl (e.g., trimethylsilyl, etc.) , and oxo. [0111] As a substituent for "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" for R and Rel, the followings are exemplified. carboxy; hydroxy; oxo; thioxo; halogen; alkyloxy; alkenyloxy; alkynyloxy; alkyloxyalkyloxy; carbamoyl optionally substituted with hydroxy, cyano, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkylalkyl, cycloalkenylalkyl, non-aromatic heterocyclylalkyl, a non-aromatic heterocyclic group, aryl or heteroaryl; sulfamoyl optionally substituted with hydroxy, cyano, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkylalkyl, cycloalkenylalkyl, non-aromatic heterocyclylalkyl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkenyl, heteroaryl, aryl, or heteroaryl; amino optionally substituted with hydroxy, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl; imino optionally substituted with hydroxy, alkyloxy, alkenyloxy, or alkynyloxy; guanidyl optionally substituted with cyanoalkyl; cycloalkyl optionally substituted with carboxy, alkyl, hydroxyalkyl, carboxyalkyl, arylalkyl, heteroarylalkyl, alkyloxyarylmethyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkyloxyalkyl, cycloalkenyloxyalkyl, non-aromatic heterocyclyloxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, oxo or thioxo; a non-aromatic heterocyclic group optionally substituted with carboxy, alkyl, hydroxyalkyl, carboxyalkyl, alkyloxycarbonyl, arylalkyl, alkyloxyarylmethyl, non-aromatic heterocyclyloxyalkyl, or oxo; aryl optionally substituted with halogen or alkyloxycarbonyl; heteroaryl optionally substituted with carboxy, alkyloxy, alkyloxycarbonyl, non-aromatic 67 heterocyclyloxyalkyloxy; alkyloxycarbonyl; alkenyloxycarbonyl; alkynyloxycarbonyl; cycloalkyloxycarbonyl; cycloalkenyloxycarbonyl; non-aromatic heterocyclyloxycarbonyl; aryloxycarbonyl; or heteroaryloxycarbonyl etc. [0112] As a substituent for "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" for RC and Rei, the followings are exemplified. halogen; hydroxy; carboxy; alkyloxy; alkyloxyalkyloxy; sulfo; cycloalkyl optionally substituted with carboxy, alkyl, hydroxyalkyl, carboxyalkyl, alkyloxycarbonyl, arylalkyl, alkyloxyarylmethyl, non-aromatic heterocyclyloxyalkyl, or oxo; a non-aromatic heterocyclic group optionally substituted with carboxy, alkyl, hydroxyalkyl, carboxyalkyl, alkyloxycarbonyl, arylalkyl, alkyloxyarylmethyl, non-aromatic heterocyclyloxyalkyl, or oxo; aryl optionally substituted with halogen or alkyloxycarbonyl; heteroaryl optionally substituted with carboxy, alkyloxy, alkyloxycarbonyl, or non-aromatic heterocyclyloxyalkyloxy; alkyloxycarbonyl; alkenyloxycarbonyl; alkynyloxycarbonyl; cycloalkyloxycarbonyl; cycloalkenyloxycarbonyl; non-aromatic heterocyclyloxycarbonyl; aryloxycarbonyl; heteroaryloxycarbonyl; carbamoyl optionally substituted with hydroxy, cyano, alkyl, hydroxyalkyl, haloalkyl, non-aromatic heterocyclylalkyl or a non-aromatic heterocyclic group; sulfamoyl optionally substituted with hydroxy, cyano, alkyl, hydroxyalkyl, haloalkyl, non-aromatic heterocyclylalkyl or a non-aromatic heterocyclic group; amino optionally substituted with hydroxy, alkyloxycarbonyl, alkenyloxycarbonyl, or alkynyloxycarbonyl; imino optionally substituted with hydroxy, alkyloxy, alkenyloxy, or alkynyloxy; guanidyl optionally substituted with cyanoalkyl; oxo; thioxo etc. [0113] As a substituent for "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" for RC and Rei, the followings are exemplified. halogen; hydroxy; carboxy; alkyloxy; alkyloxyalkyloxy; sulfo; cycloalkyl; a non-aromatic heterocyclic group optionally substituted with carboxy, alkyl, hydroxyalkyl, carboxyalkyl, alkyloxycarbonyl, arylalkyl, alkyloxyarylmethyl, non-aromatic heterocyclyloxyalkyl, or oxo; aryl optionally substituted with halogen, or alkyloxycarbonyl; heteroaryl optionally substituted with carboxy, alkyloxy, alkyloxycarbonyl, or non-aromatic heterocyclyloxyalkyloxy; alkyloxycarbonyl; alkenyloxycarbonyl; alkynyloxycarbonyl; cycloalkyloxycarbonyl; cycloalkenyloxycarbonyl; non-aromatic heterocyclyloxycarbonyl; aryloxycarbonyl; heteroaryloxycarbonyl; carbamoyl optionally substituted with hydroxy, cyano, alkyl, hydroxyalkyl, haloalkyl, non-aromatic heterocyclylalkyl or a non-aromatic heterocyclic group; sulfamoyl; amino optionally substituted with hydroxy, or alkyloxycarbonyl; imino optionally substituted with hydroxy, or alkyloxy; guanidyl optionally substituted with cyanoalkyl; oxo; thioxo etc. 68 [0114] As a substituent for "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" for RC and Rei, the followings are exemplified: fluoro, hydroxy, carboxy, methyloxy, methyloxymethyloxy, sulfo, methyloxycarbonyl, ethyloxycarbonyl, t-butyloxycarbonyl, tetrahydropyranylmethyloxycarbonyl, methylcarbamoyl, hydroxycarbamoyl, dihydroxyisopropylcarbamoyl, aminocarbamoyl, cyanocarbamoyl, trifluoromethylcarbamoyl, hydroxyethylcarbamoyl, tetrahydropyranylcarbamoyl, tetrahydropyranylethylcarbamoyl, sulfamoyl, hydroxyamino, methyloxycarbonylamino, t-butyloxycarbonylamino, hydroxyimino, methyloxyimino, guanidyl, cyanomethylguanidyl, cyclopropyl, carboxypyrrolidinyl, oxetanyl, oxodihydrooxadiazolyl, dimethyldioxaranyl, oxopyrrolidinyl, methyloxopyrrolidinyl, hydroxyethyloxopyrrolidinyl, carboxymethyloxopyrrolidinyl, oxodihydropyrrolidinyl, methyloxycarbonylmethyloxopyrrolidinyl, morpholinyl, piperazinyl, t-butyloxycarbonylpiperazinyl, oxo(phenylmethyl) (methyl) piperazinyl, oxo(methyloxyphenylmethyl) (methyl) piperazinyl, tetrahydropyranyloxyethyloxopiperazinyl, phenyl, chlorophenyl, ethyloxycarbonylphenyl, triazolyl, tetrazolyl, carboxyisoxazolyl, methyloxycarbonylisoxazolyl, ethyloxycarbonylisoxazolyl, oxazolyl, carboxyfuranyl, methyloxycarbonylfuryl, methyloxypyridyl, carboxypyridyl, methyloxycarbonylpyridyl, hydroxyethyloxypyridyl, ethyloxycarbonylthiazolyl, tetrahydropyranyloxyethyloxypyridinyl, oxo etc. [0115] Substituents for "substituted acyl" are selected from the substituents as defined above for "substituted alkyl", the above "alkyl", the above "alkenyl" and the above "alkynyl". If R in acyl (R-C(=O)-) is "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl", or "heteroaryl", then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.) , haloalkyl (e.g., CF 3 , CH 2
CF
3 , CH 2 CC1 3 , etc.) , alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like. [0116] Substituents for "substituted carbamoyl", "substituted thiocarbamoyl" and "substituted sulfamoyl" are one or more same or different groups selected from, but are not limited to, the group consisting of: hydroxy, carboxy, halogen (F, Cl, Br, I), alkyl (e.g., methyl, ethyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, aryl (e.g., phenyl, etc.), cyano, isocyano, isocyanato, thiocyanato, isothiocyanato and acyl (e.g., formyl, acetyl, etc.) [0117] Substituents for "substituted sulfonyl" or "substituted sulfinyl" are selected from the above "substituted or unsubstituted alkyl", the above "substituted or unsubstituted alkenyl", the above "substituted or unsubstituted alkynyl", the after-mentioned "substituted or unsubstituted cycloalkyl", the after-mentioned "substituted or unsubstituted cycloalkenyl", the after-mentioned "a substituted or unsubstituted non-aromatic heterocyclic group", the after-mentioned "substituted or unsubstituted aryl", and the after-mentioned "substituted or unsubstituted heteroaryl". If R in R-S(=0)2 or R-S(=O)- is "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl", 69 "heteroaryl" or the like, then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF 3 , CH 2
CF
3 , CH 2 CC1 3 , etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like. [0118] Substituents for "substituted amino", "substituted imino" and "substituted guanidyl" are one or more same or different groups selected from, but are not limited to, the group consisting of: alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF 3 , CH 2
CF
3 ,
CH
2 CC1 3 , etc.), hydroxyalkyl (e.g., hydroxyethyl, -C(CH 3
)
2
CH
2 OH, etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), haloalkyloxy (e.g.,
CF
3 0), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (methoxycarbonyl, tert-butyloxycarbonyl, etc.), alkyloxycarbonylalkyl, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino, etc.), aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, etc.), aryloxy (e.g., phenoxy etc.), a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidino, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), non-aromatic heterocyclyloxy (pipierazinooxy, piperidinooxy etc.), heteroaryloxy (pyridyloxy etc.), hydroxy, halogen,(F, Cl, Br, I), cyano, acyl (e.g., formyl, acetyl, etc.), alkylsulfonyl (e.g., methanesulfonyl etc.), alkylsulfinyl (e.g., methansulfinyl), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.), and sulfamoylalkyl (e.g, sulfamoylmethyl etc.) [0119] Substituents for "substituted cycloalkyl", "substituted cycloalkenyl", "substituted aryl", "substituted phenyl", "substituted heterocyclic group", "substituted heteroaryl", "a substituted non-aromatic carbocyclic group", "a substituted non-aromatic heterocyclic group", "a substituted nitrogen-containing non-aromatic heterocyclic group", "substituted cycloalkyloxycarbonyl", "substituted cycloalkyenyloxycarbonyl", "substituted non-aromatic heterocyclyloxycarbonyl", "substituted aryloxycarbonyl", "substituted heteroaryloxycarbonyl", "a substituted cyclopropane ring", "a substituted cyclopropene ring", "a substituted oxetane ring", "a substituted thietane ring" and "a substituted azetizine ring" are one or more same or different groups selected from, but are not limited to, the group consisting of: alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF 3 , CH 2
CF
3 ,
CH
2 CC1 3 , etc.), haloalkyloxy (e.g., CF 3 0, CHCF 2 0 etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, 70 tritylamino), hydroxyamino, amino substituted with one or two same or different substituent selected from the after-mentioned substituent Group Y, imino, hydroxy imino, alkylimino (e.g., methylimino, ethylimino, dimethylimino etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino etc.), acylimino (e.g., acetylimino, benzoylimino etc.), azido, aryl (e.g., phenyl etc.), arylalkyl (e.g., benzyl etc.), unsubstituted non-aromatic carbocyclyloxy (e.g., cyclopropyloxy etc.), non-aromatic carbocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted non-aromatic carbocyclylalkyloxy (e.g., cyclopropylmethyloxy etc.), non-aromatic carbocyclylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted aryloxy (e.g., phenoxy etc.), aryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted arylalkyloxy (e.g., benzyloxy etc.), arylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidino, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), unsubstituted non-aromatic heterocyclyloxy (e.g., piperazinooxy, piperizinooxy etc.), non-aromatic heterocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted heteroaryloxy (e.g., pyridyloxy etc.), heteroaryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), substituted or unsubstituted carbamoyl (e.g., carbamoyl, N-methyl -N-methoxycarbamoyl etc.), substituted or unsubstituted alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, hydroxyethylcarbamoyl, trifluoromethylcarbamoyl, trifluoroethylcarbamoyl etc.), sulfamoyl, alkylsulfamoyl, hydroxy, carboxy, halogen (F, Cl, Br, I), acyl (e.g., formyl, acetyl etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazino, azido, ureido, amidino, guanidino, phthalimido and oxo. A substituent Group Y includes hydroxy alkyl (e.g., hydroxyethyl, -C(CH 3
)
2
CH
2 OH etc.), alkyloxycarbonyl (methoxycarbonyl, tert-butyloxycarbonyl etc.), alkyloxycarbonylalkyl, alkylsulfonyl (e.g., methanesulfonyl etc.), alkylsulfinyl (e.g., methanesulfinyl etc.), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.) and sulfamoylalkyl (e.g., sulfamoylmethyl etc.). A substituent Group Z includes halogen, hydroxy, carboxy, cyano, nitro, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, acyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, carbamoyl, alkylcarbamoyl, haloalkylcarbamoyl, hydroxyalkylcarbamoyl, cyanocarbamoyl, amino, acylamino, amino substituted with one or two same or different substituent selected from the above substituent Group Y, sulfamoyl, methylsulfonyl, methylsulfinyl, cycloalkyl, cycloalkenyl, a non-aromatic heterocyclic group, aryl, heteroaryl, cycloalkyloxy, cycloalkenyloxy, non-aromatic heterocyclyloxy, aryloxy and heteroaryloxy. 71 [0120] As substituents for "substituted aryl" and "substituted heteroaryl" for R2, halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, a non-aromatic heterocyclic group, alkylsilylalkynyl and the like are exemplified. [0121] As substituents for "substituted aryl" and "substituted heteroaryl" for R2, halogen, alkyl, alkenyl, alkynyl, alkyloxy, cycloalkyl, alkylsilylalkynyl and the like are exemplified. [0122] As substituents for "substituted aryl" and "substituted heteroaryl" for R 2 , fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl, propenyl, vinyl, ethynyl, methyl oxy, cyclopropyl, trimethylsilylethynyl and the like are exemplified. [0123] As substituents for "substituted aryl" and "substituted heteroaryl" for R 3 , halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, dialkylamino, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl; alkenyl optionally substituted with cycloalkyl, cycloalkenyl or a non-aromatic heterocyclic group; alkynyl optionally substituted with cycloalkyl, cycloalkenyl or a non-aromatic heterocyclic group; unsubstituted alkyloxy; alkyloxy substituted with a non-aromatic heterocyclic group optionally substituted with halogen, alkyloxy, alkenyloxy, alkynyloxy, aryl, alkyl, alkenyl or alkynyl; alkylthio; alkenylthio; alkynylthio; cycloalkyl; cycloalkenyl; a non-aromatic heterocyclic group; alkylamino; alkenyl amino; alkynylamino and the like are exemplified. [0124] As substituents for "substituted aryl" and "substituted heteroaryl" for R3 are halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroarylalkyl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with a non-aromatic heterocyclic group optionally substituted with halogen, alkyloxy, aryl, or alkyl; alkylthio; cycloalkyl; cycloalkenyl; a non-aromatic heterocyclic group; alkylamino and the like are exemplified. [0125] As substituents for "substituted aryl" and "substituted heteroaryl" for R 3 , chloro, bromo, fluoro, hydroxy, methyl, trifluoromethyl, methyloxymethyl, cyanomethyl, difluoroethyl, methyloxyiminomethyl, isopropyl, propyl, trifluoroisopropyl, dimethylaminomethyl, butyl, isobutyl, isopropyloxymethyl, pentyl, cyclopropylethyl, cyclopentylmethyl, pyridylmethyl, methylisopropenyl, vinyl, cyclopropylvinyl, methyl propenyl, cyclopentylidenemethyl, cyclopropylethynyl, hydroxyethyl, methyloxy, difluoromethyloxy, trifluoromethyloxy, ethyloxy, propyloxy, methyloxy ethyloxy, oxetanyloxy, cyclobutyloxy, cyclopentyloxy, s-butyloxy, isobutyloxy, cyclopropylmethyloxy, tetrahydropyranyloxy, 2-methylbutyloxy, dimethylbutyloxy, pentanyloxy, pentane-3-yloxy, dimethylpyridyloxy, methyl pyridyloxy, pyridyloxy, phenyloxy, 72 methylthio, ethylthio, cyclopentyl, cyclopentenyl, cyclohexyl, piperazinyl, piperidinyl, azepanyl and the like are exemplified. [0126] Examples of "heteroaryloxy" as substituents for "substituted aryl" and "substituted heteroaryl" for R 3 include pyrrolyloxy, pyrazinyloxy, pyrazolyloxy, indolyloxy, tetrazolyloxy, furyloxy, thienyloxy, pyridyloxy, imidazolyloxy, triazolyloxy, tetrazolyloxy, triazinyloxy, pyridazinyloxy, pyrimidinyloxy, pyrazinyloxy, isooxazolyloxy, thiazolyloxy, isothiazolyloxy, thiadiazolyloxy, oxazolyloxy, oxadiazolyloxy and the like. [0127] As substituents for "substituted aryl" and "substituted heteroaryl" for R3, unsubstituted heteroaryloxyl, heteroaryloxyl substituted with one or more same or different substituents selected from the above Substituent Group Z and the like are exemplified. Further, halogen, hydroxy, carboxy, cyano, nitro, alkyl, haloalkyl, haloalkyloxy, alkyloxy, amino and the like are exemplified. The above heteroaryloxyl includes the following groups which are unsubstituted or substituted with one or more same or different substituents selected from the above Substituent Group Z: pyrrolyloxy, pyrazinyloxy, pyrazolyloxy, indolyloxy, tetrazolyloxy, furyloxy, thienyloxy, pyridyloxy, imidazolyloxy, triazolyloxy, tetrazolyloxy, triazinyloxy, pyridazinyloxy, pyrimidinyloxy, pyrazinyloxy, isooxazolyloxy, thiazolyloxy, isothiazolyloxy, thiadiazolyloxy, oxazolyloxy, and oxadiazolyloxy and the like. [0128] As substituents for "substituted heteroaryl" for R3, halogen; alkyl; alkenyl; alkynyl; alkyloxy; alkenyloxy; alkynyloxy; cycloalkyloxy, cycloalkenyloxy; aryloxyl; heteroaryloxyl and the like are exemplified. [0129] As substituents for "substituted heteroaryl" for R3, halogen; alkyl; alkyloxy; cycloalkyloxy and the like are exemplified. [0130] As substituents for "substituted non-aromatic heterocyclic group" for R 3 , arylalkyl, heteroarylalkyl, aryl, heteroaryl and the like are exemplified. [0131] As substituents for "substituted non-aromatic heterocyclic group" for R3, arylalkyl, aryl and the like are exemplified. [0132] As substituents for "substituted non-aromatic heterocyclic group" for R 3 , phenylmethyl, phenyl and the like are exemplified. [0133] As substituents for "substituted amino" for R9', carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.) and the like are exemplified. [0134] Examples of "substituted or unsubstituted alkyl" for R 30 and R 3 1 are methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl and the like. [0135] Examples of R9' are halogen, hydroxy, carboxy, cyano, nitro, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, acyl, alkyloxycarbonyl, alkenyloxycarbonyl, 73 alkynyloxycarbonyl, carbamoyl, alkylcarbamoyl, haloalkylcarbamoyl, hydroxyalkylcarbamoyl, cyanocarbamoyl, amino, acylamino, amino substituted with one or two same or different substituents selected from the above Substituent Group Y, sulfamoyl, methylsulfonyl, methylsulfinyl and the like. [0136] In general formula (VIII), general formula (IX), general formula (VII), general formula (IV), general formula (I), general formula (II) or general formula (III), "R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo" includes the followings: [Chemical Formula 49]
(CR
4 aR 4 b)n o R 4 a R 4 b OR 4 a R 4 b 2
R
4 a 4 R4a R4a R4a R2 R4a
R
4
R
4 b R4
R
4 b R4b bR2
R
4
R
4 b R Rb 4 a
RR
4 b R4b R RRa R R 4 4 4 R '- R 2 bR R 4R4 Ra 4 Ra
R
4 ~ ~bR 4~ a 4 b R 4 b R 4 b R 4 b R 4 b 4b R4
R
4 ~R 4 ~ 4a RR 4 a
R
4 R 4 b4b Rb2
R
4
R
4 b S wherein n, R4a, R4b and R2 are as defined in the above (1) and the like. [0137] 74 In general formula (VIII), the positions of carbon atom a, Qa atom, Qb atom, carbon atom b, Qc atom and Qd atom which constitute a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring as ring D is defined as 1-position, 2-position, 3-position, 4-position, 5-position and 6-position, respectively. Each of the position numbers of these atoms is different from position number based on IUPAC nomenclature. That is, "carbon atom a is positioned on ring D in a 1,4 relationship with respect to carbon atom b" includes the followings: [Chemical Formula 50] 2 (R 9 )s (R 9 ')s ' Lb a I D 1 4 Q C 6 Qo b x 5 wherein Qa atom, Qb atom, Qe atom and Qd atom are each independently a carbon atom or a nitrogen atom, -X-, -L-, ring D, ring B, s, s', R 9 and R 9 ' are as defined in the above (1). [0138] In general formula (VIII), the positions of carbon atom a, Qa atom, Qb atom, carbon atom b, Qe atom and Qd atom which constitute a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring as ring D is defined as 1-position, 2-position, 3-position, 4-position, 5-position and 6-position, respectively. Each of the position numbers of these atoms is different from position number based on IUPAC nomenclature. That is, "carbon atom a is positioned on ring D in a 1,3 relationship with respect to carbon atom b" includes the followings: [Chemical Formula 51]
(R
9 )s (R9') s',, L 3X/ Lj 2 1 1a D I Qd Qb 4 6 0 0 c 5 wherein Qa atom, Qb atom, Qe atom and Qd atom are each independently a carbon atom or a nitrogen atom, -X-, -L-, ring D, ring B, s, s', R9 and R9' are as defined in the above (1). [0139] In general formula (IX), the positions of carbon atom a, Qa atom, Qb atom, carbon atom b, Qe atom and Qd atom which constitute a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring as ring D is defined as 1-position, 2-position, 3-position, 4-position, 5-position and 6-position, respectively. Each of the position numbers of these atoms is different from position number based on IUPAC nomenclature. That is, "carbon atom a is positioned on ring D in a 1,4 relationship with respect to carbon atom b" includes the followings: 75 [Chemical Formula 52]
(R
9 ')s' 2 (R )s E _ C b
R
13 a R13b D 14 R-. R ~ Q 6 Q b x 5 wherein Qa atom, Qb atom, Qc atom and Qd atom are each independently a carbon atom or a nitrogen atom, -X-, -L-, ring D, Ri3a, Ri3b, ring E, s, s', R9 and R9' are as defined in the above (8). [0140] In general formula (IX), each of the position of carbon atom a, Qa atom, Qb atom, carbon atom b, Qc atom and Qd atom which constitute a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring as ring D is defined as 1-position, 2-position, 3-position, 4-position, 5-position and 6-position, respectively. Each of the position numbers of these atoms is different from position number based on IUPAC nomenclature. That is, "carbon atom a is positioned on ring D in a 1,3 relationship with respect to carbon atom b" includes the following: [Chemical Formula 53]
(R
9 ')s' (R 9 )s E2 O C Ob3 lai D X
R
1 3a R1 3 b Qd Qb 6 %QC 4 5 wherein Qa atom, Qb atom, Qc atom and Qd atom are each independently a carbon atom or a nitrogen atom, -X-, -L-, ring D, Ri3a, Ri3b, ring E, s, s', R9 and R9' are as defined in the above (8). [0141] In general formula (VIII), general formula (IX), and general formula (VII), "R11a and R11b together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non-aromatic heterocyclic ring" includes the following: 76 [Chemical Formula 54] _, (CR11aR 11b ) OH is R11a R11a V R11b V R11b OH OH OH R11a R11b R11a R11b R11b R11' R11a 5 R a R11a R11a R11a R11b R11a R R11b R11b R11b OH OHH R11b R11a R11b R11b R11a RO OH 11O1bR H R1a R11b R11b O OH OH~ H
R
11 a R1b R11a R11 V R11b , R11a R11a W W R11b W R11b OH OH OH R?11 aR 1Ob R11 11b R11a R11bR1b R11a, R11a R11a R OH R a R R11b 1a R 11 b R b R)H WW '- W ' R11a
R
1 1 b R11b R11b wherein m, R1a and R11b are as defined in the above (21); v is an integer of 0 to 3 (e.g., 0 or 1, and e.g.,0) -W- is -0-, -S- or -N(R17)- (e.g., -0-); R1 7 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl 77 and the like. [0142] In general formula (VIII), general formula (IX), and general formula (VII), "R14a and R14b together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non-aromatic heterocyclic ring" includes the followings: [Chemical Formula 55] _ _,(CR1 4 aRl 4 b)ti N(R15a)(R15b) is R14a R14a Va R1 4 b Va R1 4 b ,,k ~ < V FR1b Va N(R15a)(R15b) N(R15a)(R15b) N(15a)(15b) "
R
14 a R1 4 b
R
14 a R1 4 b
R
1 4 a R1 4 b R1 4 b ' R14a R14a R14a
R
14 a R1 4 b R 14 a R1 4 b R1 4 b R 14 a R1 4 b R1 4 b N(R1 5 a)(R1 5 b) N(R 1 5a)(R 1 5b) N(R15a)(R5b) (R )(R1R14b Va Va Va R14a R1 4 b R1 4 b R14a R'R14a 15b 14a R14b R14b N(Rl 5 a)(R)
R
1 R ~N(R15a)(R15b) N(R1 5 a)(R1 5 b) R 14 a R1 4 b R1 4 b
R
14 a R1 4 b R4 Ra14a R1 4 b R14a R14a Wa Wa R14b Wa R1 4 b rN(R15a)(R15b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) z N
R
14 a R 4 b
R
14 a R1 4 b
R
14 a R1 4 b R1 4 b ' R14a R14a R14a
R
14 a R1 4 b R 14 a R14 R1 4 b R 14 a R1 4 b R1 4 b N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) Wa Wa Wa R R14a R14b R14b WaR14a R1 4a(RlR 5 a)(Rl 5 b) R 14 a R1 4 b R1 4 b R(la(lb N(R N(RR15a)(R15b) 14aR14b R14b N(R1 5 a)(R1 5 b)
R
14 a R1 4 b R 1 Wa R1 4 b 78 wherein t, R14a and R14b are as defined in the above (24); va is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 0) -Wa- is -0-, -S- or -N(Rl7a) -(e.g., -0-) ; R17a is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl and the like. [0143] In general formula (VIII), general formula (IX), and general formula (VII), "R14a' and R14b' together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non-aromatic heterocyclic ring" includes the followings: [Chemical Formula 56] (CR14a'R 1 4b')t iP b C(=0)N(R15a')(R15b) is C(=0)N(R15a')(R15b') R14a' R1 4a' 14b' b 14b' N(R15a')(R15b') b Vb R1 4 b' Vb R / C(=0) C(=0)N(R15a)(R15 C(=0)N(R15'(15b)
R
14 a' R1 4 b
R
14 a' R1 4 b'
R
14 a' R1 4 b' R1 4 b 'R14a' R1 4a' R14 R14b' (=O)N(R 5 a')(R 5 ) R 14 a' R1 4 b' R1 4 b' C(=O)N(R1 5 a')(R1 5 b) Vb Vb R14bV R14b' R14a Vb R & b C(=0)N(R15a')(R15b) C(=0)N(R15a')(R15 R 14 ' R1 4 b' R1 4 b'
R
14 a' R1 4 b' R14a' R1 4a' R14a' 414b
R
14 a' R1 4 b' R1 4 b' R 14 a' R1 4 b' R1 4 b' C(=O)N(R1 5 a')(R1 5 b) C(=O)N(R 1 5a')(R15b) 1z >14b ' R 14a' Vb , Vb R14a' R14 [0144] 79 [Chemical Formula 57] Wb Wb C(=0)N(R15a')(R15b) C(=0)N(R1 5 a')(R1 5 b) 14bR
R
14 a R1 4 b R14a' R14a' Wb R14b, Wb R1 4 b CC(=0)N(R15a')(R15b') C(=0)N(R1 5 a')(R1 5 b)CON(laRlb
R
14 a' R1 4 b'
R
14 R1 4 b' R 4 b R1 4a' R14a'
R
14 a' R1 4 b' R 14 a' R1 4 b' R1 4 b' C(=0)N(R15a')(R15b'') C(=ON(Rla)(R~b)C(=0)N(R1 5 a')(R1 5 b) Wb Wb R1 4 b' R1 4 b' I Wb 14' Wb R4 a', R14a C(=O)N(R1 5 a')(R1 5 b') C(=0)N(R1 5 a')(R1 5 b) R 14 a R1 4 b R1 4 b
R
14 a' R1 4 b' R 14a' R14a' R14a'
R
14 a R1 4 b' R1 4 b'
R
14 a' R1 4 b' R1 4 b' C(=0)N(R1 5 a')(R1 5 b') C(=0)N(R1 5 a')(R1 5 b') R14b' , 14a' W , Wb Wb14a R14b wherein t, R14a and R14b are as defined in the above (24); va is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 0); -Wa- is -0-, -S- or -N(Rl7a) -(e.g., -0-); R17a is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl and the like. [0145] One embodiment of the compound of the present invention or the composition of the present invention is mentioned below. The following (II"-A) to (II"-C) are embodiments of a pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the formula (II"): 80 [Chemical Formula 58] 0 N NRc1 R3 N N O I I
R
5
CR
4 aR 4 b
R
2 or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (II"-A) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound wherein Re is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A;
R
2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C; R3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxyl; heteroaryloxyl optionally substituted with alkyl; a non-aromatic heterocyclic group; and alkylamino), heteroaryl optionally substituted with one or more substituents selected from Substituent Group D;
R
4 a and R4b are both hydrogen; R5 is hydrogen, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0146] (II"-B) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound wherein Re is a group of the formula: 81 [Chemical Formula 59] Rc3 Rc4 tRc2 wherein t is an integer of 1 to 4; Rc2 is halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxylcarbonyl, substituted or unsubstituted heteroaryloxylcarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxylcarbonyl, substituted or unsubstituted heteroaryloxylcarbonyl, or nitro; Rc3 and Rc4 are each independently hydrogen, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or (i) Rc3 and Rc4 are taken together to form oxo or thioxo, or, (ii) Rc3 and Rc4 attached to the same carbon atom, are taken together to form -(CRc5RG) x-; Rc5 and Rce are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
R
2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C; x is an integer of 1 to 4; R3 is aryl optionally substituted with one or more substituents selected from Substituent Group D, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D;
R
4 a and R4b are both hydrogen; R5 is hydrogen, its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0147] (II"-C) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the above (II"-A) wherein Rei is alkyl substituted with one or more substituents selected from Substituent Group E (Substituent Group E: sulfo; substituted or unsubstituted sulfamoyl; substituted or unsubstituted imino; substituted or unsubstituted guanidyl; a substituted or unsubstituted non-aromatic 82 heterocyclic group(provided that the heterocyclic group is morpholino, imidazolidine, tetrahydropyranyl and piperizino) and substituted or unsubstituted heteroaryl (provided that the heteroaryl is pyridino)), alkenyl optionally substituted with one or more substituents selected from Substituent Group E, or alkynyl substituted with one or more substituents selected from Substituent Group E, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0148] One embodiment of the compound of the present invention or the composition of the present invention is mentioned below. The following (III"-A) to (III"-C) are embodiments of a pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound of the formula (III"): [Chemical Formula 60] Ra1 N N R<NXN (III') 'I|
R
5
CR
4 aR 4 b R2 or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient . [0149] (III'-A) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound wherein Ral is alkyl substituted with one or more substituents selected from Substituent Group A(Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxy carbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group A, alkynyl substituted with one or more substituents selected from Substituent Group A, alkyloxy substituted with one or more substituents selected from Substituent Group A, alkenyloxy substituted with one or more substituents selected from Substituent Group A, alkynyloxy substituted with one or more substituents selected from Substituent Group A, alkylthio substituted with one or more substituents selected from Substituent Group A, alkenylthio substituted with one or more substituents selected from Substituent Group A, alkynylthio substituted with one or more substituents selected from Substituent Group A, alkylamino substituted with one or more substituents selected from Substituent Group A, alkenylamino substituted with one or more substituents selected from Substituent Group A or alknynylamino substituted with one or more substituents selected from Substituent Group A,
R
2 is aryl optionally substituted with one or more substituents selected from Substituent 83 Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl) or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C; R3 is aryl optionally substituted with one or more substituents selected from Substituent Group D(Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxyl; heteroaryloxyl optionally substituted with alkyl; a non-aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D;
R
4 a and R4b are both hydrogen; R5 is hydrogen, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. (III'-B) A pharmaceutical composition having an analgesic effect and/or an improving effect on a urination disorder comprising the compound wherein Ral is [Chemical Formula 61] Ro3 Rc4 YX t c2 wherein -Y- is -0-, -S- or -NRY-; RY is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted acyl; and other symbols are as defined in the above II'-B; Rc5 and Rc6 are each independently, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
R
2 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; x is an integer of 1 to 4;
R
3 is aryl optionally substituted with one or more substituents selected from Substituent Group D, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D;
R
4 a and R4b are both hydrogen;
R
5 is hydrogen, or its pharmaceutically acceptable salt or a solvate thereof as an active ingredient. [0150] One embodiment of the compound of the present invention is mentioned below. A compound of the formula (VII'): [Chemical Formula 62] 0
(R
9 )s_ 3a' (RNsN N O 1 (VII') I I
R
5 CRaRb
R
2 wherein 84 Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group A, unsubstituted alkynyl or alkynyl substituted with one or more substituents selected from Substituent Group A; R4a and R4b are both hydrogen;
R
2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyl oxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C;
R
5 is hydrogen; R9 is halogen, hydroxy, carboxy, cyano, alkyloxy, unsubstituted alkyl, alkyl optionally substituted with one or more substituents selected from Substituent Group F (Substituent Group F: halogen, hydroxy, carboxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, and heteroaryl), unsubstituted alkenyl, alkenyl optionally substituted with one or more substituents selected from Substituent Group F, unsubstituted alkynyl, or alkynyl optionally substituted with one or more substituents selected from Substituent Group F; and s is an integer of o to 2, its pharmaceutically acceptable salt or a solvate thereof. [0151] One embodiment of the compound of the present invention is mentioned below. A compound of the formula (VIII'): [Chemical Formula 63]
(R
9 )s 0 (R9')s' O N Rc1 (VIII')
R
5
CR
4 aR 4 b
R
2 wherein Re is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted 85 alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group A, unsubstituted alkynyl or alkynyl substituted with one or more substituents selected from Substituent Group A; R4a and R4b are both hydrogen; R2 is aryl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C; R5 is hydrogen;
R
9 is halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; s is an integer of 0 to 2; ring B is thiazole, isothiazole, oxazole, isoxazole, pyrazole, imidazole, triazole, furan, thiophen, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, pyridazine, triazine or benzoxazole; R9' is halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxy carbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; s' is an integer of 0 to 2; or its pharmaceutically acceptable salt or a solvate thereof. [0152] The following embodiments are examples of the compound (VIII) of the present invention. A compound of the formula (VIII-a): 86 [Chemical Formula 64] 0
(R
9 ')s' AO Rc BC N N O (Vlll-a) b H F (R31)n"; wherein RC is selected from the following (al) to (a32): [Chemical Formula 65] OH OH ( - OH OH (al) (a2) , (a3) (a4) OOH H OH OH 0 (a5) (a6) (a7) (a8) %-" OH OH -- O k -' H OH HOH OH OH OHI O (a9) (a0) ' (al1) ' (a12) OH OH OOH OH OH (a13) (a14) [0153] 87 [Chemical Formula 66] N(R15a)(R15b) N(R1 5 a)(R1 5 b) N(R15a)(R15b) (a15) (a16) (a17) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) (al 8) (al 9) (a20) N(R1 5 a)(R1 5 b) N(R15a)(R15b) N(R15a)(R5b) (a21) (a22) (a23) 0 0 N(R1 5 a')(R 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b') 0 (a24) (a25) (a26) 0 N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b 0 0 (a27) (a28) (a29) 0 N(R1 5 a)(R1 5 b) (a30) wherein R15a, R15b, R15a' and R15b' are each independently selected from the following (bi) and (b2): (bl) a hydrogen atom, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl, and (b2) a hydrogen atom, methyl, ethyl, acetyl or trifluoroacetyl, (a31) ethyl; and (a32) methyl; ring F is selected from the following (c1) to (c3) (c1) a benzene ring; (c2) a pyridine ring; and (c3) a cyclohexane ring;
R
30 is selected from the following (di) and (d2): (d1) halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl; and (d2) fluoro, chloro, methyl, monofluoromethyl, difluoromethyl, trifluoromethyl or ethyl;
R
3 1 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or 88 substituted or unsubstituted alkynyl; [0154] n" is 0 or 1; ring D is selected from the following (el) and (e2): (el) a benzene ring; and (e2) a pyridine ring; relationship of carbon atom a and carbon atom b on the ring D are selected from the following (fi) and (f2): (fl) 1,4 relationship; and (f2) 1,3 relationship; ring B is selected from the following (gi) to (g12): (g1) a thiazole ring; (g2) an isothiazole ring; (g3) an oxazole ring; (g4) an isoxazole ring; (g5) a thiadiazole ring; (g6) an oxadiazole ring; (g7) a pyridine ring; (g8) a pyrimidine ring; (g9) a pyrazine ring; (g1O) a pyridazine ring; (gil) a triazine ring; and (g12) a pyrazole ring; s' is selected from the following (hi) and (h2): (hi) 0; and (h2) 1; when s' is 1, then R 9 ' is selected from the following (ii) to (i14): (ii) hydroxy; (i2) carboxy; (i3) cyano; (i4) alkyl substituted with hydroxy, carboxy, cyano, carbamoyl, amino, sulfamoyl, methanesulfonyl or methanesulfinyl; (i5) substituted or unsubstituted carbamoyl; (i6) alkylcarbamoyl or alkenylcarbamoyl; (i7) substituted or unsubstituted amino; (i8) amino substituted with carbamoyl, alkylcarbamoyl, alkylcarbamoylalkyl, carbamoylalkyl or carboxyalkyl; (i9) substituted or unsubstituted sulfamoyl; (10) alkylsulfamoyl or alkenylsulfamoyl; (ill) substituted sulfonyl; (ii2) substituted sulfinyl; (ii3) unsubstituted alkyl, or alkyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; and (ii4) unsubstituted alkyl. 89 [0155] The compound of the formula (VIII-a) of the present invention includes the compounds comprising the combination of some or all of options of the above (al) to (a32), (bi) and (b2), (ci) to (c3), (di) and (d2), (el) and (e2), (fl) and (f2), (gi) to (g12), (hi) and (h2), and (i1) to (i14). [0156] The following embodiments are examples of the compound (VIII) of the present invention. A compound of the formula (VIII-b): [Chemical Formula 67] 0
(R
9 ')s' 0 N N'Re B D IIN N i O (VIII-b) b H F
(R
31 )n" R3o wherein Re is a group selected from the following (bal) to (ba16): (bal) a group of the formula: -(CR11aR11b)m-OH wherein R11a and R11b are each independently, a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R11a and R11b together with the carbon atom to which they are attached form a substituted or unsubstituted cyclopropane ring, a substituted or unsubstituted cyclopropene ring, a substituted or unsubstituted oxetane ring, a substituted or unsubstituted thietane ring, or a substituted or unsubstituted azetizine ring; m is an integer of 2 to 4; (ba2) a group of the formula: -(CR11aR11b)m-OH] wherein R11a is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R11b is a group of the formula: -(CR12aR12b)u-OH wherein R12a and R12b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; u is an integer of 0 to 2; m is an integer of 2 to 4; [0157] (ba3) a group of the formula: 90 [Chemical Formula 68] OHOH -OH H OH (al) (a2) , (a3) , (a4) OH OH OH ,OH 0 (a5) (a6) (a7) (a8) OH OH OH OH OH OH( (a9) (alO0) ' (all1) ' (al12) OH OH OH OH or OH (a13) (a14) [0158] (ba4) a group of the formula: [Chemical Formula 69] OH OH (a3) , (a4) OH OH OH 0 (a5) (a6) (a7) OH LOH OH H OOH or OH (a9) (al1) (a12) [0159] (ba5) a group of the formula: [Chemical Formula 70] OH OH OH OH OH or OH (a9) (al1) (al2) (ba6) a group of the formula: -(CR14aR14b)t-N(R15a)(R15b) wherein R14a and R14b are each independently hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R14a and R14b together with the carbon atom to which they are attached form a substituted or unsubstituted cyclopropane ring, a substituted or unsubstituted cyclopropene ring, a 91 substituted or unsubstituted oxetane ring, a substituted or unsubstituted thietane ring, or a substituted or unsubstituted azetizine ring; t is an integer of 2 to 4; R15a and R15b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl; [0160] (ba7) a group of the formula: [Chemical Formula 71] L N(R15a)(R15b N(R15a)(R15b N(R15a)(R15b) (a15) (a16) (a17) N(R 5 a )(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) (a18) (a19) (a20) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) or N(R1 5 a)(R1 5 b) (a21) (a22) (a23) wherein R15a and R15b are as defined in the above (ba6); [0161] (ba8) a group of the formula: [Chemical Formula 72] lz- N(R1 5a)(R15b) '7-N(R 15a) (R 15b) (a15) (a16) N(R 5 a )(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) (a18) (a19) (a20) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) (a21) (a23) wherein Rl5a and R15b are as defined in the above (ba6); (ba9) a group of the formula: -(CR14a'R14b')t'-C(=O) N(R15a') (R15b') wherein R14a' and R14b' are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R14a' and R14b' together with the carbon atom to which they are attached form a substituted or unsubstituted cyclopropane ring, a substituted or unsubstituted cyclopropene ring, a substituted or unsubstituted oxetane ring, a substituted or unsubstituted thietane ring, or a substituted or unsubstituted azetizine ring; t' is an integer of 1 to 4; Rl5a' and R15b' are each independently a hydrogen atom, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or 92 unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl; [0162] (ba10) a group of the formula: [Chemical Formula 73] 0 0 N(R1 5 a')(R1 5 b N(R1 5 a')(R1 5 b) N(R1 5 a')(R1 5 b') 0 (a24) (a25) (a26) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b % 0 0 (a27) (a28) (a29) 0 or N(R1 5 a)(R1 5 b) (a30) wherein R15a' and R15b' are as defined in the above (ba9); [0163] (ball) a group of the formula: [Chemical Formula 74] N(R1 5 a')(R1 5 b N(R1 5 a')(R 5 b) N(R1 5 a')(R1 5 b') (a24) (a25) (a26) 0 N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b) N(R 5 a')(R 5 b) or %O (a27) (a28) (a29) wherein R15a' and R15b' are as defined in the above (ba9); [0164] (ba12) a group of the formula: [Chemical Formula 75] 0 N(R1 5 a)(R1 5 b) N(Rl 5 a')(R1 5 b) ( (a24) or (a28) wherein R15a' and R15b' are as defined in the above (ba9); (ba13) unsubstituted alkyl; or alkyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; (bal4) unsubstituted alkyl; (bal5) methyl; ethyl; methyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or ethyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; and (ba16) methyl or ethyl; 93 ring F is a group selected from the following (bc1) and (bc2): (bcl) a benzene ring, a pyridine ring or a cyclohexane ring; and (bc2) a benzene ring;
R
30 is a group selected from the following (bdi) and (bd2): (bdi) halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl; and (bd2) fluoro, chloro, methyl, monofluoromethyl, difluoromethyl, trifluoromethyl or ethyl;
R
3 1 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl; n" is 0 or 1; [0165] ring D a group selected from the following (bel) to (be4): (bel) a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; (be2) a benzene ring or a pyridine ring; (be3) a benzene ring; and (be4) a pyridine ring; relationship of carbon atom a and carbon atom b on ring D is selected from the following (bfi) to (bf3): (bfi) 1, 4 relationship or 1, 3 relationship; (bf2) 1, 4 relationship; and (bf3) 1, 3 relationship; ring B is a group selected from the following (bg1) to (bg9): (bg1) an aromatic heterocyclic ring; (bg2) a five- or six-membered aromatic heterocyclic ring; (bg3) a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a thiadiazole ring, an oxadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a triazine ring, or a pyrazole ring; (bg4) a thiazole ring, an isoxazole ring, a thiadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; (bg5) a six-membered aromatic heterocyclic ring; (bg6) a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring or a triazine ring; (bg7) a five-membered aromatic heterocyclic ring; (bg8) a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a thiadiazole ring, an oxadiazole ring or a pyrazole ring; and (bg9) a thiazole ring, an isoxazole ring or a thiadiazole ring; s' is a group selected from the following (bhi) to (bh3): (bhi) 0 or 1; (bh2) 0; and (bh3) 1; when s' is 1, then R 9 ' is a group selected from the following (bil) to (bi7): (bil) hydroxy; carboxy; cyano; alkyl substituted with hydroxy, carboxy, cyano, carbamoyl, 94 amino, sulfamoyl, methanesulfonyl or methanesulfinyl; substituted or unsubstituted carbamoyl; substituted or unsubstituted amino; substituted or unsubstituted sulfamoyl; substituted sulfonyl; or substituted sulfinyl; (bi2) hydroxy; carboxy; cyano; alkyl substituted with hydroxy, carboxy, cyano, carbamoyl, amino, sulfamoyl, methanesulfonyl or methansulfinyl; carbamoyl; alkylcarbamoyl; amino substituted with alkyl, haloalkyl, hydroxy alkyl, alkyloxy, haloalkyloxy, carbamoyl, alkylcarbamoyl, alkylcarbamoylalkyl, carbamoylalkyl or carboxyalkyl; sulfamoyl; alkylsulfamoyl; alkylsulfonyl; or alkylsulfinyl; (bi3) carboxy; carbamoyl; alkylcarbamoyl; sulfamoyl; alkylsulfamoyl or alkylsulfonyl; (bi4) alkyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or unsubstituted alkyl; (bi5) unsubstituted alkyl; (bi6) methyl; ethyl; methyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or ethyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; and (bi7) methyl or ethyl, or its pharmaceutically acceptable salt or a solvate thereof. The compound of the formula (VIII-b) of the present invention includes the compounds comprising the combination of some or all of options of the above (bal) to (ba16), (bc1) and (bc2), (bd1) and (bd2), (bel) to (be4), (bfl) to (bf3), (bgl) to (bg9), (bhl) to (bh3) and (bil) to (bi7). [0166] The following embodiments are examples of the compound (IX) of the present invention. A compound of the formula (IX-a) [Chemical Formula 76] (R 9 ')s' R ED" N N C'N ',N O (IX-a) b H F (R31)n"R wherein Rc is a group selected from the following (cal) to (ca5): (cal) a group of the formula: -(CR11aR11b)m-OH wherein R11a and R11b are each independently, a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R11a and R11b together with the carbon atom to which they are attached form a substituted or unsubstituted cyclopropane ring, a substituted or unsubstituted cyclopropene ring, a substituted or unsubstituted oxetane ring, a substituted or unsubstituted thietane ring, or a substituted or unsubstituted azetizine ring; m is an integer or 2 to 4; (ca2) Rc is a group of the formula: -(CR11aR11b)m-OH 95 wherein R11a is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R11b is a group of the formula; -(CR12aR12b)u-OH; wherein R12a and R12b are each independently, hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; u is an integer of 0 to 2; m is an integer of 2 to 4; [0167] (ca3) a group of the formula: [Chemical Formula 77] OH OH LO 'OH OH (al) (a2) , (a3) , (a4) OOH H OH OH 0 (a5) (a6) (a7) (a8) OH OH OH OH OH OH "I OH OH1- OHH OH (a9) (al0) ' (al1) ' (a12) OH OH OHOH or OH (a13) (a14) [0168] (ca4) a group of the formula: [Chemical Formula 78] I -- OH OH (a3) (a4) OH OH OH 0 (a5) (a6) (a7) OH OH OH OH OH or OH (a9) (al1) (a12) and [0169] (ca5) a group of the formula: 96 [Chemical Formula 79] OH' OH OH OH OH OH or (a9) (al1) (a12) ring F is a group selected from the following (cc1) and (cc2): (cc1) a benzene ring, a pyridine ring or a cyclohexane ring; and (cc2) a benzene ring; R30 is a group selected from the following (cd1) and (cd2): (cd1) halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl; and (cd2) fluoro, chloro, methyl, monofluoromethyl, difluoromethyl, trifluoromethyl or ethyl; R31 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl; [0170] n" is 0 or 1; ring D is a group selected from the following (cel) to (ce4): (cel) a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; (ce2) a benzene ring or a pyridine ring; (ce3) a benzene ring; and (ce4) a pyridine ring; relationship of carbon atom a and carbon atom b on ring D is selected from the following (cf1) to (cf3): (cfl) 1,4 relationship, or 1,3 relationship; (cf2) 1,4 relationship; and (cf3) 1,3 relationship; ring E is a group selected from the following (cgl) to (cg3): (cgl) a cycloalkane ring or a cycloalkene ring; (cg2) a cycloalkane ring; and (cg3) a cyclopropane ring; s' is (chl) 0 or 1; (ch2) 0; and (ch3) 1; when s' is 1, then R 9 ' is a group selected from the following (cil) to (ci4): (cil) alkyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or unsubstituted alkyl; (ci2) unsubstituted alkyl; (ci3) methyl; ethyl; methyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or ethyl substituted with halogen, haloalkyloxy, 97 cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; and (ci4) methyl or ethyl, or its pharmaceutically acceptable salt or a solvate thereof. The compound of the formula (VIII-b) of the present invention includes the compounds comprising the combination of some or all of options of the above (cal) to (ca5), (cci) and (cc2), (cdi) and (cd2), (cel) to (ce4), (cf1) to (cf3), (cg1) to (cg3), (chl) to (ch3) and (cil) to (ci4). [0171] The following embodiments are examples of the compound (VIII) of the present invention. A compound of the formula (VIII-c): [Chemical Formula 80] 0
(R
9 )s' 0 N'NRc (R ') ' N R c (VIII-c) H Hal wherein Hal is halogen; Re is (dal) a group of the formula: [Chemical Formula 81] OH OH LO 'OH OH (al) (a2) , (a3) , (a4) OH OH OH -OH 0 (a5) (a6) (a7) (a8) OH OH OH OH (a9) , (a10) ,(a11) (a12) , OH OH OH orOH OOH OH (a13) (a14) (da2) a group of the formula: 98 [Chemical Formula 82] OH OH (a3) (a4) OH OH OH 0 (a5) (a6) (a7) OH' tOH tA4OH OH OH or OH (a9) (al1) (a12) or (da3) a group of the formula [Chemical Formula 83] OH%.OH OH OH OH or OH (a9) (al1) (a12) [0172] ring B is: (dg1) an aromatic heterocyclic ring; (dg2) a five-or six-membered aromatic heterocyclic ring; (dg3) a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a thiadiazole ring, an oxadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a triazine ring, or a pyrazole ring; (dg4) a thiazole ring, an isoxazole ring, a thiadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; (dg5) a six-membered aromatic heterocyclic ring; (dg6) a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring or a triazine ring; (dg7) a five-membered aromatic heterocyclic ring; (dg8) a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a thiadiazole ring, an oxadiazole ring, or a pyrazole ring; or (dg9) a thiazole ring, an isoxazole ring or a thiadiazole ring; a group of the formula (R9)s'- is: (dj1) s' is 0; (dj2) s' is 1, and R 9 ' is hydroxy; carboxy; cyano; alkyl substituted with hydroxy, carboxy, cyano, carbamoyl, amino, sulfamoyl, methansulfonyl or methansulfinyl; substituted or unsubstituted carbamoyl; substituted or unsubstituted amino; substituted or unsubstituted sulfamoyl; substituted sulfonyl; or substituted sulfinyl; (dj3) s' is 1, and R 9 ' is hydroxy; carboxy; cyano; alkyl substituted with hydroxy, carboxy, cyano, carbamoyl, amino, sulfamoyl, methansulfonyl or methansulfinyl; carbamoyl; alkylcarbamoyl; amino substituted with alkyl, haloalkyl, hydroxyalkyl, alkyloxy, 99 haloalkyloxy, carbamoyl, alkylcarbamoyl, alkylcarbamoylalkyl, carbamoylalkyl or carboxyalkyl; sulfamoyl; alkylsulfamoyl; alkylsulfonyl; or alkylsulfinyl; (dj4) s' is 1, and R 9 ' is carboxy; carbamoyl; alkylcarbamoyl; sulfamoyl; alkylsulfamoyl or alkylsulfonyl; (dj5) s' is 1, and R 9 ' is alkyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or unsubstituted alkyl; (bj6) s' is 1, and R 9 ' is unsubstituted alkyl; (dj7) s' is 1, and R9' is methyl; ethyl; methyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or ethyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; and (dj8) s' is 1, and R 9 ' is methyl or ethyl, or its pharmaceutically acceptable salt or a solvate thereof. [0173] The compound of the formula (VIII-c) of the present invention includes the compounds comprising the combination of some or all of options of the above. Specifically, the following combinations are included, (dal, dg3, di3), (dal, dg3, di4), (dal, dg3, di5), (dal, dg3, di6), (dal, dg3, di7), (dal, dg3, di8), (dal, dg4, dii), (dal, dg4, di2), (dal, dg4, di3), (dal, dg4, di4), (dal, dg4, di5), (dal, dg4, di6), (dal, dg4, di7), (dal, dg4, di8), (dal, dg5, dil), (dal, dg5, di2), (dal, dg5, di3), (dal, dg5, di4), (dal, dg5, di5), (dal, dg5, di6), (dal, dg5, di7), (dal, dg5, di8), (dal, dg6, dii), (dal, dg6, di2), (dal, dg6, di3), (dal, dg6, di4), (dal, dg6, di5), (dal, dg6, di6), (dal, dg6, di7), (dal, dg6, di8), (dal, dg7, dil), (dal, dg7, di2), (dal, dg7, di3), (dal, dg7, di4), (dal, dg7, di5), (dal, dg7, di6), (dal, dg7, di7), (dal, dg7, di8), (dal, dg8, dii), (dal, dg8, di2), (dal, dg8, di3), (dal, dg8, di4), (dal, dg8, di5), (dal, dg8, di6), (dal, dg8, di7), (dal, dg8, di8), (dal, dg9, dil), (dal, dg9, di2), (dal, dg9, di3), (dal, dg9, di4), (dal, dg9, di5), (dal, dg9, di6), (dal, dg9, di7), (dal, dg9, di8), (da2, dgl, dii), (da2, dgl, di2), (da2, dgl, di3), (da2, dgl, di4), (da2, dgl, di5), (da2, dgl, di6), (da2, dgl, di7), (da2, dg1, di8), (da2, dg2, dil), (da2, dg2, di2), (da2, dg2, di3), (da2, dg2, di4), (da2, dg2, di5), (da2, dg2, di6), (da2, dg2, di7), (da2, dg2, di8), (da2, dg3, dil), (da2, dg3, di2), (da2, dg3, di3), (da2, dg3, di4), (da2, dg3, di5), (da2, dg3, di6), (da2, dg3, di7), (da2, dg3, di8), (da2, dg4, dil), (da2, dg4, di2), (da2, dg4, di3), (da2, dg4, di4), (da2, dg4, di5), (da2, dg4, di6), (da2, dg4, di7), (da2, dg4, di8), (da2, dg5, dil), (da2, dg5, di2), (da2, dg5, di3), (da2, dg5, di4), (da2, dg5, di5), (da2, dg5, di6), (da2, dg5, di7), (da2, dg5, di8), (da2, dg6, dil), (da2, dg6, di2), (da2, dg6, di3), (da2, dg6, di4), (da2, dg6, di5), (da2, dg6, di6), (da2, dg6, di7), (da2, dg6, di8), (da2, dg7, dil), (da2, dg7, di2), (da2, dg7, di3), (da2, dg7, di4), (da2, dg7, di5), (da2, dg7, di6), (da2, dg7, di7), (da2, dg7, di8), (da2, dg8, dil), (da2, dg8, di2), (da2, dg8, di3), (da2, dg8, di4), (da2, dg8, di5), (da2, dg8, di6), (da2, dg8, di7), (da2, dg8, di8), (da2, dg9, dii), (da2, dg9, di2), (da2, dg9, di3), (da2, dg9, di4), (da2, dg9, di5), (da2, dg9, di6), (da2, dg9, di7), (da2, dg9, di8), (da3, dgi, dil), (da3, dgi, di2), (da3, dgi, di3), (da3, dgi, di4), (da3, dgi, di5), (da3, dgi, di6), (da3, dgi, di7), (da3, dgi, di8), (da3, dg2, dil), (da3, dg2, di2), (da3, dg2, di3), (da3, dg2, di4), (da3, dg2, di5), (da3, dg2, di6), (da3, dg2, di7), (da3, dg2, di8), (da3, dg3, dil), (da3, dg3, di2), (da3, dg3, di3), (da3, dg3, di4), (da3, dg3, di5), (da3, dg3, di6), (da3, dg3, di7), (da3, dg3, di8), (da3, dg4, dil), (da3, dg4, di2), (da3, dg4, di3), (da3, dg4, di4), (da3, dg4, di5), (da3, dg4, di6), (da3, dg4, di7), (da3, dg4, di8), (da3, dg5, dil), (da3, dg5, di2), (da3, dg5, di3), (da3, dg5, di4), (da3, dg5, di5), (da3, dg5, di6), (da3, dg5, di7), (da3, dg5, di8), (da3, dg6, dil), (da3, dg6, di2), (da3, dg6, di3), (da3, dg6, di4), (da3, dg6, di5), (da3, dg6, di6), (da3, dg6, di7), (da3, dg6, di8), (da3, dg7, dil), (da3, dg7, di2), (da3, dg7, di3), (da3, dg7, di4), (da3, dg7, di5), (da3, dg7, di6), (da3, dg7, di7), (da3, 100 dg7, di8), (da3, dg8, dil), (da3, dg8, di2), (da3, dg8, di3), (da3, dg8, di4), (da3, dg8, di5), (da3, dg8, di6), (da3, dg8, di7), (da3, dg8, di8), (da3, dg9, dil), (da3, dg9, di2), (da3, dg9, di3), (da3, dg9, di4), (da3, dg9, di5), (da3, dg9, di6), (da3, dg9, di7), (da3, dg9, di8) [0174] The following embodiments are examples of the compound (IX) of the present invention. A compound of the formula (IX-b): [Chemical Formula 84] ( R 9 ') s ' N E 0 ) NR N N O (IX-b) H Hal wherein Hal is halogen; Re is (eal) a group of the formula: [Chemical Formula 85] OH OH OH OH (al) (a2) , (a3) (a4) OH OH OH OH 0 (a5) (a6) (a7) (a8) OH OH OH OH OH OH OH OH (a9) (a0) ' (al1) ' (a12) OH OH - OH " Z ~OH Il or OH (a13) (a14) (ea2) a group of the formula: 101 [Chemical Formula 86] OH OH (a3) (a4) OH OH OH 0 (a5) (a6) (a7) OH LOH OH OH OH or OH (a9) (al1) (a12) (ea3) a group of the formula: [Chemical Formula 87] OHH OH OH OH OH or OH (a9) (al1) (a12) [0175] ring E is (eg1) a cycloalkane ring or a cycloalkene ring; (eg2) a cycloalkane ring; (eg3) a cyclopropane ring; a group of the formula: (R9')s'- is (eji) s' is 0; (ej2) s' is 1, and R 9 ' is alkyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or unsubstituted alkyl; (ej3) s' is 1, and R 9 ' is unsubstituted alkyl; (ej4) s' is 1, and R9' is methyl; ethyl; methyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or ethyl substituted with halogen, haloalkyloxy, cycloalkyl, cycloalkenyl, alkyloxy or alkenyloxy; or (ej5) s' is 1, and R 9 ' is methyl or ethyl, or its pharmaceutically acceptable salt or a solvate thereof [0176] The compound of the formula (IX-b) of the present invention includes the compounds comprising the combination of some or all of options of the above. Specifically, the following combinations are included. (eal, egi, eil), (eal, egl, ei2), (eal, egl, ei3), (eal, egl, ei4), (eal, egl, ei5), (eal, eg2, eil), (eal, eg2, ei2), (eal, eg2, ei3), (eal, eg2, ei4), (eal, eg2, ei5), (eal, eg3, eil), (eal, eg3, ei2), (eal, eg3, ei3), (eal, eg3, ei4), (eal, eg3, ei5), (ea2, egl, eil), (ea2, egl, ei2), (ea2, egl, ei3), (ea2, egi, ei4), (ea2, egl, ei5), (ea2, eg2, eil), (ea2, eg2, ei2), (ea2, eg2, ei3), (ea2, eg2, ei4), (ea2, eg2, ei5), (ea2, eg3, eil), (ea2, eg3, ei2), (ea2, eg3, ei3), (ea2, eg3, ei4), (ea2, eg3, ei5), (ea3, egl, eil), (ea3, egl, ei2), (ea3, egl, ei3), (ea3, egl, ei4), (ea3, egl, ei5), (ea3, eg2, eil), (ea3, eg2, ei2), (ea3, eg2, ei3), (ea3, eg2, ei4), (ea3, eg2, ei5), (ea3, eg3, eil), (ea3, eg3, ei2), (ea3, eg3, ei3), (ea3, eg3, ei4), (ea3, eg3, ei5) [0177] 102 The following is a general method for synthesizing the compounds of this invention. The starting materials and reagents used for synthesizing these compounds are commercially available or can be manufactured in accordance with a widely known method in this field using commercially available compounds. [0178] For example, the compounds of the general formula (I), general formula (II), general formula (III), general formula (IV), general formula (VII), general formula (VIII) and general formula (IX) described in this invention can be manufactured by the following synthesis route: [0179] [Method A] [Chemical Formula 88] H [N N N 0 NH Re-NCO R- N NRe R 2 - (CR 4 aR 4 b) 1 Lg(NH2 or Lg N Z 2 (iv) Step 1 H Step 2 0i) (iii) 0 0 0 Rc R 3 -X-H 0 R N N (vi) N N Lg N Z2 , R N Z2 1 Step 3
(CR
4 aR 4 ) n
(CR
4 aR 4 b) R2 R2 (v) (II) wherein, Lg is a leaving group of the formula: [Chemical Formula 89] Lg = R10 or N (R 27 )n' R10 is alkyl, R 27 is alkyl, n' is an integer from 0 to 3, Lgl is a leaving group and other symbols are as defined above. (Step 1) The compound (i) or its hydrochloride or bromate is reacted with isocyanate (ii) or 1-carbamoyl imidazole (ii)' in a solvent, such as N,N-dimethylformamide, N,N-dimethylacetamide, N,N'-dimethyl imidazolidinone and dimethylsulfoxide, in the presence of a base, such as DBU, triethylamine and pyridine (preferably DBU) at a temperature between -20 and 50 'C, preferably at a temperature between -10 0 C and below zero. After that, the compound (iii) can be manufactured by reacting the reactive mixture with a carbonylating or thiocarbonylating agent, such as 1,1'-carbonyldiimidazole, 1,1'-thiocarbonyldiimidazole, phosgene, thiophosgene and triphosgene, etc., and a base, such as DBU, triethylamine or pyridine (preferably DBU) at a temperature between -20 and 50 0 C ,preferably at a temperature between -10 0 C and below zero. (Step 2) The compound (v) can be manufactured by reacting the compound (iii) with the 103 compound (iv) in a solvent, such as acetonitrile, acetone, DMF and DMSO, in the presence of a base, such as potassium carbonate and sodium carbonate, at a temperature between 50 0 C to reflux, preferably at reflux. The examples of leaving group include halogen and -OS02 (CtF2t+l) wherein t is an integer from 1 to 4. As halogen, chloro, iodo and bromo are preferred. As -OS02 (CtF2t+l) group, -OTf group (trifluoromethanesulfonate) is preferred. This leaving group can also be used in the aforementioned (60'). The base and/or carbonylating agent or thiocarbonylating agent in (Step 1) and (Step 2) can also be used in the aforementioned (60'). The "carbonylating agent" and "thiocarbonylating agent" include a reagent that is used in a reaction where -C (=O) or -C (=S) - is inserted. (Step 3) The compound indicated by the general formula (II) can be manufactured by reacting the compound (v) with the compound (vii) in a solvent, such as NMP, DMF and DMSO, or under solvent-free conditions under microwave irradiation at a temperature between 150 0 C and 250 0 C, preferably at a temperature between 200 0 C and 230 0 C, or in a solvent, such as t-butanol, in the presence of an acid, such as acetic acid, at a temperature between 60 0 C and 150 0 C, preferably at a temperature between 80 0 C and 120 0 C. Using optically active isocyanate (ii) enables to synthesize optically active compound (II). [0180] [Method B] [Chemical Formula 90] 0
R
10 -Ha 2 A0R 3 -X-H S (viii)R10 N NH (Vi)
H
2 NN (CR 4 aR 4 bnR2 Step 1 HN N (CRnaRbyR2 Step 2 RS N O Step 3 H H IlStp (vii) (ix) (CR 4 aR 4 b)n 0 0 K N NH Rc- Hal 3 N N Rc ( X I - - (xii) X Ij1,N- 0 R3 N 0 , 3
(CR
4 aR 4 b Step 4 (CR 4 aR 4 b)n (xi) (I wherein Hal 2 and Hal 3 are halogen and other symbols are as defined above. (Step 1) The compound (ix) can be manufactured by reacting the compound (vii) with alkylating agent (viii), such as methyl iodide and ethyl iodide, in a solvent, such as methanol and ethanol, at a temperature between - 40 and 30 0 C, preferably below zero. (Step 2) The compound (x) can be manufactured by reacting the compound (ix) with isocyanate, such as N-(chlorocarbonyl) isocyanate, in a solvent, such as dichloromethane, chloroform, 1,2-dichloroethane, in the presence of a base, such as triethylamine and N,N-diisopropylethylamine, at a temperature between - 20 and 30 0 C, preferably below zero. (Step 3) 104 The compound (xi) can be manufactured by reacting the compound (x) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol and acetonitrile, in the presence of an acid, such as acetic acid, formic acid and methanesulfonic acid, at reflux. (Step 4) The compound indicated by the general formula (II) can be manufactured by reacting the compound (xi) with the compound (xii) in a solvent, such as DMF and NMP, in the presence of a base, such as potassium t-butoxide and sodium hydride, at a temperature between 40 and 100'C, preferably at a temperature between 50 and 70'C. Using optically-active compound (xii) enables to synthesize optically-active compound (II). [0181] [Method C] [Chemical Formula 91] 0 0 0 N NH HO O' N N O Pg 1 N' N{' OH S s1 A _ 3 X-H S N O (Xii) S N 0 )O X N O
(CR
4 aR 4 b Step 1 (CR 4 aR 4 b)n Step 2 (CR 4 aR 4 b)n
R
2
R
2
R
2 (x) (xiii) (xiv) wherein Pg 1 is an appropriate hydroxy protecting group, s is an integer from 1 to 4 and other symbols are as defined above. (Step 1) The compound (xiii) can be manufactured by reacting a mixture of the compound (x) obtained by the method B, the alcohol (xii) whose one hydroxyl group is protected, such as 2-(tetrahydro-2H-pyran-2-yloxy) ethanol and a solvent, such as THF and dioxane, etc, with triphenylphosphine, and diethyl azodicarboxylate, etc. (Step 2) The compound (xiv) can be manufactured by reacting the compound (xiii) with the compound (vi) in the presence of an acid, such as formic acid and acetic acid, etc., at reflux. [0182] [Method D] [Chemical Formula 92] 0 0 0 0 N N ' N 1
N{)NH
2 N N N R 1 1 R3.)%) H R3~ t~ R' R"-O 2 __' H X N 0 t -H X N O Rx Vr AN Ot H Step 1 Step 2
(CR
4 aR 4 b)n (CR 4 aR 4 b)n (CR 4 aR 4 b)n (xv) (xvi) (xviii) wherein Pg 2 is an appropriate amino protecting group, R11 is substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or 105 unsubstituted heteroaryl, R1 2 is hydroxy or halogen, t is an integer from 1 to 4 and other symbols are as defined above.) (Step 1) The compound (xvi) can be manufactured by reacting the compound (xv) obtained by the method A or B with acid, such as hydrochloric acid-dioxane solution, hydrochloric acid-methanol, hydrochloric acid-ethyl acetate solution and trifluoroacetic acid, etc. (Step 2) The compound (xviii) can be manufactured by reacting the compound (xvi) with the acid halide (xvii) (R12 is halogen) in a solvent, such as THF and dioxane, etc., in the presence of a base, such as triethylamine and diisopropylethylamine, etc. If necessary, dimethylaminopyridine, etc., can be added. Alternatively, the compound (xviii) can be manufactured by reacting the compound (xvi) with the carboxylic acid (xvii, R1 2 is hydroxy) in a solvent, such as THF and DMF, in the presence of a condensing agent, such as 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, and a base, such as triethylamine and diisipropylethylamine, etc. [0183] [Method E] [Chemical Formula 93] 0 R 2 0 R 2 Ob 0 R 20 a R 20 b 0 R 20 a R 2 ob N kNH Hal CUOO 2 R13 N N CO2R13R3-X-H N NkVO 2 R13 R 1 0% 1 1 ).(xx N --- 0u(vi) R x )11,N --'-0 S N O I R I Step 1 (CR 4 aR 4 b)n Step 2 CR4aR4b
(CR
4 aR 4 bn ( )n (x) OR20a R 2 ob (xx) (xxi) N Nk ( 0 C0 2 H S R3 xAN - -O Step 3
(CR
4 aR 4 b) R2 (xxii) wherein R13 is substituted or unsubstituted alkyl, R20a and R20b are hydrogen, halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl or R20a and R20b are taken together to form oxo or thioxo, u is an integer from 1 to 4, and other symbols are as defined above. (Step 1) The compound (xx) can be manufactured by reacting the compound (x) obtained by the 106 method B with the compound (xix) in a solvent, such as DMF, NMP and THF, in the presence of a base, such as DBU, potassium t-butoxide and sodium hydride, at a temperature between 0 and 80'C, preferably at a temperature between 30 and 50'C. (Step 2) The compound (xxi) can be manufactured by reacting the compound (xx) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol and acetonitrile, in the presence of an acid such as formic acid, acetic acid and methanesulfonic acid, etc., at reflux. (Step 3) The compound (xxii) can be manufactured by reacting the compound (xxi) with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol and ethanol, or in a mixture of such solvent and a solvent, such as THF and dioxane, etc. [0184] [Method F] [Chemical Formula 94]
R
14 0 2 C N N HO 2 C A ,Rc R 15 -NH R 1 7-NOC O Re X N O Step1 X N O xv) R 5 O1 IC~Rb Step 2 X N 0_
S(CR
4 aR 4 b) n
(CR
4 aR 4 b) n R2 R 2 |2 (Xxiii) (xxiv) (xxvi) wherein R14 is substituted or unsubstituted alkyl, R1 5 and R1 6 are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, u is an integer from 1 to 4 and other symbols are as defined above. (Step 1) The compound (xxiv) can be manufactured by reacting the compound (xxiii) obtained by the method A or B with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol and ethanol, or in a mixture of such solvent and a solvent, such as dioxane and THF, etc. (Step 2) The compound (xxvi) can be manufactured by reacting the compound (xxiv) with the compound (xxv) in a solvent, such as THF, DMF and NMP, in the presence of a condensing agent, such as 1-hydroxybenzotriazole, HOAt, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, HATU and PyBOP, and a base, such as triethylamine and diisipropylethylamine, etc. [0185] [Method G] 107 [Chemical Formula 95] R20 D20b 0k C 20aRD20bA0 pg1 N NH NA N O S R 3 N SN NN X N 0 , RX N O x0 R X N O I 4R Step 1 Step 2
(CR
4 aR 4 b)n
(CR
4 aR 4 b)n
(CR
4 aR 4 b)n R2 2 (xi) . R20a R20b (xxvii) (Xxviii) O $OH As 'j1 S N N Step 3 R X N O
(CR
4 aR 4 bn R2 (xxix) wherein Pg 1 is an appropriate hydroxy protecting group and other symbols are as defined above. (Step 1) The compound (xxvii) can be manufactured by reacting the compound (xi) obtained by the method B with a halogenating agent, such as phosphorous oxychloride and phosphorous oxybromide, under solvent-free conditions or in a solvent, such as toluene and tetrahydrofuran, at a temperature between 0 and 100'C, preferably at a temperature between 40 and 60'C. (Step 2) The compound (xxviii) can be manufactured by reacting a mixture of the alcohol (xv) whose one hydroxyl group is protected, such as 2-(tetrahydro-2H-pyran-2-yloxy) ethanol, and a solvent, such as THF, dioxane and DMF, with the compound (xv) after adding a base, such as sodium hydride and potassium t-butoxide. (Step 3) The compound (xxix) can be manufactured by reacting the compound (xxviii) with an acid, such as hydrochloric acid, p-toluenesulfonic acid or its hydrate and pyridine p-toluenesulfonate, in a solvent, such as methanol, etc. [0186] [Method H]
R?
22
R
21 CI R22 R2 N'2 N NR 21 -NH N N 1X I N -O ( RX N O I Step 1 (CR 4 aR 4 b) (ORwaR~b)n(Ra~ (xxvii) (XXXi) [Chemical Formula 96] wherein R 2 1 is substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, 108 substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R 2 2 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted acyl, and other symbols are as defined above. (Step 1) The compound (xxxi) can be manufactured by reacting the compound (xxvii) obtained by the method G with the compound (xxx) in a solvent, such as THF and dioxane, etc. [0187] [Method I] [Chemical Formula 97] CI S'" 2 N NN R 21 -SH N N R x )si ' . (xxxii) R kN-_ RXAN 0 R{AN O I Step1
(CR
4 aR 4 b)n (CR 4 aR 4 b) |n (xxvii) (xxxiii) wherein the symbols in the formula are as defined above. (Step 1) The compound (xxxiii) can be manufactured by reacting the compound (xxvii) obtained by the method G with the compound (xxxii) in a solvent, such as THF and dioxane, after adding a base, such as sodium hydride, etc. [0188] [Method J] [Chemical Formula 98] CI R18 N N Q-R N N R IIIL ) (xxxiii) RQ. A l,' ' - RXAN 0 RXAN 0 I Step 1
(CR
4 aR 4 b)n
(CR
4 aR 4 b) R 2 R 2 (xxvii) (xxxiv) wherein R1 8 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl, Q is dihydroxyboran, dialkoxyboran or dialkylboran, [Chemical Formula 99] B- B- or B and other symbols are as defined above. The compound (xxxiv) can be manufactured by reacting the compound (xxvii) obtained by the method G with the compound (xxxiii) in a solvent, such as THF and dioxane, in the 109 presence of a palladium catalyst, and a solution, such as potassium carbonate, cesium carbonate and sodium carbonate aqueous solution, etc., at a temperature between 50'C and reflux, preferably at reflux, or under microwave irradiation at a temperature of 120 and 200'C, preferably at a temperature between 130 and 150'C. [0189] [Method K] [Chemical Formula 100] C0 2
R
19
CO
2 H CO 2 H N |V v V v N N N N N N RX NO Step 1 R. X< N O Step 2 RX <N O
(CR
4 aR 4 b) (CR 4 aR 4 b) (CR 4 aR 4 b) | nn n (xxxv) (xxxvi) (xxxvii) wherein R1 9 is substituted or unsubstituted alkyl, v is an integer from 0 to 4 and other symbols are as defined above. The compound (xxxvi) can be manufactured by hydrolyzing the compound (xxxv) using a mixture of an ethers solvent, such as dioxane, THF and DME, etc., an alcohols solvent, such as ethanol and methanol, or a solvent, such as DMF, DMA, DMSO and NMP, and water, as well as using a base, such as sodium hydroxide and lithium hydroxide. Although the preferable reaction temperature is room temperature, it can be increased if the reaction proceeds slowly. [0190] (Step 2) The compound (xxxvii) can be obtained by dissolving the compound (xxxvi) in an alcohols solvent, such as methanol and ethanol, and performing catalytic reduction using a hydrogenation reactor (such as H-Cube [10%Pt-C, H2 = 1 atm]) or a metallic catalyst, such as palladium-carbon, platinum oxide and chlorotris (triphenylphosphine) rodiumu (I), etc. [0191] [Method L] [Chemical Formula 101] 0 0 0 N NH HO-Rc N N'RR 3 N N Rc RS N O (xxxviii) R N O R X N 0
(CR
4 aR 4 b) Step 1 (CR 4 aR 4 b) Step 2 (CR 4 aR 4 ) R2 ) C R2 ) R R2 4 ) (x (ix1) (I wherein the symbols in the formula are as defined above. (Step 1) The compound (ix1) can be manufactured by reacting a mixture of the compound (x) obtained by the method B, the alcohol (xxxviii) and a solvent, such as THF and dioxane, with triphenylphosphine, etc., and diethyl azodicarboxylate, etc. (Step 2) The compound (II) can be manufactured by reacting the compound (ix1) with the 110 compound (vi) in the presence of an acid, such as formic acid and acetic acid, at reflux. Using the optically-active alcohol (xxxviii) enables to synthesize the optically-active compound (II). The alcohol used as an intermediate (xxxviii) is commercially available or can be manufactured according to a method specified in the following documents: Tetrahedron (1993), 49(11), 2325-44. Chemical Communications (2008), (47), 6408-6410. Tetrahedron (1990), 46(24), 8207-28. Synlett (1994), (3), 199-200. Bulletin of the Chemical Society of Japan (1994), 67(8), 2244-7 Canadian Journal of Chemistry (1996), 74, 1731-1737 Chemistry--A European Journal (2010), 16(2), 577-587 Bioorganic & Medicinal Chemistry Letters (2009), 19(21), 6196-6199. Chemische Berichte (1985), 118(10), 3966-79. Tetrahedron: Asymmetry (1992), 3(4), 515-16. Organic Letters (1999), 1(6), 957-959. Chimia (1986), 40(5), 172-3. [Method M] [Chemical Formula 102] R22 0 R2 R240 0 2 R24 R _R R X ORc R 23 R 3X ORc S p2 R. ORc A '~ Stepi Step 2 XN 0 -_
(CR
4 aR 4 b)n (CR 4 aR 4 b)ln (CR 4 aR 4 b) I I )n (xxxvii) (xxxix) (X1) wherein R 2 1 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, etc., R22 is bromo or iodo, R23 and R24 are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and other symbols are as defined above. (Step 1) The compound (xxxix) can be manufactured by reacting the compound (xxxvii) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF and dioxane, in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate and sodium carbonate aqueous solution, etc., at a temperature between 50 0 C and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120 and 200 0 C, preferably at a temperature between 130 and 150 0 C. [0192] (Step 2) The compound (x1) can be obtained by dissolving the compound (xxxix) in an alcohols solvent, such as methanol and ethanol, and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10%Pt-C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide, chlorotris (triphenylphosphine) rhodium (I), etc. 111 [0193] [Method N] [Chemical Formula 103] o o 0 N ,Re R24 ,Re N N R3X N O R23 R3X N ORX NO
(CR
4 aR 4 b (xxxviii) (CR 4 aR 4 b (CR 4 aR 4 bn Step 1 Step 2 21 | -22 R -3 R24 R 23R2 LK~J Ii N~R23 (xil) (xi) (xili) wherein the symbols in the formula are as defined above. (Step 1) The compound (xlii) can be manufactured by reacting the compound (xli) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF and dioxane, in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate and sodium carbonate aqueous solution, etc., at a temperature between 50 0 C and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120 and 200 0 C, preferably at a temperature between 130 and 150 0 C. [0194] (Step 2) The compound (xliii) can be obtained by dissolving the compound (xlii) in an alcohols solvent, such as methanol and ethanol, and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10%Pt-C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide and chlorotris (triphenylphosphine) rhodium (I), etc. [0195] [Method 0] [Chemical Formula 104] 0 0 0 N UNR N kNR R3-R26 N N Rc N N ___z' -x Ii)R3A, R25O Stp 1- H2N N O N N O R (CR 4 a R 4 b) Step 1 1 tp )n (CR 4 aR 4 b)n (CR 4 aR 4 b)n R2 R 2 R 2 (xliv) (xlvi) (xlviii) wherein R 2 5 is substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, R26 is bromo or iodo, and other symbols are as defined above. (Step 1) The compound (xlvi) can be obtained from the compound (xlvi) in the presence of Lewis acid or trifluoroacetic acid, etc., under solvent-free conditions or in an appropriate solvent at a temperature between 0 0 C and reflux. [0196] (Step 2) The compound (xlviii) can be manufactured by reacting the compound (xlvi) with the 112 compound (xlvii) in a solvent, such as THF and dioxane, in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate and sodium carbonate aqueous solution, etc., at a temperature between 50 0 C and reflux, preferably at reflux, or under microwave irradiation at a temperature of 120 and 200 0 C, preferably at a temperature between 130 and 150 0 C. [0197] [Method P] [Chemical Formula 105] OH
(CR
4 aR 4 b) 0 0 O n N N'Rc N N'Rc N N' (X) R1S N 0 (vi) R N 0 S N O Step 1 (CR 4 aR 4 b)n Step 2 (CR 4 aR 4 b (iii) R 2
R
2 (x1i) (x1ii) wherein the symbols in the formula are as defined above. (Step 1) The compound (xli) can be manufactured by reacting a mixture of the compound (iii) obtained by the method A, the alcohol (xl) and a solvent, such as THF and dioxane, with triphenylphosphine, etc., and diethyl azodicarboxylate, etc. (Step 2) The compound (xlii) can be manufactured by reacting the compound (xli) with the compound (vi) in the presence of formic acid and acetic acid, etc., at reflux. [0198] [Method Q] [Chemical Formula 106] 0 N R Nc0 o R 3 - (CR 4 aR 4 b) - Hall R 3 - (CR 4 aR 4 b) N N RI N N N 11 H VR(l n N N R1 N O t (xiv) 0 O N 0 I Step 1 Step 2 (C 4 aR 4 b)
(CR
4 aR 4 b)n (CR 4 aR 4 b) (CR )n R2 2 R2 (v) (x1iii) (x1v) wherein the symbols in the formula are as defined above. (Step 1) The compound (xliii) can be manufactured by reacting the compound (v) obtained by the method A in a solvent, such as water, acetic acid and methanol, in the presence of an oxidation agent, such as hydrogen peroxide water and MCPBA, at a temperature between -20 and 100 0 C, preferably at room temperature. (Step 2) The compound (x1v) can be manufactured by reacting the compound (xliii) with the compound (xliv) in a solvent, such as acetonitrile, acetone, DMF and DMSO, in the presence of a base, such as potassium carbonate and sodium carbonate, at a temperature between 50 0 C and reflux, preferably at reflux. [0199] The compounds of this invention (I) are not limited to a specific isomer but include all 113 possible isomers and racemates. For example, they include a tautomer as shown below. The compounds indicated by the formula (VIII), formula (IX) and formula (VII), etc., also include similar tautomers. [Chemical Formula 107] Ra Rb Ra Rb Re 41Re N N /R H'N N' N N Re Re H Rf Rf [0200] In addition, one or more hydrogen atoms, carbon atoms or other atoms of the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like can be replaced by an isotope of the hydrogen atom, carbon atom or other atoms. Compounds of the formula (I), formula (VIII), formula (IX), formula (VII) and the like include all radiolabeled forms of compounds of the formula (I), formula (VIII), formula (IX), formula (VII) and the like. The "radiolabeled," "radiolabeled form" and the like of the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like are encompassed by the present invention and useful as a research and/or diagnostic tool in metabolism pharmacokinetic studies and in binding assays. It is also useful for a medicament. [0201] Examples of isotopes that can be incorporated into the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, iodine and chlorine, such as 2H, 3H, 11C, 1 3 C, 14C, 15N, 180, 170, 31P, 32P, 35S, 18F, 1231 and 3 6 C1, respectively. Radiolabeled compounds of the present invention can be prepared by methods known in the art. For example, tritiated compounds of formula (I) can be prepared by introducing tritium into the particular compound of formula (I), for example, by catalytic dehalogenation with tritium. This method may include reacting a suitably halogen-substituted precursor of a compound of formula (I), formula (VIII), formula (IX), formula (VII) and the like with tritium gas in the presence of a suitable catalyst such as Pd/C, in the presence or absence of a base. Other suitable methods for preparing tritiated compounds can be found in Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A) Chapter 6, (1987). 1 4C-labeled compounds can be prepared by employing starting materials having a 14C carbon. [0202] The compounds of the above formula (I), formula (VIII), formula (IX), formula (VII) and the like or its salt can be converted into hydrate or solvate thereof by known methods. Examples of suitable solvates are solvate with acetone, 2-butanol, 2-propanol, ethanol, ethyl acetate, tetrahydrofuran, diethyl ether or the like. For example, it includes a non-toxic and water-soluble hydrate or solvate such as a solvate with ethanol. As pharmaceutically acceptable salt of the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like, examples include salts with alkaline metals (e.g. lithium, sodium and potassium), alkaline earth metals (e.g. calcium and barium), magnesium, transition metal (e.g. zinc and iron), ammonia, organic bases (e.g. trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, diethanolamine, ethylenediamine, pyridine, picoline, quinoline), and amino acids, and salts with inorganic acids (e.g. hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid and hydroiodic acid) and 114 organic acids (e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid and ethanesulfonic acid) . Especially preferable are salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, or methanesulfonic acid. These salts may be formed by usual methods. The compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like or its pharmaceutically acceptable salt may form solvate such as hydrate, and/or crystalline polymorphism, and the present invention also includes such various kinds of solvate and crystalline polymorphism. The "solvate" includes a compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like which coordinate arbitrary number of solvent molecules such as water molecules. The compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like or its pharmaceutically acceptable salt can adhere water or form hydrate by absorbing water molecules after leaving in the atmosphere. Moreover, the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like or its pharmaceutically acceptable salt can form the crystalline polymorphism by recrystallization. The compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like of the present invention or its pharmaceutically acceptable salt may form prodrug, and the present invention also includes such various kinds of prodrug. Prodrug is a derivative of the compound of the present invention having a group which can be chemically or metabolically decomposed and the one which becomes a pharmaceutically active compound of the present invention by solvolysis or physiological conditions in vivo. Prodrug includes a compound which converts into the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like by enzymatical oxidation, reduction, hydrolysis or the like under physiological conditions in a living body, and a compound which converts into the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like by hydrolyzing by stomach acid or the like. The method of selecting suitable prodrug derivatives and the method of manufacturing them are disclosed in Design of Prodrugs, Elsevier, and Amsterdam 1985. Prodrug itself may possess the activity. When the compound of the formula (I), formula (VIII), formula (IX), formula (VII) and the like or its pharmaceutically acceptable salt has a hydroxy group, examples of the prodrug includes acyloxy derivatives and sulfonyloxy derivatives which can be manufactured by reacting a compound having a hydroxy group with a suitable acid halide, suitable acid anhydride, suitable sulfonyl chloride, suitable sulfonylanhydride and mixed anhydride. For example, CH 3 COO-, C 2
H
5 COO-, t-BuCOO-, C 1 5
H
3 1 COO-, PhCOO-, (m-NaOOCPh)COO-, NaOOCCH2CH2COO-, CH 3
CH(NH
2 ) COO-, CH 2
N(CH
3 ) 2COO-,
CH
3
SO
3 -, CH 3
CH
2
SO
3 -, CF 3
SO
3 -, CH 2
FSO
3 -, CF 3
CH
2
SO
3 -, p-CH3-0-PhSO3-, PhSO 3 -, and p-CH3PhSO3- are exemplified. [0203] The compound of the general formula (I), formula (VIII), formula (IX), formula (VII) and the like has an antagonistic effect on P2X 3 and/or P2X 2
/
3 receptor, and therefore, is useful as a therapeutic agent for diseases associated with a P2X 3 and/or P2X 2
/
3 receptor. Since P2X 3 and/or P2X 2
/
3 receptor is believed to associate with pain and diseases in urinary system (Nature 407, 26, 1011-1015 (2000), Nature, Vol.407, No.26, 1015-1017 (2000), Non-Patent Document 1, Non-Patent Document 2, etc.), the compound of the invention is useful in the treatment, alleviation of symptoms or prevention of diseases, 115 such as for example, pain associated with rheumatoid arthritis, pain associated with osteoarthritis, headache, migraine, orofacial pain, toothache, glossagra, pain associated with temporomandibular arthrosis, trigeminal neuralgia, shoulder pain, pain associated with hernia of intervertebral disk, pain associated with cervical spondylosis deformans, pain associated with spinal canal stenosis, pain associated with thoracic outlet syndrome, pain associated with traumatic brachial plexus injury syndrome, pain associated with shoulder-hand syndrome, pain associated with whiplash injury, chest pain, abdominal pain, colic pain, pain associated with cholelithiasis, pain associated with pancreatitis, pain associated with urinary calculosis, pain associated with irritable bowel syndrome, lumbar backache, sciatica, pain associated with bone fracture, pain associated with osteoporosis, joint pain, pain associated with gout, pain associated with cauda equina syndrome, pain associated with ankylosing spondylitis, sore muscle, pain associated with painful spasm, pain associated with myofascial pain syndrome, pain associated with fibromyalgia syndrome, complex regional pain syndrome, pain associated with arteriosclerosis obliterans, pain associated with Buerger's disease, pain associated with Raynaud's phenomenon, pain associated with zoster, causalgic pain, pain associated with entrapment neuropathy, pain associated with carpal canal syndrome, pain associated with diabetes, pain associated with Guillain-Barre syndrome, pain associated with Hansen's disease, pain associated with drug therapy, pain associated with radiation therapy, pain associated with cord injury, pain associated with syringomyelia, pain associated with stroke, thalamic pain, pain associated with deafferentation, sympathetically-maintained pain, ABC syndrome, multiple sclerosis, pain associated with skin disease, cancer pain, postoperative pain, pain associated with injury, pain associated with gangrene, pain associated with somatoform disorder, pain associated with somatization disorder, pain associated with depression, pain associated with Parkinson's disease, knee joint pain, pain associated with arthritis, neuropathic pain such as menstrual pain, intermenstrual pain, labor pain, etc., inflammatory pain, nociceptive pain, psychogenic pain, pain of bladder such as overactive bladder, blader inflammation etc., incontinence, pollakiuria, urinary urgency, cystatrophia, prostatic hypertrophy, prostatitis, prostate pain, detrusor hyperreflesxia, urination disorder, nervous pollakiuria, chronic prostatitis, chronic cystitis, etc. [0204] "A pharmaceutical composition having an improving effect on a urination disorder" includes "a pharmaceutical composition for treating overactive bladder", "a pharmaceutical composition for treating interstitial bladder cystitis" and the like. [0205] The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with reduced side-effect such as effect on motor function because it has a high affinity for ATP receptor, especially P2X3 receptor, and also has high subtype selectivity and high selectivity for other receptors. Also, the compound encompassed by the present invention or the pharmaceutical composition encompassed by the present invention is advantageous because of its high P2X3 receptor inhibitor activity in the presence of RSA, high metabolic stability, high oral absorption, good bioavailability, low clearance, long half-life, prolonged duration of action, low activity of hepatic enzyme inhibition, high unbound fraction in serum and/or high safety etc. [0206] In another embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of the compound of the present invention, in 116 combination with a pharmaceutically acceptable carrier. [0207] For use of the compound of the present invention as a medicament, a pharmaceutical composition can be prepared according to conventional methods, using pharmaceutically acceptable carriers well-known in the art, such as excipients, binders, disintegrants, lubricants, colourants, flavors, surfactants, etc. [0208] For the pharmaceutical composition of the present invention to be administered in the treatment of mammals including human, an appropriate unit dosage form may be selected depending on the purpose of the treatment and the route of administration. Specifically, such unit dosage form includes oral formulations such as tablet, coated tablet, powder, granule, capsule, liquid, pill, suspension, emulsion, etc., and parenteral formulations such as injectable solution, suppository, ointment, patch, aerosol, etc. Such unit dosage form can be formulated according to methods well-known in the art. [0209] The amount of the present compound in a formulation can vary depending on its dosage form, route for administration, dosing regimen, etc. [0210] Means for administration of the present pharmaceutical composition may be selected depending on dosage form, patient's age, sex, body weight, severity of the disease, and other factors, etc., and route for administration can be selected from various routes such as oral, subcutaneous, transdermal, rectal, intranasal, buccal, etc. [0211] Dose of the present compound in the present pharmaceutical composition can be determined depending on the choice of route for administration, patient's age, sex, body weight, severity of the disease, the compound to be administered, and other factors, etc., and can be generally from 0.05 to 1000 mg/kg/day, preferably from 0.1 to 10 mg/kg/day, for oral administration to adults. For parenteral administration, dose can vary widely depending on its route but generally from 0.005 to 100 mg/kg/day, preferably from 0.01 to 1 mg/kg/day. Such pharmaceutical composition of the present invention may be administered once a day or in several times at a divided dosage in a day. [0212] In some embodiments of the present compounds, there is provided compounds of the following general formula (V) and the general formula (VI) having the following groups are provided: [Chemical Formula 108] N NRP N N R RP N (V) NK N O (VI) H H
(CH
2 )
(OH
2 ) Rq Rq wherein RP, Rq, and Rr are selected from the following Tables 1 to 3. 117 [Table 1] Rp Rpl HO(CH2)2 Rp2 HO(CH2)3 Rp3 (HOCH2)2CHCH2 Rp4 (HOCH2)2C(Me)CH2 Rp5 HOCH2CH(OH)CH2 Rp6 HOCO(CH2)2 Rp7 HOCOC(Me)2CH2 Rp8 HOCOC(-CH2CH2-)CH2 Rp9 HOCOCH(Me)CH2 Rp10 HOCOCH(Me)CH(Me) Rp1 1 HOCOC(CH2)3 [Table 2] Rq Rql 4-Me-Ph Rq2 4-Et-Ph Rq3 4-Cl-Ph Rq4 4-Br-Ph Rq5 cyclohexyl 118 [Table 3] Rr Rr Rr1 2-Me-benzothiazol-6-yl Rr20 2-Piperidino-5-pyridyl Rr2 2-Me-benzothiazol-5-yl Rr2l 5-c-PrCH20-2-pyridyl Rr3 2-Me-benzimidazol-6-yl Rr22 5-c-BuO-2-pyridyl Rr4 2-Me-benthoiphen-5-yl Rr23 5-PhO-2-pyridyl Rr5 3-Me-benzisoxazol-6-yl Rr24 5-Piperidino-2-pyridyl Rr6 3-Me-2H-1,4-benzoxazin-7-y Rr25 2-c-BuO-3-CI-5-pyridyl Rr7 7-Me-1,8-naphthyridin-3-yl Rr26 2-c-BuO-3-Me-5-pyridyl Rr8 7-Me-quinolin-3-yl Rr27 2-c-PentylO-3-CI-5-pyridyl Rr9 2-Me-quinazolin-6-yl Rr28 2-c-PentylO-3-Me-5-pyridyl Rr 0 4-c-PrO-Ph Rr29 2-PhO-3-CI-5-pyridyl Rr 1 3-Me-4-c-PrO-Ph Rr30 3-Me-4-i-PrCONH-Ph Rrl2 3-CI-4-c-PrO-Ph Rr3l 3-CI-4-i-PrCONH-Ph Rr 3 4-c-PrCH2-Ph Rr32 3-Me-4-i-PrNHCO-Ph Rr1 4 3-Me-4-c-PrCH2-Ph Rr33 3-CI-4-i-PrNHCO-Ph Rr1 5 3-CI-4-c-PrCH2-Ph Rr34 3-Me-4-i-PrSO2NH-Ph Rr 6 4-c-BuCH2-Ph Rr35 3-CI-4-i-PrSO2NH-Ph Rr1 7 3-MeO-4-c-BuCH2-Ph Rr36 3-Me-4-i-PrNHSO2-Ph Rrl8 2-c-PrCH20-5-pyridyl Rr37 3-CI-4-i-PrNHSO2-Ph Rr 9 2-PhO-5-pyridyl I I In the above tables, Me is methyl, Et is ethyl, i-Pr is isopropyl, c-Pr is cyclopropyl, c-Bu is cyclobutyl, and Ph is phenyl. [0213] The combination of Rp, Rq and Rr, i.e., (Rp, Rq, Rr), is any one of the following combinations: (Rp,Rq,Rr) = (Rpl,Rql,Rrl),(Rp1,Rql,Rr2),(Rpl,Rql,Rr3),(Rpl,Rql,Rr4),(Rp1,Rql,Rr5),(Rpl,Rql,Rr6), (Rpl,Rql,Rr7),(Rp1,Rql,Rr8),(Rpl,Rql,Rr9),(Rpl,Rql,RrlO),(Rpl,Rql,Rrl1),(Rpl,Rql,Rr 12),(Rp1,Rql,Rrl3),(Rp1,Rql,Rrl4),(Rpl,Rql,Rrl5),(Rp1,Rql,Rrl6),(Rp1,Rql,Rrl7),(Rpl, Rql,Rrl8),(Rpl,Rql,Rrl9),(Rp1,Rql,Rr2O),(Rpl,Rql,Rr2l),(Rpl,Rql,Rr22),(Rpl,Rql,Rr23 ),(Rp1,Rql,Rr24),(Rpl,Rql,Rr25),(Rp1,Rql,Rr26),(Rpl,Rql,Rr27),(Rp1,Rql,Rr28),(Rp1,Rq 1,Rr29),(Rp1,Rql,Rr3O),(Rp1,Rql,Rr3l),(Rpl,Rql,Rr32),(Rp1,Rql,Rr33),(Rpl,Rql,Rr34),( 119 Rp 1,Rql,Rr35),(Rp 1,Rql,Rr36),(Rp 1,Rql,Rr37),(Rp 1,Rq2,Rr1),(Rp 1,Rq2,Rr2),(Rp 1,Rq2,Rr 3), (Rp 1,Rq2,Rr4),(Rp 1,Rq2,Rr5),(Rp 1,Rq2,Rr6),(Rp 1,Rq2,Rr7),(Rp 1,Rq2,Rr8),(Rp 1,Rq2,Rr 9),(Rp1,Rq2,Rr1O),(Rp1,Rq2,Rr 1),(Rp 1,Rq2,Rrl2),(Rp 1,Rq2,Rr13),(Rp 1,Rq2,Rrl4),(Rp 1,R q2,Rr15),(Rp1,Rq2,Rrl6),(Rp1,Rq2,Rr17),(Rp1,Rq2,Rr18),(Rp 1,Rq2,Rr19),(Rp 1,Rq2,Rr2O), (Rp 1,Rq2,Rr2 1),(Rp 1,Rq2,Rr22),(Rp 1,Rq2,Rr23),(Rp 1,Rq2,Rr24),(Rp 1,Rq2,Rr25),(Rp 1,Rq2 ,Rr26), (Rp 1,Rq2,Rr27),(Rp 1,Rq2,Rr28),(Rp 1,Rq2,Rr29),(Rp 1,Rq2,Rr3O),(Rp 1,Rq2,Rr3 ),(R p 1,Rq2,Rr32),(Rp 1,Rq2,Rr33),(Rp 1,Rq2,Rr34),(Rp 1,Rq2,Rr35),(Rp 1,Rq2,Rr36),(Rp 1,Rq2,R r37), (Rp 1,Rq3,Rr1),(Rp 1,Rq3,Rr2),(Rp 1,Rq3,Rr3),(Rp 1,Rq3,Rr4),(Rp 1,Rq3,Rr5),(Rp 1,Rq3, Rr6),(Rp 1,Rq3,Rr7),(Rp 1,Rq3,Rr8),(Rp 1,Rq3,Rr9),(Rp 1,Rq3,RrlO),(Rp 1,Rq3,Rrl 1),(Rp 1,R q3,Rrl2),(Rp1,Rq3,Rrl3),(Rp1,Rq3,Rrl4),(Rp1,Rq3,Rr15),(Rp 1,Rq3,Rr16),(Rp 1,Rq3,Rr17), (Rp 1,Rq3,Rrl8),(Rp 1,Rq3,Rrl9),(Rp 1,Rq3,Rr2O),(Rp 1,Rq3,Rr2 1),(Rp 1,Rq3,Rr22),(Rp 1,Rq3 ,Rr23), (Rp 1,Rq3,Rr24),(Rp 1,Rq3,Rr25),(Rp 1,Rq3,Rr26),(Rp 1,Rq3,Rr27),(Rp 1,Rq3,Rr28),(R p 1,Rq3,Rr29),(Rp 1,Rq3,Rr3O),(Rp 1,Rq3,Rr3 1),(Rp 1,Rq3,Rr32),(Rp 1,Rq3,Rr33),(Rp 1,Rq3,R r34), (Rp 1,Rq3,Rr35),(Rp 1,Rq3,Rr36),(Rp 1,Rq3,Rr37),(Rp 1,Rq4,Rr1),(Rp 1,Rq4,Rr2),(Rp 1,R q4,Rr3),(Rp 1,Rq4,Rr4),(Rp 1,Rq4,Rr5),(Rp 1,Rq4,Rr6),(Rp 1,Rq4,Rr7),(Rp 1,Rq4,Rr8),(Rp 1,R q4,Rr9),(Rp 1,Rq4,Rr1O),(Rp 1,Rq4,Rr1 1),(Rp 1,Rq4,Rrl2),(Rp 1,Rq4,Rr13),(Rp 1,Rq4,Rrl4),( Rp 1,Rq4,Rr1 5),(Rp 1,Rq4,Rr1 6),(Rp 1,Rq4,Rr17),(Rp 1,Rq4,Rr18),(Rp 1,Rq4,Rr19),(Rp 1,Rq4, Rr20),(Rp 1,Rq4,Rr2 1),(Rp 1,Rq4,Rr22),(Rp 1,Rq4,Rr23),(Rp 1,Rq4,Rr24),(Rp 1,Rq4,Rr25),(R p 1,Rq4,Rr26),(Rp 1,Rq4,Rr27),(Rp 1,Rq4,Rr28),(Rp 1,Rq4,Rr29),(Rp 1,Rq4,Rr3O),(Rp 1,Rq4,R r3 1), (Rp 1,Rq4,Rr32),(Rp 1,Rq4,Rr33),(Rp 1,Rq4,Rr34),(Rp 1,Rq4,Rr35),(Rp 1,Rq4,Rr36),(Rp 1 ,Rq4,Rr37),(Rp 1,Rq5,Rr1),(Rp 1,Rq5,Rr2),(Rp 1,Rq5,Rr3),(Rp 1,Rq5,Rr4),(Rp 1,Rq5,Rr5),(Rp 1,Rq5,Rr6),(Rp 1,Rq5,Rr7),(Rp 1,Rq5,Rr8),(Rp 1,Rq5,Rr9),(Rp 1,Rq5,Rr1O),(Rp 1,Rq5,Rrl 1),( Rp 1,Rq5,Rrl2),(Rp 1,Rq5,Rr13),(Rp 1,Rq5,Rrl4),(Rp 1,Rq5,Rr15),(Rp1,Rq5,Rr16),(Rp1,Rq5, Rr17),(Rp 1,Rq5,Rr18),(Rp 1,Rq5,Rr19),(Rp 1,Rq5,Rr2O),(Rp 1,Rq5,Rr2 1),(Rp 1,Rq5,Rr22),(R p 1,Rq5,Rr23),(Rp 1,Rq5,Rr24),(Rp 1,Rq5,Rr25),(Rp 1,Rq5,Rr26),(Rp 1,Rq5,Rr27),(Rp 1,Rq5,R r28), (Rp 1,Rq5,Rr29),(Rp 1,Rq5,Rr3O),(Rp 1,Rq5,Rr3 1),(Rp 1,Rq5,Rr32),(Rp 1,Rq5,Rr33),(Rp 1 ,Rq5,Rr34),(Rp 1,Rq5,Rr35),(Rp 1,Rq5,Rr36),(Rp 1,Rq5,Rr37),(Rp2,Rql,Rr1),(Rp2,Rql,Rr2), (Rp2,Rq1,Rr3),(Rp2,Rq1,Rr4),(Rp2,Rq1,Rr5),(Rp2,Rq1,Rr6),(Rp2,Rq1,Rr7),(Rp2,Rq1,Rr8), (Rp2,Rql,Rr9),(Rp2,Rql,Rr1O),(Rp2,Rql,Rr1 1),(Rp2,Rql,Rrl2),(Rp2,Rql,Rr13),(Rp2,Rql, Rr14),(Rp2,Rql,Rr15),(Rp2,Rql,Rr16),(Rp2,Rq1,Rr17),(Rp2,Rql,Rr18),(Rp2,Rql,Rrl9),(R p2,Rql,Rr2O),(Rp2,Rql,Rr2 1),(Rp2,Rql,Rr22),(Rp2,Rql,Rr23),(Rp2,Rql,Rr24),(Rp2,Rql,R r25),(Rp2,Rql,Rr26),(Rp2,Rql,Rr27),(Rp2,Rql,Rr28),(Rp2,Rq1,Rr29),(Rp2,Rq1,Rr30),(Rp2 ,Rq1,Rr3 1),(Rp2,Rql,Rr32),(Rp2,Rql,Rr33),(Rp2,Rql,Rr34),(Rp2,Rql,Rr35),(Rp2,Rq1,Rr3 6), (Rp2,Rql,Rr37),(Rp2,Rq2,Rrl),(Rp2,Rq2,Rr2),(Rp2,Rq2,Rr3),(Rp2,Rq2,Rr4),(Rp2,Rq2,R r5),(Rp2,Rq2,Rr6),(Rp2,Rq2,Rr7),(Rp2,Rq2,Rr8),(Rp2,Rq2,Rr9),(Rp2,Rq2,Rr10),(Rp2,Rq2, Rr 1),(Rp2,Rq2,Rrl2),(Rp2,Rq2,Rrl3),(Rp2,Rq2,Rrl4),(Rp2,Rq2,Rr15),(Rp2,Rq2,Rrl 6),(R p2,Rq2,Rr17),(Rp2,Rq2,Rr1 8),(Rp2,Rq2,Rr19),(Rp2,Rq2,Rr2O),(Rp2,Rq2,Rr2 1),(Rp2,Rq2,R r22), (Rp2,Rq2,Rr23),(Rp2,Rq2,Rr24),(Rp2,Rq2,Rr25),(Rp2,Rq2,Rr26),(Rp2,Rq2,Rr27),(Rp2 ,Rq2,Rr28),(Rp2,Rq2,Rr29),(Rp2,Rq2,Rr3O),(Rp2,Rq2,Rr3 1),(Rp2,Rq2,Rr32),(Rp2,Rq2,Rr3 3), (Rp2,Rq2,Rr34),(Rp2,Rq2,Rr35),(Rp2,Rq2,Rr36),(Rp2,Rq2,Rr37),(Rp2,Rq3,Rr1),(Rp2,Rq 3,Rr2), (Rp2,Rq3,Rr3),(Rp2,Rq3,Rr4),(Rp2,Rq3,Rr5),(Rp2,Rq3,Rr6),(Rp2,Rq3,Rr7),(Rp2,Rq 3,Rr8), (Rp2,Rq3,Rr9),(Rp2,Rq3,Rr1O),(Rp2,Rq3,Rr1 1),(Rp2,Rq3,Rrl2),(Rp2,Rq3,Rrl 3),(Rp 2,Rq3,Rr14),(Rp2,Rq3,Rr15),(Rp2,Rq3,Rr16),(Rp2,Rq3,Rr17),(Rp2,Rq3,Rr18),(Rp2,Rq3,Rr 19),(Rp2,Rq3,Rr2O),(Rp2,Rq3,Rr2 1),(Rp2,Rq3,Rr22),(Rp2,Rq3,Rr23),(Rp2,Rq3,Rr24),(Rp2, Rq3,Rr25),(Rp2,Rq3,Rr26),(Rp2,Rq3,Rr27),(Rp2,Rq3,Rr28),(Rp2,Rq3,Rr29),(Rp2,Rq3,Rr3O ),(Rp2,Rq3,Rr3 1),(Rp2,Rq3,Rr32),(Rp2,Rq3,Rr33),(Rp2,Rq3,Rr34),(Rp2,Rq3,Rr35),(Rp2,Rq 3,Rr36),(Rp2,Rq3,Rr37),(Rp2,Rq4,Rr1),(Rp2,Rq4,Rr2),(Rp2,Rq4,Rr3),(Rp2,Rq4,Rr4),(Rp2, Rq4,Rr5),(Rp2,Rq4,Rr6),(Rp2,Rq4,Rr7),(Rp2,Rq4,Rr8),(Rp2,Rq4,Rr9),(Rp2,Rq4,Rr10),(Rp 120 2,Rq4,Rr1 1),(Rp2,Rq4,Rrl2),(Rp2,Rq4,Rr1 3),(Rp2,Rq4,Rrl4),(Rp2,Rq4,Rr1 5),(Rp2,Rq4,Rr 16),(Rp2,Rq4,Rr17),(Rp2,Rq4,Rr18),(Rp2,Rq4,Rr1 9),(Rp2,Rq4,Rr2O),(Rp2,Rq4,Rr2 1),(Rp2, Rq4,Rr22),(Rp2,Rq4,Rr23),(Rp2,Rq4,Rr24),(Rp2,Rq4,Rr25),(Rp2,Rq4,Rr26),(Rp2,Rq4,Rr27 ),(Rp2,Rq4,Rr28),(Rp2,Rq4,Rr29),(Rp2,Rq4,Rr3O),(Rp2,Rq4,Rr3 1),(Rp2,Rq4,Rr32),(Rp2,Rq 4,Rr33),(Rp2,Rq4,Rr34),(Rp2,Rq4,Rr35),(Rp2,Rq4,Rr36),(Rp2,Rq4,Rr37),(Rp2,Rq5,Rr1),(R p2,Rq5,Rr2),(Rp2,Rq5,Rr3),(Rp2,Rq5,Rr4),(Rp2,Rq5,Rr5),(Rp2,Rq5,Rr6),(Rp2,Rq5,Rr7),(R p2,Rq5,Rr8),(Rp2,Rq5,Rr9),(Rp2,Rq5,Rr1O),(Rp2,Rq5,Rr1 1),(Rp2,Rq5,Rrl2),(Rp2,Rq5,Rr1 3), (Rp2,Rq5,Rr14),(Rp2,Rq5,Rr15),(Rp2,Rq5,Rr16),(Rp2,Rq5,Rr17),(Rp2,Rq5,Rr18),(Rp2,R q5,Rr19),(Rp2,Rq5,Rr2O),(Rp2,Rq5,Rr2 1),(Rp2,Rq5,Rr22),(Rp2,Rq5,Rr23),(Rp2,Rq5,Rr24), (Rp2,Rq5,Rr25),(Rp2,Rq5,Rr26),(Rp2,Rq5,Rr27),(Rp2,Rq5,Rr28),(Rp2,Rq5,Rr29),(Rp2,Rq5 ,Rr30), (Rp2,Rq5,Rr3 1),(Rp2,Rq5,Rr32),(Rp2,Rq5,Rr33),(Rp2,Rq5,Rr34),(Rp2,Rq5,Rr35),(R p2,Rq5,Rr36),(Rp2,Rq5,Rr37),(Rp3,Rq1,Rr1),(Rp3,Rq1,Rr2),(Rp3,Rq1,Rr3),(Rp3,Rq1,Rr4), (Rp3,Rq1,Rr5),(Rp3,Rq1,Rr6),(Rp3,Rq1,Rr7),(Rp3,Rq1,Rr8),(Rp3,Rq1,Rr9),(Rp3,Rq1,Rr10 ),(Rp3,Rql,Rrl 1),(Rp3,Rql,Rrl2),(Rp3,Rql,Rrl3),(Rp3,Rql,Rrl4),(Rp3,Rql,Rrl5),(Rp3,Rq 1,Rrl6),(Rp3,Rql,Rr17),(Rp3,Rql,Rr18),(Rp3,Rql,Rr19),(Rp3,Rql,Rr2O),(Rp3,Rql,Rr2 1),( Rp3,Rq1,Rr22),(Rp3,Rq1,Rr23),(Rp3,Rq1,Rr24),(Rp3,Rq1,Rr25),(Rp3,Rq1,Rr26),(Rp3,Rq1, Rr27),(Rp3,Rql,Rr28),(Rp3,Rql,Rr29),(Rp3,Rq1,Rr30),(Rp3,Rql,Rr31),(Rp3,Rql,Rr32),(R p3,Rq1,Rr33),(Rp3,Rq1,Rr34),(Rp3,Rq1,Rr35),(Rp3,Rq1,Rr36),(Rp3,Rq1,Rr37),(Rp3,Rq2,R r1),(Rp3,Rq2,Rr2),(Rp3,Rq2,Rr3),(Rp3,Rq2,Rr4),(Rp3,Rq2,Rr5),(Rp3,Rq2,Rr6),(Rp3,Rq2,R r7),(Rp3,Rq2,Rr8),(Rp3,Rq2,Rr9),(Rp3,Rq2,RrlO),(Rp3,Rq2,Rrl 1),(Rp3,Rq2,Rrl2),(Rp3,Rq 2,Rrl3),(Rp3,Rq2,Rr14),(Rp3,Rq2,Rr15),(Rp3,Rq2,Rr16),(Rp3,Rq2,Rr17),(Rp3,Rq2,Rrl8),( Rp3,Rq2,Rr1 9),(Rp3,Rq2,Rr2O),(Rp3,Rq2,Rr2 1),(Rp3,Rq2,Rr22),(Rp3,Rq2,Rr23),(Rp3,Rq2, Rr24),(Rp3,Rq2,Rr25),(Rp3,Rq2,Rr26),(Rp3,Rq2,Rr27),(Rp3,Rq2,Rr28),(Rp3,Rq2,Rr29),(R p3,Rq2,Rr3O),(Rp3,Rq2,Rr3 1),(Rp3,Rq2,Rr32),(Rp3,Rq2,Rr33),(Rp3,Rq2,Rr34),(Rp3,Rq2,R r35), (Rp3,Rq2,Rr36),(Rp3,Rq2,Rr37),(Rp3,Rq3,Rrl),(Rp3,Rq3,Rr2),(Rp3,Rq3,Rr3),(Rp3,Rq 3,Rr4), (Rp3,Rq3,Rr5),(Rp3,Rq3,Rr6),(Rp3,Rq3,Rr7),(Rp3,Rq3,Rr8),(Rp3,Rq3,Rr9),(Rp3,Rq 3,Rr1O),(Rp3,Rq3,Rr1 1),(Rp3,Rq3,Rrl2),(Rp3,Rq3,Rr13),(Rp3,Rq3,Rrl4),(Rp3,Rq3,Rrl5),( Rp3,Rq3,Rr16),(Rp3,Rq3,Rr17),(Rp3,Rq3,Rr18),(Rp3,Rq3,Rr19),(Rp3,Rq3,Rr2),(Rp3,Rq3, Rr2 1),(Rp3,Rq3,Rr22),(Rp3,Rq3,Rr23),(Rp3,Rq3,Rr24),(Rp3,Rq3,Rr25),(Rp3,Rq3,Rr26),(R p3,Rq3,Rr27),(Rp3,Rq3,Rr28),(Rp3,Rq3,Rr29),(Rp3,Rq3,Rr3O),(Rp3,Rq3,Rr3 1),(Rp3,Rq3,R r32), (Rp3,Rq3,Rr33),(Rp3,Rq3,Rr34),(Rp3,Rq3,Rr35),(Rp3,Rq3,Rr36),(Rp3,Rq3,Rr37),(Rp3 ,Rq4,Rr1),(Rp3,Rq4,Rr2),(Rp3,Rq4,Rr3),(Rp3,Rq4,Rr4), (Rp3,Rq4,Rr5),(Rp3,Rq4,Rr6),(Rp3 ,Rq4,Rr7),(Rp3,Rq4,Rr8),(Rp3,Rq4,Rr9),(Rp3,Rq4,Rr1O),(Rp3,Rq4,Rr1 1),(Rp3,Rq4,Rrl2),( Rp3,Rq4,Rr1 3),(Rp3,Rq4,Rr14),(Rp3,Rq4,Rr15),(Rp3,Rq4,Rr16),(Rp3,Rq4,Rr17),(Rp3,Rq4, Rr18),(Rp3,Rq4,Rr19),(Rp3,Rq4,Rr2O),(Rp3,Rq4,Rr2 1),(Rp3,Rq4,Rr22),(Rp3,Rq4,Rr23),(R p3,Rq4,Rr24),(Rp3,Rq4,Rr25),(Rp3,Rq4,Rr26),(Rp3,Rq4,Rr27),(Rp3,Rq4,Rr28),(Rp3,Rq4,R r29), (Rp3,Rq4,Rr3O),(Rp3,Rq4,Rr3 1),(Rp3,Rq4,Rr32),(Rp3,Rq4,Rr33),(Rp3,Rq4,Rr34),(Rp3 ,Rq4,Rr35),(Rp3,Rq4,Rr36),(Rp3,Rq4,Rr37),(Rp3,Rq5,Rr1), (Rp3,Rq5,Rr2),(Rp3,Rq5,Rr3),( Rp3,Rq5,Rr4),(Rp3,Rq5,Rr5),(Rp3,Rq5,Rr6),(Rp3,Rq5,Rr7), (Rp3,Rq5,Rr8),(Rp3,Rq5,Rr9),( Rp3,Rq5,Rr1O),(Rp3,Rq5,Rr1 1),(Rp3,Rq5,Rrl2),(Rp3,Rq5,Rr13),(Rp3,Rq5,Rrl4),(Rp3,Rq5, Rr 15), (Rp 3,Rq5,Rr 16), (Rp 3,Rq5,Rr 17), (Rp 3,Rq5,Rr 18), (Rp 3,Rq5,Rr 19), (Rp 3,Rq5,Rr2 0), (R p3,Rq5,Rr2 1),(Rp3,Rq5,Rr22),(Rp3,Rq5,Rr23),(Rp3,Rq5,Rr24),(Rp3,Rq5,Rr25),(Rp3,Rq5,R r26), (Rp3,Rq5,Rr27),(Rp3,Rq5,Rr28),(Rp3,Rq5,Rr29),(Rp3,Rq5,Rr3O),(Rp3,Rq5,Rr3 1),(Rp3 ,Rq5,Rr32),(Rp3,Rq5,Rr33),(Rp3,Rq5,Rr34),(Rp3,Rq5,Rr35),(Rp3,Rq5,Rr36),(Rp3,Rq5,Rr3 7), (Rp4,Rql,Rrl),(Rp4,Rql,Rr2),(Rp4,Rql,Rr3),(Rp4,Rql,Rr4),(Rp4,Rql,Rr5),(Rp4,Rql,Rr 6), (Rp4,Rql,Rr7),(Rp4,Rql,Rr8),(Rp4,Rql,Rr9),(Rp4,Rql,RrlO),(Rp4,Rql,Rrl 1),(Rp4,Rq1, Rr12),(Rp4,Rql,Rr13),(Rp4,Rql,Rrl4),(Rp4,Rq1,Rr15),(Rp4,Rql,Rr16),(Rp4,Rql,Rrl7),(R p4,Rq1,Rr18),(Rp4,Rql,Rr1 9),(Rp4,Rq1,Rr20),(Rp4,Rq1,Rr2 1),(Rp4,Rql,Rr22),(Rp4,Rql,R 121 r23), (Rp4,Rql ,Rr24), (Rp4,Rql ,Rr2 5), (Rp4,Rql ,Rr2 6), (Rp4,Rql1,Rr27), (Rp4,Rql1,Rr2S), (Rp4 ,Rql,Rr29),(Rp4,Rql ,Rr3O),(Rp4,Rql ,Rr3 1),(Rp4,Rql ,Rr32),(Rp4,Rql ,Rr33),(Rp4,Rql,Rr3 4), (Rp4,Rql ,Rr3 5), (Rp4,Rql ,Rr3 6), (Rp4,Rql1,Rr3 7), (Rp4,Rq2,Rrl), (Rp4,Rq2,Rr2), (Rp4,Rq2 , Rr3), (Rp 4,Rq2,Rr4), (Rp 4,Rq2,Rr5), (Rp 4,Rq2,Rr6), (Rp4,Rq2,Rr7), (Rp 4,Rq2,Rr8), (Rp 4,Rq2 ,Rr9),(Rp4,Rq2,RrlO),(Rp4,Rq2,RrlI 1),(Rp4,Rq2,Rrl2),(Rp4,Rq2,Rrl3),(Rp4,Rq2,Rrl4),(Rp 4,Rq2,Rrl 5), (Rp4,Rq2,Rrl 6), (Rp4,Rq2,Rrl 7), (Rp4,Rq2,Rrl 8), (Rp4,Rq2,Rrl 9), (Rp4,Rq2,Rr 20), (Rp4,Rq2,Rr2 1), (Rp4,Rq2,Rr22), (Rp4,Rq2,Rr2 3), (Rp4,Rq2,Rr24), (Rp4,Rq2,Rr25), (Rp4, Rq2,Rr2 6), (Rp4,Rq2,Rr2 7), (Rp 4,Rq2,Rr2S8), (Rp4,Rq2,Rr2 9), (Rp4,Rq2,Rr3O), (Rp4,Rq2,Rr3 1 ), (Rp 4,Rq2,Rr32), (Rp4,Rq2,Rr3 3), (Rp 4,Rq2,Rr34), (Rp4,Rq2,Rr3 5), (Rp 4,Rq2,Rr3 6), (Rp 4,Rq 2,Rr3 7), (Rp 4,Rq3,Rrl1), (Rp 4,Rq3,Rr2), (Rp4,Rq3,Rr3), (Rp 4,Rq3,Rr4), (Rp 4,Rq3,Rr5), (Rp4,R q3,Rr6),(Rp4,Rq3,Rr7),(Rp4,Rq3,RrS),(Rp4,Rq3,Rr9),(Rp4,Rq3,RrlO),(Rp4,Rq3,Rrl 1),(Rp4 ,Rq3,Rrl12), (Rp4,Rq3,Rrl13), (Rp4,Rq3,Rrl 4), (Rp4,Rq3,Rrl15), (Rp4,Rq3,Rrl 6), (Rp4,Rq3,Rrl1 7), (Rp4,Rq3,Rrl 8),(Rp4,Rq3,Rrl 9),(Rp4,Rq3,Rr2O),(Rp4,Rq3,Rr2 1),(Rp4,Rq3,Rr22),(Rp4,R q3,Rr2 3), (Rp4,Rq3,Rr24), (Rp4,Rq3,Rr2 5), (Rp4,Rq3,Rr2 6), (Rp 4,Rq3,Rr2 7), (Rp 4,Rq3,Rr2 8), (Rp4,Rq3,Rr29), (Rp4,Rq3,Rr3O), (Rp4,Rq3,Rr3 1), (Rp4,Rq3,Rr32), (Rp4,Rq3,Rr3 3), (Rp4,Rq3 ,Rr34), (Rp4,Rq3,Rr3 5), (Rp4,Rq3,Rr3 6), (Rp4,Rq3,Rr3 7), (Rp4,Rq4,Rrl1), (Rp4,Rq4,Rr2), (Rp4 ,Rq4,Rr3), (Rp4,Rq4,Rr4), (Rp4,Rq4,Rr5), (Rp4,Rq4,Rr6), (Rp4,Rq4,Rr7), (Rp4,Rq4,RrS), (Rp4 ,Rq4,Rr9),(Rp4,Rq4,RrlO),(Rp4,Rq4,RrlI 1),(Rp4,Rq4,Rrl2),(Rp4,Rq4,Rrl 3),(Rp4,Rq4,Rrl4 ), (Rp4,Rq4,Rrl15), (Rp4,Rq4,Rrl 6), (Rp4,Rq4,Rrl17), (Rp4,Rq4,Rrl 8), (Rp4,Rq4,Rrl 9), (Rp4,Rq 4,Rr2O), (Rp4,Rq4,Rr2 1), (Rp4,Rq4,Rr22), (Rp4,Rq4,Rr2 3), (Rp4,Rq4,Rr24), (Rp4,Rq4,Rr2 5), ( Rp 4,Rq4,Rr2 6), (Rp 4,Rq4,Rr2 7), (Rp 4,Rq4,Rr2 8), (Rp 4,Rq4,Rr2 9), (Rp4,Rq4,Rr3O), (Rp4,Rq4, Rr3 1), (Rp4,Rq4,Rr32), (Rp4,Rq4,Rr33), (Rp4,Rq4,Rr34), (Rp4,Rq4,Rr35), (Rp4,Rq4,Rr3 6), (R p 4,Rq4,Rr3 7), (Rp4,Rq5,Rrl1), (Rp4,Rq5,Rr2), (Rp4,Rq5,Rr3), (Rp 4,Rq5,Rr4), (Rp4,Rq5,Rr5), ( Rp4,Rq5,Rr6),(Rp4,Rq5,Rr7),(Rp4,Rq5,RrS),(Rp4,Rq5,Rr9), (Rp4,Rq5,RrlO),(Rp4,Rq5,Rrl 1 ), (Rp4,Rq5,Rrl12), (Rp4,Rq5,Rrl 3), (Rp4,Rq5,Rrl14), (Rp4,Rq5,Rrl 5), (Rp4,Rq5,Rrl 6), (Rp4,Rq 5,Rrl 7), (Rp4,Rq5,Rrl18), (Rp4,Rq5,Rrl19), (Rp4,Rq5,Rr2O), (Rp4,Rq5,Rr2 1), (Rp4,Rq5,Rr22), ( Rp 4,Rq5,Rr2 3), (Rp 4,Rq5,Rr2 4), (Rp 4,Rq5,Rr2 5), (Rp 4,Rq5,Rr2 6), (Rp4,Rq5,Rr2 7), (Rp4,Rq5, Rr2S), (Rp4,Rq5,Rr29), (Rp4,Rq5,Rr3O), (Rp4,Rq5,Rr3 1), (Rp4,Rq5,Rr32), (Rp4,Rq5,Rr3 3), (R p 4,Rq5,Rr34), (Rp4,Rq5,Rr3 5), (Rp 4,Rq5,Rr3 6), (Rp 4,Rq5, Rr3 7), (Rp 5,Rql ,Rrl1), (Rp 5,RqlI,Rr 2), (Rp5,Rql,Rr3), (Rp5,Rql,Rr4), (Rp5,Rql,Rr5), (Rp5,Rql,Rr6), (Rp5,Rql,Rr7), (Rp5,Rql,Rr 8), (Rp5,Rql,Rr9),(Rp5,Rql,RrlO),(Rp5,Rql,Rrl 1),(Rp5,Rql,Rrl2),(Rp5,Rql,Rrl 3),(Rp5,Rq 1,Rrl 4), (Rp 5,RqlI,Rrl15), (Rp 5,RqlI,Rrl16), (Rp5,Rql,Rrl 7), (Rp 5,Rql,Rrl18), (Rp5,Rql,Rrl 9), ( Rp5,Rql,Rr2O),(Rp5,Rql,Rr2 1),(Rp5,Rql,Rr22),(Rp5,Rql,Rr23),(Rp5,Rql,Rr24),(Rp5,Rql, Rr2 5), (Rp 5,Rql1,Rr2 6), (Rp 5,Rql1,Rr2 7), (Rp 5,Rql1,Rr2 8), (Rp 5,Rql,Rr2 9), (Rp 5,Rq,Rr3), (R p 5,Rql1,Rr3l1), (Rp5,Rql,Rr32), (Rp 5,Rql1,Rr33), (Rp 5,Rql,Rr34), (Rp5,Rql,Rr3 5), (Rp 5,Rql,R r36), (Rp5,Rql ,Rr3 7), (Rp 5,Rq2,Rrl), (Rp5,Rq2,Rr2), (Rp 5,Rq2,Rr3) ,(Rp 5,Rq2,Rr4), (Rp5,Rq2 , Rr5), (Rp 5,Rq2,Rr6), (Rp 5,Rq2,Rr7), (Rp 5,Rq2,Rr8), (Rp 5,Rq2,Rr9), (Rp 5,Rq2,Rr10), (Rp 5,Rq 2,Rrl 1),(Rp5,Rq2,Rrl2),(Rp5,Rq2,RrlI3),(Rp5,Rq2,Rrl4),(Rp5,Rq2,RrlI5),(Rp5,Rq2,Rrl 6),( Rp 5,Rq2,Rrl 7), (Rp 5,Rq2,Rrl 8), (Rp 5,Rq2,Rrl19), (Rp 5,Rq2,Rr2O), (Rp5,Rq2,Rr2 1), (Rp5,Rq2, Rr22), (Rp 5,Rq2,Rr2 3), (Rp 5,Rq2,Rr24), (Rp 5,Rq2,Rr2 5), (Rp 5,Rq2,Rr2 6), (Rp 5,Rq2,Rr2 7), (R p 5,Rq2,Rr2S), (Rp5,Rq2,Rr2 9), (Rp 5,Rq2,Rr3O), (Rp 5,Rq2,Rr3 1), (Rp5,Rq2,Rr32), (Rp 5,Rq2,R r33), (Rp5,Rq2,Rr34), (Rp 5,Rq2,Rr3 5), (Rp 5,Rq2,Rr3 6), (Rp 5,Rq2,Rr37), (Rp 5,Rq3,Rrl1), (Rp 5, Rq3,Rr2), (Rp 5,Rq3,Rr3), (Rp 5,Rq3,Rr4), (Rp 5,Rq3,Rr5), (Rp 5,Rq3,Rr6), (Rp 5,Rq3,Rr7), (Rp 5, Rq3,RrS),(Rp5,Rq3,Rr9),(Rp5,Rq3,RrlO),(Rp5,Rq3,Rrl 1),(Rp5,Rq3,Rrl2),(Rp5,Rq3,Rrl3),( Rp 5,Rq3,Rrl 4), (Rp 5,Rq3,Rrl 5), (Rp 5,Rq3,Rrl16), (Rp 5,Rq3,Rrl17), (Rp5,Rq3,Rrl1), (Rp5,Rq3, Rrl19), (Rp5,Rq3,Rr2O), (Rp5,Rq3,Rr2 1), (Rp5,Rq3,Rr22), (Rp5,Rq3,Rr23), (Rp5,Rq3,Rr24), (R p 5,Rq3,Rr2 5), (Rp 5,Rq3,Rr2 6), (Rp 5,Rq3,Rr2 7), (Rp 5,Rq3, Rr2 8), (Rp 5,Rq3,Rr2 9), (Rp 5,Rq3,R r30), (Rp5,Rq3,Rr3 1),(Rp5,Rq3,Rr32),(Rp5,Rq3,Rr33),(Rp5,Rq3,Rr34),(Rp5,Rq3,Rr35),(Rp5 122 ,Rq3,Rr36), (Rp5,Rq3,Rr37), (Rp5,Rq4,Rrl), (Rp5,Rq4,Rr2), (Rp5,Rq4,Rr3), (Rp 5,Rq4,Rr4), (R p 5,Rq4,Rr5), (Rp 5,Rq4,Rr6), (Rp 5,Rq4,Rr7), (Rp 5,Rq4,Rr8), (Rp 5,Rq4,Rr9), (Rp 5,Rq4,Rr10), ( Rp5,Rq4,Rrl 1),(Rp5,Rq4,Rrl2),(Rp5,Rq4,RrlI3),(Rp5,Rq4,Rrl4),(Rp5,Rq4,RrlI5),(Rp5,Rq4, RrlI6),(Rp5,Rq4,Rrl7),(Rp5,Rq4,Rrl),(Rp5,Rq4,Rr9),(Rp5,Rq4,Rr2O),(Rp5,Rq4,Rr2 i),R p 5,Rq4,Rr22), (Rp 5,Rq4,Rr2 3), (Rp 5,Rq4,Rr24), (Rp 5,Rq4, Rr2 5), (Rp 5,Rq4,Rr2 6), (Rp 5,Rq4,R r27), (Rp5,Rq4,Rr2S8), (Rp 5,Rq4,Rr2 9), (Rp 5,Rq4,Rr3O), (Rp 5,Rq4,Rr3 1), (Rp 5,Rq4,Rr32), (Rp5 ,Rq4,Rr3 3), (Rp 5,Rq4,Rr34), (Rp 5,Rq4,Rr3 5), (Rp 5,Rq4,Rr3 6), (Rp 5,Rq4,Rr3 7), (Rp 5,Rq5,RrI ), (Rp 5,Rq5,Rr2), (Rp 5,Rq5,Rr3), (Rp 5,Rq5,Rr4), (Rp 5,Rq5, Rr5), (Rp 5,Rq5,Rr6), (Rp 5,Rq5,Rr7 ),(Rp5,Rq5,RrS),(Rp5,Rq5,Rr9),(Rp5,Rq5,RrlO),(Rp5,Rq5,Rrl 1),(Rp5,Rq5,Rrl2),(Rp5,Rq5, Rrl13), (Rp5,Rq5,Rrl4), (Rp5,Rq5,Rrl 5), (Rp5,Rq5,Rrl16), (Rp5,Rq5,Rrl 7), (Rp5,Rq5,Rrl ), (R p 5,Rq5,Rrl19), (Rp5,Rq5,Rr2O), (Rp 5,Rq5,Rr2 1), (Rp 5,Rq5,Rr22), (Rp5,Rq5,Rr2 3), (Rp 5,Rq5,R r24), (Rp5,Rq5,Rr2 5), (Rp 5,Rq5,Rr2 6), (Rp 5,Rq5,Rr2 7), (Rp 5,Rq5,Rr2S), (Rp 5,Rq5,Rr29), (Rp5 ,Rq5,Rr3O), (Rp5,Rq5,Rr3 1), (Rp5,Rq5,Rr32), (Rp 5,Rq5,Rr33), (Rp 5,Rq5,Rr34), (Rp 5,Rq5,Rr3 5), (Rp5,Rq5,Rr3 6), (Rp5,Rq5,Rr3 7), (Rp 6,Rql1,Rrl), (Rp6,Rql ,Rr2), (Rp 6,Rql1,Rr3), (Rp 6,Rql, Rr4), (Rp 6,Rql1,Rr5), (Rp 6,Rql ,Rr6), (Rp 6,Rql1,Rr7) ,(Rp 6,Rql1,RrS), (Rp 6,Rql ,Rr9), (Rp 6,Rql1, RrlO),(Rp6,Rql,Rrl 1),(Rp6,Rql,Rrl2),(Rp6,Rql,RrlI3),(Rp6,Rql,Rrl4),(Rp6,Rql,Rrl 5),(R p 6,RqlI,Rrl16), (Rp6,Rql,Rrl 7), (Rp 6,RqlI,Rr1), (Rp 6,Rql,Rr9), (Rp6,Rql,Rr2O), (Rp 6,Rql,R r2 1), (Rp6,Rql ,Rr22), (Rp 6,Rql ,Rr2 3), (Rp 6,Rql ,Rr24), (Rp 6,Rql1,Rr25), (Rp 6,Rql1,Rr26), (Rp6 ,Rql,Rr27),(Rp6,Rql ,Rr2S),(Rp6,Rql ,Rr29),(Rp6,Rql ,Rr3O),(Rp6,Rql ,Rr3 1),(Rp6,Rql,Rr3 2), (Rp6,Rql ,Rr3 3), (Rp6,Rql ,Rr34), (Rp 6,Rql1,Rr3 5), (Rp 6,Rql1,Rr3 6), (Rp 6,Rql1,Rr3 7), (Rp 6,R q2,Rrl1), (Rp 6,Rq2,Rr2), (Rp 6,Rq2,Rr3), (Rp 6,Rq2,Rr4), (Rp 6,Rq2,Rr5), (Rp 6,Rq2,Rr6), (Rp 6,R q2,Rr7),(Rp6,Rq2,RrS),(Rp6,Rq2,Rr9),(Rp6,Rq2,RrlO),(Rp6,Rq2,Rrl 1),(Rp6,Rq2,Rrl2),(Rp 6,Rq2,Rrl 3), (Rp 6,Rq2,Rrl 4), (Rp 6,Rq2,Rrl 5), (Rp 6,Rq2,Rrl 6), (Rp 6,Rq2,Rrl 7), (Rp 6,Rq2,Rr 1 8),(Rp6,Rq2,RrlI9),(Rp6,Rq2,Rr2O),(Rp6,Rq2,Rr2 1),(Rp6,Rq2,Rr22),(Rp6,Rq2,Rr23),(Rp6, Rq2,Rr24), (Rp 6,Rq2,Rr2 5), (Rp 6,Rq2,Rr2 6), (Rp 6,Rq2,Rr2 7), (Rp 6,Rq2,Rr2 8), (Rp 6,Rq2,Rr2 9 ),(Rp6,Rq2,Rr3O),(Rp6,Rq2,Rr3 1),(Rp6,Rq2,Rr32),(Rp6,Rq2,Rr33),(Rp6,Rq2,Rr34),(Rp6,Rq 2,Rr3 5), (Rp 6,Rq2,Rr36), (Rp 6,Rq2,Rr37), (Rp6,Rq3,Rrl), (Rp6,Rq3,Rr2), (Rp6,Rq3,Rr3), (Rp6 ,Rq3,Rr4), (Rp 6,Rq3,Rr5), (Rp6,Rq3,Rr6), (Rp6,Rq3,Rr7), (Rp6,Rq3,RrS), (Rp6,Rq3,Rr9), (Rp6 ,Rq3,RrlO),(Rp6,Rq3,RrlI 1),(Rp6,Rq3,Rrl2),(Rp6,Rq3,RrlI3),(Rp6,Rq3,Rrl4),(Rp6,Rq3,RrlI 5), (Rp6,Rq3,Rrl 6), (Rp6,Rq3,Rrl 7), (Rp 6,Rq3,Rrl 8), (Rp 6,Rq3,Rrl 9), (Rp 6,Rq3,Rr2O), (Rp 6,R q3,Rr2 1), (Rp6,Rq3,Rr22), (Rp6,Rq3,Rr2 3), (Rp6,Rq3,Rr24), (Rp 6,Rq3,Rr2 5), (Rp 6,Rq3,Rr2 6), (Rp6,Rq3,Rr27),(Rp6,Rq3,Rr2S),(Rp6,Rq3,Rr29),(Rp6,Rq3,Rr3O),(Rp6,Rq3,Rr3 1),(Rp6,Rq3 ,Rr32), (Rp6,Rq3,Rr3 3), (Rp 6,Rq3,Rr34), (Rp 6,Rq3,Rr3 5), (Rp 6,Rq3,Rr36), (Rp 6,Rq3,Rr37), (R p 6,Rq4,Rrl1), (Rp 6,Rq4,Rr2), (Rp 6,Rq4,Rr3), (Rp 6,Rq4,Rr4), (Rp 6,Rq4,Rr5), (Rp 6,Rq4,Rr6), (R p6,Rq4,Rr7),(Rp6,Rq4,RrS),(Rp6,Rq4,Rr9),(Rp6,Rq4,RrlO),(Rp6,Rq4,Rrl 1),(Rp6,Rq4,Rrl2 ), (Rp 6,Rq4,Rrl13), (Rp6,Rq4,Rrl 4), (Rp 6,Rq4,Rrl15), (Rp6,Rq4,Rrl 6), (Rp 6,Rq4,Rrl 7), (Rp 6,Rq 4,Rrl 8),(Rp6,Rq4,RrlI9),(Rp6,Rq4,Rr2O),(Rp6,Rq4,Rr2 1),(Rp6,Rq4,Rr22),(Rp6,Rq4,Rr23),( Rp 6,Rq4,Rr2 4), (Rp 6,Rq4,Rr2 5), (Rp 6,Rq4,Rr2 6), (Rp 6,Rq4,Rr2 7), (Rp 6,Rq4,Rr2 8), (Rp 6,Rq4, Rr29), (Rp6,Rq4,Rr3O), (Rp6,Rq4,Rr3 1), (Rp6,Rq4,Rr32), (Rp6,Rq4,Rr33), (Rp6,Rq4,Rr34), (R p 6,Rq4,Rr3 5), (Rp 6,Rq4,Rr3 6), (Rp 6,Rq4,Rr3 7), (Rp 6,Rq5,Rrl1), (Rp 6,Rq5,Rr2), (Rp 6,Rq5,Rr3 ), (Rp 6,Rq5,Rr4), (Rp 6,Rq5,Rr5), (Rp 6,Rq5,Rr6), (Rp 6,Rq5, Rr7), (Rp 6,Rq5,Rr8), (Rp 6,Rq5,Rr9 ),(Rp6,Rq5,RrlO),(Rp6,Rq5,Rrl 1),(Rp6,Rq5,Rrl2),(Rp6,Rq5,Rrl 3),(Rp6,Rq5,Rrl4),(Rp6,Rq 5,Rrl 5), (Rp 6,Rq5,Rrl16), (Rp 6,Rq5,Rr17), (Rp6,Rq5,RrS), (Rp 6,Rq5,Rr9), (Rp6,Rq5,Rr2O), ( Rp6,Rq5,Rr2 1),(Rp6,Rq5,Rr22),(Rp6,Rq5,Rr23),(Rp6,Rq5,Rr24),(Rp6,Rq5,Rr25),(Rp6,Rq5, Rr26),(Rp6,Rq5,Rr27),(Rp6,Rq5,Rr2S),(Rp6,Rq5,Rr29),(Rp6,Rq5,Rr3O),(Rp6,Rq5,Rr3 i),R p 6,Rq5,Rr32), (Rp 6,Rq5,Rr3 3), (Rp 6,Rq5,Rr34), (Rp 6,Rq5, Rr3 5), (Rp 6,Rq5,Rr3 6), (Rp 6,Rq5,R r37), (Rp7,Rql,Rrl), (Rp7,Rql,Rr2), (Rp7,Rql1,Rr3) ,(Rp 7,Rql,Rr4), (Rp7,Rql,Rr5), (Rp7,Rq , Rr6),(Rp7,Rql,Rr7),(Rp7,Rql,RrS),(Rp7,Rql,Rr9),(Rp7,Rql,RrlO),(Rp7,Rql,Rrl 1),(Rp7,R 123 qlI,Rrl12), (Rp7,Rql,Rrl 3), (Rp7,Rql,Rrl 4), (Rp7,Rql,Rrl 5), (Rp 7,RqlI,Rrl 6), (Rp 7,RqlI,Rrl 7), (Rp7,Rql,RrlS),(Rp7,Rql,RrlI9),(Rp7,Rql,Rr2O),(Rp7,Rql,Rr2 1),(Rp7,Rql,Rr22),(Rp7,RqlI ,Rr23), (Rp7,Rql ,Rr24), (Rp 7,Rql1,Rr2 5), (Rp 7,Rql ,Rr2 6), (Rp 7,Rql1,Rr27), (Rp 7,Rql1,Rr2S), (R p 7,Rql1,Rr29), (Rp7,Rql ,Rr3O), (Rp 7,Rql1,Rr3 1), (Rp 7,Rql1,Rr32), (Rp7,Rql ,Rr3 3), (Rp 7,Rql ,R r34), (Rp7,Rql ,Rr3 5), (Rp 7,Rql ,Rr3 6), (Rp 7,Rql ,Rr3 7), (Rp 7,Rq2,Rrl1), (Rp7,Rq2,Rr2), (Rp7,R q2,Rr3), (Rp 7,Rq2,Rr4), (Rp 7,Rq2,Rr5), (Rp 7,Rq2,Rr6), (Rp 7,Rq2,Rr7), (Rp 7,Rq2,Rr8), (Rp 7,R q2,Rr9),(Rp7,Rq2,RrlO),(Rp7,Rq2,RrlI 1),(Rp7,Rq2,Rrl2),(Rp7,Rq2,RrlI3),(Rp7,Rq2,Rrl4),( Rp 7,Rq2,Rrl 5), (Rp 7,Rq2,Rrl 6), (Rp 7,Rq2,Rrl17), (Rp 7,Rq2,Rrl18), (Rp7,Rq2,Rrl19), (Rp7,Rq2, Rr2O), (Rp7,Rq2,Rr2 1), (Rp7,Rq2,Rr22), (Rp7,Rq2,Rr23), (Rp7,Rq2,Rr24), (Rp7,Rq2,Rr2 5), (R p 7,Rq2,Rr2 6), (Rp 7,Rq2,Rr2 7), (Rp 7,Rq2,Rr2 8), (Rp 7,Rq2, Rr2 9), (Rp 7,Rq2,Rr3O), (Rp 7,Rq2,R r3 1), (Rp7,Rq2,Rr32), (Rp 7,Rq2,Rr3 3), (Rp 7,Rq2,Rr34), (Rp 7,Rq2,Rr35), (Rp 7,Rq2,Rr36), (Rp7 , Rq2,Rr3 7), (Rp 7,Rq3,Rrl1), (Rp 7,Rq3,Rr2), (Rp 7,Rq3,Rr3), (Rp 7,Rq3,Rr4), (Rp 7,Rq3,Rr5), (Rp 7,Rq3,Rr6),(Rp7,Rq3,Rr7),(Rp7,Rq3,RrS),(Rp7,Rq3,Rr9),(Rp7,Rq3,RrlO),(Rp7,Rq3,Rrl 1),( Rp 7,Rq3,Rrl 2), (Rp 7,Rq3,Rrl 3), (Rp 7,Rq3,Rrl14), (Rp 7,Rq3,Rrl15), (Rp7,Rq3,Rrl16), (Rp7,Rq3, Rrl17), (Rp7,Rq3,RrlS), (Rp7,Rq3,Rr 9), (Rp7,Rq3,Rr2O), (Rp7,Rq3,Rr2 1), (Rp7,Rq3,Rr22), (R p 7,Rq3,Rr2 3), (Rp 7,Rq3,Rr2 4), (Rp 7,Rq3,Rr2 5), (Rp 7,Rq3, Rr2 6), (Rp 7,Rq3,Rr2 7), (Rp 7,Rq3,R r28), (Rp7,Rq3,Rr29),(Rp7,Rq3,Rr3O),(Rp7,Rq3,Rr3 1),(Rp7,Rq3,Rr32),(Rp7,Rq3,Rr33),(Rp7 , Rq3,Rr34), (Rp 7,Rq3,Rr3 5), (Rp 7,Rq3,Rr3 6), (Rp 7,Rq3,Rr3 7), (Rp 7,Rq4,Rrl), (Rp 7,Rq4,Rr2), (Rp 7,Rq4,Rr3), (Rp 7,Rq4,Rr4), (Rp 7,Rq4,Rr5), (Rp 7,Rq4,Rr6), (Rp 7,Rq4,Rr7), (Rp 7,Rq4,Rr), (Rp7,Rq4,Rr9),(Rp7,Rq4,RrlO),(Rp7,Rq4,RrlI 1),(Rp7,Rq4,Rrl2),(Rp7,Rq4,Rrl 3),(Rp7,Rq4, Rrl14), (Rp7,Rq4,Rrl 5), (Rp7,Rq4,Rrl 6), (Rp7,Rq4,Rrl17), (Rp7,Rq4,RrlS8), (Rp7,Rq4,Rrl 9), (R p7,Rq4,Rr2O),(Rp7,Rq4,Rr2 1),(Rp7,Rq4,Rr22),(Rp7,Rq4,Rr23),(Rp7,Rq4,Rr24),(Rp7,Rq4,R r25), (Rp7,Rq4,Rr2 6), (Rp 7,Rq4,Rr2 7), (Rp 7,Rq4,Rr2S8), (Rp 7,Rq4,Rr29), (Rp 7,Rq4,Rr3O), (Rp7 ,Rq4,Rr3 1), (Rp7,Rq4,Rr32), (Rp7,Rq4,Rr3 3), (Rp 7,Rq4,Rr34), (Rp 7,Rq4,Rr3 5), (Rp 7,Rq4,Rr3 6), (Rp7,Rq4,Rr3 7), (Rp7,Rq5,Rrl), (Rp7,Rq5,Rr2), (Rp 7,Rq5,Rr3), (Rp7,Rq5,Rr4), (Rp7,Rq5,R r5), (Rp 7,Rq5,Rr6), (Rp 7,Rq5,Rr7), (Rp 7,Rq5,Rr8), (Rp 7,Rq5,Rr9), (Rp 7,Rq5,Rr10), (Rp 7,Rq5, Rr 1),(Rp7,Rq5,Rrl2),(Rp7,Rq5,Rrl3),(Rp7,Rq5,Rrl4),(Rp7,Rq5,Rrl5),(Rp7,Rq5,Rrl 6),(R p7,Rq5,RrlI7),(Rp7,Rq5,Rrl 8),(Rp7,Rq5,RrlI9),(Rp7,Rq5,Rr2O),(Rp7,Rq5,Rr2 1),(Rp7,Rq5,R r22), (Rp7,Rq5,Rr2 3), (Rp 7,Rq5,Rr24), (Rp 7,Rq5,Rr2 5), (Rp 7,Rq5,Rr26), (Rp 7,Rq5,Rr27), (Rp7 ,Rq5,Rr2S), (Rp7,Rq5,Rr29), (Rp7,Rq5,Rr3O), (Rp 7,Rq5,Rr3 1), (Rp 7,Rq5,Rr32), (Rp 7,Rq5,Rr3 3), (Rp7,Rq5,Rr34), (Rp7,Rq5,Rr3 5), (Rp 7,Rq5,Rr3 6), (Rp 7,Rq5,Rr3 7), (RpS8,Rqli,Rrl), (Rp8,Rq 1 ,Rr2), (RpS,Rql ,Rr3), (RpS,Rql1,Rr4), (RpS8,Rql ,Rr5), (RpS,Rql ,Rr6), (RpS,Rql1,Rr7), (RpS8,Rq 1,RrS), (Rp,Rql,Rr9),(Rp,Rql,RrlO),(RpS,Rql,RrlI 1),(Rp,Rql,Rrl2),(RpS,Rql,Rrl 3),(Rp 8,Rql,Rrl 4), (Rp 8,RqlI,Rrl 5), (Rp 8,RqlI,Rrl 6), (Rp 8,RqlI,Rrl 7), (Rp 8,Rql,RrS), (Rp 8,Rql,Rr 1 9), (RpS8,Rql1,Rr2O), (RpS8,Rql1,Rr2 1), (RpS,Rql ,Rr22), (RpS8,Rql1,Rr23), (RpS8,Rql1,Rr24), (RpS, Rql1,Rr2 5), (Rp 8,Rql1,Rr2 6), (Rp 8,Rql1,Rr2 7), (Rp 8,Rql,Rr2 ), (Rp 8,Rql,Rr2 9), (Rp 8,Rq,Rr3O ), (RpS8,Rql1,Rr3 1), (RpS,Rql ,Rr32), (RpS8,Rql ,Rr33), (RpS,Rql ,Rr34), (RpS8,Rql ,Rr3 5), (RpS8,Rq 1 ,Rr3 6), (RpS8,Rql1,Rr3 7), (RpS8,Rq2,Rrl), (RpS,Rq2,Rr2), (RpS,Rq2,Rr3), (Rp ,Rq2,Rr4), (Rp , Rq2,Rr5), (Rp 8,Rq2,Rr6), (Rp 8,Rq2,Rr7), (Rp 8,Rq2,Rr8), (Rp 8,Rq2,Rr9), (Rp 8,Rq2,Rr10), (Rp 8,Rq2,Rrl 1),(RpS,Rq2,Rrl2),(RpS,Rq2,Rrl 3),(RpS,Rq2,Rrl4),(RpS,Rq2,Rrl 5),(RpS,Rq2,Rr 1 6), (RpS8,Rq2,Rrl17), (RpS8,Rq2,Rrl18), (RpS,Rq2,Rrl 9), (RpS8,Rq2,Rr2O), (RpS8,Rq2,Rr2 1), (RpS, Rq2,Rr22), (Rp 8,Rq2,Rr2 3), (Rp 8,Rq2,Rr24), (Rp 8,Rq2,Rr2 5), (Rp 8,Rq2,Rr2 6), (Rp 8,Rq2,Rr2 7 ),(RpS,Rq2,Rr2S),(RpS,Rq2,Rr29),(RpS,Rq2,Rr3O),(RpS,Rq2,Rr3 1),(RpS,Rq2,Rr32),(RpS,Rq 2,Rr3 3), (Rp 8,Rq2,Rr34), (Rp 8,Rq2,Rr3 5), (Rp 8,Rq2,Rr3 6), (Rp 8,Rq2,Rr3 7), (Rp 8,Rq3,Rr1), (R p 8,Rq3,Rr2), (Rp 8,Rq3,Rr3), (Rp 8,Rq3,Rr4), (Rp 8,Rq3,Rr5), (Rp 8,Rq3,Rr6), (Rp 8,Rq3,Rr7), (R pS,Rq3,RrS),(RpS,Rq3,Rr9),(RpS,Rq3,RrlO),(RpS,Rq3,RrlI 1),(RpS,Rq3,Rrl2),(RpS,Rq3,RrlI 3), (RpS,Rq3,Rrl 4), (RpS,Rq3,Rrl 5), (RpS8,Rq3,Rrl 6), (RpS8,Rq3,Rrl 7), (RpS8,Rq3,Rrl 8), (RpS8,R q3,RrlI9),(RpS,Rq3,Rr2O),(RpS,Rq3,Rr2 1),(RpS,Rq3,Rr22),(RpS,Rq3,Rr23),(RpS,Rq3,Rr24), 124 (Rp 8,Rq3,Rr2 5), (Rp 8,Rq3,Rr2 6), (Rp 8,Rq3,Rr2 7), (Rp 8,Rq3,Rr2 8), (Rp 8,Rq3,Rr2 9), (Rp 8,Rq3 ,Rr3O), (RpS,Rq3,Rr3 1),(RpS,Rq3,Rr32),(RpS,Rq3,Rr33),(RpS,Rq3,Rr34),(RpS,Rq3,Rr35),(R p 8,Rq3,Rr3 6), (Rp 8,Rq3,Rr3 7), (Rp 8,Rq4,Rrl1), (Rp 8,Rq4,Rr2), (Rp 8,Rq4,Rr3), (Rp 8,Rq4,Rr4), (Rp 8,Rq4,Rr5), (Rp 8,Rq4,Rr6), (Rp 8,Rq4,Rr7), (Rp 8,Rq4,Rr8), (Rp 8,Rq4,Rr9), (Rp 8,Rq4,Rr10 ),(RpS,Rq4,Rrl 1),(Rp,Rq4,Rrl2),(RpS,Rq4,Rrl3),(RpS,Rq4,Rrl4),(RpS,Rq4,Rrl 5),(RpS,Rq 4,Rrl 6),(RpS,Rq4,RrlI7),(RpS,Rq4,RrlIS),(RpS,Rq4,Rrl 9),(RpS,Rq4,Rr2O),(RpS,Rq4,Rr2 1),( Rp 8,Rq4,Rr2 2), (Rp 8,Rq4,Rr2 3), (Rp 8,Rq4,Rr24), (Rp 8,Rq4,Rr2 5), (Rp 8,Rq4,Rr2 6), (Rp 8,Rq4, Rr27), (RpS,Rq4,Rr2S), (RpS,Rq4,Rr29), (RpS,Rq4,Rr3O), (RpS,Rq4,Rr3 1), (RpS,Rq4,Rr32), (R p 8,Rq4,Rr3 3), (Rp 8,Rq4,Rr3 4), (Rp 8,Rq4,Rr3 5), (Rp 8,Rq4, Rr3 6), (Rp 8,Rq4,Rr3 7), (Rp 8,Rq5,R rl1), (Rp 8,Rq5,Rr2), (Rp 8,Rq5,Rr3), (Rp 8,Rq5,Rr4), (Rp 8,Rq5,Rr5), (Rp 8,Rq5,Rr6), (Rp 8,Rq5,R r7),(RpS,Rq5,RrS),(RpS,Rq5,Rr9),(RpS,Rq5,RrlO),(RpS,Rq5,Rrl 1),(RpS,Rq5,Rrl2),(RpS,Rq 5,Rrl 3), (Rp 8,Rq5,Rrl14), (Rp 8,Rq5,Rrl15), (Rp8,Rq5,Rrl 6), (Rp 8,Rq5,Rrl17), (Rp8,Rq5,Rrl 8), ( RpS8,Rq5,Rrl 9), (RpS8,Rq5,Rr2O), (RpS8,Rq5,Rr2 1), (RpS8,Rq5,Rr22), (RpS,Rq5,Rr23), (RpS,Rq5, Rr24), (Rp 8,Rq5,Rr2 5), (Rp 8,Rq5,Rr2 6), (Rp 8,Rq5,Rr2 7), (Rp 8,Rq5,Rr2 8), (Rp 8,Rq5,Rr2 9), (R pS,Rq5,Rr3O),(RpS,Rq5,Rr3 1),(RpS,Rq5,Rr32),(RpS,Rq5,Rr33),(RpS,Rq5,Rr34),(RpS,Rq5,R r35), (RpS,Rq5,Rr3 6), (RpS8,Rq5,Rr3 7), (Rp 9,Rql ,Rrl), (Rp9,Rql ,Rr2), (Rp9,Rql ,Rr3), (Rp 9,Rq 1 ,Rr4), (Rp9,Rql ,Rr5), (Rp9,Rql1,Rr6), (Rp 9,Rql ,Rr7), (Rp9,Rql ,RrS), (Rp9,Rql1,Rr9), (Rp 9,Rq 1,RrlO),(Rp9,Rql,RrlI 1),(Rp9,Rql,Rrl2),(Rp9,Rql,Rrl 3),(Rp9,Rql,Rrl4),(Rp9,Rql,Rrl 5),( Rp 9,Rql,Rrl 6), (Rp 9,Rql,Rrl 7), (Rp 9,RqlI,Rr1), (Rp 9,Rq,Rr9), (Rp9,Rq,Rr2O), (Rp9,Rql, Rr2l1), (Rp9,Rql,Rr22), (Rp9,Rql,Rr23), (Rp9,Rql1,Rr24), (Rp9,Rql,Rr25), (Rp9,Rql,Rr2 6), (R p9,Rql,Rr27),(Rp9,Rql ,Rr2S),(Rp9,Rql,Rr29),(Rp9,Rql,Rr3O),(Rp9,Rql ,Rr3 1),(Rp9,Rql ,R r32), (Rp9,Rql ,Rr3 3), (Rp 9,Rql ,Rr34), (Rp 9,Rql ,Rr3 5), (Rp 9,Rql1,Rr36), (Rp 9,Rql1,Rr37), (Rp9 ,Rq2,Rrl1), (Rp 9,Rq2,Rr2), (Rp9,Rq2,Rr3), (Rp9,Rq2,Rr4), (Rp9,Rq2,Rr5), (Rp9,Rq2,Rr6), (Rp9 ,Rq2,Rr7),(Rp9,Rq2,RrS),(Rp9,Rq2,Rr9),(Rp9,Rq2,RrlO),(Rp9,Rq2,RrlI 1),(Rp9,Rq2,Rrl2),( Rp 9,Rq2,Rrl 3), (Rp 9,Rq2,Rrl 4), (Rp 9,Rq2,Rrl15), (Rp 9,Rq2,Rrl16), (Rp9,Rq2,Rrl17), (Rp9,Rq2, Rrl18), (Rp9,Rq2,Rrl 9), (Rp9,Rq2,Rr2O), (Rp9,Rq2,Rr2 1), (Rp9,Rq2,Rr22), (Rp9,Rq2,Rr2 3), (R p 9,Rq2,Rr24), (Rp 9,Rq2,Rr2 5), (Rp 9,Rq2,Rr2 6), (Rp 9,Rq2, Rr2 7), (Rp 9,Rq2,Rr2 8), (Rp 9,Rq2,R r29), (Rp9,Rq2,Rr3O),(Rp9,Rq2,Rr3 1),(Rp9,Rq2,Rr32),(Rp9,Rq2,Rr33),(Rp9,Rq2,Rr34),(Rp9 ,Rq2,Rr35), (Rp9,Rq2,Rr36), (Rp9,Rq2,Rr3 7), (Rp 9,Rq3,Rrl1), (Rp9,Rq3,Rr2), (Rp 9,Rq3,Rr3),( Rp 9,Rq3,Rr4), (Rp9,Rq3,Rr5), (Rp 9,Rq3,Rr6), (Rp 9,Rq3,Rr7), (Rp9,Rq3,RrS), (Rp 9,Rq3,Rr9),( Rp9,Rq3,RrlO),(Rp9,Rq3,Rrl 1),(Rp9,Rq3,Rrl2),(Rp9,Rq3,RrlI3),(Rp9,Rq3,Rrl4),(Rp9,Rq3, Rr 15), (Rp 9, Rq3 ,Rr 16), (Rp 9, Rq3 ,Rr 17), (Rp 9, Rq3, Rr 18), (Rp 9, Rq3 ,Rr 19), (Rp 9, Rq3 ,Rr2 0), (R p 9,Rq3,Rr2 1), (Rp9,Rq3,Rr22), (Rp 9,Rq3,Rr23), (Rp 9,Rq3,Rr24), (Rp9,Rq3,Rr2 5), (Rp 9,Rq3,R r26), (Rp9,Rq3,Rr2 7), (Rp 9,Rq3,Rr2 8), (Rp 9,Rq3,Rr2 9), (Rp 9,Rq3,Rr3O), (Rp 9,Rq3,Rr3 1), (Rp9 , Rq3,Rr32), (Rp 9,Rq3,Rr3 3), (Rp 9,Rq3,Rr3 4), (Rp 9,Rq3,Rr3 5), (Rp 9,Rq3,Rr3 6), (Rp 9,Rq3,Rr3 7), (Rp9,Rq4,Rrl), (Rp9,Rq4,Rr2), (Rp9,Rq4,Rr3), (Rp9,Rq4,Rr4), (Rp9,Rq4,Rr5), (Rp9,Rq4,Rr 6), (Rp9,Rq4,Rr7),(Rp9,Rq4,Rr8),(Rp9,Rq4,Rr9),(Rp9,Rq4,RrlO),(Rp9,Rq4,Rrl 1),(Rp9,Rq4, Rrl12), (Rp9,Rq4,Rrl 3), (Rp9,Rq4,Rrl4), (Rp9,Rq4,Rrl15), (Rp9,Rq4,Rrl 6), (Rp9,Rq4,Rrl 7), (R p 9,Rq4,Rrl18), (Rp9,Rq4,Rrl 9), (Rp 9,Rq4,Rr2O), (Rp 9,Rq4,Rr2 1), (Rp9,Rq4,Rr22), (Rp 9,Rq4,R r23), (Rp9,Rq4,Rr24), (Rp 9,Rq4,Rr2 5), (Rp 9,Rq4,Rr2 6), (Rp 9,Rq4,Rr27), (Rp 9,Rq4,Rr28), (Rp9 ,Rq4,Rr29),(Rp9,Rq4,Rr3O),(Rp9,Rq4,Rr3 1),(Rp9,Rq4,Rr32),(Rp9,Rq4,Rr33),(Rp9,Rq4,Rr3 4), (Rp9,Rq4,Rr3 5), (Rp9,Rq4,Rr3 6), (Rp 9,Rq4,Rr3 7), (Rp 9,Rq5,Rrl), (Rp 9,Rq5,Rr2), (Rp9,Rq5 , Rr3), (Rp 9,Rq5,Rr4), (Rp 9,Rq5,Rr5), (Rp 9,Rq5,Rr6), (Rp 9,Rq5,Rr7), (Rp 9,Rq5,Rr8), (Rp 9,Rq5 ,Rr9),(Rp9,Rq5,RrlO),(Rp9,Rq5,RrlI 1),(Rp9,Rq5,Rrl2),(Rp9,Rq5,Rrl3),(Rp9,Rq5,Rrl4),(Rp 9,Rq5,Rrl 5), (Rp 9,Rq5,Rrl 6), (Rp 9,Rq5,Rrl 7), (Rp 9,Rq5,Rrl 8), (Rp 9,Rq5,Rrl 9), (Rp 9,Rq5,Rr 20), (Rp 9,Rq5,Rr2 1), (Rp 9,Rq5,Rr22), (Rp9,Rq5,Rr2 3), (Rp 9,Rq5,Rr24), (Rp 9,Rq5,Rr25), (Rp9, Rq5,Rr2 6), (Rp 9,Rq5,Rr2 7), (Rp 9,Rq5,Rr2 8), (Rp 9,Rq5,Rr2 9), (Rp 9,Rq5,Rr3O), (Rp 9,Rq5,Rr3 1 )(Rp 9,Rq5,Rr32), (Rp 9,Rq5,Rr3 3), (Rp 9,Rq5,Rr34), (Rp 9,Rq5,Rr3 5), (Rp 9,Rq5,Rr3 6), (Rp 9,Rq 125 5,Rr37),(Rp 10,Rql,Rr1),(Rp 10,Rql,Rr2),(Rp10,Rql,Rr3),(Rp10,Rql,Rr4),(Rp10,Rql,Rr5),( Rp 10,Rql,Rr6),(Rp 10,Rql,Rr7),(Rp 10,Rql,Rr8),(Rp10,Rql,Rr9),(Rp 10,Rql,Rr1O),(Rp10,R ql,Rr1 1),(Rp10,Rql,Rrl2),(Rp 10,Rql,Rr13),(Rp 10,Rql,Rrl4),(Rp10,Rql,Rr15),(Rp 10,Rql, Rr16),(Rp10,Rql,Rr17),(Rp 10,Rql,Rr18),(Rp 10,Rql,Rr19),(Rp10,Rql,Rr20),(Rp 10,Rql,Rr 2 1),(Rp 10,Rql,Rr22),(Rp 10,Rql,Rr23),(Rp10,Rql,Rr24),(Rp 10,Rql,Rr25),(Rp10,Rql,Rr26) ,(Rp10,Rql,Rr27),(Rp10,Rql,Rr28),(Rp 10,Rql,Rr29),(Rp10,Rql,Rr30),(Rp 10,Rql,Rr3 1),(R p 10,Rql,Rr32),(Rp10,Rql,Rr33),(Rp10,Rql,Rr34),(Rp 10,Rql,Rr35),(Rp10,Rql,Rr36),(Rp1 0,Rql,Rr37),(Rp 10,Rq2,Rr1),(Rp 10,Rq2,Rr2),(Rp 10,Rq2,Rr3), (Rp 10,Rq2,Rr4),(Rp 10,Rq2,R r5),(Rp 10,Rq2,Rr6),(Rp 10,Rq2,Rr7),(Rp 10,Rq2,Rr8),(Rp 10,Rq2,Rr9),(Rp 10,Rq2,Rrl0),(Rp 1 0,Rq2,Rr 1),(Rp 10,Rq2,Rrl2),(Rp10,Rq2,Rr13),(Rp 10,Rq2,Rrl4),(Rp10,Rq2,Rr15),(Rp 10,R q2,Rr16),(Rp10,Rq2,Rr17),(Rp 10,Rq2,Rr18),(Rp 10,Rq2,Rr19),(Rp10,Rq2,Rr20),(Rp 10,Rq2, Rr2 1),(Rp 10,Rq2,Rr22),(Rp 10,Rq2,Rr23),(Rp 10,Rq2,Rr24),(Rp 10,Rq2,Rr25),(Rp 10,Rq2,Rr 26),(Rp 10,Rq2,Rr27),(Rp 10,Rq2,Rr28),(Rp 10,Rq2,Rr29),(Rp 10,Rq2,Rr30),(Rp 10,Rq2,Rr3 1) ,(Rp 10,Rq2,Rr32),(Rp 10,Rq2,Rr33),(Rp 10,Rq2,Rr34),(Rp 10,Rq2,Rr35),(Rp 10,Rq2,Rr36),(R p 10,Rq2,Rr37),(Rp 10,Rq3,Rr1),(Rp 10,Rq3,Rr2),(Rp 10,Rq3,Rr3),(Rp 10,Rq3,Rr4),(Rp 10,Rq3 ,Rr5),(Rp 10,Rq3,Rr6),(Rp 10,Rq3,Rr7),(Rp 10,Rq3,Rr8),(Rp 10,Rq3,Rr9),(Rp 10,Rq3,Rrl0),(R p 10,Rq3,Rr 1),(Rp10,Rq3,Rrl2),(Rp10,Rq3,Rr13),(Rp 10,Rq3,Rrl4),(Rp10,Rq3,Rr15),(Rp1 0,Rq3,Rr16),(Rp 10,Rq3,Rr17),(Rp10,Rq3,Rr18),(Rp 10,Rq3,Rr19),(Rp10,Rq3,Rr20),(Rp 10,R q3,Rr2 1),(Rp 10,Rq3,Rr22),(Rp 10,Rq3,Rr23),(Rp 10,Rq3,Rr24),(Rp 10,Rq3,Rr25),(Rp 10,Rq3, Rr26),(Rp 10,Rq3,Rr27),(Rp 10,Rq3,Rr28),(Rp 10,Rq3,Rr29),(Rp 10,Rq3,Rr30),(Rp 10,Rq3,Rr 3 1),(Rp 10,Rq3,Rr32),(Rp 10,Rq3,Rr33),(Rp 10,Rq3,Rr34),(Rp 10,Rq3,Rr35),(Rp 10,Rq3,Rr36) ,(Rp 10,Rq3,Rr37),(Rp 10,Rq4,Rrl),(Rp 10,Rq4,Rr2),(Rp 10,Rq4,Rr3),(Rp 10,Rq4,Rr4),(Rp 10, Rq4,Rr5),(Rp 10,Rq4,Rr6),(Rp 10,Rq4,Rr7),(Rp 10,Rq4,Rr8),(Rp 10,Rq4,Rr9),(Rp 10,Rq4,Rr1O ),(Rp 10,Rq4,Rr 1),(Rp10,Rq4,Rrl2),(Rp10,Rq4,Rr13),(Rp 10,Rq4,Rrl4),(Rp10,Rq4,Rrl5),( Rp 10,Rq4,Rr16),(Rp10,Rq4,Rr17),(Rp 10,Rq4,Rr18),(Rp10,Rq4,Rr19),(Rp 10,Rq4,Rr2O),(Rp 10,Rq4,Rr2 1),(Rp 10,Rq4,Rr22),(Rp 10,Rq4,Rr23),(Rp 10,Rq4,Rr24),(Rp 10,Rq4,Rr25),(Rp 10, Rq4,Rr26),(Rp 10,Rq4,Rr27),(Rp 10,Rq4,Rr28),(Rp 10,Rq4,Rr29), (Rp 10,Rq4,Rr3O),(Rp 10,Rq 4,Rr3 1),(Rp 10,Rq4,Rr32),(Rp 10,Rq4,Rr33),(Rp 10,Rq4,Rr34),(Rp 10,Rq4,Rr35),(Rp 10,Rq4,R r36), (Rp 10,Rq4,Rr37),(Rp 10,Rq5,Rr1),(Rp 10,Rq5,Rr2),(Rp 10,Rq5,Rr3),(Rp 10,Rq5,Rr4),(Rp 10,Rq5,Rr5),(Rp 10,Rq5,Rr6),(Rp 10,Rq5,Rr7),(Rp 10,Rq5,Rr8), (Rp 10,Rq5,Rr9),(Rp 10,Rq5,R r1O),(Rp10,Rq5,Rr1 1),(Rp10,Rq5,Rrl2),(Rp 10,Rq5,Rr13),(Rp10,Rq5,Rrl4),(Rp 10,Rq5,Rr15 ),(Rp 10,Rq5,Rr16),(Rp10,Rq5,Rr17),(Rp10,Rq5,Rr18),(Rp 10,Rq5,Rrl9),(Rp10,Rq5,Rr2O),( Rp 10,Rq5,Rr2 1),(Rp 10,Rq5,Rr22),(Rp 10,Rq5,Rr23),(Rp 10,Rq5,Rr24),(Rp 10,Rq5,Rr25),(Rp 10,Rq5,Rr26),(Rp 10,Rq5,Rr27),(Rp 10,Rq5,Rr28),(Rp 10,Rq5,Rr29),(Rp 10,Rq5,Rr3O),(Rp 10, Rq5,Rr3 1),(Rp 10,Rq5,Rr32),(Rp 10,Rq5,Rr33),(Rp 10,Rq5,Rr34), (Rp 10,Rq5,Rr35),(Rp 10,Rq 5,Rr36),(Rp 10,Rq5,Rr37),(Rp1 1,Rql,Rr1),(Rp1 1,Rql,Rr2),(Rp 1 1,Rql,Rr3),(Rp 1 1,Rql,Rr4), (Rp1 1,Rql,Rr5),(Rp1 1,Rql,Rr6),(Rp 1 1,Rql,Rr7),(Rp1 1,Rql,Rr8),(Rp 1 1,Rql,Rr9),(Rp1 1,Rq 1,Rr1O),(Rp 11,Rql,Rr 1),(Rp 1 1,Rql,Rrl2),(Rp 11,Rql,Rrl3),(Rp 1 1,Rql,Rrl4),(Rp 1 1,Rql,R r15),(Rp1 1,Rql,Rr16),(Rp1 1,Rql,Rrl7),(Rp 1 1,Rql,Rr18),(Rp1 1,Rql,Rrl9),(Rp 1 1,Rql,Rr20 ),(Rp 1 1,Rql,Rr2 1),(Rp1 1,Rql,Rr22),(Rp1 1,Rql,Rr23),(Rp 1 1,Rql,Rr24),(Rp1 1,Rql,Rr25),( Rp 1 1,Rql,Rr26),(Rp1 1,Rql,Rr27),(Rp 1 1,Rql,Rr28),(Rp1 1,Rql,Rr29),(Rp 1 1,Rql,Rr30),(Rp 1 1,Rql,Rr31),(Rp1 1,Rql,Rr32),(Rp 1 1,Rql,Rr33),(Rp1 1,Rql,Rr34),(Rp1 1,Rql,Rr35),(Rp 11, Rql,Rr36),(Rp1 1,Rql,Rr37),(Rp 1 1,Rq2,Rr1),(Rp 1 1,Rq2,Rr2),(Rp 1 1,Rq2,Rr3),(Rp1 1,Rq2,Rr 4), (Rp 1 1,Rq2,Rr5),(Rp 1 1,Rq2,Rr6),(Rp 11,Rq2,Rr7),(Rp 11,Rq2,Rr8),(Rp 1 1,Rq2,Rr9),(Rp 11, Rq2,Rr1O),(Rp1 1,Rq2,Rr 1),(Rp 1 1,Rq2,Rrl2),(Rp1 1,Rq2,Rr13),(Rp1 1,Rq2,Rrl4),(Rp 1 1,Rq 2,Rrl5),(Rp 1 1,Rq2,Rrl6),(Rp1 1,Rq2,Rr17),(Rp 1 1,Rq2,Rrl8),(Rp1 1,Rq2,Rr19),(Rp1 1,Rq2,R r20), (Rp 1 1,Rq2,Rr2 1),(Rp 1 1,Rq2,Rr22),(Rp 1 1,Rq2,Rr23), (Rp 1 1,Rq2,Rr24),(Rp 11,Rq2,Rr25 ),(Rp 1 1,Rq2,Rr26),(Rp1 1,Rq2,Rr27),(Rp1 1,Rq2,Rr28),(Rp 1 1,Rq2,Rr29),(Rp1 1,Rq2,Rr3O),( 126 Rp 1 1,Rq2,Rr31),(Rp1 1,Rq2,Rr32),(Rp 1 1,Rq2,Rr33),(Rp1 1,Rq2,Rr34),(Rp 1 1,Rq2,Rr35),(Rp 1 1,Rq2,Rr36),(Rp 1 1,Rq2,Rr37),(Rp 11,Rq3,Rr1),(Rp 11,Rq3,Rr2),(Rp 11,Rq3,Rr3),(Rp 1 1,Rq3 ,Rr4),(Rp 11,Rq3,Rr5),(Rp 1 1,Rq3,Rr6),(Rp 1 1,Rq3,Rr7),(Rp 1 1,Rq3,Rr8),(Rp 11,Rq3,Rr9),(Rp 1 1,Rq3,Rr1O),(Rp1 1,Rq3,Rr 1),(Rp 1 1,Rq3,Rrl2),(Rp1 1,Rq3,Rr13),(Rp1 1,Rq3,Rrl4),(Rp 11, Rq3,Rr15),(Rp1 1,Rq3,Rr16),(Rp 1 1,Rq3,Rr17),(Rp1 1,Rq3,Rr18),(Rp1 1,Rq3,Rr19),(Rp 1 1,Rq 3,Rr2O),(Rp 11,Rq3,Rr2 1),(Rp 1 1,Rq3,Rr22),(Rp 11,Rq3,Rr23),(Rp 1 1,Rq3,Rr24),(Rp 1 1,Rq3,R r25), (Rp 1 1,Rq3,Rr26),(Rp 1 1,Rq3,Rr27),(Rp 1 1,Rq3,Rr28), (Rp 1 1,Rq3,Rr29),(Rp 11,Rq3,Rr3O ),(Rp 11,Rq3,Rr3 1),(Rp 1 1,Rq3,Rr32),(Rp 1 1,Rq3,Rr33),(Rp 11,Rq3,Rr34),(Rp 1 1,Rq3,Rr35),( Rp 1 1,Rq3,Rr36),(Rp1 1,Rq3,Rr37),(Rp 11,Rq4,Rr1),(Rp 11,Rq4,Rr2),(Rp1 1,Rq4,Rr3),(Rp11, Rq4,Rr4),(Rp 11,Rq4,Rr5),(Rp 1 1,Rq4,Rr6),(Rp 11,Rq4,Rr7),(Rp 11,Rq4,Rr8),(Rp 11,Rq4,Rr9) ,(Rp1 1,Rq4,Rr1O),(Rp1 1,Rq4,Rr 1),(Rp 1 1,Rq4,Rrl2),(Rp1 1,Rq4,Rr13),(Rp 1 1,Rq4,Rrl4),(R p1 1,Rq4,Rrl5),(Rp1 1,Rq4,Rr16),(Rp1 1,Rq4,Rr17),(Rp 1 1,Rq4,Rr18),(Rp1 1,Rq4,Rr19),(Rp1 1,Rq4,Rr2O),(Rp 11,Rq4,Rr2 1),(Rp 1 1,Rq4,Rr22),(Rp 11,Rq4,Rr23),(Rp 1 1,Rq4,Rr24),(Rp 11 ,R q4,Rr25),(Rp 1 1,Rq4,Rr26),(Rp 11,Rq4,Rr27),(Rp 11,Rq4,Rr28),(Rp 1 1,Rq4,Rr29),(Rp 11,Rq4, Rr30),(Rp 1 1,Rq4,Rr3 1),(Rp 11,Rq4,Rr32),(Rp 1 1,Rq4,Rr33),(Rp 1 1,Rq4,Rr34),(Rp 11,Rq4,Rr 35),(Rp 11,Rq4,Rr36),(Rp 11,Rq4,Rr37),(Rp 1 1,Rq5,Rr1), (Rp 1 1,Rq5,Rr2),(Rp 1 1,Rq5,Rr3),(R p11 ,Rq5,Rr4),(Rp 11,Rq5,Rr5),(Rp 11,Rq5,Rr6),(Rp 11,Rq5,Rr7),(Rp 11,Rq5,Rr8),(Rp 1 1,Rq5, Rr9),(Rp 1 1,Rq5,Rr1O),(Rp1 1,Rq5,Rr 1),(Rp 1 1,Rq5,Rrl2),(Rp1 1,Rq5,Rr13),(Rp 1 1,Rq5,Rr1 4),(Rp1 1,Rq5,Rr15),(Rp 1 1,Rq5,Rrl6),(Rp1 1,Rq5,Rr17),(Rp1 1,Rq5,Rr18),(Rp 1 1,Rq5,Rrl9),( Rp 11,Rq5,Rr2O),(Rp 1 1,Rq5,Rr2 1),(Rp 11,Rq5,Rr22),(Rp 1 1,Rq5,Rr23),(Rp 11,Rq5,Rr24),(Rp 1 1,Rq5,Rr25),(Rp1 1,Rq5,Rr26),(Rp 1 1,Rq5,Rr27),(Rp1 1,Rq5,Rr28),(Rp1 1,Rq5,Rr29),(Rp 11, Rq5,Rr3O),(Rp 1 1,Rq5,Rr3 1),(Rp 11,Rq5,Rr32),(Rp 1 1,Rq5,Rr33), (Rp 11,Rq5,Rr34),(Rp 11,Rq 5,Rr35),(Rp 1 1,Rq5,Rr36),(Rp1 1,Rq5,Rr37). [0214] Following examples illustrate the present invention in more detail, but the present invention is not limited by these examples. The meaning of each abbreviation is as folllows: Me: methyl Et: ethyl Bu: butyl Ac: acetyl TMS: tetramethylsilane TMS-Cl: trimethylsilyl chloride DMSO: dimethyl sulfoxide DMF: dimethylformamide THF: tetrahydrofuran DBU: 1,8-diazabicyclo [5.4.0]undeca-7-ene NMP: N-methyl-2-pyrrolidone HOAt:1-hydroxy-7-azabenzotriazole HATU: 2-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate PyBOP: benzotriazole-1-yl-oxytrispyrrolidinophosphonium hexafluorophosphate rt: room temperature M: mol/L [Example 1] [0215] Preparation of 6-(ethylthio)-1-(4-fluorbenzyl)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion 127 [Chemical Formula 109] 0 NH N N N N EtS NH 2 EtS N O EtS N- 0 HBr H To a mixture of S-ethylisothiourea hydrobromide (14.8 g, 80 mmol) and DMF (75 mL) were added isopropyl isocyanate (8.2 mL, 84 mmol) and DBU (12.6 mL, 84 mmol) under ice-cooling, and the resulting mixture was stirred for 6 hours under ice-cooling. To the reaction mixture were added 1,1'-carbonyldiimidazole (15.57 g, 96 mmol) and DBU (18.0 mL, 120 mmol) under ice-cooling, and the resulting mixture was stirred for additional 2 hours. To the reaction mixture was added 2mol/L hydrochloric acid (240 mL) under ice-cooling over 50 minutes, and the precipitated solid was filtered off. The resulting solid was dissolved in ethyl acetate, and the mixture was dried over anhydrous magnesium sulfate and concentrated in vacuo to give 6-(ethylthio)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (12.29 g, Yield: 71%) as pale brown solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, t, J=7.2 Hz)), 1.33 (6H, d, J=6.9 Hz), 3.05 (2H, q, J=7.2 Hz), 4.81 (1H, sept, J=6.9 Hz). To a mixture of 6-(ethylthio)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (4.09 g, 19 mmol), potassium carbonate (7.88 g, 57 mmol) and acetonitrile (80 mL), 4-fluorbenzyl bromide (3.55 mL, 28.5 mmol) was added, and the resulting mixture was heated under reflux for 1.5 hours. To the mixture was added iced water (200 mL), and the mixture was extracted with ethyl acetate (100 mL). The extract was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by ethyl acetate and hexane to give 6-(ethylthio)-1-(4-fluorbenzyl)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (5.96 g, Yield: 97%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (3H, t, J=7.5 Hz), 1.47 (6H, d, J=6.9 Hz), 3.21 (2H, q, J=7.5 Hz), 5.02 (1H, sept, J=6.9), 5.06 (2H, s), 7.01-7.07 (2H, m), 7.31-7.36 (2H, m). [Example 2] [0216] Preparation of 1-(4-fluorbenzyl)-6-(4-isopropoxyphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (1-0133) [Chemical Formula 110] 0 0 N N N N EtS N 0 N N O H F H -1 F 128 A mixture of 6-(ethylthio)-1-(4-fluorbenzyl)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (0.323 g, 1 mmol), 4-isopropoxyaniline (0.907 g, 6 mmol) and 1-methyl-2-pyrrolidone (1 mL) was stirred at 230'C for 30 minutes under microwave irradiation. To the mixture was added water (100 mL), and the resulting mixture was extracted with ethyl acetate (100 mL). The extract was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by ethyl acetate and hexane to give 1-(4-fluorbenzyl)-6-(4-isopropoxyphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (0.21 g, Yield: 51%) as colorless solid. Melting point: 176-177 0 C 1H-NMR (6 ppm TMS/CDCl 3 ): 1.34 (6H, d, J=6.0 Hz), 1.44 (6H, d, J=6.9 Hz), 4.49 (1H, sept, J=6.0 Hz),4.96 (iH, sept, J=6.9 Hz), 5.18 (2H, s), 6.75-7.06 (6H, m), 7.53-7.57 (2H, m). [Example 3] [0217] Preparation of 6-(3-chloro-4-isopropoxyphenylamino)-1-(4-chlorobenzyl)-3-isopropyl-1,3,5-triazine-2,4(1H ,3H)-dion (I-0228) [Chemical Formula 111] 0 CI 0 N N 0 N N EtS N O N N O Ci H C A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (0.60 g, 1.78 mmol), 3-chloro-4-isopropoxyaniline (0.99 g, 5.3 mmol) and acetic acid (10 mL) was stirred at 90 0 C for 6 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (100 mL), and extracted with ethyl acetate (100 mL). The extract was washed by saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by diethyl ether and hexane to give 6-(3-chloro-4-isopropoxyphenylamino)-1-(4-chlorobenzyl)-3-isopropyl-1,3,5-triazine-2,4(1H ,3H)-dion (0.605 g, Yield: 73%)as colorless solid. Melting point: 167 0 C 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (6H, d, J=6.0 Hz), 1.34 (6H, d, J=6.9 Hz), 4.62 (1H, m), 4.83 (1H, sept, J=6.9 Hz), 5.18 (2H, brs), 7.12-7.15 (2H, m), 7.34-7.37 (3H, m), 7.43 (2H, d, J=8.7 Hz), 9.23 (1H, brs). [Example 4] [0218] Preparation of 1-(4-chlorobenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dion 129 [Chemical Formula 112] 0 S N NH 1) Mel
H
2 N N MeS N O H CI- 2) CICON=C=O To a mixture of 1-(4-chlorobenzyl)thiourea (11.19 g, 55.8 mmol) and methanol (50 mL) was added methyl iodide (4.18 ml, 66.9 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 5 hours. The mixture was concentrated in vacuo. To the resulting residue were added dichloromethane (60 ml) and N,N-diisopropylethylamine (29.2 ml, 167 mmol), and then a solution of N-chlorocarbonyl isocyanate (4.94 ml, 61.4 mmol) in dichloromethane (20 ml) was added gradually under ice-cooling. The resulting mixture was stirred at room temperature for 1 hour. The precipitated solid was filtered off and the resulting solid was washed by small amount on dichloromethane. The mixture was dried under reduced pressure to give 1-(4-chlorobenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dion (9.19 g, Yield: 58%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 2.46 (3H, s), 5.04 (2H, s), 7.31-7.43 (4H, m), 11.60 (1H, brs). [Example 5] [0219] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2,4(1H,3H)-dion (I-0269) [Chemical Formula 113] F 0 0 IF 0 N NH 0,TON NH MeS N O NH 2 N N O Cl H C A mixture of 1-(4-chlorobenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dion (4.21 g, 14.8 mmol), 3-fluoro-4-isopropoxyaniline (3.77 g, 22.3 mmol), t-butanol (84 ml) and acetic acid (17 mL) was heated under reflux for 8 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (300 mL), and the resulting mixture was extracted with ethyl acetate (100 mL). The extract was washed by saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue is precipitated by diisopropyl ether to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2,4(1H,3H)-dion (4.54 g, Yield: 76%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl3): 1.36 (6H, d, J=6.1 Hz), 4.49 (1H, sept, J=6.1 Hz), 5.14 (2H, 130 s), 6.47 (1H, m), 6.59 (1H, m), 6.97 (1H, m), 7.30 (2H, d, J=8.5 Hz), 7.47 (2H, d, J=8.5 Hz), 8.06 (1H, brs). [Example 6] [0220] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-pyridylmethyl)-1,3,5-triazin e-2,4(1H,3H)-dion (I-300) [Chemical Formula 114] F 0 F 0 N O- N N N N ONN H CI H CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2,4(1H,3H)-dion (0.15 g, 0.37 mmol) and DMF (3 mL) was added potassium tert-butoxide (0.09 mg, 0.82 mmol) at room temperature and stirred for 5 minutes. To the mixture was added 2-(bromomethyl)pyridine hydrobromide (0.103 g, 0.41 mmol) and the resulting mixture was stirred at 60 0 C for 2 hours. To the reaction mixture was added water (20 mL), and the mixture was extracted with ethyl acetate (20 mLx2). The extract was washed by brine (20 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-pyridylmethyl)-1,3,5-triazin e-2,4(1H,3H)-dion (0.069 g, Yield: 37%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.36 (2H, d, J=6.2 Hz), 4.47 (1H, sept, J=6.2 Hz), 5.15 (2H, s), 5.19 (2H, s), 6.51 (1H, m), 6.62 (1H, m), 6.97 (1H, m), 7.17-7.48 (7H, m), 7.65 (1H, m), 8.53 (1H, m). [Example 7] [0221] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-hydroxyethyl)-1,3,5-triazine -2,4(1H,3H)-dion (I-0273) [Chemical Formula 115] 0 0 F 0 N NH N N0 0N.N N,,OH MeS N O : MeS N O N N 0 I- CI CI H CI To a mixture of 1-(4-chlorobenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dion (0.28 g, 1 mmol), 2-(tetrahydro-2H-pyrane-2-yloxy)ethanol (0.15 g, 1.000 mmol), triphenylphosphine (0.53 g, 2 mmol) and THF (5 mL) was gradually added diisopropyl azodicarboxylate (0.23 ml, 1.2 mmol) under ice-cooling, and then the mixture was stirred at room temperature for 131 3 hours. To the reaction mixture was added water (20 mL), and the resulting mixture was extracted with ethyl acetate (20 mLx2). The extract was washed by brine (20 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(methylthio)-3-[2-(tetrahydro-2H-pyrane-2-yloxy)ethyl]-1,3,5-triazine -2,4(1H,3H)-dion (0.32 g, Yield: 78%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.42-1.83 (6H, m), 2.58 (3H, s), 3.47 (1H, m), 3.74-4.32 (5H, m), 4.63 (1H, m), 5.10 (2H, s), 7.28-7.33 (4H, m). A mixture of 1-(4-chlorobenzyl)-6-(methylthio)-3-[2-(tetrahydro-2H-pyrane-2-yloxy)ethyl]-1,3,5-triazine -2,4(1H,3H)-dion (0.32 g, 0.78 mmol), 3-fluoro-4-isopropoxyaniline (0.40 g, 2.4 mmol) and acetic acid(3 mL) was stirred at 100 0 C for 3 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (100 mL), and extracted with chloroform (100 mLx2). The extract was dried over anhydrous sodium sulphate and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (methanol/chloroform), and The obtained residue was precipitated by diisopropyl ether and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-hydroxyethyl)-1,3,5-triazine -2,4(1H,3H)-dion (0.12 g, Yield: 33%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=5.9 Hz), 1.96 (1H, t, J=5.9 Hz), 3.83 (2H, m), 4.05 (2H, m), 4.47 (iH, sept, J=5.9 Hz), 5.17 (2H, s), 6.48 (1H, m), 6.58 (1H, m), 6.97 (1H, m), 7.30 (2H, d, J=8.5), 7.47 (2H, d, J=8.5), 7.56 (1H, brs). [Example 8] [0222] Preparation of 3-(2-aminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2 ,4(1H,3H)-dion hydrochloride (I-0290) [Chemical Formula 116] F 0 F 0 N N N NH2 HCI H C H C To 3-(2-t-butoxycarbonylaminoethyl)- 1- (4-chlorobenzyl) - 6-(3-fluoro-4-isopropoxyphenylamino )-1,3,5-triazine-2,4(1H,3H)-dion (0.44 g, 0.8 mmol) was added 4mol/L hydrogen chloride in dioxane (5 mL) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. The resulting precipitated solid was filtered off. The resulting solid was washed by diethyl ether and dried under reduced pressure to give 3-(2-aminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2 ,4(1H,3H)-dion hydrochloride (0.31 g, Yield: 81%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.9 Hz), 3.01 (2H, m), 3.98 (2H, m), 4.57 132 (iH, sept, J=5.9 Hz), 5.27 (2H, brs), 6.98-7.17 (3H, m), 7.42 (3H, s), 7.87 (2H, brs). [Example 9] [0223] Preparation of 3-(2-acetylaminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-tria zine-2,4(1H,3H)-dion (1-0292) [Chemical Formula 117] F 0 F 0 H N N N N -,.NH2 HCI O N N Me H C H C To a mixture of 3-(2-aminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2 ,4(1H,3H)-dion hydrochloride (0.104 g, 0.22 mmol), triethylamine (0.074 mL, 0.54 mmol), dimethylaminopyridine (0.026 g, 0.22 mmol) and THF (2 mL) was added dropwise acetyl chloride (0.023 mL, 0.32 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 30 minutes. To the reaction mixture was added water (20 mL), and the mixture was extracted with ethyl acetate (10 mLx2). The extract was washed by brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by diisopropyl ether and hexane to give 3-(2-acetylaminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-tria zine-2,4(1H,3H)-dion (0.104 g, Yield: 99%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.1 Hz), 1.86 (3H, s), 3.51 (2H, m), 4.00 (2H, m), 4.47 (iH, sept, J=6.1 Hz), 5.16 (2H, s), 5.83 (1H, m), 6.51 (1H, m), 6.60 (1H, m), 6.97 (1H, m), 7.27-7.51 (5H, m). [Example 10] [0224] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methoxycarbonylmethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (I-0338) [Chemical Formula 118] 0 0 F 0 N NH N N OMe O N >N OMe MeS NO - - MeS N O N N O CI CI H CI To a mixture of 1-(4-chlorobenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dion (0.28 g, 1 mmol) and THF (3 mL) was added DBU (0.166 mL, 1.1 mmol), and the mixture was stirred at room temperature for 5 minutes. Further, methyl bromoacetate (0.104 mL, 1.1 mmol) was added to the mixture, and the resulting mixture was stirred at room temperature for 3 hours. To the reaction mixture was added water (20 mL). The precipitated solid was 133 filtered off, dried, and purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-3-(methoxycarbonylmethyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-di on (0.25 g, Yield: 69%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 2.59 (3H, s), 3.78 (3H, s), 4.69 (2H, s), 5.13 (2H, s), 7.27-7.35 (4H, m). A mixture of 1-(4-chlorobenzyl)-3-(methoxycarbonylmethyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-di on (0.24 g, 0.68 mmol), 3-fluoro-4-isopropoxyaniline (0.17 mg, 1.03 mmol), t-butanol (4.8 mL) and acetic acid (0.4 mL) was heated at reflux for 32 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (20 mL), and the resulting mixture was extracted with ethyl acetate (10 mL). The extract was washed by brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane), and The obtained residue was precipitated by diisopropyl ether to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methoxycarbonylmethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (0.31 g, Yield: 95%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=5.9 Hz), 3.78 (3H, s), 4.47 (1H, sept, J=5.9 Hz), 4.58 (2H, s), 5.17 (2H, s), 6.50 (1H, m), 6.60 (1H, m), 6.97 (1H, m), 7.28-7.47 (5H, m). [Example 11] [0225] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(hydroxycarbonylmethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (I-0284) [Chemical Formula 119] F 0 F 0 0 N k NKN.>OMe 0 O N N OH _( N N- - 0 _( N11 NN-O Y H CHC CI CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methoxycarbonylmethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (0.30 g, 0.63 mmol), methanol (3 mL), and THF (3 mL) was added 1mol/L lithium hydroxide (3.8 mL) under ice-cooling, and the mixture was stirred at room temperature for hour. The pH of the mixture was adjusted with 2mol/L hydrochloric acid to a pH of less than 2. To the mixture was added brine (20 mL), and the resulting mixture was extracted by chloroform (10 mLx3). The extract was dried over anhydrous sodium sulphate and concentrated in vacuo. The obtained residue was precipitated by diethyl ether and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(hydroxycarbonylmethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (0.28 g, Yield: 97%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.36 (6H, d, J=6.1 Hz), 4.47 (1H, sept, J=6.1 Hz), 4.62 (2H, 134 s), 5.18 (2H, s), 6.51 (1H, m), 6.60 (1H, m), 6.96 (1H, m), 7.30 (2H, d, J=8.7 Hz), 7.45 (2H, d, J=8.7 Hz), 7.64 (1H, brs). [Example 12] [0226] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methylcarbamoymethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (1-0294) [Chemical Formula 120] F 0 F 0 0 N O N," rH O N IDKN>NHMe -6 N N_O 0N NO H CHC CI C To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(hydroxycarbonylmethyl)-1,3,5 -triazine-2,4(1H,3H)-dion (0.083 g, 0.19 mmol) and DMF (2 mL) were added methylamine hydrochloride (0.015 g, 0.21 mmol), 1-hydroxybenzotriazole hydrate (0.03 g, 0.2 mmol), 4-dimethylaminopyridine (0.002 g, 0.02 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.038 g, 0.2 mmol) and triethylamine (0.03 mL, 0.21 mmol), and the resulting mixture was stirred at 60'C for 4 hours. The reaction mixture was poured into water (20 mL), and extracted with ethyl acetate (20 mL). The extract was washed by brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by diisopropyl ether to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methylcarbamoylmethyl)-1,3, 5-triazine-2,4(1H,3H)-dion (0.076 g, Yield: 89%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.1 Hz), 2.85 (3H, d, J=4.9 Hz), 4.37 (2H, s), 4.46 (iH, sept, J=6.1 Hz), 5.15 (2H, s), 5.78 (1H, d, J=4.7 Hz), 6.46 (1H, m), 6.57 (1H, m), 6.95 (1H, m), 7.27-7.46 (4H, m), 7.99 (1H, ms). [Example 13] [0227] Preparation of 4-chloro- 1 -(4-chlorobenzyl)- 6- (3 -fluoro-4-isopropoxyphenylamino) -1,3,5 -triazine-2(1H)-one [Chemical Formula 121] F 0 F CI 0 No N IkNH N1 N N N N 0 N N 0 H C H C Phosphorus oxychloride (2.24 mL, 24 mmol) was added to 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2,4(1H,3H)-dion (0.486 g, 1.2 mmol), and the mixture was stirred at 50 0 C for 2 hours. The resulting 135 mixture was concentrated in vacuo. The resulting residue was dissolved in ethyl acetate (30 mL), and the mixture was washed by saturated aqueous sodium bicarbonate (10 mL) and brine (10 mL). The extract was dried over anhydrous sodium sulphate and concentrated in vacuo to give 4-chloro- 1 -(4-chlorobenzyl) -6- (3 -fluoro-4-isopropoxyphenylamino) -1,3,5 -triazine-2(1H)-one (0.57 g) as crude product. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.35 (6H, d, J=6.3 Hz), 4.51 (iH, sept, J=6.3 Hz), 5,28 (2H, s), 6.72 (1H, brs), 6.80 (1H, m), 6.91 (1H, m), 7.08 (1H, m), 7.30 (2H, d, J=8.4 Hz), 7.44 (2H, d, J=8.4 Hz). [Example 14] [0228] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-4-(2-hydroxyethoxy)-1,3,5-triazi ne-2(1H)-one (I-0434) [Chemical Formula 122] F CI F O F NN N N H C H C H C To a mixture of 2-(tetrahydro-2H-pyrane-2-yloxy)ethanol (0.17 mL, corresponding to 1.25 mmol) and THF (5.6 mL) was added 60% sodium hydride (0.05 g, 1.25 mmol), and the mixture was stirred at room temperature for 10 minutes. To the mixture was added a solution of crude 4-chloro- 1 -(4-chlorobenzyl)- 6- (3 -fluoro-4-isopropoxyphenylamino) -1,3,5 -triazine-2(1H)-one (0.224 g, corresponding to 0.5 mmol) in THF (2 mL) under ice-cooling, and the resulting mixture was stirred at room temperature for 5 hours. To the reaction mixture was added half-saturated aqueous ammonium chloride (50 mL), and the mixture was extracted with ethyl acetate (50 mL). The extract was washed by brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-4-(2-(tetrahydro-2H-pyrane-2-ylo xy)ethoxy)-1,3,5-triazine-2(1H)-one (0.166 g, Yield: 62%) as colorless as oil. To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-4-(2-(tetrahydro-2H-pyrane-2-ylo xy)ethoxy)-1,3,5-triazine-2(1H)-one (0.15 g, 0.28 mmol) and methanol (1.5 mL) was added p-toluenesulfonic acid hydrate (0.08 g, 0.4 mmol), and the resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into half-saturated aqueous sodium bicarbonate (10 mL), and the mixture was extracted with ethyl acetate (20 mL). The extract was washed by brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (methanol/chloroform). The obtained residue was precipitated by hexane to give 136 1-(4-chlorobenzyl) -6-(3 -fluoro-4-isopropoxyphenylamino) -4-(2-hydroxyethoxy) -1,3,5-triazi ne-2(1H)-one (0.104 g, Yield: 83%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.34 (6H, d, J=6.1 Hz), 2.53 (1H, brs), 3.91 (2H, brs), 4.44-4.52 (3H, m), 5.30 (2H, s), 6.60 (1H, brs), 6.75-7.10 (3H, m), 7.27-7.43 (4H, m). [Example 15] [0229] Preparation of 4-benzylamino-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1 H)-one (I-0435) [Chemical Formula 123] F IF HN N0O N' _6 N 1 'N 0 - -6 ,N )IN -- 0 H H C To a mixture of crude 4-chloro- 1 -(4-chlorobenzyl)- 6- (3 -fluoro-4-isopropoxyphenylamino) -1,3,5 -triazine-2(1H)-one (0.19 g, corresponding to 0.4 mmol) and THF (4.7 mL) was added benzylamine (0.108 mL, 1 mmol), and the mixture was stirred at room temperature for 6 hours. To the reaction mixture were added water (10 mL) and ethyl acetate (10 mL), and the precipitated solid was filtered off. The resulting solid was washed by ethyl acetate, dried under reduced pressure to give 4-benzylamino-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1 H)-one (0.102 g, Yield: 52%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.25 (6H, d, J=5.7 Hz), 4.28 (1H, m), 4.41 (1H, m), 4.54 (1H, sept, J=5.7 Hz), 5.22 (2H ,m), 7.08-7.52 (8H, m), 7.90 (1H, brs), 8.94 (1H, brs). [Example 16] [0230] Preparation of 1-(4-chlorobenzyl)-4-(dodecylthio)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1 H)-one (I-0436) [Chemical Formula 124] F CI F 0 N O N O1 N 1: N 1 'N 0 - _I N 1 'N- 0 H H C To a mixture of 1-dodecanthiol (0.24 mL, 1.0 mmol) and THF (4.8 mL) was added 60% sodium hydride (0.045 g, 1.0 mmol), and the mixture was stirred at room temperature for 10 minutes. To the resulting mixture was added a solution of crude 4-chloro- 1 -(4-chlorobenzyl)- 6- (3 -fluoro-4-isopropoxyphenylamino) -1,3,5 -triazine-2(1H)-one (0.19 g, corresponding to 0.4 mmol) in THF (2 mL) under ice-cooling, and the mixture was 137 stirred at 50'C for 5 hours. To the reaction mixture was added half-saturated aqueous ammonium chloride (50 mL), and the mixture was extracted with ethyl acetate (50 mL). The extract was washed by brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by hexane to give 1-(4-chlorobenzyl)-4-(dodecylthio)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1 H)-one (0.092 g, Yield: 39%) as colorless oil. 1H-NMR (6 ppm TMS/CDCl 3 ): 0.89 (3H, t, J=6.9 Hz), 1.27 (14H, s), 1.34 (6H, d, J=6 Hz), 1.50-1.70 (6H, m), 3.02 (2H, t, J=7.5 Hz), 4.48 (iH, sept, J=6 Hz), 5.26 (2H, s), 6.52 (1H, brs), 6.75 (1H, m), 6.88 (1H, m), 7.10 (1H, m), 7.28-7.50 (4H, m). [Example 17] [0231] Preparation of 1-(4-chlorobenzyl)-6-(4-hydroxycarbonylphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3 H)-dion (1-0252) [Chemical Formula 125] 0 000 MeO N N HO N N _I~ N 'N O -I_ N 'N CCI To a mixture of 1-(4-chlorobenzyl)-6-(4-methoxycarbonylphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3 H)-dion (0.70 g, 1.63 mmol), methanol (4 mL) and THF (4 mL) was added 2mol/L lithium hydroxide (4.9 mL) under ice-cooling, and the mixture was stirred at room temperature for 8 hours. The reaction mixture was poured into water (50 mL), adjusted with 2mol/L hydrochloric acid to a pH of less than 3, and extracted with ethyl acetate (50 mLx2). The extract was washed by brine (50 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting solid was washed by diethyl ether to give 1-(4-chlorobenzyl)-6-(4-hydroxycarbonylphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3 H)-dion (0.60 g, Yield: 89%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.46 (6H, d, J=6.9 Hz), 4.98 (1H, sept, J=6.9 Hz), 5.19 (2H, s), 6.90 (2H, d, J=8.1 Hz), 7.31 (2H, d, J=8.7 Hz), 7.50 (2H, d, J=8.7 Hz), 7.90 (2H, d, J=8.1 Hz). [Example 18] [0232] Preparation of 1-(4-chlorobenzyl)-6-[4-(N-benzylcarbamoyl)phenylamino]-3-isopropyl-1,3,5-triazine-2,4(1 H,3H)-dion (1-0259) 138 [Chemical Formula 126] 0 0 0 0 HO NU N N _I N 1 'N- 0 _I~ N N- 0 HO N CI H CI To a mixture of 1-(4-chlorobenzyl)-6-(4-hydroxycarbonylphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3 H)-dion (0.08 g, 0.19 mmol) and THF (2 mL) were added benzylamine (0.023 mL, 0.21 mmol), 1-hydroxybenzotriazole (0.03 g, 0.21 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.041 g, 0.2 mmol) and triethylamine (0.03 mL, 0.21 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was poured into water (30 mL), and the mixture was extracted with ethyl acetate (30 mL). The extract was washed by brine (30 mL), dried over anhydrous sodium sulphate, concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by diethyl ether to give 1-(4-chlorobenzyl)-6-[4-(N-benzylcarbamoyl)phenylamino]-3-isopropyl-1,3,5-triazine-2,4(1 H,3H)-dion (0.07 g, Yield: 72%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.43 (6H, d, J=6.9 Hz), 4.67 (2H, d, J=4.0 Hz), 4.96 (1H, sept, J=6.9 Hz), 5.18 (2H, s), 6.34 (1H, m), 6.88 (2H, d, J=8.4 Hz), 7.17 (1H, brs), 7.29-7.34 (6H, m), 7.50 (2H, d, J=8.4 Hz), 7.80 (2H, d, J=8.4 Hz). [Example 19] [0233] Preparation of 1-(4-chlorobenzyl)6-(3-chloro-4-isopropoxyphenylamino)-4-hydroxycarbonylethyll,3,5-tria zine-2(1H)-one (I-0579) [Chemical Formula 127] COOFt CI CI CI N O N NO H H C To a mixture of 4-chloro- 1 -(4-chlorobenzyl)- 6- (3 -fluoro-4-isopropoxyphenylamino) -1,3,5 -triazine-2(1H)-one (0.15 g, 0.34 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium (II) (22.23 mg, 0.034 mmol) and THF (3 mL) were added (E)-ethyl 3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolane-2-yl)acrylate (0.063.g, 0.49 mmol) and 2mol/L potassium carbonate (0.682 ml, 1.364 mmol) under nitrogen atmosphere, and the resulting mixture was heated at reflux for 7 hours. To the mixture was added water (30 mL), and the resulting mixture was extracted with chloroform (30 mL). The extract was dried over anhydrous sodium sulphate and concentrated in vacuo. The resulting residue was 139 purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 50-80%) to give 1-(4-chlorobenzyl)6-(3-chloro-4-isopropoxyphenylamino)-ethoxycarbonylethenyll,3,5-triaz ine-2(1H)-one (0.05 g, Yield: 30%) as pale orange oil. 1H-NMR (6 ppm TMS/DMSO-d6): 1.20-1.28 (9H, m), 4.17-4.22 (2H, m), 4.54 (1H, brs), 5.10 (2H, brs), 7.40 (8H, brs), 8.14 (1H, s), 9.77 (1H, s). [Chemical Formula 128] COOEt COOH COOH CI CI CI N N O NN O N zN H C H C H C To a mixture of 1-(4-chlorobenzyl)6-(3-chloro-4-isopropoxyphenylamino)-ethoxycarbonylethenyll,3,5-triaz ine-2(1H)-one (0.05 g, 0.1 mmol), THF (1 ml), EtOH (1 ml) and water (0.3 ml) was added lithium hydroxide hydrate (12.5 mg, 0.3 mmol), and the resulting mixture was stirred at room temperature for 3 days. The reaction mixture was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylamino)-4-hydroxycarbonylethenyl-1,3,5 triazine-2(1H)-one (27 mg, Yield: 57%) as pale orange oil. The obtained intermediate was dissolved in methanol (3 mL) and conducted by catalytic reduction by using H-Cube (10% Pt-C, H2 = latm). Then, the mixture was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 50-80%) to give 1-(4-chlorobenzyl)6-(3-chloro-4-isopropoxyphenylamino)-4-hydroxycarbonylethyl-1,3,5-tri azine-2(1H)-one (2.3 mg, Yield: 8.5%) as colorless oil. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.36 (6H, d, J=5.7 Hz), 2.22 (1H, t, J=7.8 Hz), 2.74 (3H, brs), 4.48 (1H, sept, J=5.7 Hz), 5.18 (2H, s), 6.88 (2H, s), 7.13 (1H, s), 7.30 (2H, d, J=8.4 Hz), 7.45 (2H, d, J=8.4 Hz). [Example 20] [0234] Preparation of (R)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-methoxycarbonylpropyl) -1,3,5-triazinane-2,4-dion (I-0461) [Chemical Formula 129] 0 0 0 F 0 0 N NH N N ' 0 ,Me 0 HN N 'Me Me K- Me EtS N -O EtS N O N N O CI CI CI To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (1.00 g, 3.4 mmol), di-2-methoxyethylazodicarboxylate (1.02 g, 4.4 mmol), triphenylphosphine (1.15 g, 4.4 mmol) and dioxane (8 mL) was gradually added (R)-(-)-3-methyl 2-hydroxyisobutyrate 140 (0.52 g, 4.4 mmol), and the mixture was stirred at room temperature for hour. To the reaction mixture was added water (40 mL), and the resulting mixture was extracted with ethyl acetate (20 mLx2). The extract was washed by brine (20 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (R)-1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,3H )-dion (0.98 g, Yield: 74%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.19 (3H, d, J=5.7 Hz), 1.37 (3H, t, J=7.1 Hz), 2.96 (1H, m), 3.12 (2H, q, J=7.1 Hz), 3.60 (3H, s), 3,98 (1H, m), 4.21 (1H, m), 5.08 (2H, s), 7.29-7.34 (4H, m). A mixture of (R)-1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,3H )-dion (0.32 g, 0.8 mmol), 3-fluoro-4-isopropoxyaniline (0.20 g, 1.2 mmol), acetic acid (0.72 g, 12 mmol ) and t-butanol (6) was heated at reflux over night. The reaction mixture was poured into saturated aqueous sodium bicarbonate (40 mL), and the mixture was extracted with ethyl acetate (40 mLx2). The extract was washed by 2mol/L aqueous hydrochloric acid (20 mLx2), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by diethyl ether to give (R)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-methoxycarbonylpropyl) -1,3,5-triazinane-2,4-dion (0.29 g, Yield: 71%) as pale purple powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.19 (3H, d, J=5.7 Hz), 1.37 (6H, d, J=5.7 Hz), 2.90 (1H, m), 3.60 (3H, s), 3.91 (1H, m), 4.10 (1H, m), 4.47 (iH, sept, J=5.7 Hz), 5.16 (2H, m), 6.49-6.62 (2H, m), 6.96 (1H, m), 7.29-7.47 (5H, m). [Example 21] [0235] Preparation of (R)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-hydroxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (1-0464) [Chemical Formula 130] F 0 0 F 0 0 O HN N fR= Me HN N OH Pe K- Me N -- N"- 0 N 'N- 0 -CI To a mixture of (R)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-methoxycarbonylpropyl) -1,3,5-triazinane-2,4-dion (0.26 g, 0.5 mmol) and dioxane (4 mL) was added 1mol/L lithium hydroxide (1.6 mL), and the mixture was stirred at 50 0 C for 6 hours. To the mixture was added water (50 mL), adjusted with 2mol/L hydrochloric acid to a pH of about 3, and the precipitated solid was filtered off. The solid was dried at 40 0 C to give (R)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-hydroxycarbonylpropyl) 1,3,5-triazine-2,4(1H,3H)-dion (0.21 g, Yield: 84%) as colorless solid. 141 1H-NMR (6 ppm TMS/CDCl 3 ): 1.19 (3H, d, J=5.7 Hz), 1.34 (6H, d, J=5.7 Hz), 2.91 (1H, m), 3.89 (1H, m), 4.11 (iH, m), 4.44 (iH, sept, J=5.7 Hz), 5.16 (2H, s), 6.47-6.60 (2H, m), 6.93 (1H, m), 7.28-7.44 (4H, m), 7.94 (1H, brs). [Example 22] [0236] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-[2,2-di(hydroxymethyl)propyl] 1,3,5-triazine-2,4(1H,3H)-dion (1-0274) [Chemical Formula 131] F 0 F 0 i-Pr-O N k'N O i-Pr-O N 'N OH N NO O N N O OH H C H To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2,2,5-trimethyl-1,3-dioxane5 yl)methyl-1,3,5-triazine-2,4(1H,3H)-dion (7.9 g, 14.44 mmol) and methanol (160 mL) was added p-toluenesulfonic acid monohydrate (5.49 g, 28.9 mmol) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into saturated aqueous sodium bicarbonate (200 mL), and extracted with ethyl acetate (300 mLx2). The extract was washed by brine (300 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by water and the filtered off. The residue was dried at 70 0 C for 6 hours to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-[2,2-di(hydroxymethyl)propyl] 1,3,5-triazine-2,4(1H,3H)-dion (5.12 g, Yield: 70%) as a white powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.0 Hz), 3.26-3.46 (6H, m), 3.99 (2H, s), 4.48 (1H, sept, J=6.0 Hz), 5.19 (2H, s), 6.49-6.64 (2H, m), 6.99 (1H, m), 7.30-7.51 (5H, m). Elementary analysis Calculated value C24H28ClFN405 - 1/3H20, C: 56.19, H: 5.63, Cl: 6.91, F: 3.70, N: 10.92 water:1.18% Measured value C: 56.33, H: 5.60, Cl: 6.79, F: 3.58, N: 11.06 Karl Fischer water determination: 1.02% [Example 23] [0237] Preparation of 1-(4-chlorobenzyl)-6-(Ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion 142 [Chemical Formula 132] 0 0 O N N N NH NHN:EtS N O : EtS N O EtS NH 2 EtS N 0 CI CI HBr H Ia il c To a mixture of S-ethylisothiourea hydrobromide (1.85 g, 10 mmol) and DMF (9.3 mL) were added t-butylisocyanide (1.2 mL, 10.5 mmol) and DBU (1.9 mL, 12.8 mmol) under ice-cooling, and the mixture was stirred under ice-cooling for 6 hours. To the reaction mixture were added 1,1'-carbonyldiimidazole (1.95 g, 12 mmol) and DBU (1.9 mL, 12.8 mmol) under ice-cooling, and the resulting mixture was stirred for additional 2 hours. To the mixture was added 2mol/L hydrochloric acid (80 mL) under ice-cooling over about 50 minutes, and the precipitated solid was filtered off. The resulting solid was dissolved in ethyl acetate, and the mixture was dried over anhydrous magnesium sulfate and concentrated in vacuo to give 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dion (1.15g, Yield: 50%) as pale brown solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (3H, t, J=7.3 Hz), 1.55 (9H, s), 3.03 (2H, q, J=7.3), 12.30 (1H, brs) To a mixture of 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dion (22.93 g, 100 mmol), 4-chlorobenzylbromide (22.60 g, 110 mmol) and acetonitrile (200 mL) was added potassium carbonate (17.97 g, 130 mmol), and the mixture was heated at reflux for 3 hours. The reaction mixture was filtered to remove the insoluble. The filtrate was concentrated in vacuo to give 39.9g of crude 3-t-butyl-1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion as pale brown oil. To the obtained crude product was added trifluoroacetic acid (100 mL) under ice-cooling, and the mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated in vacuo to give crude residue. The residue was precipitated to give 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (29.03 g, Yield: 97%) as pale brown solid. 1H-NMR (6 ppm TMS/d6-DMSO): 1.25 (3H, t, J=7.3 Hz), 3.08 (2H, q, J=7.3 Hz), 5.02 (2H, s), 7.30-7.33 (2H, m), 7.39-7.42 (2H, m), 11.61 (1H, s). [Example 24] [0238] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-sulfoethyl)-1,3,5-triazinane 2,4-dion (1-0654) [Chemical Formula 133] F 0 F 0 0 N- H N~ SO 3H H N NH 4N NO H 'C I _ a C I 143 To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)- 1,3,5-triazine-2,4(1H, 3H)-dion (100 mg, 0.247 mmol) and DMF (2 mL) was added cesium carbonate (105 mg, 0.321 mmol), and the mixture was stirred at room temperature for 5 minutes. Further, 2-bromoethanesulfonic acid sodium (62.5 mg, 0.296 mmol) was added to the mixture, and the resulting mixture was stirred at 120 0 C for 1 hour. To the reaction mixture was added 1mol/L aqueous hydrochloric acid to be acidic. The resulting mixture was extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3%
HCO
2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-sulfoethyl)-1,3,5-triazinane 2,4-dion (22 mg, Yield: 17%) as pale brown solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=6.1 Hz), 2.62-2.67 (2H, m), 3.93-3.99 (2H, m), 4.54 (1H, sept, J=6.1 Hz), 5.17 (2H, s), 6.90 (1H, m), 7.07-7.12 (2H, m), 7.35-7.42 (4H, M). [Example 25] [0239] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(3-sulfopropyl)-1,3,5-triazinane -2,4-dion (I-0645) [Chemical Formula 134] F 0 F 0 N NO NH NO S3H H C C To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-1,3,5-triazine-(1H,3H)-2,4-dion (200 mg, 0.494 mmol) and DMF (4 mL) was added potassium tert-butoxide (83 mg, 0.741 mmol), and the mixture was stirred at room temperature for 10 minutes. Further, 1,3-propanesultone (91 mg, 0.741 mmol) was added and the resulting mixture was stirred at 90 0 C for 2 hours. To the reaction mixture was added 4mol/L hydrogen chloride in dioxane (20 mL) to be acidic. The mixture was concentrated in vacuo and the resulting residue was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%). The resulting residue was precipitated by ethyl acetate to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(3-sulfopropyl)-1,3,5-triazinane -2,4-dion (96 mg, Yield: 37%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=6.1 Hz), 1.81 (2H, m), 2.35-2.40 (2H, m), 3.70-3.74 (2H, m), 4.54 (1H, sept, J=6.1 Hz), 5.19 (2H, s), 6.90 (1H, m), 7.07-7.13 (2H, m), 7.34-7.42 (4H, m). [Example 26] [0240] 144 Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(5-tetrazolylmethyl)-1,3,5-triaz inane-2,4-dion (1-1297) [Chemical Formula 135] F 0 F 0 F 0 HN NH H N N - CICI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-1,3,5-triazinane-2,4(1H,3H)-dion (1.214 g, 3 mmol), 2-bromoacetonitrile (0.4 g, 3.3 mmol) and DMF (6 mL) was added potassium carbonate (0.54 g, 3.9 mmol), and the mixture was stirred at 60 0 C for 1 hour. To the reaction mixture was added water (150 mL), and the mixture was extracted with ethyl acetate (150 mL). The extract was washed by brine (150 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The obtained residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-cyanomethyl-1,3,5-triazinane-2 ,4-dion (0.78 g, Yield: 59%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.1 Hz), 4.47 (1H, sept, J=6.1 Hz), 4.69 (2H, s), 5.18 (2H, s), 6.49 (1H, m), 6.59 (1H, m), 6.99 (1H, m), 7.32 (2H, d, J=6.6 Hz), 7.49 (2H, d, J=6.6 Hz), 7.74 (1H, s). To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-cyanomethyl-1,3,5-triazinane-2 ,4-dion (0.10g, 0.23 mmol), ammonium chloride (84 mg, 1.58 mmol) and DMF (2 mL) was added sodium azide (73.2 mg, 1.13 mmol), and the mixture was stirred at 95 0 C for 2 hours. To the reaction mixture was added water (150 mL), and the mixture was extracted with ethyl acetate (150 mL). The extract was washed by brine (150 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by HPLC and the obtained residue was precipitated by ethyl ether to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(5-tetrazolylmethyl)-1,3,5-triaz inane-2,4-dion (60 mg, Yield: 55%) as colorless powder. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.9 Hz), 4.59 (1H, m), 5.15-5.27 (4H, m), 6.60 (1H, brs), 7.00-7.45 (7H, m), 9.44 (1H, mbrs). [Example 27] [0241] Preparation of 1-(4-chlorobenzyl) -6-(3-fluoro-4-isopropoxyphenylimino)- 3- (2-amino-2-hydroxyiminoethyl) -1,3,5-triazinane-2,4-dion (1-0599) 145 [Chemical Formula 136] F O F 0 0 N O NH 2 _6 N N- 0 - N --- N 0 OH -CI CI To a mixture of sodium methoxide (34.1 mg, 0.63 mmol) and methanol (2 mL) was added hydroxylamine hydrochloride (43.8 mg, 0.631 mmol) under ice-cooling. After the mixture was neutralized, 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-cyanomethyl-1,3,5-triazinane-2 ,4-dion (0.14 g, 0.315 mmol) was added and the resulting mixture was heated at reflux for 2 hours. To the mixture was added water (150 mL), and the mixture was extracted with ethyl acetate (150 mL). The extract was washed by brine (150 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was precipitated by ethyl ether to give 1-(4-chlorobenzyl) -6-(3 -fluoro-4-isopropoxyphenylimino)- 3- (2-amino-2-hydroxyiminoethyl) -1,3,5-triazinane-2,4-dion (91 mg, Yield: 61%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.9 Hz), 4.34 (2H, brs), 4.58 (1H, m), 5.25 (2H, brs), 5.43 (2H, brs), 7.00-7.45 (7H, m), 8.99 (1H, brs), 9.28 (1H, brs). [Example 28] [0242] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(5-oxo-4,5-dihydro-1,2,4-oxadia zol-3-ylmethyl)-1,3,5-triazinane-2,4-dion (1-0601) [Chemical Formula 137] F 0 F 0 ~ HH O N N NH2 0 *-._ N. N HN NC _C= N 'N 0 OH~ To a mixture of 1-(4-chlorobenzyl) -6-(3 -fluoro-4-isopropoxyphenylimino)- 3- (2-amino-2-hydroxyiminoethyl) -1,3,5-triazinane-2,4-dion (80 mg, 0.17 mmol) and pyridine (2 mL) was added ethyl chlorocarbonate (20 mg, 0.19 mmol), and the mixture was stirred at room temperature overnight. Further, the reaction mixture was heated at reflux for 7 hours. The resulting reaction mixture was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(5-oxo-4,5-dihydro-1,2,4-oxadia zol-3-ylmethyl)-1,3,5-triazinane-2,4-dion (20 mg, Yield: 24%) as colorless amorphous. 1H-NMR (6 ppm TMS/DMSO-d6): 1,27 (6H, d, J=5.9 Hz), 4.60 (1H, sept, J=5.9 Hz), 4.86 (2H, s), 5.27 (2H, s), 7.00-7.50 (7H, m), 9.44 (1H, brs), 12.48 (1H, brs). 146 [Example 29] [0243] Preparation of (R)-1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(2,3-dihydroxypropyl)-1,3,5 -triazinane-2,4-dion (I-0638) [Chemical Formula 138] CI 0 CI 0 O 0 HN lu NH _10 H kN --- \ N N AO N N a CI CI CI 0 0 r HN N N OH _6 '_)I OH N N OOH -aCI A mixture of 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (300 mg, 0.712 mmol), (S)-4-(bromomethyl)-2,2-dimethyl-1,3-dioxolane (222 mg, 1.14 mmol), potassium tert-butoxide (176 mg, 1.57 mmol) and DMF (6 mL) was stirred at 60'C for 16 hours. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (R)-1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-[(2,2-dimethyl-1,3-dioxolan e4-yl)methyl]-1,3,5-triazinane-2,4-dion (116 mg, Yield: 30%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.23-1.32 (12H, m), 3.73-3.76 (2H, m), 3.94-3.98 (2H, m), 4.24-4.26 (1H, m), 4.64 (1H, brs), 5.25 (2H, s), 7.16-7.25 (2H, m), 7.38-7.47 (5H, m), 9.30 (1H, s). To a solution of (R)-1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-[(2,2-dimethyl-1,3-dioxolan e4-yl)methyl]-1,3,5-triazinane-2,4-dion (110 mg, 0.205 mmol) in methanol (4 mL) was added p-toluenesulfonic acid monohydrate (59 mg, 0.31 mmol), and the mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated, and the residue was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by dichloromethane and hexane to give (R)-1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(2,3-dihydroxypropyl)-1,3,5 -triazinane-2,4-dion (88 mg, Yield: 86%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (6H, d, J=5.6 Hz), 3.68-3.84 (4H, m), 4.54 (1H, brs), 4.73 (1H, brs), 5.25 (2H, s), 7.16-7.25 (2H, m), 7.38-7.46 (5H, m), 9.23 (1H, s). [Example 30] 147 [0244] Preparation of 6-(3-chloro-4-isopropoxyphenylimino)-3-(2-ethoxycarbonylethyl)- 1-(4-methylbenzyl)-1,3,5 triazinane-2,4-dion (1-0866) [Chemical Formula 139] 0 O N N "' CO2Et NH HBr , N N ' CO2Et EtS N -O EtS
NH
2 EtS NO Me CI O EtS N 0 -C2 O ~ NN~ CO2Et Me To a mixture of S-ethylisothiourea hydrobromide (6.00 g, 32.4 mmol) and DMF (30 mL) were added ethyl 6-isocyanatocaproate (4.48 mL, 34.0 mmol) and DBU (5.13 mL, 34.0 mmol) under ice-cooling, and the mixture was stirred under ice-cooling for 5 hours. To the reaction mixture were added 1,1'-carbonyldiimidazole (6.31 g, 38.9 mmol) and DBU (7.33 mL, 49.0 mmol) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. To the reaction mixture was added 2mol/L hydrochloric acid (96 mL) under ice-cooling over 15 minutes, and the mixture was extracted with ethyl acetate. The extract was washed by water and brine, dried over anhydrous sodium sulphate. The extract was concentrated in vacuo to give 6-(ethylthio)-3-(2-ethoxycarbonylethyl)-1,3,5-triazine-2,4(1H,3H)-dion (7.86 g, Yield: 89%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl3): 1.22 (3H, t, J = 7.1 Hz), 1.33 (3H, t, J = 7.3 Hz), 2.67 (2H, t, J = 7.2 Hz), 3.16 (2H, q, J = 7.3 Hz), 4.07-4.17 (4H, m). To the mixture of 6-(ethylthio)-3-(2-ethoxycarbonylethyl)-1,3,5-triazine-2,4(1H,3H)-dion (4.00 g, 14.6 mmol), 4-methylbenzylbromide (3.25 g, 17.6 mmol) and acetonitrile (80 mL) was added potassium carbonate (3.03 g, 22.0 mmol), and the mixture was heated at reflux for 2 hours. The reaction mixture was filtered off to remove insoluble, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 6-(ethylthio)-3-(2-ethoxycarbonylethyl)-1-(4-methylbenzyl)-1,3,5-triazine-2,4(1H,3H)-dion (5.10 g, Yield: 92%) as pale yellow solid. 1H-NMR (6 ppm TMS/CDCl3): 1.25 (3H, t, J = 7.1 Hz), 1.37 (3H, t, J = 7.4 Hz), 2.35 (3H, s), 2.71 (2H, t, J= 7.3 Hz), 3.21 (2H, q, J= 7.4 Hz), 4.12 (2H, q, J= 7.1 Hz), 4.24 (2H, t, J = 7.3 Hz), 5.09 (2H, s), 7.16 (4H, d, J = 8.2 Hz), 7.23 (4H, d, J = 8.2 Hz). A mixture of 6-(ethylthio)-3-(2-ethoxycarbonylethyl)-1-(4-methylbenzyl)-1,3,5-triazine-2,4(1H,3H)-dion (398 mg, 1.05 mmol), 3-chloro-4-isopropoxyaniline (294 mg, 1.58 mmol), acetic acid (0.905 mL) and t-butanol (4 mL) was heated at reflux for 5 hours. To the reaction mixture was 148 added saturated aqueous sodium bicarbonate, and the mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 6-(3-chloro-4-isopropoxyphenylimino)-3-(2-ethoxycarbonylethyl)-1-(4-methylbenzyl)-1,3,5 triazinane-2,4-dion (393 mg, Yield: 74%) as pale pink solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.13-1.20 (3H, m), 1.28 (6H, d, J = 6.1 Hz), 2.28 (3H, s), 2.55 (2H, t, J = 6.9 Hz), 3.33-3.39 (2H, m), 3.98-4.06 (2H, m), 4.60-4.62 (1H, m), 5.21 (2H, s), 7.12-7.23 (6H, m), 7.41-7.46 (1H, m), 9.26 (1H, brs). [Example 31] [0245] Preparation of 6-(3-chloro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylethyl)-1-(4-methylbenzyl)-1,3, 5-triazinane-2,4-dion (1-0896) [Chemical Formula 140] CI 0 CI 0 O -C2 0 N HNNC02H N -'N- 0 N--' N -- 0 Me Me To a mixture of 6-(3-chloro-4-isopropoxyphenylimino)-3-(2-ethoxycarbonylethyl)-1-(4-methylbenzyl)-1,3,5 triazinane-2,4-dion (371 mg, 0.741 mmol), methanol (2 mL) and THF (2 mL) was added 1mol/L lithium hydroxide (2.4 mL, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was concentrated. To the reaction mixture was added 2mol/L hydrochloric acid (1.3 mL). The precipitated crystalline was filtered off, and the residue was precipitated by ethyl acetate/hexane to give 6-(3-chloro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylethyl)-1-(4-methylbenzyl)-1,3, 5-triazinane-2,4-dion (247 mg, Yield: 71%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (6H, d, J = 5.8 Hz), 2.28 (3H, s), 2.49-2.52 (2H, m), 3.93-3.95 (2H, m), 4.59-4.62 (1H, m), 5.19 (2H, s), 7.12-7.23 (7H, m). [Example 32] [0246] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydrazinecarbonylethyl)-1,3, 5-triazinane-2,4-dion (1-0644) 149 [Chemical Formula 141] F 0 F 0 IL 0 HNJ ^,C2 O N NH N IN - N0 H C C F 0 O HN N s.CONHNH2 N- N -'-0 CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-1,3,5-triazine-2,4(1H,3H)-dion (2 g, 4.94 mmol) and DMF (30 mL) was added potassium tert-butoxide (1.331 g, 11.86 mmol) at room temperature and the resulting mixture was stirred for 5 minutes. Further, to the reaction mixture was added methylacrylate (1.074 mL, 11.86 mmol), and the resulting mixture was stirred at 60'C for 1.5 hours. To the reaction mixture were added potassium tert-butoxide (0.554 g, 4.94 mmol) and methylacrylate (0.448 mL, 4.94 mmol), and the resulting mixture was stirred at 60 0 C for 2 hours. Water (0.5 mL) was added to the mixture and the resulting mixture was stirred at 80 0 C for 2 hours. The reaction mixture was concentrated in vacuo and 2mol/L aqueous hydrochloric acid (80 mL) was added to the resulting residue. The mixture was extracted with ethyl acetate (50 mLx3). The extract was washed by brine (100 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (methanol/chloroform). The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylethyl)-1,3,5 triazinane-2,4-dion (1.64 g, Yield: 70%) as colorless solid. 1H-NMR (6 ppm TMS / CDCl 3 ): 1.37 (6H, d, J=6.1 Hz), 2.71 (2H, t, J=7.2 Hz), 4.16 (2H, t, J=7.2 Hz), 4.47 (1H, sept, J=6.1 Hz), 5.17 (2H, s), 6.50 (1H, br. d, J=8.8 Hz), 6.60 (1H, br. d, 11.1 Hz), 6.97 (1H, t, J=8.8 Hz), 7.31 (2H, d, J=8.2 Hz), 7.48 (2H, d, J=8.2 Hz), 7.57 (1H, br. s). To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylethyl)-1,3,5 triazinane-2,4-dion (300 mg, 0.629 mmol), 0-(7-azabenzotriazoll-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (287 mg, 0.755 mmol), triethylamine(0.13 mL, 0.94 mmol) and DMF (6 mL) was added hydrazine monohydrate (0.015 g, 0.21 mmol), and the mixture was stirred at room temperature overnight. The mixture was added to water (200 mL), and the resulting mixture was extracted with ethyl acetate (300 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO2H H20/MeCN 40-70%). The resulting residue was precipitated by ethyl acetate and hexane to give 150 1-(4-chlorobenzyl) -6-(3 -fluoro-4-isopropoxyphenylimino)- 3- (2-hydrazinecarbonylethyl) -1,3, 5-triazinane-2,4-dion (184 mg, Yield: 60%) as colorless solid. 1H-NMR (6 ppm TMS / CDCl 3 ): 1.31 (6H, m), 2.55 (4H, m), 4.08 (2H, m), 4.42 (1H, m), 5.16 (1H, m), 6.48 (2H, m), 6.90 (2H, m), 7.28 (2H, m), 7.40 (1H, m). [Example 33] [0247] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(5-oxo-4,5-dihydro-1,3,4-oxadia zol-2-yl)methyl-1,3,5-triazinane-2,4-dion (1-0646) [Chemical Formula 142] F 0 HN'NH2 F 0 H k -O H N NNH N-' N 0 -- N-' N O CI CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydrazinecarbonylethyl)-1,3, 5-triazinane-2,4-dion (134.6 mg, 0.274 mmol) and DMF (2 mL) was added 1,1'-carbonyldiimidazole (53.3 mg, 0.329 mmol), and the mixture was stirred at room temperature overnight. The mixture was added to water (200 mL), and extracted with ethyl acetate (300 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was precipitated by hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(5-oxo-4,5-dihydro-1,3,4-oxadia zol-2-yl)methyl-1,3,5-triazinane-2,4-dion (113 mg, Yield: 80%) as colorless powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.1 Hz), 2.89 (2H, m), 4.16 (2H, m), 4.48 (1H, sept, J=6.0 Hz), 5.16 (2H, s), 6.49-6.62 (2H, m), 6.98 (1H, t, J=9.0 Hz), 7.31-7.48 (4H, m), 8.00-8.40 (1H, m). [Example 34] [0248] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-[2-(1,2,4-triazol-5-yl)ethyl]-1,3, 5-triazinane-2,4-dion (1-0672) 151 [Chemical Formula 143] F 0 0 F O O 0N 1 N-- O - HN- N- ' NH, N N OH0H N NH2 CI CI F 0 HN-N 110 - HN I '- N NON N aci To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylethyl)-1,3,5 triazinane-2,4-dion (2.86 g, 6 mmol) and DMF (20 mL) were added ammonium chloride (0.385 g, 7.20 mmol), 1-hydroxybenzotriazole hydrate (1.011 g, 6.60 mmol), 4-dimethylaminopyridine (0.073 g, 0.600 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.265 g, 6.60 mmol) and triethylamine (0.998 mL, 7.20 mmol), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water (200 mL), and the mixture was extracted with ethyl acetate (200 mL). The extract was washed by saturated aqueous sodium bicarbonate (200 mL) and brine (200 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-carbamoylethyl)-1,3,5-triazi nane-2,4-dion (2.29 g, Yield: 84%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (6H, d, J=6.1 Hz), 2.34 (2H, t, J=7.6 Hz), 3.90 (2H, t, J=7.6 Hz), 4.55 (1H, m), 5.22 (2H, brs), 6.50 (1H, brs), 6.84 (brs), 7.00-7.40 (7H, m), 9.25 (1H, brs) A mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-carbamoylethyl)-1,3,5-triazi nane-2,4-dion (150 mg, 0.315 mmol) and N,N-dimethylformamide dimethyl acetal (2 mL) was stirred at 80 0 C for 1.5 hours. The reaction mixture was concentrated in vacuo. To the residue were added acetic acid (1 mL) and hydrazine monohydrate (0.046 mL, 0.944 mmol), and the mixture was strirred at 90 0 C for 0.5 hour. The reaction mixture was poured into water (200 mL), and the resulting mixture was extracted with chloroform (200 mLx2). The extract was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-[2-(1,2,4-triazol-5-yl)ethyl]-1,3, 5-triazinane-2,4-dion (75.3 mg, Yield: 48%) as colorless powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.3 Hz), 3.20 (2H, t, J=6.4 Hz), 4.24 (2H, t, J=6.4 Hz), 4.47 (1H, sept, J=5.9 Hz), 5.14 (2H, s), 6.48-6.52 (1H, m), 6.59 (1H, dd, J=11.7, 2.6 Hz), 6.97 (1H, t, 8.5 Hz), 7.30 (2H, d, J=8.2 Hz), 7.46 (2H, d, J=8.2 Hz), 7.78-7.89 (1H, m), 11.2 (1H, brs). 152 [Example 35] [0249] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-[2-(cyanocarbamoyl)ethyl]-1,3, 5-triazinane-2,4-dion (1-0758) [Chemical Formula 144] F 0 0 F 0 0 0 H N aN " > OH 0 NCN _b N ' N- 0 6 N,N "O H CI CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylethyl)-1,3,5 triazinane-2,4-dion (300 mg, 0.629 mmol), triethylamine (0.105 mL, 0.755 mmol) and DMF (3 mL), methyl chlorocarbonate (0.063 mL, 0.755 mmol) was added under ice-cooling, and the resulting mixture was stirred at 0 0 C for 2 hours. To the mixture were added cyanamide monosodium salt (121 mg, 1.89 mmol) and 4-dimethylaminopyridine (23 mg, 0.19 mmol), and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water (200 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-[2-(cyanocarbamoyl)ethyl]-1,3, 5-triazinane-2,4-dion (20 mg, Yield: 6%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=5.8 Hz), 2.50 (2H, m), 3.93-3.97 (2H, m), 4.42-4.64 (1H, m), 5.06, 5.23 (2H, s), 6.43-6.60 (1H, m), 7.01-7.10 (2H, m), 7.28-7.43 (4H, m), 9.26 (1H, s). [Example 36] [0250] Preparation of 1-(4-chlorobenzyl)-6-(3-methyl-4-isopropoxyphenylimino)-3-(4-methoxycarbonyl-2-oxazolyl )-1,3,5-triazinane-2,4-dion (1-0780) 153 [Chemical Formula 145] 0 0 N NH N N -NCO2Me EtS N O - EtS N 0 I- ci I- ci Me 0 0 -HN H N< j -CO 2 Me & N -',NO0 ci To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (300 mg, 1.01 mmol) and DMF (3 mL) were added potassium carbonate (167 mg, 1.21 mmol) and methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate (212 mg, 1.21 mmol), and the resulting mixture was strirred at 70 0 C for 2 hours. The reaction mixture was poured into water (200 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(4-methoxycarbonyl-2-oxazolyl)-1,3,5-triazinane-2,4-dio n (520 mg) as crude product as yellow amorphous. To the obtained crude 1-(4-chlorobenzyl)-6-(ethylthio)-3-(4-methoxycarbonyl-2-oxazolyl)-1,3,5-triazinane-2,4-dio n were added 3-methyl-4-isopropoxyaniline (248 mg, 1.5 mmol), t-butyl alcohol (8 mL) and acetic acid (0.86 mL), and the resulting mixture was heated under reflux for 5 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (100 mL), and extracted with ethyl acetate (100 mL). The extract was washed by saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(3-methyl-4-isopropoxyphenylimino)-3-(4-methoxycarbonyl-2-oxazolyl )-1,3,5-triazinane-2,4-dion (535 mg , Yield: 99%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.31, 1.35 (6H, d, J=6.1 Hz), 2.15, 2.20 (3H, s), 3.91 (3H, s), 4.47 (1H, sept, J=6.1 Hz), 5.17, 5.19, 5.23, 5.32 (4H, m), 6.57-6.63 (2H, m), 6.82-6.88 (1H, m), 7.28-7.34 (2H, m), 7.45-7.53 (2H, m), 8.17 (1H, s). [Example 37] [0251] Preparation of 1-(4-chlorobenzyl)-6-(3-methyl-4-isopropoxyphenylimino)-3-(4-hydroxycarbonyl-2-oxazolyl )-1,3,5-triazinane-2,4-dion (1-0800) 154 [Chemical Formula 146] Me 0 Me 0 HN 0 HN : H ~ CO 2 Me HC2H CI To a mixture of 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(4-methoxycarbonyl-2-oxazolyl) -1,3,5-triazinane-2,4-dion (520 mg, 0.963 mmol), methanol (5 mL), and water (2.5 mL) was added 4mol/L lithium hydroxide (0.722 mL), and the resulting mixture was stirred at room temperature for 2 hours. To the mixture were added water (100 mL) and 2mol/L hydrochloric acid (10 mL), and the resulting mixture was extracted with ethyl acetate (300 mL). The extract was washed by brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(4-hydroxycarbonyl-2-oxazolyl) -1,3,5-triazinane-2,4-dion (370 mg, Yield: 73%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.35 (6H, d, J=5.9 Hz), 2.19 (3H, s), 4.47 (1H, sept, J=5.9 Hz), 5.20 (2H, s), 5.20 (2H, s), 6.64-6.81 (3H, m), 7.31-7.59 (4H, m), 8.26 (1H, s). [Example 38] [0252] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(4-cyanoimino-4-phenoxy-3-iso butyl)-1,3,5-triazinane-2,4-dion (I-0652) [Chemical Formula 147] F 0 HI F 0 H 0ITO N NkNN NH2 IO N N-N. rOPh H CN NC To a mixture of 3-(2-aminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-1,3,5-triazinane -2,4-dion hydrochloride (200 mg, 0.413 mmol) and ethyl ether (8 mL) were added triethylamine (0.126 mL, 0.908 mmol) and diphenyl-N-cyanocarbonimidate (216 mg, 0.908 mmol), and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(4-cyanoimino-4-phenoxy-3-aza butyl)-1,3,5-triazinane-2,4-dion (170 mg, Yield: 70%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.40 (6H, d, J=6.0 Hz), 3.70 (2H, m), 4.07 (2H, m), 4.49 (1H, sept, J=6.0 Hz), 5.17 (2H, s), 6.47-6.61 (1H, m), 6.94 (1H, t, J=8.7 Hz), 7.16-7.20 (4H, m), 7.30-7.46 (4H, m), 7.79 (1H, m), 8.25 (1H, s). 155 [Example 39] [0253] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(4-cyanoimino-4-methylamino 3-azabutyl)-1,3,5-triazinane-2,4-dion (I-0653) [Chemical Formula 148] F 0 F 0 O P hNN , OPh " O H Me H NN N H_ N< Me N -N-- 0NC' N 0 CON C1 CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(4-cyanoimino-4-phenoxy-3-aza butyl)-1,3,5-triazinane-2,4-dion (155 mg, 0.262 mmol), 2-propanol (2 mL) and ethyl acetate (1 mL) was added 2mol/L methylamine in THF (1.964 mL, 3.93 mmol), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(4-cyanoimino-4-methylamino 3-azabutyl)-1,3,5-triazinane-2,4-dion (135 mg, Yield: 98%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=5.9 Hz), 2.71-2.84 (3H, m), 3.47-3.56 (2H, m), 4.01-4.16 (2H, m), 4.48 (iH, sept, J=5.9 Hz), 5.18-5.27 (2H, m), 5.40-5.46 (1H, m), 6.57-6.68 (1H, m), 6.80-7.02 (2H, m), 7.32 (2H, d, J=8.4 Hz), 7.49 (2H, d, J=8.4 Hz), 7.73 (1H, br. s). [Example 40] [0254] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(4-imino-4-amino-3-azabutyl)-1 ,3,5-triazinane-2,4-dion (I-0659) [Chemical Formula 149] F 0 F 0 O HNN -NH2 O HNN N NH 2 N . N , O H C I _ _N_ _NO N H N . I ci I- CI To a mixture of 3-(2-aminoethyl)-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-1,3,5-triazinane -2,4-dion hydrochloride (150 mg, 0.31 mmol) and DMF (3 mL) were added diisopropylethylamine(0.270 mL, 1.548 mmol) and 1H-pyrazole-1-carboxyimidate hydrochloride (136 mg, 0.929 mmol), and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (300 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO2H H20/MeCN 40-70%). 156 The resulting residue was precipitated by ethyl acetate to give 1-(4-chlorobenzyl) -6-(3 -fluoro-4-isopropoxyphenylimino)- 3- (4-imino-4-amino-3 -azabutyl) -1 ,3,5-triazinane-2,4-dion (96 mg, Yield: 63%)> flesh color solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.22 (6H, d, J=6.1 Hz), 3.19 (2H, m), 3.70 (2H, t, J=6.25 Hz), 4.35 (1H, sept, J=5.9 Hz), 5.09 (2H, s), 6.65-6.68 (1H, m), 6.84 (1H, t, J=9.0 Hz), 7.07 (1H, dd, J=14.3, 2.4 Hz), 7.17 (2H, brs), 7.30-7.38 (4H, m), 7.59 (1H, m). [Example 41] [0255] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(6-methoxy-3-pyridyl)methyl-1, 3,5-triazinane-2,4-dion (I-0641) [Chemical Formula 150] 0 0 F 0 N IkNH N I kN -1 HN 1 N EtS NO -. EtS NON OMe N NON OMe C1 CI CI To a mixture of 1-(4-chlorobenzyl)-6-(Ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (0.5 g, 1.68 mmol), (6-methoxy-3-pyridyl)methanol (0.3 g, 2.18 mmol), triphenylphosphine (0.57 g, 2.18 mmol) and dioxane (10 mL) was gradually added di-2-methoxyethylazodicarboxylate (0.57 g, 2.18 mmol), and the mixture was stirred at room temperature overnight. To the reaction mixture was added water (200 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(6-methoxy-3-pyridyl)methyl-1,3,5-triazinane-2,4-dion (0.64 g, Yield: 91%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.40 (3H, t, J=7.2 Hz), 3.25 (2H, q, J=7.4 Hz), 3.96 (3H, s), 5.06 (2H, s), 5.11 (2H, s), 6.73 (1H, d, J=8.66 Hz), 7.29-7.38 (4H, m), 7.82 (1H, dd, J=8.4, 2.4 Hz), 8.39 (1H, m). The mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-(6-methoxy-3-pyridyl)methyl-1,3,5-triazine-2,4(1H,3H) dion (0.32 g, 0.76 mmol), 3-fluoro-4-isopropoxyaniline (0.19 g, 1.15 mmol), t-butanol (6.4 mL) and acetic acid (0.66 mL) was heated at reflux for 24 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (100 mL), and extracted with ethyl acetate (100 mL). The extract was washed by saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL), dried over anhydrous magnesium sulfate. The extract was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was precipitated by hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(6-methoxy-3-pyridyl)methyl-1, 3,5-triazinane-2,4-dion (0.33 g, Yield: 82%) as colorless powder. 157 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (6H, d, J=6.1 Hz), 3.93 (3H, s), 4.74 (1H, sept, J=6.1 Hz), 4.93 (2H, s), 5.16 (2H, s), 6.47 (1H, m), 6.58 (1H, m), 6.70 (1H, d, J=8.8 Hz), 6.96 (1H, t, J=8.8 Hz), 7.29-7.49 (4H, m), 7.71 (1H, m), 8.30 (1H, m). [Example 42] [0256] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(6-oxo-1,6-dihydro-3-pyridyl)m ethyl-1,3,5-triazinane-2,4-dion (1-0649) [Chemical Formula 151] F 0 F 0 _ -'r HN u N -,T HN llN ,N NO N OMe NN 0 A mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(6-methoxy-3-pyridyl)methyl-1, 3,5-triazinane-2,4-dion (245 mg, 0.466 mmol), sodium iodide (209 mg, 1.397 mmol), acetonitrile (5 mL) and chlorotrimethylsilane (0.179 mL, 1.397 mmol) was heated at reflux for 1 hour. The reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (300 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(6-oxo-1,6-dihydro-3-pyridyl)m ethyl-1,3,5-triazinane-2,4-dion (237 mg, Yield: 99%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=6.0 Hz), 4.62 (3H, m), 5.22 (2H, m), 6.26 (1H, d, J=9.3 Hz), 7.05-7.15 (2H, m), 7.31-7.42 (5H, m), 9.31 (1H, m), 11.5 (1H, m). [Example 43] [0257] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(1-mehtyl-2-oxo-1,2-dihydro-3 pyridyl)mehtyl-1,3,5-triazinane-2,4-dion (1-0689) 158 [Chemical Formula 152] 0 OMe 0 0 0 0 N N NH N N N.Me N I N ' N ' EtS 1 N O EtS N 0 - EtS N O CI CI CI F 0 0 O H N N.Me N N O -aCI A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-mehtyl-2-oxo-1,2-dihydro-3-pyridyl)methyl-1,3,5-tria zine-2,4(1H,3H)-dion (340 mg, 0.812 mmol), sodium iodide (365 mg, 2.44 mmol), chlorotrimethylsilane (0.311 mL, 2.44 mmol) and acetonitrile (14 mL) was stirred at 100'C for 1 hour. To the reaction mixture was added 10% aqueous sodium hydrogensulfate, and the resulting mixture was extracted with ethyl acetate and THF. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-oxo-1,2-dihydro-3-pyridyl)methyl-1,3,5-triazine-2,4(1 H,3H)-dion(260 mg, Yield: 79%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (3H, t, J=7.6 Hz), 3.13 (2H, q, J=7.6 Hz), 4.70 (2H, s), 5.09 (2H, s), 6.14 (1H, t, J=6.8 Hz), 7.20 (1H, d, J=6.0 Hz), 7.31 (1H, d, J=6.0 Hz), 7.37-7.43 (4H, m), 11.71 (1H, s). A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-oxo-1,2-dihydro-3-pyridyl)methyl-1,3,5-triazine-2,4(1 H,3H)-dion (150 mg, 0.370 mmol), 60% sodium hydride (21 mg, 0.52 mmol), trifluoromethanesulfonic acid methyl ester (0.049 mL, 0.45 mmol) and DMF (3 mL) was stirred at room temperature for 3 hours. To the mixture was added 10% aqueous citric acid and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(1-methyl-2-oxo-1,2-dihydro-3-pyridyl)mehtyl-1,3,5-tria zine-2,4(1H,3H)-dion (130 mg, Yield: 84%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (3H, t, J=7.6 Hz), 3.13 (2H, q, J=7.6 Hz), 3.46 (3H, s), 4.72 (2H, s), 5.09 (2H, s), 6.17 (1H, t, J=6.8 Hz), 7.20 (1H, d, J=6.0 Hz), 7.37-7.43 (4H, m), 7.63 (1H, d, J=6.0 Hz). A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-(1-methyl-2-oxo-1,2-dihydro-3-pyridyl)methyl-1,3,5-tria zine-2,4(1H,3H)-dion (125 mg, 0.298 mmol), 3-fluoro-4-isopropoxyaniline (76 mg, 0.45 159 mmol),acetic acid (0.256 mL) and t-butanol (2.4 mL) was heated at reflux for 9 hours. The reaction mixture was concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(1-methyl-2-oxo-1,2-dihydro-3 pyridyl)methyl-1,3,5-triazinane-2,4-dion (50 mg, Yield: 32%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.6 Hz), 3.45 (3H, s), 4.57 (1H, brs), 4.68 (2H, s), 5.24 (2H, brs), 5.09 (2H, s), 6.17 (1H, t, J=6.8 Hz), 7.11-7.14 (3H, m), 7.42 (4H, brs), 7.62 (1H, d, J=6.0 Hz). [Example 44] [0258] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-sulfamoylethyl)-1,3,5-triazin ane-2,4-dion (I-0693) [Chemical Formula 153] 0 0 0 N NH N N SO3H N N S02NH2 EtS N -O EtS N O EtS N O CI CI CI F 0 O S2NH 2 N 'lN 0 N. ci To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (500 mg, 1.679 mmol) and N-methyl-2-pyrrolidone (2.5 mL) were added cesium carbonate (1094 mg, 3.36 mmol) and 2-bromoethanesulfonic acid sodium (709 mg, 3.36 mmol), and the resulting mixture was stirred at 140 0 C under microwave irradiation for 1 hour. To the reaction mixture was added 2mol/L aqueous hydrochloric acid (2.5 mL) and purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-sulfoethyl)-1,3,5-triazine-2,4(1H,3H)-dion (120 mg, Yield: 18%) as pale yellow amorphous. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04, 1.24 (3H, t, J=7.0 Hz), 2.63-2.72 (2H, m), 3.09, 3.42 (2H, q, J=7.0 Hz), 3.91-4.03 (2H, m), 4.83 (2H, s), 7.35-7.38 (4H, m), 11.7 (1H, s). To 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-sulfoethyl)-1,3,5-triazine-2,4(1H,3H)-dion (120 mg, 0.296 mmol) was added phosphorus oxychloride (2.5 mL), and the mixture was heated at reflux for 2 hours. The reaction mixture was concentrated in vacuo and the resulting residue was dissolved in dioxane (5 mL). The dioxane solution of the residue was gradually added to 0.5mol/L ammonia in dioxane (5.9 mL) under ice-cooling, and the resulting mixture was stirred at room temperature overnight. The precipitated insoluble were filtered off and the filtrate was concentrated in vacuo. The resulting residue was 160 purified by HPLC to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-sulfamoylethyl)-1,3,5-triazine-2,4(1H,3H)-dion (7.4 mg, Yield: 6%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.37 (3H, t, J=7.5 Hz), 3.22 (2H, q, J=7.5 Hz), 3.48-3.51 (2H, m), 4.43-4.49 (2H, m), 5.12 (1H, s), 5.20 (2H, s), 7.25-7.35 (4H, m). A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-sulfamoylethyl)-1,3,5-triazine-2,4(1H,3H)-dion (6.9 mg, 0.017 mmol), 3-fluoro-4-isopropoxyaniline (4.33 mg, 0.026 mmol), t-butanol (1 mL) and acetic acid (0.015 mL) was heated at reflux for 24 hours. The reaction was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-sulfamoylethyl)-1,3,5-triazin ane-2,4-dion (5 mg, Yield: 57%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.25 (6H, d, J=5.8 Hz), 3.19-3.26 (2H, m), 4.06-4.12 (2H, m), 4.50 (1H, sept, J=5.8 Hz), 5.17 (2H, s), 6.83-7.38 (9H, m). [Example 45] [0259] Preparation of (S)-1-(4-chlorobenzyl)-3-(2-methoxycarbonylpropyl)-6-(4-phenoxy-phenylimino)-1,3,5-triaz inane-2,4-dion (1-0989) [Chemical Formula 154] 0 0 0 0 0 N NH N N iOMe O HN N O'Me AkA A Me K KN) Me EtS N - :EtS N Oe N N O e CI CI C To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (5.96 g, 20 mmol), triphenylphosphine (6.29 g, 24 mmol), (S)-3-methyl 2-hydroxyisobutyrate (2.84 g, 24 mmol) and dioxane (40 mL) was added di-2-methoxyethylazodicarboxylate (5.62 g, 24 mmol) over 10 minutes, and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water (250 mL) and the resulting mixture was extracted with ethyl acetate (250 mL). The extract was washed by brine (250 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was precipitated by ethyl acetate and hexane to give (S)-1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,3H )-dion (6.0 g, Yield: 75%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.19 (3H, d, J=5.7 Hz), 1.37 (3H, t, J=7.1 Hz), 2.96 (1H, m), 3.12 (2H, q, J=7.1 Hz), 3.60 (3H, s), 3,98 (1H, m), 4.21 (1H, m), 5.08 (2H, s), 7.29-7.34 (4H, m). A mixture of (S)-1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,3H 161 )-dion (0.279 g, 0.7 mmol), 4-phenoxyaniline (0.194 g, 1.05 mmol), acetic acid(0.6 mL) and t-butanol(6 mL) was heated at reflux for 5 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (150 mL), and the resulting mixture was extracted with ethyl acetate (150 mL). The extract was washed by brine (150 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-3-(2-methoxycarbonylpropyl)-6-(4-phenoxyphenylimino)-1,3,5-triazi nane-2,4-dion (0.34 g, Yield: 93%) as pale brown amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.19 (3H, d, J=7.1 Hz), 2.90 (1H, m), 3.61 (3H, s), 3.90 (1H, m), 4.12 (1H, m), 5.15 (1H, d, J=14.3 Hz), 5.23 (1H, d, J=14.3 Hz), 6.80 (2H, d, J=8.5 Hz), 7.01-7.40 (10H, m), 7.50 (2H, d, J=8.5 Hz). [Example 46] [0260] Preparation of (S)-1-(4-chlorobenzyl)-3-(2-hydroxycarbonylpropyl)-6-(4-phenoxyphenylimino)-1,3,5-triazi nane-2,4-dion (1-0991) [Chemical Formula 155] 0 0 0 0 0 N H N D N S e0 HN' N SO O Me O N N 0 NNO0 CI CI To a mixture of (S)-1-(4-chlorobenzyl)-3-(2-methoxycarbonylpropyl)-6-(4-phenoxyphenylimino)-1,3,5-triazi nane-2,4-dion (0.313 g, 0.6 mmol), methanol (1 mL) and THF (1 mL) was added 4mol/L lithium hydroxide (0.75 mL), and the resulting mixture was stirred at 60 0 C for 1 hour. To the reaction mixture were added water (100 mL) and 2mol/L hydrochloric acid (2 mL) and the resulting mixture was extracted with ethyl acetate (100 mL). The extract was washed by brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-1-(4-chlorobenzyl)-3-(2-hydroxycarbonylpropyl)-6-(4-phenoxyphenylimino)-1,3,5-triazi nane-2,4-dion (0.29 g, Yield: 95%) as pale brown powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.20 (3H, d, J=6.6 Hz), 2.95 (1H, m), 3.90 (1H, m), 4.10 (1H, m), 5.19 (2H, s), 6.79 (2H, d, J=8.5 Hz), 6.98-7.36 (9H, m), 7.47 (2H, d, J=8.0 Hz), 7.80 (1H, s). [Example 47] [0261] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-ethoxycarbonyl-2-methoxyim inoethyl)-1,3,5-triazinane-2,4-dion (I-0735) 162 [Chemical Formula 156] Me CI T F0 m COdet Br 0Br EtI N 1 NJ N EtS lkN -k0 Me MeN- c F 06 -0 HN' 'ul d COO~t I-ci To a mixture of ethyl 3-bromo-2-oxo-propionate (5.85 g, 30 mmol) and ethanol (30 mL) was added 0-methoxyamine hydrochloride (5.01 g, 60.0 mmol), and the resulting mixture was stirred at room temperature for 3 hours. To the reaction mixture was added water (200 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give crude ethyl 3-bromo-2-methoxyiminopropionate 6.02g as colorless oil. To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (1.49 g, 5 mmol), ethyl 3-bromo-2-methoxyiminopropionate (1.34 g, 6.00 mmol), and DMF (10 mL) was added potassium carbonate (0.898 g, 6.50 mmol), and the resulting mixture was stirred at 60 0 C for 2 hours. To the reaction mixture was added water (200 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-ethoxycarbonyl-2-methoxyiminoethyl)-1,3,5-triazine 2,4(1H,3H)-dion (2.10 g, Yield: 95%) as colorless oil. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.28-1.38 (6H, m), 3.21 (2H, q, J=7.4 Hz), 4.03 (3H, s), 4.28 (2H, q, J=7.1 Hz), 4.97 (2H, s). 5.11 (2H, s), 7.26-7.34 (4H, m). A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-ethoxycarbonyl-2-methoxyiminoethyl)-1,3,5-triazine 2,4(1H,3H)-dion (0.35 g, 0.8 mmol), 3-fluoro-4-isopropoxyaniline (0.20 g, 1.2 mmol), acetic acid(0.72 g, 12 mmol) and t-butanol(7 mL) was heated at reflux overnight. The reaction mixture was poured into saturated aqueous sodium bicarbonate (100 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-ethoxycarbonyl-2-methoxyim inoethyl)-1,3,5-triazinane-2,4-dion (0.31 g, Yield: 70%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.30 (3H, t, J=7.3 Hz), 1.37 (6H, d, J=6.1 Hz), 4.04 (3H, s), 163 4.27 (2H, q, J=7.3 Hz), 4.48 (iH, sept, J=6.1 Hz), 4.89 (2H, s), 5.17 (2H, s), 6.48-6.52 (1H, m), 6.60 (iH, dd, J=11.7, 2.6 Hz), 6.97 (1H, t, J=8.5 Hz), 7.28-7.47 (5H, m). [Example 48] [0262] Preparation of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-methoxyi minoethyl)-1,3,5-triazinane-2,4-dion (1-0737) [Chemical Formula 157] Me Me F F F O O'N F O O'N O N Hk N COOEt N 1 COOH N_ N _O N_- N-_O CI CI To a mixture of 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-ethoxycarbonyl-2-methoxyim inoethyl)-1,3,5-triazinane-2,4-dion (0.29 g, 0.53 mmol), methanol (3 mL) and water (1.5 mL) was added 4mol/L lithium hydroxide (0.4 mL), and the resulting mixture was stirred at room temperature overnight. To the reaction mixture was added water (100 mL). The pH of the mixture was adjusted with 2mol/L hydrochloric acid to a pH of about 3, and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-methoxyi minoethyl)-1,3,5-triazinane-2,4-dion (0.27 g, Yield: 99%) as colorless powder. 1H-NMR (6 ppm TMS/DMSO-d6): 1.28 (6H, d, J=6.0 Hz), 3.81 (3H, s), 4.53 (1H, sept, J=6.0 Hz), 4.68 (2H, s), 5.21 (2H, s), 7.05 (3H, m), 7.41 (4H, m). [Example 49] [0263] Preparation of (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-ethoxycarbonyl-propyl)-6-(3-mehyl-4 isopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (1-0717) [Chemical Formula 158] O 0 Boc' NH Me O Boc'NH NKNH N N (CO 2 Et O HN N_ CO2Et EtS N 0 : EtS N O N N O N ci L' c - c To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (1.2 g, 4.03 mmol), (S)-4-hydroxy-2-t-butoxycarbonylamino-ethyl butyrate (1.034 g, 4.18 mmol), triphenylphosphine (1.268 g, 4.84 mmol) and dioxane (12 mL) was gradually added 164 di-2-methoxyethylazodicarboxylate (1.133 g, 4.84 mmol), and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water (200 mL), and the resulting mixture was extracted with ethyl acetate (300 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-ethoxycarbonylpropyl)-6-(ethylthio) 1,3,5-triazine-2,4(1H,3H)-dion (2.15 g, Yield: 100%) as colorless amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.23 (3H, t, J=7.1 Hz), 1.33 (3H, t, J=7.4 Hz), 1.42 (9H, s), 2.10-2.16 (2H, m), 3.17 (2H, q, J=7.4 Hz), 3.97-4.02 (2H, m), 4.05-4.14 (2H, m), 4.34 (1H, m), 5.06 (2H, m), 5.49 (1H, m), 7.28-7.35 (4H, m). A mixture of (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-ethoxycarbonylpropyl)-6-(ethylthio) 1,3,5-triazine-2,4(1H,3H)-dion (500 mg, 0.949 mmol), 3-methyl-4-isopropoxyaniline (235 mg, 1.423 mmol), acetic acid(0.814 mL) and t-butanol (10 mL) was heated at reflux overnight. The reaction mixture was added to saturated aqueous sodium bicarbonate (100 mL), and the resulting mixture was extracted with ethyl acetate (300 mL). The extract was washed by brine (200 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was precipitated by methanol to give (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-ethoxycarbonylpropyl)-6-(3-mehyl-4-i sopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (550 mg, Yield: 92%) as pale purple powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.24-1.32 (3H, m), 1.35 (6H, d, J=6.1 Hz), 1.45 (9H, s), 2.05-2.14 (2H, m), 2.19 (3H, s), 3.94 (2H, t, J=7.2 Hz), 4.09-4.18 (2H, m), 4.33-4.40 (1H, m), 4.46 (1H, sept, J=6.1 Hz), 5.17 (2H, s), 5.31 (1H, m), 6.54-6.60 (2H, m), 6.82 (1H, d, J=8.4 Hz), 7.29-7.53 (5H, m). [Example 50] [0264] Preparation of (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-hydroxycarbonylpropyl)-6-(3-mehyl-4 -isopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (1-0732) [Chemical Formula 159] Me 0 Boc'NH Me 0 Boc'NH O H N- - <S7CO 2 Et H N CO2H N '-N- 0 N - N 0 CI CI To a mixture of (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-ethoxycarbonylpropyl)-6-(3-mehyl-4-i 165 sopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (530 mg, 0.841 mmol), methanol (5 mL) and water (2.5 mL) was added 4mol/L lithium hydroxide (0.63 mL), and the resulting mixture was stirred at room temperature for 2 hours. To the reaction mixture were added water (100 mL) and saturated aqueous ammonium chloride (10 mL), and the resulting mixture was extracted with ethyl acetate (300 mL). The extract was dried over anhydrous magnesium sulfate and concentrated in vacuo to give (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-hydroxycarbonylpropyl)-6-(3-mehyl-4 -isopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (474 mg, Yield: 94%) as pale purple amorphous. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.33 (6H, d, J=5.8 Hz), 1.44 (9H, s), 2.17 (5H, m), 3.97 (2H, m), 4.32 (1H, m), 4.45 (iH, sept, J=5.8 Hz), 5.17 (2H, s), 5.40 (1H, m), 6.60-6.81 (3H, m), 7.33-7.46 (4H, m). [Example 51] [0265] Preparation of (S)- 1- (4-chlorobenzyl)- 3 -(3-amino-3 -hydroxycarbonylpropyl)- 6- (3 -mehyl-4-isopropoxyphen ylimino)-1,3,5-triazinane-2,4-dion hydrochloride (1-0736) [Chemical Formula 160] Me 0 Boc NH Me 0 NH 2 0~H NN~~< 2 0 0 HNH NH N CO2H H N CO2 CI CI To a mixture of (S)-1-(4-chlorobenzyl)-3-(3-t-butoxycarbonylamino-3-hydroxycarbonylpropyl)-6-(3-mehyl-4 -isopropoxyphenylimino)-1,3,5-triazinane-2,4-dion (460 mg, 0.764 mmol) and dioxane (2.3 mL) was added 4mol/L hydrogen chloride in dioxane (3.82 mL) under ice-cooling, and the resulting mixture was stirred at room temperature for 2 hours. To the reaction mixture were added ethyl acetate (2 mL) and hexane (10 mL). The precipitated solid was filtered off and obtained solid was washed by hexane. The obtained solid was dried under reduced pressure to give (S)- 1- (4-chlorobenzyl)- 3 -(3-amino-3 -hydroxycarbonylpropyl)- 6- (3 -mehyl-4-isopropoxyphen ylimino)-1,3,5-triazinane-2,4-dion hydrochloride (403 mg, Yield: 98%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=6.1 Hz), 1.94-2.14 (2H, m), 2.10 (3H, s), 3.86-3.96 (3H, m), 4.54 (1H, sept, J=6.1 Hz), 5.25 (2H, s), 6.90-7.03 (3H, m), 7.36 (2H, d, J=8.7 Hz), 7.43 (2H, d, J=8.7 Hz), 8.30 (3H, brs), 9.28 (1H, brs). [Example 52] [0266] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-meth oxy-ethyl)-1,3,5-triazinane-2,4-dion (I-0806) 166 [Chemical Formula 161] 0 0 Me 0 N NH NCO 2 Me O HN N C "'TM IK ) A Me EtS N -O EtS N OMe 0 N N O CI I CI CI To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (550 mg, 1.85 mmol), di-2-methoxyethylazodicarboxylate (606 mg, 2.59 mmol), triphenylphosphine (969 mg, 3.69 mmol) and dioxane (11 mL) was gradually added (S)-3-hydroxy-2-methoxy-methyl propionate (297 mg, 2.22 mmol), and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was added water, the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-methoxycarbonyl-2-methoxy-ethyl)-1,3,5-triazine 2,4(1H,3H)-dion (559 mg, Yield: 73%) as colorless oil. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (3H, t, J=7.6 Hz), 3.12 (2H, q, J=7.6 Hz), 3.27 (3H, s), 3.61 (3H, s), 3.99-4.10 (3H, m), 5.08 (2H, s), 7.32 (2H, d, J=8.0 Hz), 7.44 (2H, d, J=8.0 Hz). A mixture of (S)-1-(4-chlorobenzyl)-6-(ethylthio)-3-(2-methoxycarbonyl-2-methoxy-ethyl)-1,3,5-triazine 2,4(1H,3H)-dion (300 mg, 0.725 mmol), 3-methyl-4-isopropoxyaniline (180 mg, 1.09 mmol), acetic acid (0.622 mL) and t-butanol (6 mL) was heated at reflux for 8 hours. The reaction mixture was added to saturated aqueous sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-meth oxyethyl)-1,3,5-triazinane-2,4-dion(365 mg, Yield: 97%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.6 Hz), 2.11 (3H, s), 3.26 (3H, s), 3.57 (3H, s), 3.98-4.05 (3H, m), 4.56 (1H, sept, J=5.9 Hz), 5.26 (2H, s), 6.94 (1H, d, J=8.0 Hz), 7.04-7.07 (2H, m), 7.33 (2H, d, J=8.0 Hz), 7.46 (2H, d, J=8.0 Hz), 9.25 (1H, s). [Example 53] [0267] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-meth oxyethyl)-1,3,5-triazinane-2,4-dion (I-0807) 167 [Chemical Formula 162] Me 0 Me 0 O H N C2Me O HN N C0 2 H 1,1, k , OMe - J CY0Me 'N N 0 e N N O e CI C To a mixture of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-meth oxyethyl)-1,3,5-triazinane-2,4-dion (340 mg, 0.658 mmol), methanol (2 mL) and THF (2 mL) was added 1mol/L lithium hydroxide (2 mL), and the resulting mixture was stirred at 60'C for 30 minutes. To the reaction mixture was added 10% aqueous citric acid, extracted with ethyl acetate. The extract was washed, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by dichloromethane and hexane to give (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-meth oxyethyl)-1,3,5-triazinane-2,4-dion (243 mg, Yield: 74%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=5.6 Hz), 2.11 (3H, s), 3.25 (3H, s), 3.94-4.05 (3H, m), 4.55 (1H, sept, J=5.9 Hz), 5.27 (2H, s), 6.93 (1H, d, J=8.0 Hz), 7.04-7.07 (2H, m), 7.33 (2H, d, J=8.0 Hz), 7.45 (2H, d, J=8.0 Hz), 9.20 (1H, s), 12.89 (1H, brs). [Example 54] [0268] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-hydro xyethyl)-1,3,5-triazinane-2,4-dion (I-0852) [Chemical Formula 163] Me 0 Me 0 0 HN N C2H HN N CO2H I ~ &OMe I 0 OH N N O e N N 0 CI C To a solution of sodium iodide (119 mg, 0.795 mmol) in acetonitrile (3.2 mL) were added chlorotrimethylsilane (0.102 mL, 0.795 mmol) and (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-meth oxyethyl)-1,3,5-triazinane-2,4-dion (80 mg, 0.16 mmol), and the resulting mixture was heated at reflux for 4 hours. The reaction mixture was added to 10% aqueous sodium hydrogensulfate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-hydro xyethyl)-1,3,5-triazinane-2,4-dion (23 mg, Yield: 30%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (6H, d, J=5.6 Hz), 2.11 (3H, s), 3.93-3.95 (2H, m), 4.24-4.28 (1H, m), 4.55 (1H, sept, J=5.9 Hz), 5.27 (2H, s), 6.93 (1H, d, J=8.0 Hz), 7.04-7.07 168 (2H, m), 7.34 (2H, d, J=8.0 Hz), 7.45 (2H, d, J=8.0 Hz), 9.15 (1H, s), 12.57 (1H, brs). [Example 55] [0269] Preparation of (S)- 1- (4-chlorobenzyl)- 6-(3-mehyl-4-isopropoxyphenylimino)- 3- [2-methoxycarbonyl-2- (met hoxy-methyloxy)ethyl] - 1,3,5-triazinane-2,4-dion (I-0993) [Chemical Formula 164] 0 0 Me 0 N NH N' N 0C2Me HN N CO2Me EtS N O- EtS N OOMOM I N'NOOMOM -CI C CI To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion(440 mg, 1.48 mmol), di-2-methoxyethylazodicarboxylate (485 mg, 2.07 mmol), triphenylphosphine (775 mg, 2.96 mmol) and dioxane (9 mL) was gradually added (S)-3-hydroxy-2-methoxy-methyloxypropanoic acid methyl (291 mg, 1.77 mmol), and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was added water, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)- 1-(4-chlorobenzyl)-6-(ethylthio)-3- [2-methoxycarbonyl-2-(methoxymethyloxy)ethyl] -1,3 ,5-triazine-2,4(1H,3H)-dion (650 mg, Yield: 99%) as colorless oil. 1H-NMR (6 ppm TMS/DMSO-d6): 1.26 (3H, t, J=7.6 Hz), 3.07-3.15 (5H, m), 3.63 (3H, s), 4.01-4.21 (2H, m), 4.38-4.4.42 (1H, m), 4.58 (2H, s), 5.09 (2H, s), 7.33 (2H, d, J=8.0 Hz), 7.44 (2H, d, J=8.0 Hz). A mixture of (S)- 1-(4-chlorobenzyl)-6-(ethylthio)-3- [2-methoxycarbonyl-2-(methoxymethyloxy)ethyl] -1,3 ,5-triazine-2,4(1H,3H)-dion (650 mg, 1.46 mmol), 3-methyl-4-isopropoxyaniline (363 mg, 2.20 mmol), acetic acid(1.26 mL) and t-butanol (6.5 mL) was heated at reflux for 6 hours. The reaction mixture was added to saturated aqueous sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)- 1- (4-chlorobenzyl)- 6-(3-mehyl-4-isopropoxyphenylimino)- 3- [2-methoxycarbonyl-2- (met hoxymethyloxy)ethyl] -1,3,5-triazinane-2,4-dion (590 mg, Yield: 74%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.6 Hz), 2.11 (3H, s), 3.17 (3H, s), 3.59 (3H, s), 3.97-4.12 (2H, m), 4.34-4.40 (1H, m), 4.56 (3H, s), 5.26 (2H, s), 6.95 (1H, d, J=8.0 Hz), 7.04 (2H, brs), 7.35 (2H, d, J=8.0 Hz), 7.46 (2H, d, J=8.0 Hz), 9.25 (1H, s). [Example 56] [0270] Preparation of 169 (S)- 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-hydr oxyethyl)-1,3,5-triazinane-2,4-dion (I-0994) [Chemical Formula 165] Me 0 Me 0 0O HN N CO2Me OHN N CO2Me N N OOMOM N -N OOH CI C A mixture of (S)- 1- (4-chlorobenzyl)- 6-(3-mehyl-4-isopropoxyphenylimino)- 3- [2-methoxycarbonyl-2- (met hoxymethyloxy)ethyl] -1,3,5-triazinane-2,4-dion (585 mg, 1.07 mmol) and 4mol/L hydrogen chloride in dioxane (6 mL), and the resulting mixture was stirred at room temperature for 15 minutes. The reaction mixture was added to saturated aqueous sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo to give (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-hydr oxyethyl)-1,3,5-triazinane-2,4-dion (537 mg, Yield: 100%) as pale purple solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.6 Hz), 2.11 (3H, s), 3.53 (3H, s), 3.94-3.96 (2H, m), 4.27-4.30 (1H, m), 4.54-4.57 (1H, m), 5.26 (2H, s), 5.72-5.79 (1H, m), 6.94 (1H, d, J=8.0 Hz), 7.04-7.07 (2H, m), 7.35 (2H, d, J=8.0 Hz), 7.46 (2H, d, J=8.0 Hz), 9.20 (1H, s). [Example 57] [0271] Preparation of 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-oxoethyl )-1,3,5-triazinane-2,4-dion (1-0996) [Chemical Formula 166] Me 0 Me 0 0O HN N CO2Me OHN N 1 N CO2Me N N OOH d N<N0 O CI C To a solution of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-hydr oxyethyl)-1,3,5-triazinane-2,4-dion (150 mg, 0.298 mmol) in dichloromethane (6 mL) was added 0.3mol/L Dess-Martin reagent in dichloromethane (1.19 mL, 0.358 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture were added 10% aqueous sodium hydrogensulfate and saturated aqueous sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3%
HCO
2 H H20/MeCN 50-80%), to give 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-oxoethyl )-1,3,5-triazinane-2,4-dion (17 mg, Yield: 11%) as colorless solid. 170 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.6 Hz), 2.12 (3H, s), 3.81 (3H, s), 4.54-4.57 (1H, m), 5.03 (2H, s), 5.28 (2H, s), 6.94 (1H, d, J=8.0 Hz), 7.05 (2H, brs), 7.35 (2H, d, J=8.0 Hz), 7.47 (2H, d, J=8.0 Hz), 9.37 (1H, s). [Example 58] [0272] Preparation of 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-oxoethyl) -1,3,5-triazinane-2,4-dion (1-1009) [Chemical Formula 167] Me 0 Me 0 O CO2Me OHN 1N1y C02H N 'N- - 0 -'N 0 -CI CI To a mixture of 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonyl-2-oxoethyl )-1,3,5-triazinane-2,4-dion (15 mg, 0.030 mmol), methanol (0.3 mL) and THF (0.3 mL) was added 1mol/L lithium hydroxide (0.09 mL), and the resulting mixture was stirred at 50 0 C for 3 hours. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by dichloromethane and hexane to give 1-(4-chlorobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonyl-2-oxoethyl) -1,3,5-triazinane-2,4-dion (5 mg, Yield: 34%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.27 (6H, d, J=5.6 Hz), 2.11 (3H, s), 4.53-4.57 (1H, m), 4.98 (2H, s), 5.28 (2H, s), 6.94 (1H, d, J=8.0 Hz), 7.05 (2H, brs), 7.35 (2H, d, J=8.0 Hz), 7.47 (2H, d, J=8.0 Hz), 9.35 (1H, s). [Example 59] [0273] Preparation of (S)-1-(4-methylbenzyl)-6-(3-vinyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (1-0907) [Chemical Formula 168] Br 0' 0 ITO H CO 2 Me 0 N C2Me N4 N 0 N -N -'- Me Me A mixture of (S)-1-(4-methylbenzyl)-6-(3-bromo-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl) -1,3,5-triazinane-2,4-dion (350 mg, 0.642 mmol), vinyl boronic acid pinacol ester (0.163 mL, 0.963 mmol), dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) (42 mg, 171 0.064 mmol), THF (7 mL), and 2mol/L aqueous potassium carbonate (1.28 mL) was heated at reflux for 40 minutes. To the reaction mixture was added water and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-methylbenzyl)-6-(3-vinyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (302 mg, Yield: 96%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04-1.07 (3H, m), 1.27 (6H, d, J=5.6 Hz), 2.28 (3H, s), 2.80-2.83 (1H, m), 3.49 (3H, s), 3.78-3.97 (2H, m), 4.58-4.61 (1H, m), 5.24-5.28 (3H, m), 5.70 (1H, d, J=16.0 Hz), 6.90-7.04 (2H, m), 7.20 (5H, s), 7.39 (1H, s), 9.24 (1H, s). [Example 60] [0274] Preparation of (S)-1-(4-methylbenzyl)-6-(3-vinyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (1-0910) [Chemical Formula 169] O0 HN N CO 2 Me HN N CO2H N N 0 N N O Me Me To a mixture of (S)-1-(4-methylbenzyl)-6-(3-vinyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (85 mg, 0.17 mmol), methanol (0.6 mL) and THF (0.6 mL) was added 1mol/L lithium hydroxide (0.52 mL), and the resulting mixture was stirred at room temperature for 3 days. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-1-(4-methylbenzyl)-6-(3-vinyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (59 mg, Yield: 71%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04-1.07 (3H, m), 1.27 (6H, d, J=5.6 Hz), 2.28 (3H, s), 2.80-2.83 (1H, m), 3.78-3.97 (2H, m), 4.58-4.61 (1H, m), 5.24-5.28 (3H, m), 5.70 (1H, d, J=16.0 Hz), 6.90-7.04 (2H, m), 7.20-7.38 (5H, m), 7.47 (1H, s), 9.24 (1H, brs). [Example 61] [0275] Preparation of (S)- 1- (4-methylbenzyl) -6-(3-ethyl-4-isopropoxyphenylimino)- 3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (1-0908) 172 [Chemical Formula 170] O0 0 HN N CO 2 Me HN N C2Me N N 0 N NO Me Me A solution of (S)-1-(4-methylbenzyl)-6-(3-vinyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (200 mg, 0.406 mmol) in methanol (20 mL) was hydrogenated under 5% Pt/C. The reaction mixture was concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)- 1- (4-methylbenzyl) -6-(3-ethyl-4-isopropoxyphenylimino)- 3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (188 mg, Yield: 94%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.03-1.12 (6H, m), 1.27 (6H, d, J=5.6 Hz), 2.28 (3H, s), 2.50-2.53 (2H, m), 2.80-2.83 (1H, m), 3.56 (3H, s), 3.78-3.96 (2H, m), 4.56-4.58 (1H, m), 5.20 (2H, m), 6.93-7.11 (3H, m), 7.20 (4H, s), 9.16 (iH, s). [Example 62] [0276] Preparation of (S)- 1- (4-methylbenzyl) -6-(3-ethyl-4-isopropoxyphenylimino)- 3-(2-hydroxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (1-0911) [Chemical Formula 171] O0 0 HN N C0 2 Me HN N CO2H N N 0 N N -O Me Me To a mixture of (S)- 1- (4-methylbenzyl) -6-(3-ethyl-4-isopropoxyphenylimino)- 3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (160 mg, 0.324 mmol), methanol (1 mL) and THF(i mL) was added 1mol/L lithium hydroxide (1 mL), and the resulting mixture was stirred at 60 0 C for 1 hour. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)- 1- (4-methylbenzyl) -6-(3-ethyl-4-isopropoxyphenylimino)- 3-(2-hydroxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (122 mg, Yield: 79%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.01 (3H, d, J=6.8 Hz), 1.10 (3H, t, J=7.6 Hz), 1.27 (6H, d, J=5.6 Hz), 2.28 (3H, s), 2.50-2.53 (2H, m), 2.80-2.83 (1H, m), 3.78-3.96 (2H, m), 4.56-4.58 (1H, m), 5.24 (2H, m), 6.81-7.19 (3H, m), 7.28 (4H, s), 9.11 (1H, s), 12.30 (1H, brs). [Example 63] [0277] 173 Preparation of (S)-1-(4-vinylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (I-0892) [Chemical Formula 172] Me 0 Me 0 0 O CO 2 Me 0 CO2Me N -N 0 NI ' N N"NO Br To a mixture of (S)-1-(4-bromobenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl) 1,3,5-triazinane-2,4-dion (300 mg, 0.550 mmol), vinyl boronic acid pinacol ester (0.140 mL, 0.825 mmol), dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) (36 mg, 0.055 mmol), THF (6 mL) and 2mol/L aqueous potassium carbonate (1.10 mL) was heated at reflux for 1 hour. To the reaction mixture was added water and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-vinylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (256 mg, Yield: 95%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04 (3H, d, J=6.8 Hz), 1.27 (6H, d, J=5.6 Hz), 2.11 (3H, s), 2.80-2.83 (1H, m), 3.49 (3H, s), 3.79-3.96 (2H, m), 4.53-4.56 (1H, m), 5.24-5.27 (3H, m), 5.83 (1H, d, J=16.0 Hz), 6.69-6.76 (1H, m), 6.93 (1H, d, J=8.0 Hz), 7.05-7.07 (2H, m), 7.28 (2H, d, J=8.0 Hz), 7.49 (2H, d, J=8.0 Hz), 9.19 (1H, s). [Example 64] [0278] Preparation of (S)-1-(4-vinylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (I-0897) [Chemical Formula 173] Me O Me 0 O H CO 2 Me O HNtN CO2H N J N N -NO A mixture of (S)-1-(4-vinylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (50 mg, 0.10 mmol), methanol (0.4 mL) and THF(0.4 mL) was added 1mol/L lithium hydroxide (0.3 mL), and the resulting mixture was stirred at room temperature 6 hours. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue 174 was precipitated by ethyl acetate and hexane to give (S)-1-(4-vinylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (36 mg, Yield: 74%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.01 (3H, d, J=6.8 Hz), 1.26 (6H, d, J=5.6 Hz), 2.10 (3H, s), 2.76-2.80 (1H, m), 3.78-3.97 (2H, m), 4.50-4.55 (1H, m), 5.24-5.27 (3H, m), 5.83 (1H, d, J=16.0 Hz), 6.69-6.76 (1H, m), 6.93 (1H, d, J=8.0 Hz), 7.04-7.07 (2H, m), 7.28 (2H, d, J=8.0 Hz), 7.49 (2H, d, J=8.0 Hz), 9.14 (1H, s), 12.29 (1H, brs). [Example 65] [0279] Preparation of (S)-1-(4-ethylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (I-0894) [Chemical Formula 174] Me O Me 0 0 N CO 2 Me O CO2Me N -N 0 NO A solution of (S)-1-(4-vinylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (190 mg, 0.386 mmol) in methanol (19 mL) was hydrogenated under 5% Pt/C. The reaction mixture was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-ethylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (99 mg, Yield: 52%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04 (3H, d, J=6.8 Hz), 1.15 (3H, t, J=7.6 Hz), 1.27 (6H, d, J=5.6 Hz), 2.11 (3H, s), 2.58 (2H, q, J=7.6 Hz), 2.79-2.84 (1H, m), 3.47 (3H, s), 3.78-3.96 (2H, m), 4.53-4.57 (1H, m), 5.23 (2H, s), 6.93 (1H, d, J=8.0 Hz), 7.05-7.08 (2H, m), 7.22 (4H, s), 9.18 (1H, s). [Example 66] [0280] Preparation of (S)-1-(4-ethylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (I-0898) [Chemical Formula 175] Me O Me 0 0 C O 2 Me O0O2 N )N 02 I HN k N OH 175 To a mixture of (S)- 1-(4-ethylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)- 1 ,3,5-triazinane-2,4-dion (94 mg, 0.19 mmol), methanol (1 mL) and THF(1 mL) was added 1mol/L lithium hydroxide (0.57 mL), and the resulting mixture was stirred at 60'C for 3 hours. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-1-(4-ethylbenzyl)-6-(3-mehyl-4-isopropoxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1 ,3,5-triazinane-2,4-dion (78 mg, Yield: 85%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.01 (3H, d, J=6.8 Hz), 1.16 (3H, t, J=7.6 Hz), 1.26 (6H, d, J=5.6 Hz), 2.10 (3H, s), 2.58 (2H, q, J=7.6 Hz), 2.79-2.84 (1H, m), 3.74-3.97 (2H, m), 4.53-4.57 (1H, m), 5.24 (2H, s), 6.92 (1H, d, J=8.0 Hz), 7.05-7.08 (2H, m), 7.22 (4H, s), 9.12 (1H, s), 12.31 (1H, brs). [Example 67] [0281] Preparation of 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(1-hydroxymethyl-3-oxacyclobu tyl)methyl-1,3,5-triazinane-2,4-dion (I-1010) [Chemical Formula 176] 0 N N OTBDPS HO'<OTBDPS HO% OTBDPS E N O O -EtS N 0 0 OHOH 0 -CI CI O CI O 0 NH NW OTBDPS H NW OH N 00 N 0 CI C To a solution of 2-(t-butyl-diphenylsilyloxymethyl)-2-hydroxymethyl-propane-1,3-diol (441 mg, 1.18 mmol) in THF (9 mL) were added 1.67 mol/L n-butyllithium/n-hexane solution (1.55 mL, 2.59 mmol) and p-toluenesulfonyl chloride (247 mg, 1.30 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 20 hours. To the reaction mixture was added water, and the resulting mixture was extracted with diethyl ether. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1 -(t-butyl-diphenylsilyloxymethyl)- 1-hydroxymethyl-3-oxacylcobutane (148 mg, Yield: 35%) as colorless oil. 1H-NMR (6 ppm TMS/DMSO-d6): 1.01 (9H, s), 3.67 (2H, d, J = 4.8 Hz), 3.80 (2H, s), 4.33-4.36 (4H, m), 4.90-4.93 (1H, m), 7.42-7.47 (6H, m), 7.63 (4H, d, J = 6.8 Hz). 176 To a mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dion (150 mg, 0.504 mmol), 1-(t-butyl-diphenylsilylocxymethyl)-1-hydroxymethyl-3-oxacyclobutane (198 mg, 0.554 mmol), triphenylphosphine (198 mg, 0.756 mmol) and dioxane (2 mL) was added di-2-methoxyethylazodicarboxylate (165 mg, 0.705 mmol), and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was added water, extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(ethylthio)-3-[1-(t-butyly-diphenylsilyloxymethyl)-3-oxacyclobutyl]me thyl-1,3,5-triazine-2,4(1H,3H)-dion (273 mg, Yield: 85%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 0.99 (9.0H, s), 1.26 (3.0H, t, J= 7.2 Hz), 3.11 (2.0H, q, J 7.2 Hz), 3.86 (2.0H, s), 4.11 (2.0H, s), 4.20 (2.0H, d, J = 6.1 Hz), 4.47 (2.0H, d, J = 6.1 Hz), 5.06 (2.0H, s), 7.32-7.37 (4.0H, m), 7.41-7.47 (6.0H, m), 7.61 (4.0H, d, J = 7.3 Hz). A mixture of 1-(4-chlorobenzyl)-6-(ethylthio)-3-[1-(t-butyl-diphenylsilyloxymethyl)-3-oxacylobutyl] met hyl-1,3,5-triazine-2,4(1H,3H)-dion (273 mg, 0.429 mmol), 3-chloro-4-isopropoxyaniline (119 mg, 0.644 mmol), acetic acid (0.368 mL) and t-butanol (3 mL) was heated at reflux for 7 hours. The reaction mixture was added to saturated aqueous sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino) 3-[1-(t-butyl-diphenylsilyloxymethyl)-3-oxacylobutyl]methyl-1,3,5-triazinane-2,4-dion (248 mg, Yield: 76%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.00 (9H, s), 1.29 (6H, d, J = 5.8 Hz), 3.83 (2H, s), 4.05 (2H, s), 4.19 (2H, d, J = 6.1 Hz), 4.44 (2H, d, J = 6.1 Hz), 4.57-4.66 (1H, m), 5.22 (2H, s), 7.10-7.50 (13H, m), 7.61 (4H, d, J = 7.1 Hz), 9.35 (1H, brs). To a solution of 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino) 3-[1-(t-butyl-diphenylsilyloxymethyl)-3-oxacylobutyl]methyl-1,3,5-triazinane-2,4-dion (240 mg, 0.316 mmol) in THF (3 mL) was added a solution of 1mol/L tetra-n-butylammonium fluoride in THF (0.88 mL, 0.88 mmol), and the resulting mixture was stirred at 45 0 C for 3 hours. The reaction mixture was added to aqueous ammonium chloride, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(1-hydroxymethyl-3-oxacyclobu tyl)methyl-1,3,5-triazinane-2,4-dion (120 mg, Yield: 73%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.29 (6H, d, J = 5.8 Hz), 3.61 (2H, d, J = 4.5 Hz), 3.95 (2H, s), 4.18 (2H, d, J = 6.1 Hz), 4.40 (2H, d, J = 6.1 Hz), 4.60-4.62 (1H, m), 4.93-4.95 (1H, m), 5.22 (2H, s), 7.12-7.44 (7H, m). [Example 68] 177 [0282] Preparation of 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(1-hydroxycarbonyl-3-oxacyclo butyl)methyl-1,3,5-triazinane-2,4-dion (I-1011) [Chemical Formula 177] CI 0 CI 0 H N OH O U~~ CO2H N N W00N N,0 CI CI To a solution of 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(1-hydroxymethyl-3-oxacyclobu tyl)methyl-1,3,5-triazinane-2,4-dion (50 mg, 0.096 mmol)in acetone (0.8 mL) was added 2.67mol/L Jones reagent (0.079 mL, 0.21 mmol), and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture were added isopropanol and water, and the resulting mixture was extracted with ethyl acetate. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give 1-(4-chlorobenzyl)-6-(3-chloro-4-isopropoxyphenylimino)-3-(1-hydroxycarbonyl-3-oxacyclo butyl)methyl-1,3,5-triazinane-2,4-dion (8 mg, Yield: 16%) as colorless solid. 1H-NMR (6 ppm TMS/CDCl3): 1.36 (6H, d, J = 6.0 Hz), 4.43 (2H, s), 4.44-4.52 (1H, m), 4.67 (2H, d, J = 6.7 Hz), 4.76 (2H, d, J = 6.7 Hz), 5.16 (2H, s), 6.65-6.67 (1H, m), 6.86-6.90 (2H, m), 7.31 (2H, d, J = 8.4 Hz), 7.41 (2H, d, J = 8.4 Hz). [Example 69] [0283] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-cyclopropylethynylphenylimino)-3-(2-methoxycarbony lpropyl)-1,3,5-triazinane-2,4-dion (I-1041) [Chemical Formula 178] Me 0 Me HNCO2Me M
CO
2 Me N N ~CI C A mixture of (S)-1-(4-chlorobenzyl)-6-(4-iodo-3-methylphenylimino)-3-(2-methoxycarbonylpropyl)-1,3,5 triazinane-2,4-dion (268 mg, 0.471 mmol), ethynylcyclopropane (0.080 mL, 0.94 mmol), bis(triphenylphosphine)palladium (II) dichloride (8.3 mg, 0.012 mmol), cuprous iodide (I) (4.5 mg, 0.024 mmol), triethylamine (0.131 mL, 0.942 mmol) and DMF (3 mL) was stirred at 60 0 C for 2 hours. To the reaction mixture was added 5% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulphate, and 178 concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-cyclopropylethynylphenylimino)-3-(2-methoxycarbony lpropyl)-1,3,5-triazinane-2,4-dion (200 mg, Yield: 84%) as brown solid. 1H-NMR (6 ppm TMS/CDCl3): 0.75-0.95 (4H, m), 1.18 (3H, d, J=6.9 Hz), 1.49 (1H, m), 2.37 (3H, s), 2.89 (1H, m), 3.60 (3H, s), 3.87 (1H, dd, J=6.0, 13.8 Hz), 4.09 (1H, m), 5.10-5.24 (2H, m), 6.57 (1H, m), 6.63 (1H, m), 7.26-7.36 (4H, m), 7.48 (2H, d, J=8.4 Hz). [Example 70] [0284] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-cyclopropylethynylphenylimino)-3-(2-hydroxycarbonyl propyl)-1,3,5-triazinane-2,4-dion (I-1042) [Chemical Formula 179] Me 0 Me 0 HN N CO2Me HN N CO2H N N O N N O CI CI To a mixture of (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-cyclopropylethynylphenylimino)-3-(2-methoxycarbony lpropyl)-1,3,5-triazinane-2,4-dion (180 mg, 0.355 mmol), methanol (1 mL) and THF (1 mL) was added 1mol/L sodium hydroxide (1.1 mL), and the resulting mixture was stirred at room temperature for 2.5 hours. To the reaction mixture was added 2mol/L hydrochloric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-1-(4-chlorobenzyl)-6-(3-mehyl-4-cyclopropylethynylphenylimino)-3-(2-hydroxycarbonyl propyl)-1,3,5-triazinane-2,4-dion (78 mg, Yield: 85%) as pale brown solid. 1H-NMR (6 ppm TMS/CDCl3): 0.75-0.95 (4H, m), 1.19 (3H, d, J=6.9 Hz), 1.48 (1H, m), 2.35 (3H, s), 2.92 (1H, m), 3.87 (1H, dd, J=6.3, 13.5 Hz), 4.10 (1H, dd, J=7.2, 13.2 Hz), 5.16 (2H, s), 6.55 (1H, m), 6.61 (1H, s), 7.24-7.34 (3H, m), 7.44 (2H, d, J=8.4 Hz), 7.66 (1H, s). [Example 71] [0285] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-fluoro-4-methoxyiminomethylphenylimino)-3-(2-methoxycarbo nylpropyl)methyl-1,3,5-triazinane-2,4-dion (I-0881) 179 [Chemical Formula 180] 0 0 N N CO2Me OMe HN <N CO2Me EtS N 0 -e '- N N 0 CI MOCI 0 F 0 NN - CO2Me MeO'N A HNA.N CO2Me
H
2 N )IN-* 0m N ,NO ' 1%CI 1CI A mixture of (S)-1-(4-chlorobenzyl)-6-(ethylthio) 3-(2-methoxycarbonylpropyl)methyl-1,3,5-triazine-2,4(1H,3H)-dion (1.00 g, 2.51 mmol), 2,4-dimethoxybenzylamine (630 mg, 3.77 mmol), acetic acid (2.16 mL) and t-butanol (20 mL) was heated at reflux for 15 hours. The reaction mixture was added to saturated aqueous sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The extract was washed by 2mol/L hydrochloric acid and brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-6-(2,4-dimethoxybenzylimino)-3-(2-methoxycarbonylpropyl)methyl 1,3,5-triazinane-2,4-dion (1.19 g, Yield: 94%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04 (3H, d, J=6.8 Hz), 2.82 (1H, q, J=6.8 Hz), 3.48 (3H, s), 3.72 (6H, s), 3.77-3.82 (1H, m), 3.90-3.95 (1H, m), 4.37 (2H, s), 5.15 (2H, s), 6.35 (1H, d, J=8.4 Hz), 6.51 (1H, s), 6.73 (1H, d, J=8.4 Hz), 7.27 (2H, d, J=7.6 Hz), 7.44 (2H, d, J=7.6 Hz), 7.94 (1H, brs). A solution of (S)-1-(4-chlorobenzyl)-6-(2,4-dimethoxy-benzylimino)-3-(2-methoxycarbonylpropyl)methyl 1,3,5-triazinane-2,4-dion (1.15 g, 2.29 mmol) in trifluoro acetic acid (11 mL) was stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was extracted with chloroform. The extract was washed by saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-6-amino-i-(4-chlorobenzyl) 3-(2-methoxycarbonylpropyl)methyl-1,3,5-triazine-2,4(1H,3H)-dion (0.80 g, Yield: 99%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04 (3H, d, J=6.8 Hz), 2.81 (1H, q, J=6.8 Hz), 3.49 (3H, s), 3.74-3.81 (1H, m), 3.89-3.94 (1H, m), 5.03 (2H, s), 7.27 (2H, d, J=7.6 Hz), 7.43 (2H, d, J=7.6 Hz), 7.86 (2H, brs). A mixture of (S)-6-amino-1-(4-chlorobenzyl) 3-(2-methoxycarbonylpropyl)methyl-1,3,5-triazine-2,4(1H,3H)-dion (80 mg, 0.35 mmol), 3-fluoro-4-methoxyiminomethylaniline (146 mg, 0.414 mmol), acetic acid palladium (7.7 180 mg, 0.034 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyl-xanthene (30 mg, 0.052 mmol), cesium carbonate (157 mg, 0.483 mmol) and dioxane (2.4 mL) was heated at reflux for 24 hours. To the reaction mixture was added water, and the resulting mixture was extracted with ethyl acetate and THF. The extract was washed by brine, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-1-(4-chlorobenzyl)-6-(3-fluoro-4-methoxyiminomethylphenylimino)-3-(2-methoxycarbo nylpropyl)methyl-1,3,5-triazinane-2,4-dion (53 mg, Yield: 31%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.07 (3H, d, J=6.8 Hz), 2.81 (1H, q, J=6.8 Hz), 3.50 (3H, s), 3.83 (1H, brs), 3.90 (4H, brs), 5.09 (2H, s), 6.65-6.69 (1H, m), 7.41 (5H, brs), 7.63 (1H, brs), 8.25 (1H, s), 10.97 (1H, brs). [Example 72] [0286] Preparation of (S)-1-(4-chlorobenzyl)-6-(3-fluoro-4-methoxyiminomethylphenylimino)-3-(2-hydroxycarbon ylpropyl)methyl-1,3,5-triazinane-2,4-dion (I-0893) [Chemical Formula 181] F 0 F 0 MeO HN' C0 2 Me MeO'N A CO2H N N 0Cf N ),N 0 O ' CI CI To a mixture of (S)-1-(4-chlorobenzyl)-6-(3-fluoro-4-methoxyiminomethylphenylimino)-3-(2-methoxycarbo nylpropyl)methyl-1,3,5-triazinane-2,4-dion (50 mg, 0.099 mmol), methanol (1 mL) and THF (1 mL) was added 1mol/L lithium hydroxide (0.3 mL), and the resulting mixture was stirred at 60 0 C for 2 hours. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-1-(4-chlorobenzyl)-6-(3-fluoro-4-methoxyiminomethylphenylimino)-3-(2-hydroxycarbon ylpropyl)methyl-1,3,5-triazinane-2,4-dion (44 mg, Yield: 91%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.04 (3H, d, J=6.8 Hz), 2.76 (1H, q, J=6.8 Hz), 3.81 (1H, brs), 3.90 (4H, brs), 5.12 (2H, s), 6.67 (1H, brs), 7.40 (5H, s), 7.65 (1H, brs), 8.24 (1H, s), 10.92 (1H, brs), 12.36 (1H, brs). [Example 73] [0287] Preparation of (S)-6-(3-chloro-4-isopropoxyphenylimino)-1-(4-methoxybenzyl)-3-(2-methoxycarbonylpropy 1)methyl-1,3,5-triazinane-2,4-dion (I-1143) 181 [Chemical Formula 182] CI O 0 CO 2 Me O CO 2 Me N N 0- 0 HN U OM -- 'N -- N O CI H CI 0 O HN CO 2 Me N-' N O OMe A mixture of (S)-6-(3-chloro-4-isopropoxyphenylimino)-1-(4-chlorobenzyl)-3-(2-methoxycarbonylpropyl) methyl-1,3,5-triazinane-2,4-dion (800 mg, 1.53 mmol) in methanol (75 mL) and DMF (5 mL) was hydrogenated under 10% Pd/C. The reaction mixture was concentrated in vacuo. The resulting residue was purified by high speed liquid chromatography (0.3% HCO 2 H H20/MeCN 40-70%) to give (S)-6-(3-chloro-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)methyl-1,3,5-triazi nane-2,4-dion (498 mg, Yield: 82%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.05 (3H, d, J=6.8 Hz), 1.29 (6H, d, J=5.6 Hz), 2.81 (1H, q, J=6.8 Hz), 3.56 (3H, s), 3.77-3.82 (1H, m), 3.87-3.92 (1H, m), 4.62 (1H, sept, J=5.6 Hz), 7.16 (1H, d, J=8.4 Hz), 7.34 (1H, d, J=8.4 Hz), 7.69 (1H, s), 8.14 (1H, s). To a mixture of (S)-6-(3-chloro-4-isopropoxyphenylimino)-3-(2-methoxycarbonylpropyl)methyl-1,3,5-triazi nane-2,4-dion (480 mg, 1.21 mmol), 4-methoxybenzyl chloride (341 mg, 2.18 mmol) and DMF (10 mL) was added potassium carbonate (301 mg, 2.18 mmol), and the resulting mixture was stirred at room temperature 12 hours. To the reaction mixture was added water, extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (S)-6-(3-chloro-4-isopropoxyphenylimino)-1-(4-methoxybenzyl)-3-(2-methoxycarbonylpropy 1)methyl-1,3,5-triazinane-2,4-dion (190 mg, Yield: 30%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.05 (3H, d, J=6.8 Hz), 1.29 (6H, d, J=5.6 Hz), 2.81 (1H, q, J=6.8 Hz), 3.49 (3H, s), 3.73 (3H, s), 3.77-3.82 (1H, m), 3.87-3.92 (1H, m), 4.64 (1H, sept, J=5.6 Hz), 5.20 (2H, s), 6.94 (2H, d, J=7.2 Hz), 7.16-7.28 (4H, m), 7.47 (1H, s), 9.28 (1H, s). [Example 74] [0288] Preparation of (S)-6-(3-chloro-4-isopropoxyphenylimino)-1-(4-methoxybenzyl)-3-(2-hydroxycarbonylpropy 1)methyl-1,3,5-triazinane-2,4-dion (I-1159) 182 [Chemical Formula 183] CI 0 CI 0 0 HN H CO 2 Me 0 O CO2H NINN N-NO OMe OMe To a mixture of (S)-6-(3-chloro-4-isopropoxyphenylimino)-1-(4-methoxybenzyl)-3-(2-methoxycarbonylpropy 1)methyl-1,3,5-triazinane-2,4-dion (180 mg, 0.348 mmol), methanol (2 mL) and THF (2 mL) was added 1mol/L lithium hydroxide (1 mL), and the resulting mixture was stirred at 50 0 C for 5 hours. To the reaction mixture was added 10% aqueous citric acid, and the resulting mixture was extracted with ethyl acetate. The extract was washed by water, dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by ethyl acetate and hexane to give (S)-6-(3-chloro-4-isopropoxyphenylimino)-1-(4-methoxybenzyl)-3-(2-hydroxycarbonylpropy 1)methyl-1,3,5-triazinane-2,4-dion (160 mg, Yield: 91%) as colorless solid. 1H-NMR (6 ppm TMS/DMSO-d6): 1.02 (3H, d, J=6.8 Hz), 1.29 (6H, d, J=5.6 Hz), 2.76 (1H, q, J=6.8 Hz), 3.73 (3H, s), 3.77-3.82 (1H, m), 3.87-3.92 (1H, m), 4.63 (1H, sept, J=5.6 Hz), 5.21 (2H, s), 6.93 (2H, d, J=7.2 Hz), 7.15-7.28 (4H, m), 7.47 (1H, s), 9.23 (1H, s), 12.33 (1H, brs). [Example 75] [0289] Preparation of 6-(4-chlorobenzyloxy)-4-(3-fluoro-4-isopropoxyphenylimino)-1-t-butyl-1,3,5-triazine-2(1H) one (1-1296) [Chemical Formula 184] NA N N NN NO EtS N O EtSN O N H Ct CI To a mixture of 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dion (1.0 g, 4.4 mmol), 4-chlorobenzyl alcohol (1.02 g, 4.4 mmol), triphenylphosphine (1.49 g, 5.7 mmol) and THF (10 mL) was gradually added di-2-methoxyethylazodicarboxylate (1.33 g, 5.7 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was water (200 mL), and the resulting mixture was extracted with ethyl acetate (200 mL). The extract was washed by brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give crude 6-(4 chlorobenzyloxy)-4-ethylthio- 1-t-butyl- 1,3,5-triazine-2(1H)-one. To the obtained crude product were added 3-fluoro-4-isopropoxyaniline (0.18 g, 1.09 mmol) and acetic acid (10 mL), and the resulting mixture was stirred at room temperature for 2.5 hours. To the reaction mixture was added saturated aqueous sodium bicarbonate (200 mL), and the resulting mixture was extracted with ethyl acetate (300 mL). The extract was washed by 183 brine (200 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was precipitated by ethyl acetate and hexane to give 6(4 chlorobenzyloxy)-4- (3-fluoro-4-isopropoxyphenylimino)- 1 -t-butyl- 1,3,5-triazine-2 (1 H) -one (0.12 g, Yield: 6%) as a white powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.35(6H, d, J=6.1 Hz), 1.66 (9H, s), 4.48 (1H, sept, J=6.1 Hz), 5.37 (2H, s), 6.93 (1H, m), 7.26-7.43 (7H, m). [Example 76] [0290] Preparation of 1-(4-chlorobenzyl)-3-isopropyl-5-(4-trifluoromethylbenzyl)-1,3,5-triazine-2,4,6-trione (I-1289) [Chemical Formula 185] 0 0 0 N N HN N "- N N MeS N O NN- F 3 C 0-N0O CI CI CI To a mixture of 1-(4-chlorobenzyl)-6-(methylthio)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion (0.2 g, 0.6 mmol) and acetic acid (10 mL) was added 30% hydrogen peroxide solution (0.7 g, 6 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 18 hours. To the reaction mixture was added brine (30 mL), and the resulting mixture was extracted with dichloromethane (30 mLx2). The extract was washed by brine (30 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was precipitated by hexane to give 1-(4-chlorobenzyl)-3-isopropyl-1,3,5-triazine-2,4,6-trione (0.2 g) as a white powder. 1H-NMR (6 ppm TMS/DMSO-d6): 1.35 (6H, d, J = 6.9 Hz), 4.81 (1H, q, J = 6.9 Hz), 4.84 (2H,s), 7.36 (4H, d, J = 8.7 Hz), 11.66 (1H, s). To a mixture of 1-(4-chlorobenzyl)-3-isopropyl-1,3,5-triazine-2,4,6-trione (80 mg, 0.27 mmol), 4-trifluorbenzyl alcohol (52.4 mg, 0.3 mmol), triphenylphosphine (92 mg, 0.35 mmol) and THF (2 mL) was gradually added di-2-methoxyethylazodicarboxylate (82 mg, 0.35 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was precipitated by hexane to give 1-(4-chlorobenzyl)-3-isopropyl-5-(4-trifluoromethylbenzyl)-1,3,5-triazine-2,4,6-trione (65 mg, Yield: 53%) as a white powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.45 (6H, d, J = 6.9 Hz), 4.96 (1H, m), 4.98 (2H, s), 5.05 (2H, s), 7.26-7.32 (2H, m), 7.36-7.44 (2H, m), 7.52-7.62 (4H, m). [Example 77] 184 [0291] Preparation of 1-(4-chlorobenzyl)-3-isopropyl-6-(4-isopropoxyphenylimino)-2-thioxo-1,3,5-triazinane-4-on e (1-2253) [Chemical Formula 186] "N'N " I N S''N' H N OH N O H ~~ HHIC IC CII CII To a suspension of 1-(4-chlorobenzyl)-3-(4-isopropoxyphenyl)guanidine (500 mg, 1.57 mmol) in toluene (5.0 mL) was added 2-isocyanatepropane (0.187 mL, 1.89 mmol) under ice-cooling, and the resulting mixture was stirred at room temperature for 17 hours. The resulting pale yellow solution was concentrated in vacuo, and the residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-((4-chlorobenzylamino)(4-isopropoxyphenylamino)methylene)-3-isopropylurea (629 mg, Yield:99%) as colorless gum. The isopropylurea derivative (201 mg, 0.500 mmol) was dissolved in THF (2.2 mL). To the mixture was added thiophosgene (0.042 mL, 0.550 mmol), and the resulting mixture was heated at reflux for 16 hours. Further, potassium carbonate (152 mg, 1.10 mmol) was added to the mixture, and the resulting mixture was heated at reflux for 2.5 hours. To the resulting solution was added ethyl acetate (50 mL), and the resulting mixture was washed by water (20 mLx2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by reversed-phase HPLC (0.l1% formic acid in acetonitrile/water) and silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-3-isopropyl-6-(4-isopropoxyphenylimino)-2-thioxo-1,3,5-triazinane-4-on e (0.32 mg, Yield: 0.1%) as colorless oil. 1H-NMR (6 ppm TMS/CDCl3): 1.34 & 1.37 (d x 2, 6H), 1.53 (d, 6H), 4.52-4.64 (m, 1H), 5.17 (s, 2H), 5.86-5.97 (m, 1H), 6.85 & 7.39 (s x 2, 1H), 6.98 (d, 2H), 7.08 (d, 2H), 7.28 (d, 2H), 7.45 (d, 2H). [Example 78] [0292] Preparation of 1-(4-chlorobenzyl)-3-isopropyl-6-(4-isopropoxyphenylimino)-4-thioxo-1,3,5-triazinane-2-on e (1-2254) [Chemical Formula 187] S S O N N OO H N H ---- N_) N -' H H ICC HI H NCI I-a ci To a suspension of 1-(4-chlorobenzyl)-3-(4-isopropoxyphenyl)guanidine (654 mg, 2.06 mmol) in toluene (6.5 mL) was added isopropyl isocyanate (0.307 mL, 2.88 mmol) under 185 ice-cooling, and the resulting mixture was stirred at room temperature for 18 hours, 60 0 C for 2 hours, and 70 0 C for 2.5 hours. The resulting mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-((4-chlorobenzylamino)(4-isopropoxyphenylamino)methylene)-3-isopropyl-thiourea (619 mg, Yield:72%) as white solid. The thiourea derivative (200 mg, 0.477mmol) was dissolved in THF (2.0 mL), and carbonyldiimidazole (77 mg, 0.477 mmol) was added to the solution under ice-cooling. The resulting mixture was heated at reflux for 22 hours under nitrogen atmosphere. Further, carbonyldiimidazole (77mg, 0.477 mmol) and triethylamine (0.066 mL, 0.477 mmol) were added to the mixture, and the resulting mixture was heated at reflux for 3.5 hours. To the mixture was added ethyl acetate (50 mL), and the resulting mixture was washed by water (20 mLx2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane), and the resulting residue was precipitated by ethyl acetate/hexane to give aimed 1-(4-chlorobenzyl)-3-isopropyl-6-(4-isopropoxyphenylimino)-4-thioxo-1,3,5-triazinane-2-on e (8.3 mg, Yield: 3.9%) as a white powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.35 (d, 6H), 1.49 (d, 6H), 4.45-4.55 (m, 1H), 5.14 (s, 2H), 5.65-5.80 (m, 1H), 6.74 (d, 2H), 6.89 (d, 2H), 7.30 (d, 2H), 7.48 (d, 2H), 8.48 (br, s, 1H). [Example 79] [0293] Preparation of 1-(4-chlorobenzyl)-3-isopropyl-6-(4-isopropoxyphenylimino)-1,3,5-triazinane-2,4-dithione (I-2256) [Chemical Formula 188] S S O N NO N O -N ' H H CI H H CC In the similar manner as described the above, 1-((4-chlorobenzylamino)(4-isopropoxyphenylamino)methylene)-3-isopropylthiourea was synthesized. The thiourea derivative (199 mg, 0.475 mmol) was dissolved in THF (2.0 mL). To the colorless solution was added thiophosgene (0.040 mL, 0.522 mmol) under ice-cooling, and the resulting mixture was stirred for 2 hours in an ice-bath. To the resulting yellow solution was added ethyl acetate (50 mL), and washed by saturated aqueous sodium bicarbonate (20 mLx2), 5% aqueous citric acid (20 mLx2), and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The resulting residue was crystallized by ethyl acetate/hexane to give 1-(4-chlorobenzyl)-3-isopropyl-6-(4-isopropoxyphenylimino)-1,3,5-triazinane-2,4-dithione (14.8 mg; Yield6.8%) as yellow crystalline. 1H-NMR (6 ppm TMS/CDCl3): 1.16 (d, 6H), 1.32 (d, 6H), 4.00 & 4.61 (br, s x 2, 1H), 186 4.44-4.54 (m, 1H), 6.08 (s, 2H), 6.82 (d, 2H), 6.99 (d, 2H), 7.26 (d, 2H), 7.46 (d, 2H). [Example 80] [0294] Preparation of 1-(4-chlorobenzyl)-3-isopropyl-6-(3-chloro-4-isopropoxyphenylimino)-4-thioxo-1,3,5-triazin ane-2-one (1-2257) [Chemical Formula 189] CI 0 CI S - HN N reagen -6 H N N Lawesson's reagent CI C To a suspension of 6-(3-chloro-4-isopropoxyphenylamino)-1-(4-chlorobenzyl)-3-1,3,5-triazine-2,4-dion (95.4 mg, 0.206 mmol) in toluene (2.0 mL) was added Lawesson's reagent (666 mg, 1.65 mmol). The resulting mixture was heated at reflux for 10 hours. To the resulting yellow suspension was added ethyl acetate, and the insoluble are filtered off by using Celite. The filtrate (about 100 mL) was washed by saturated aqueous sodium bicarbonate (30 mLx2) and brine (15 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane). The residue was crystallized by hot hexane to give 1-(4-chlorobenzyl)-3-isopropyl-6-(3-chloro-4-isopropoxyphenylimino)-4-thioxo-1,3,5-triazin ane-2-one (73.7 mg, Yield:75%) as white solid. 1H-NMR (6 ppm TMS/CDCl3): 1.39 (d, 6H), 1.50 (d, 6H), 4.43-4.57 (m, 1H), 5.12 (s, 2H), 5.65-5.81 (m, 1H), 6.66 (dd, 1H), 6.89 (d, 1H), 6.95 (d, 1H), 7.31 (d, 1H), 7.47 (d, 1H), 8.41 (br, s, 1H). [Example 81] [0295] Preparation of 1-(4-chlorobenzyl)-3-isopropyl-6-(3-chloro-4-isopropoxyphenylimino)-4-methylimino-1,3,5 triazinane-2-one (1-2259) [Chemical Formula 190] CI c C SMe CI NMe N N N N01cl 0 NN> -O cl To a solution of 4-thiocarbonyl derivative (37.5 mg, 0.078 mmol) in acetone (0.8 mL) was added methyl iodide (0.0073 mL, 0.117 mmol), and resulting mixture was heated at reflux for 15 hours. Methyl iodide and solvate were removed under reduced pressure, and methanol (0.36 mL) and 40% methylaminemethanol solution (0.04 mL, 0.391 mmol) were added to the residue. The resulting mixture was heated at reflux for 8.5 hours, and concentrated in vacuo. The residue was purified by silica gel column chromatography 187 (ethyl acetate/hexane) to give aimed 1-(4-chlorobenzyl)-3-isopropyl-6-(3-chloro-4-isopropoxyphenylimino)-4-methylimino-1,3,5 triazinane-2-one (23.6 mg, Yield: 63%) as pale yellow oil. 1H-NMR (6 ppm TMS/CDCl3): 1.35 (d, 6H), 1.47 (d, 6H), 2.90 (d, 3H), 4.45 (sept. 1H), 4.70 (br, s, 1H), 4.82 (sept. 1H), 5.20 (s, 2H), 6.88 (d, 1H), 7.00 (dd, 1H), 7.26 (d, 2H), 7.40 (d, 1H), 7.50 (d, 2H). [Example 82] [0296] Preparation of 1-(4-chlorobenzyl)-3-ethyl-6- [4-(5-methoxycarbonyl-3-pyridyloxy)phenylimino] -4-thioxo- 1, 3,5-triazinane-2-one (I-2262) [Chemical Formula 191] OMe S
N
O N AN-N O S N N Lawesson's reagent ,-S N -- O O HN N S N O N N O CI IICI To a solution of 1-(4-chlorobenzyl)-3-ethyl-6-(ethylthio)-1,3,5-triazine-2,4-(1H, 3H)-dion (1.02g, 3.13 mmol) in toluene (10 mL) was added Lawesson's reagent (2.53 g, 6.26 mmol), and the resulting mixture was stirred at reflux for 3 hours. To the resulting yellow suspension was added ethyl acetate(200 mL), and the resulting mixture was washed by water (100 mL) and brine(50 mL). The organic layer was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1 -(4-chlorobenzyl)-3-ethyl-6-(ethylthio)-4-thioxo-3,4-dihydro- 1,3,5-triazine-2 (1H)-one (939 mg, Yield: 88%) as yellow solid. 4-Thioxo derivative (257 mg, 0.752 mmol) and 5-(-4-aminophenoxy)nicotinic acid methyl ester (257 mg, 1.05 mmol) were suspended in t-butanol (2.5 mL), and the suspension was heated at reflux for 5 hours. To the resulting reaction mixture was added ethyl acetate (60 mL), and the mixture was washed by saturated aqueous sodium bicarbonate (25 mLx2) and brine (15 mL). The organic layer was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzyl)-3-ethyl-6- [4-(5-methoxycarbonyl-3-pyridyloxy)phenylimino] -4-thioxo- 1, 3,5-triazinane-2-one (258 mg, Yield: 66%) as white solid. 1H-NMR (6 ppm TMS/CDCl3): 1.30 (t, 3H), 3.94 (s, 3H), 4.35 (q, 2H), 5.19 (s, 2H), 6.87 (dt, 2H), 7.07 (dt, 2H), 7.32 (dt, 2H), 7.51 (dt, 2H), 7.85 (dd, 1H), 8.40 (br, s, 1H), 8.60 (d, 1H), 8.96 (d, 1H). [Example 83] [0297] Preparation of 188 1-(4-chlorobenzyl) -3 -ethyl-4-methylthio-6- [4- (5-methoxycarbonyl- 3-pyridyloxy)phenylimin o]-1,3,5-triazine-2-(1H)-one (I-2264) [Chemical Formula 192] OMe OMe NN 0 NN 0 N OS NMe O / HN N*' N; NA N N O N N 0 CI Thiocarbonyl derivative (50 mg, 0.095 mmol) was suspended in acetone (1.0 mL), and methyl iodide (0.009 mL, 0.143 mmol) was added to the suspension. The mixture was stirred at room temperature for 15 hours and at 40'C for 15 hours. To the reaction mixture was added ethyl acetate (30 mL). The organic layer was washed by saturated aqueous sodium bicarbonate (10 mLx2) and brine (10 mL), dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane), 1-(4-chlorobenzyl)-3-ethyl-4-methylthio-6-[4-(5-methoxycarbonyl-3-pyridyloxy)phenylimin o]-1,3,5-triazine-2-(1H)-one (40.5 mg, Yield:79%) as white solid. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.30 (t, 3H), 2.32 (s, 3H), 3.92 (s, 3H), 3.93 (q, 2H), 5.22 (s, 2H), 6.97 (d, 2H), 7.08 (d, 2H), 7.29 (d, 2H), 7.54 (d, 2H), 7.73-7.79 (m ,1H), 8.54 (d, 1H), 8.89 (s, 1H). [Example 84] [0298] Preparation of (E)-3-(4-chlorobenzyl)-4-(4-isopropoxyphenylimino)-1-isopropyl-3,4-dihydro-1,3,5-triazine 2(1H)-one (I-2276) [Chemical Formula 193] S ' " O- HN N NN CI C (Reference: Tetrahedron Lett. 2004, 45, 7197-7199.) To a solution of thiocarbonyl derivative (49.3 mg, 0.111 mmol) in methanol (1.0 mL) was added hydrogen peroxide urea (52.1 mg, 0.554 mmol), and the resulting mixture was stirred at room temperature for 5.5 hours. To the reaction mixture was added ethyl acetate (30 mL), and the mixture was washed by 5% aqueous citric acid (15 mLx2), saturated aqueous sodium bicarbonate (15 mLx2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give (E)-3-(4-chlorobenzyl)-4-(4-isopropoxyphenylimino)-1-isopropyl-3,4-dihydro-1,3,5-triazine 2(1H)-one (31.6 mg, Yield: 69%) as brown solid. 189 1H-NMR (6 ppm TMS/CDCl 3 ): 1.32 (d, 6H, J = 6.1 Hz), 1.37 (d, 6H, J = 6.6 Hz), 4.44-4.50 (m, 1H), 4.66-4.72 (m, 1H), 5.21 (s, 2H), 6.84 (d, 2H, J = 11.7 Hz), 6.91 (d, 2H, J = 6.6 Hz), 7.28 (d, 2H, J = 8.1 Hz), 7.55 (d, 2H, J = 8.1 Hz), 7.61 (s, IH). [Example 85] [0299] Preparation of 2-methyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion [Chemical Formula 194] NH 0 NH
SNH
2 N HCI j H To a mixture of methylamine hydrochloride (276 g, 4.09 mol) and DMA (2 L) was added DBU (679 mL, 4.50 mol) at 10'C over 4 minutes. Then, 1,1'-carbonyldiimidazole (730 g, 4.50 mol) was added to the mixture at 20 0 C, and the resulting mixture was stirred at 0 0 C for 2 hours. To the reaction mixture was added 1-amidinopyrazole-hydrochloride (500 g, 3.41 mol) at -5 0 C over 3 minutes. Then, DBU (540 mL, 3.58 mol) was added to the mixture at 10 0 C over 25 minutes, and the resulting mixture was stirred at 45 0 C for 7.5 hours. Further, to the reaction mixture was added 1,1'-carbonyldiimidazole (830 g, 5.11 mol), and DBU (771 mL, 5.11 mol) was added to the mixture at 6 0 C over 2 hours. The resulting mixture was stirred at 0 0 C for 40 minutes. To the reaction mixture was added 2.8 mol/L hydrochloric acid (10 L) at 20 0 C over 1 hour. The precipitated solid was filtered off to give 2-methyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion (421 g, Yield: 64%) as pale brown powder. 1H-NMR (6 ppm TMS/DMSO-d6): 3.16 (3H, s), 6.71 (1H, dd, J= 3.0, 1.5 Hz), 8.04 (1H, d, J= 1.0 Hz), 8.57 (1H, d, = 3.0 Hz). [Example 86] [0300] Preparation of 2-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion [Chemical Formula 195] 0 NH N N N O HCI U1 H To the mixture of 1-amidinopyrazole- hydrochloride (58.6 g, 400 mmol), ethyl isocyanate (33.2 mL, 420 mmol) and DMA (240 mL) was added DBU (63.3 mL, 420 mmol) dropwise at -10 0 C over 15 minutes, and the resulting mixture was stirred under ice-cooling for 30 minutes. To the reaction mixture was added 1,1'-carbonyldiimidazole (30 g, 600 mmol) under ice-cooling, and DBU (93 mL, 620 mmol) was added -5 0 C over 30 minutes to the mixture. The resulting mixture was stirred under ice-cooling for 1 hour. Further, the mixture was stirred at room temperature for 1 hour. To the mixture was added 2mol/L hydrochloric acid (1.16 L) at 20 0 C over 1 hour. The precipitated solid was filtered off to give 2-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion (73.0 g, Yield: 88%)as pale brown powder. 190 1H-NMR (6 ppm TMS/CDCl3): 1.30 (6H, t, J=7.0 Hz), 4.02 (2H, q, J=7.0 Hz), 6.59 (1H, m), 7.34 (1H, m), 8.48 (1H, m), 9.79 (1H, brs). [Example 87] [0301] Preparation of 1-(4-chlorobenzyl)-2-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion (II-3) 0 O N N-^ N N N 0 N'N N O N N H CI To a mixture of 2-ethyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion (89 g, 480 mmol), 4-chlorobenzylbromide (108 g, 528 mmol) and DMA (400 mL) was added diisopropylethylamine (92 mL, 528 mmol) dropwise at room temperature over 10 minutes, and the mixture was stirred at 60 0 C for 2 hours. To the reaction mixture was added water (800 mL) dropwise under ice-cooling for 40 minutes, and hexane (200 mL) was added to the mixture. The precipitated solid was filtered off to give 1-(4-chlorobenzyl)-2-ehtyl-6-(1-pyrazolyl)-1,3,5-triazine-2,4(1H,3H)-dion (11-3,156 g, Yield: 97.6%) as pale brown powder. 1H-NMR (6 ppm TMS/CDCl 3 ): 1.30 (3H, t, J=7.1 Hz), 4.04 (2H, q, J=7.1 Hz), 5.86 (2H, s), 6.48 (1H, m), 7.02 (2H, d, J=8.6 Hz), 7.20-7.25 (2H, m), 7.84 (1H, m), 8.33 (1H, m). [Example 88] [0302] Preparation of 1-(4-chlorobenzyl) -6- [4- (3 -cyanophenoxy)phenylimino] - 3-ethyl- 1,3,5 -triazinane-2,4-dion (1-2305) [Chemical Formula 196] o 0 N N- HN N NN'N'N O WN- N O N 0 CI CN CI A mixture of 1-(4-chlorobenzyl)-2-ethyl-6-(1-pyrazolyl)- 1,3,5-triazine-2,4(1H,3H)-dion (0.30 g, 0.9 mmol), 4-(3-cyanophenoxy)aniline (0.209 g, 1 mmol) and t-butanol (6 mL) was stirred at 90 0 C for 15 hours. To the reaction mixture was added 50% ethyl acetate/hexane (6 mL), and the precipitated solid was filtered off to give 1-(4-chlorobenzyl) -6- [4- (3 -cyanophenoxy)phenylimino] - 3-ethyl- 1,3,5 -triazinane-2,4-dion (1-2305, 0,385 g, Yield: 89.8%) as pale brown powder. 1H-NMR (6 ppm TMS/CDCl3): 1.24 (3H, t, J=7.2 Hz), 3.91 (2H, q, J=7. 2Hz), 5.20 (2H, s), 6.84 (2H, d, J=8.7 Hz), 7.04 (2H, d, J=8.4 Hz), 7.2-7.46 (6H, m), 7.51 (2H, d, J=8.4 Hz). [0303] The following compound of the invention and intermediate thereof were synthesized in a 191 manner similar to those described in the above general procedures for the synthesis of the compound of the invention and Examples. The chemical structure of the compounds and the physical properties of them are described below. (Method of identification for the compound) LC/MS data of compound of the present invention were measured under any one of the following 2 conditions (Method 1 and 2), and a retention time and [M+H]+ are shown. (Method 1) Column: Luna C18(2) (5pm, i.d.4.6x5Omm) (Phenomenex) Flow rate: 3 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetonitrile solution Gradient: Linear gradient of 10% to 100% solvent [B] for 3 minutes was performed, and 100% solvent [B] was maintained for 1 minute. (Method 2) Column: Xbridge C18 (5pm, i.d.4.6x5Omm) (Waters) Flow rate: 3 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetonitrile solution Gradient: Linear gradient of 10% to 100% solvent [B] for 3 minutes was performed, and 100% solvent [B] was maintained for 1 minute. (Method 3) Column: Shim-pack XR-ODS (2.2pm, i.d.50x3.Omm) (Shimadzu) Flow rate: 1.6 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetonitrile solution Gradient: Linear gradient of 10% to 100% solvent [B] for 3 minutes was performed, and 100% solvent [B] was maintained for 1 minute. (Method 4) Column: Develo sil RPAq, (50x4.6mm) Flow rate: 1.5 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetonitrile solution Gradient: 60% solvent [B] was maintained for 0.5 minute, linear gradient of 60% to 100% solvent [B] for 4.5 minutes was performed, and 100% solvent [B] was maintained for 10 minutes. (Method 5) Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7pm, i.d.2. 1x3.Omm) 192 Flow rate: 0.8 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetonitrile solution Gradient: Linear gradient of 10% to 100% solvent [B] for 3.5 minutes was performed, and 100% solvent [B] was maintained for 0.5 minute. 193 [VUdVJ [Table 41 Retention Structure Compound Time [M+H] Method No. (min) F 0 F F N N F F F 1-0001 2.46 469 3 N&N 0 o N C O N N 0 ON N 1-0002 2.49 493 3 O 0 N N CN CI O N N H 1-0003 2.31 399 3 O 0 N k N H~a 1-0004 2.47 473 3 0~' N ) N l NC I H 1-0005 2.37 461 3 0 1 [Table 5] Retention Structure Compound Time [M+H] Method No. (min) 0 N N ; O o N 1-0006 2.48 457 3 Y -007 234 41 ~~0 N O Y6 1-0008 2.22 475 3 0 N N O O , N N H 1-0009 2.23 425 3 0 1N O N 01N 2.4 4 3 H 10 1-00 10 2. 22 457 5 3
N
[Table 6] Compound Retention Structure Co Time [M+H] Method No. (min) 0 F 0 -WN HO 1-0011 2.47 433 3 0 X NN N F 0" -N N WO H Y 0 1-0012 2.51 478 3 O F ON N H o 1-0013 2.23 383 3 F o F F H 1-0014 2.65 483 3 N 00 N )N F 0 N N NO H 1-0015 2.29 428 3 0o [Table 7] Compound Retention Structure Co Time [M+H] Method No. (min) __ 0 N N O- , N N H 1-0016 2.29 445 3 N o F O F F N ) N NO F H 1-0017 2.45 433 3 N o F N N O\ H 1-0018 2.09 494 3 0 -~ N ) NJ, F-Ir N N 0 1-0019 2.16 405 4 FF H 0 N N N NH 1-0020 3.88 439 4 [Table 8] Compound Retention Structure Co Time [M+H] Method No. (min) 0 N NI NJ F N rN O 1-0021 3.63 419 4 FF H 0 N N F IN N - O F NH NO 1-0022 4.43 474 4 F H NNC -CI 0 N ),NO F -1-0023 3.91 473 4 F FF 0 NN N )NO F NH A ' F -.- 1-0024 3.93 473 4 F F F 0 -~ N ) NI, F.-N AN '-O FF H1-0025 3.33 419 4 [Table 9] Compound Retention Structure Co Time [M+HJ Method No. (m) 0 0 N N F N N XO F aH 1-0026 3.16 449 4 ,O 0 N N F - N ' lN
O--
F FN H 1-0027 2.26 419 4 F HA 0 N N F N N 0 1-0028 3.27 453 4 FF H I 0 N N N N 01-0029 2.95 433 4 FF H 0 N N O F F H 01 1-0030 3.94 488 4
-CI
[Table 10] Retention Structure Compound Time [M+H] Method No. (min) 0 N N NO F 1-0031 2.61 433 4 0 N N Fya N N O FF H 1-0032 2.39 463 4 ,o 0 NO Fy N 1 N O--- 1-0034 4.86 481 4 F H F F N kN 0 N ilN '-0 1-0035 4.68 461 4
F
[Table 11] Compound Retention Structure Co Time [M+H] Method No. (min) 0 F N N - 1-0036 3.73 516 4 F F H F FFC CI 0 N N F0H 1-0037 4.80 515 4 FFF F F 0 -a N IN/ N N F H F A 1-0038 4.83 515 4 F F F 0 N )N N N NH 1-0039 3.67 461 4 0 N/ F F H N 1-0040 3.47 491 4
A,
[Table 12] Compound Retention Structure Cou Time [M+H] Method 0 -x N 'kN N N 1-0041 4.09 445 4 F F H 0 N N FN N 1-0042 4.45 459 4 F F H N J)N F >r N ),N - O IF F H CI 1 -0043 3.51 514 4 CI NN F H1-0044 4.65 513 4 F F F F 1-0045 4.62 513 4 F F [Table 133 Compound Retention Structure Co Time [M+H] Method No. (min) __ 0 NNo N O F H l - FO 1-0046 3.17 489 4 .'0 0 ON F NN F N N 0 1-0047 3.46 453 4 FF H 0 NN F N N 0 1-0048 4.09 487 4 FF H N N. 0 FN N NN F Ia NJ N 0-- 1-0049 3.83 467 4 FF H (0 LUOJ [Table 141 Retention Structure Compound Time [M+H] Method No. (min) 0 A -x N N' N NH 1-0051 4.09 521 4 F F FF F H 1-0052 4.12 521 4 F F F N NO F H-0054 3.42 497 4 SF N H 1-0055 3.12 47 4 FF 0 A FF N N0 1-0055 3.57 487 4 F -- a N AlN-'0 FF H [Table 15] Retention Structure Compound Time [M+H] Method (min No CI O F N 1-0056 4.49 522 4 NO F~r N Ol N-05 4.26 501 F F H CI 0 N O 1-0057 4.26 501 4 FC NO FN O I-0059 4.94 555 4 F F H FF 0 N F CI 0 N F N> N-'-)O 1-0060 4.54 556 4 F N NO FF H FF H [Table 16] Retention Structure Compound Time [M+H] Method No (min 0~ O F N NYO 1-0061 3.99 501 4 F F H N A F N OH 1-0062 3.86 531 4 ~0 F N 1-0063 2.81 467 4 FF H F 0~~
-
N N F ') N1-' 1-0064 2.40 501 4 0~~ F NN A 1-0065 3.32 481 4 N )INO- F F H [Table 17] Retention Structure Compound Time [M+H] Method No. (min) 0 N N F Nt" -' 1-0066 4.30 534 4 F NFNO F FF I-CI 0 N N N N 0 1-0067 3.60 535 4 F F F N NF F N H 1-0068 3.60 535 4 FH F- F F 0 Fra 'N )N-N-0 1-0069 3.91 481 4 FF H F0 N F) F1-0070 2.76 511 4 [Table 18] Retention Structure Compound Time [M+H] Method No. (min) GI o 'N SNN 1-0071 3.43 522 4 F H F GI CI F , N NO1-0072 4.12 556 4 F CI C F N O 1-0073 486 536 4 Fya N N 0ilN F H S N F FO 1-0074 4.68 591 4 CI CI N, FNNO1-0075 4.07 590 4 FF H
F
[Table 19] Compound Retention Structure Co Time [M+H] Method No. (mi) FF H 1-0076 4.11 590 4 F- IF cI cI F N F N NKNXO 1-0077 3.55 536 4 F N FP NINN F N N O F H 1-0078 3.49 566 4 F NNA 1-0079 2.38 483 4 N O F F N 0 F N N NT 1-0080 3.21 517 4 F N ci [Table 201 Compound Retention Structure Co Time [M+H] Method No. (min) 0o' 0 Nx NN 1-008 1 2.85 497 4 F - N 11,N- 0 F H F 0~~ F 1-0082 3.85 552 4 F N F H F F 0~~ F , F F NO -0085 2 497 4 F F IF N F- N N 0-- 1-0085 3.23 551 4 F, H
F
[Table 21] Retention Structure Compound Time [M+H] Method No. (m) xN 0 F N NO F1-0086 2.29 527 4 N N F N NO N N 0 F NHN F F1H00g7 2.7 467 4 F F H CI1-0088 3.54 501 4 C)I o NN F-N N 0 F H a 1-0089 3.19 481 4 F0 N N N N- 0 F IF Hci 1-0090 4.15 536 4 Sl [Table 221 Compound Retention Structure Co Time [M+H] Method No. (min) o -N ' N F ilN N O F H 1-0091 3.49 535 4 FF F F N N FT N N O FF H F 1-0092 3.57 535 4 F F F oI N N FN O F 1-0093 3.03 481 4 0 IN N N F H F 1-0094 2.79 511 4 N N F N N O F F H 1-0095 3.58 419 4 [Table 23] Compound Retention Structure Co Time [M+HJ Method No. (min) __ 0 ' N N F N N O F F H 1-0096 4.22 453 4 CI 0 N N F N N 0 F F H 1-0097 4.21 433 4 0 N N F- N )J"N- 0 F cI 1-0098 4.03 488 4 Cl F > N N- 0 FH F 1-0099 3.38 487 4 IF F F N N0 N F ~ Ft
FF
LUtJUUJ [Table 241 Retention Structure Compound Time [M+H] Method No. (min) 0 N N F N N O F FH1-0101 3138 459 4 F > N N C11 F7 : H F H1-0102 4.16 487 4 F F F 0 N F H F~a 1-0103 4.18 487 4 F F F 0 N N F N N O F F H 1-0104 4.69 479 4 Cl 0 N N F r N N O F H 1-0105 3.38 448 4
N
[Table 25] Retention Structure compound Time [M+H] Method No. (m) N N F -N N O F 1 H -0106 3.59 462 4 N Fa N) N"0 1-0107 4.05 490 4 F H NN 0 F > N N 0 F F H 1-0108 3.85 488 4 N X x F } N NF 0 1019 3.66 496 4 FyaH CA N NN F N NLO0 1-0110 3.97 530 4 F H [Table 261 Compound Retention Structure Co Time [M+H] Method No. (m) 0 F N N 2o 1-0111 3.84 510 4 F H F N NF0 1-0112 3.67 526 4 F H F N o N N F-N N- O -14 24 47 1 F H o o F N N F HII - - 1-0114 3.77 510 4 F 0 0 N N [ 1-0115 2.67 443 1
H
[Table 271 Structure Compound Retention Strctre o. Time [M+H] Method No. (min) __ 0 N N N N N 0 H 1-0116 2.59 443 1 C N 0 N N N N 1-0117 2.52 385 1 H NS N NH 1-0118 2.44 397 1 )-0 0 A N N N N 0 1-0119 2.52 409 1 H - 0 N N 0 1-0120 2.70 407 1
H
[Table 28] Structure Compound Retention SrcueNo. Time [M+H] Method ________ (min) _ _ 0 N N N N 0 H 1-0122 2.68 407 1 0 Hp N N H 1-0123 2.05 390 1 "NN N N H 1-0124 2.04 436 1 N " N N N N 0 H 1-0125 2.31 433 1 [Table 29] Retention Structure Co Time [M+H] Method No. (min) F F F 0 N N- O H 1-0126 2.51 423 1 F 0 0 N N N N 0 1-0127 2.60 447 1 H F 0 N NLO O- N, N - O H 1-0128 2.52 447 1 F CI 0 I~ N N N N O H 1-0129 2.44 389 1 F s 0 b N 11,N 0 H 1-01 30 2.36 401 1
XF
[Table 30] Structure Compound Retention Strctre o. Time [M+H] Method No. (min) __ O 0 N N N N O 1-0131 2.44 413 1 H F XF 0 nN~ N N N N O H 1-0134 2.31 413 1 F 0 N N N NF-509 H 1-0134 2.58 411 1 F 0 N N> k N ),N 0 H 1-0135 1.96 394 1
F
[Table 311 Compound Retention Structure Co Time [M+H] Method No. (min) N ~N N N O H 1-0136 1. 93 440 1 H F N N N - -O H F 1-0137 2.18 437 1 F F F F F F F 0 N N 0 F 1-0138 2.35 409 1 F F 0, 0 NAN KN N O 1-0139 2.18 407 1 H F N0 N 1-0140 2.44 433 H
F
[Table 32] Compound Retention Structure Cou Time [M+H] Method (min)o N -011 2_7___ N0 00 N N H N N<O 1-0141 2.37 433 1 H F C 0 N JN N N 0 H 1-0142 2.26 374 1 F 0 0 N ) N N 'L'N 0k H 1-0143 2.17 387 1 F 0 0 N N N N N 0 1-0144 2.27 399 1 H 0 N N 0 F 1-0145 2.45 397 1 [Table 33] Structure Compound Re tion [M+H Method No. (min) __ 0 N N N N 0 H 1-0146 2.13 399 1 NN F N N N N O H 1-0147 2.42 397 1 F H N N N N N N 0- H 1-0148 1.78 380 1 F 0 N IkN -> N 11,N 0k NH 1-0149 2.04 423 FF F F F F F 0 N N'k H 1-0150 2.40 440 N CI LUov I [Table 34] Compound Retention Structure No. Time [M+H] Method No'_ (min) F 0 0 N)N N N O 1-0151 2.24 438 1 H N CI 00 0 NN oI- 1-0152 2.44 464 1 H CI O N N N N O H 1-0153 2.30 407 1 S o N Cl s 0 N N 0 H 1-0154 2.25 418 1 N N I 00 N N 1-0155 2.34 430 1 H I N C I [Table 35] Retention Structure Compound Time [M+H] Method No. (min) __ N N -O H [-0156 2.53 428 1 N cl 0 N N H 1-0157 2.21 430 1 N C1 0 N N 0 H 1-0158 2.51 428 1 N CI 0 H N N N N N O H 1-0159 1.83 411 1 N Cl N > N N 1::: N 0 N- H 1-01 60 1.77 457 1 N ICI [Table 361 Retention Structure compound Time [M+HI Method No. (m) N N N N 0 H 1-0161 2.04 454 1 FF F N CI F F F 0 N N 0 1-0162 2.40 440 1 H C F O N N F F-'0 0 N N O 1-0163 2.24 438 1 H N C HNCI NN 0 NAN N0 N 1-0164 2.48 464 1 H CI N
-
C ClN 0 N ) N 'N N N 0z H 1-0165 2.31 407 1
N
[Table 371 CompundRetention Structure Compound Time [M+H] Method No. (min) __ 0 0 N N N N O 1-0166 2.38 430 1 H N N N N 0 1-0167 2.58 428 1 YnNx N> N N N N 0 H 1-0169 2.60 430 1 N CN H N N 0 H 1-0170 1.94 411 1 N CI [Table 38] CompundRetention Structure Compound Time [M+H] Method No. (min) N N N N N 0 H 1-0171 1.92 457 1 N >o N N N N 0 H 1-0172 2.20 454 1 F F1 F N F CI 0 FyO N N F I N N 0 H 1-0173 2.30 438 3 0 Fyo N 'kN FI H 1-0174 2.38 421 3 F N 'LN 0 H a F1-01 75 2.20 385 3 [Table 391 Retention Structure Compound Time [M+H} Method No. (min) __ F F FN N N N1-0176 2.70 423 3 F F F X 0 O F AN N N N 0 1-0177 2.70 439 3 H F F F~a N N O H 1-0178 2.30 373 3 F CIN ) NJ" NH 1-0179 2.50 389 3 F 0 ON N NH 1-0180 2.40 385 3
F
[Table 40] Compound Retention Structure Cou Time [M+H] Method No. (min) __ 0 F FO N JN F H I -F -0 181 2.70 439 3 F N N 0 H 1-0182 2.40 373 3 F N N N N O H 1-0183 2.30 385 3 F 0 N ) NJ" N N O H 1-0184 2.60 389 3 F N N N )J"N- -O H 1-0185 2.90 411 3 F .0'a Jm [Table 411 Retention Structure Compound Time [M+H] Method No. (m) N N N N O H 1-0186 2.40 373 3 F N N N N O H 1-0187 2.70 439 3 F > F F N N N N 0 H 1-0188 1.20 403 3 CIa 0 N N N N O H a1-0189 1.20 399 3 0 N ' NJ N N 0" H 1-0190 2.10 437 3 F F ,aF [Table 42] StrctreCompound Retention Structure Co Time [M+HJ Method 0 (min) N N O N N O H F 1-0191 1.90 399 3 O N N N N O H 1-0192 1.90 399 3 F N N N N 0 1-0193 2.20 403 3 F CI N N N N F 1-0194 2.20 403 3 F F F F N N N )-"N O H 1-0195 2.30 437 3
F
[Table 43] Retention Structure Compound Time [M+H] Method Stru tur No (m in) _ _ _ N N N N 0 1-0196 1.70 337 3 F 0 CI N N H 1-0197 2.80 424 3 F 0 CI N N FN N O F H 1-0198 2.80 457 3 F 0 N N N N 'J"N- 0 H 1F -0199 1.40 452 3 0 N N H 1-0200 2.60 429 3 Cl [Table 44] Retention Structure Compound Time [M+H] Method No. (min) N N IN N 0O H 1-0201 2.70 463 3 IF F F 0 N N H 1-0202 2.40 425 3 CI 0 N N H 1-0203 2.70 447 3 F F F 0 O N N N N O 1-0204 2.80 481 3 H 0 N N N N N O H 1-0205 1.20 376 3
F
[Table 45] Retention Structure Compound Time [M+H] Method No. (min) __ 0 N N <N N O H 1-0206 1.80 398 3 F 0 0 > N NJ O N N 0 H 1-0207 2.20 413 3 F 0 O N < :N N- 0 H 1-0208 2.30 420 3 0 N N 09 6 2 H 1-0209 2.60 429 3 0 NAN N )NJ-0 H 1-0210 2,40 425 3 [Table 46] Structure Compound Retention Strctre o. Time [M+H] Method No. (min) __ N N H 1-0211 2.40 420 3 0 N N H NF 1-0212 2.70 463 3 F 0 O N N N- 0 H 1-0213 2.40 425 3 Ob 0 O N N 'iN- 0 H 1-0214 2.60 429 3 CI 0 N N 0 H 1-0215 2.40 420 3
NA
[Table 47] Retention Structure Compound Time [M+H] Method No. (min) __ 0 0 NAN - N N 0, H HFI1-0216 2.70 463 3 F F N N 0 H 1-0217 2.60 427 3 OF N N N N O H 1-0218 2.50 454 3 0 ON 0- 2 N N 09453 H 1-0219 2.40 413 3 I-aF 0 N N11 0 H1-0220 2.90 451 3 [Table 48] Structure Compound Retention Strctre o. Time [M+H] Method No. (min) __ o 0 O N N N N 0 H F -0221 2.40 413 3 0 N N 'J~iN N I- F 1-0222 2.40 427 3 N N O H 1-0223 2.40 417 3 F F 00 0 N N N N 0-5 3 2 H 1-0224 2.40 417 3 F 0 N 'JNJ-0 C)) H 1-0225 2.70 427 3 FF
FF
[Table 49] Compound Retention Structure Co u Time [M+H] Method No. (min) ___ 0 CI -1k NAN ciN N N N O N H 1-0226 2.60 414 3 F 0 O N N N N O H 1-0227 2.50 438 3 F y 0 oN N CI N N O H 1-0228 2.90 463 3 Cl 0 N N Cl N - N 0 H 1-0229 2.40 437 3 00 ON N HF1-0230 2.60 475 3 [Table 50] Retention Structure Compound Time [M+H] Method No. (min) 0 N N H 1-0231 2.40 417 3 F 0 CI N x N N o N N O H 1-0232 2.40 447 3 0 F 0 N N CI>N N 0 H 1-0233 2.40 417 3 F N N CI > N N- 0 H 1-0234 2.60 465 3 N CI CN CI > N N 0 H 1-0235 2.60 464 3 IN C [Table 51] Retention Structure Compound Time [M+H] Method No. (min) 0 'NN l NJ-0 CN N- H F 1-0236 2.40 417 3 CH O N <N N II, N N NO H H'F 1-0237 2.60 479 3 0 CI 0 O N H C-a 1-0239 2.70 505 3 CI O O N N O H "N c 1-0239 2.70 447 3 0 ' ' J I '-" HN 1-0240 2.70 405 3 [Table 52] Compound Retention Structure Co Time [M+H] Method No. (min) ___ o CI 0 N N N N O H 1-0241 2.70 507 3 CI N N H 1-0242 1.60 505 3 C1aC Cl 0 O N N N N O H 1-0243 2.60 435 3 -CI F 0 0 ' N j' N N O H 1-0244 2.80 447 3 CI 0N H C 1-0245 2.70 454 3 [Table 53] Compound Retention Structure C ou Time [M+H] Method No. (min) __ 0 H N1 N N O H 1-0246 2.20 428 3 CI 0 N -> N ) N' O > N N 0 H 1-0247 2.50 470 3 CI o 0 N0 -< NN N N O H 1-0248 2.60 429 3 C1 N N H H 1-0249 2.20 428 3 CI N N 0- 4 N >= N N 0 H Ia 1-0250 2.60 470 3 LUOIUJ [Table 541 Compound Retention Structure No. Time [M+H] Method _________ (min) _ _ F 0 N N N N O 1-0251 2.40 377 3 H o 0 HO N N N N 0 H 1-0252 2.30 415 3 Cl F 0 T N N N O 1-0253 2.30 375 3 H N N N N N O H 1-0254 2.90 453 3 CI ~N N 0iN' H 1-0255 2.40 456 3 [Table 55] Compound Retention Structure No. Time [M+H] Method 0 ~N N 0 H C 1-0256 2.50 470 3 0 0 N O N N H N N O H 1-0257 2.20 454 3 Cl N N NN N NO H H C 1-0258 2.40 468 3 O'NN H C-0259 2.50 504 3 0)- 0 0 N N O H Ia l1-0259 2.50 504 3 [Table 56] Retention Structure Compound Time [M+H] Method No. (min) N=K IkNt H l1-0261 2.60 482 3 N N,, - N NKNO H C 1-0262 2.20 484 3 H O N N NJ0 H 1-0263 2.10 428 3 CI o0 N Jj N)AN' N N ',N-k0 H H C 1-0264 2.50 482 3 O O NN N N N N 0 H 1-0265 2.30 442 3
K-
[Table 571 Compound Retention Structure Co Time [M+H] Method No. (min) 0 0 X)- N) NJ H N N O H C 1-0266 2.60 490 3 H I N N H H 1-0267 2.00 458 3 0 /N > N ) N, o N 1-0268 2.60 484 3 H H CI IF O Y O--- N '1 NH N N O H 1-0269 2.03 405 1 CI F 0 N N -1:5 N 1 ,N 0 H 1-0270 2.42 477 1 0 C1 [Table 581 Retention Structure Compound Time [M+H] Method No. (min) __ F O N N I~b N N 0- H I-0271 2.49 459 1 CI F O O N N IN AN-k0 H 1-0272 1.44 476 1 F O O N OH IN N- 0 H 1-0273 1.96 449 1 CI F 0 ON N N 0 OH H C[ -0274 1.98 507 1 F 0 -Y - NA) N N NO H 1-0275 2.27 503 1
CI-
[Table 59] Retention Structure Compound Time [M+H] Method No. (min) ___ F 0 0 N OH N N 0 OH H C 1-0276 1.85 493 1 F O o
N
7 N -T~t N N 0- H 1-0277 2.34 433 1 CI N 0 N N OH N - O 1C 1-0278 1.70 440 1 0 a N N OH N N O H 1-0279 1.90 439 1 F 0 Y O N ) N- N,-O N N 0O H 1-0280 2.21 463 1
CA
[Table 601 Retention Structure Compound Time [M+H] Method No. (min) __ F O0 O N N 0 H C 1-0281 1.47 518 1 F, 00 O N N -_N N N -kN-k0 H C 1-0282 1.50 516 1 F O O O N N OH -YO-6 N '1,N 110FF H C 1-0283 1.82 513 1 Ik OH F 0 ON N OH N t N -kN--- 0 H 1-0284 1.96 463 1 CI F O O N N N OH H 1-0285 2.00 463 1 [Table 611 Retention Structure Compound Time [M+H] Method No. (min) __ F b OH -Y
-
N Nf O N11 N 0- H 1-0286 1.80 479 1 O N N O N N H 1-0287 1.30 509 1 F 0 O Nt N ) N N" N 0'O H c 1-0288 2.15 444 1 F 0 0 N N OH H N-0289 2.00 477 1 F 0 0T A N ) N -_,NH 2 N N 0 HC H 1-0290 1.40 448 1
C
[Table 62] Retention Structure Compound Time [M+H] Method No. (min) F 0 O N N N N H 1-0291 2.15 458 1 CI F 0 H N N H 1-0292 1.90 489 1 F 0 O N N -- & N J,,N-- 0 H 1-0293 2.00 490 1 CI F 0 H O N NJI N- 0 H 1-0294 1.91 476 1 F 0 N N NH2 H 1-0295 1.85 462 1
CI
[Table 63] CompundRetention Structure Compound Time [M+H] Method No. (min) ___ F 0 0 N -ON N 0 H 1-0296 2.18 447 1 Cl F 0 0 I N ) N-N H c 1-0297 2.04 504 1 F 0 0 N N YOI- H N ',N _0 H 1-0298 1.90 490 1 CI F 0 0 ONN N NH 2 N IJN 0k H C 1-0299 1.86 476 1 F 0 ON yoN ) N N IN N 0 H 1-0300 2.06 496 1
CI
LUOIJJ [Table 641 Retention Structure Compound Time [M+H] Method No. (m) F 0 O N AN N N 0OU H 1-0301 2.53 495 1 0 CI N N OH N N1 O H 1-0302 1.50 417 1 I-aCl 0 0 0 N 7 N OH N N O H 1-0303 1.60 417 1 F 0 N N OH N N 0 H 1-0304 1.50 434 1 CI F OH N NO N N N O H 1-0305 1.69 421 1
CI
[Table 65] Retention Structure Compound Time [M+H] Method No (mi) N N O N N O H 1-0306 1.11 444 1 Cl ON N OHN N N O H 1-0307 1.72 417 1 C1 0 N N OH F N N 0 H 1-0308 1.80 391 1 CI 0 F N N OH O N N O F H 1-0309 2.09 457 1 Cl F 0 F N N 7 N F . N '1,N- 0 H 1-0310 2.21 455 1
CI
[Table 661 Retention Structure Compound Time [M+H] Method No. (min) __ N N OH N N O H 1-0311 1.14 456 1
K
CI F O N N OH N N 0 H 1-0312 1.83 435 1 CI FN N F N N O F H 1-0313 2.00 441 2 CI 0 N « N OH N N O H 1-0314 1.70 440 2 NJCI F FF 0 F N N OH N N O H 1-0315 2.09 459 2
CI
[Table 67] Retention Structure Compound Time [M+H] Method No. (min) ___ F O N N 0 H 1-0316 1.84 409 2 F O N N 0 HCI H C 1-0317 1.40 462 2 0 N N OHN N N 0 H [-0318 2.01 415 2 CI 0 N<N >OH N N 0 H 1-0319 1.68 379 2 CI 0 O NAN OH N N 0 H 1-0320 1.83 431 2 C1 [Table 68] Retention Structure Compound Time [M+H] Method No. (m) F O N N 0 HC 1-0321 1.99 449 2 F N N OHN N N 0 H H C 1-0322 2.03 457 2 0 N N -> OH H - C l 1-0324 16 473 2 O N NO H Ia 1-0324 .61 473 2 N ) 0 - NjI N 0- H H 1-0325 1.10 325 2 [Table 69] Retention Structure Compound Time [M+H] Method No. (min) F 0 0 0r N JN WKN N N 0 H 1-0326 1.93 504 2 -N HN O N N O H C1 1-0327 1.03 472 2 0 N N OH N N O H 1-0328 2.15 429 2 F 0N Fy-a NN) FN N O H 1-0329 1.80 439 2 N O0 k O N ) N -_,OH N N 0 H I-0330 1.56 428 2
-CI
[Table 701 Retention Structure Compound Time [M+H] Method No. (m) F 0 O N N
NH
2 I NI1, - HCI H CI 1-0331 1.49 490 2 F 0 N N OH H C 1-0332 2.26 491 2 F 0 N NOH H 1-0333 1.80 433 2 F 0 IN- O-0334 2.35 465 3 HC F 0 N N OH H CN03 N219 H Ia 1-0335 2.19 489 2 [Table 711 Retention Structure Compound Time [M+H] Method No. (m) O N N 0O H 1-0336 1.61 373 2 C1 0 N N AN 'jN - O H 1-0337 2.39 362 2 CI F 0 0 N N N 'N 0 H 1-0338 2.45 477 3 Cl F 0 N OH N ) N N )JN 0 H F 1-0339 1.88 451 2 F F O N 'JN O N N 0O H 1-0340 1.84 451 2 F F [Table 72] Compound Retention Structure Cou Time [M+H] Method F 0
---
r N J N-,,OH O N N O H F 1-0341 2.01 467 2 CI F 0 N NO0 H H - Cl 1-0342 2.81 548 3 N N 0 0 H N 1-0343 2.50 525 2 CI1 0 I k N<N -, H N N- 0 H H C 1-0344 2.48 429 3 \/O N N H 1-0345 2.74 412 2
CI
[Table 73] Retention Structure Compound Time [M+H] Method No. (min) F 0 O N N N- 0 H 1-0346 2.34 445 2 C1 S N 0OH H 1-0347 1.78 460 2 0 F 0 YO NA
N-
ON N 0 H [-0348 2.45 447 2 C1 F 0 N -- N N 0 H 1-0349 2.20 413 2 -yo N ) N SN 1-0350 2.55 549 2 H
C[
[Table 74] Retention Structure Compound Time [M+H] Method No. (m) CI 0 C0 O N N N 0N H 1-0351 2.06 465 2 CI F 0 0 FO N -'
N
t N N- OH O&N N H H H 1-0352 1.78 520 2 CI 0 H I1-0353 1.77 506 2 0 AJ -O N N N OH N NH0 1-0354 2.17 521 2 H 0 OH N N ),N-k0 [ c c -0355 2,10 493 2 [Table 75] Retention Structure Compound Time [M+H] Method No. (m) F 0 0 0, NA) N l Y n N NO0 1-0356 2.33 505 2 H C F F- F 0 IN )N---OH N N 0 1-0357 2.07 455 2 H Cf N N OH H N O H 1-0358 2.23 442 2 O N N OH N N 0 H 1-0359 1.85 445 2 F O N N OH F N N Ok H 1-0360 1.84 453 2 [Table 76] CompundRetention Structure Compound Time [M+HJ Method No (mi) 0 N I NOH N N O H 1-0361 1.77 431 2 CI CI 0 O N N OH N-j N 0 H 1-0362 2.12 479 2 F 0 O N OH H C 1-0363 2.05 491 2 F 0 0 O N N OH N N" 0 H 1-0364 2.12 505 2 CI F 0 y 0, NN N NOH H 1-0365 2.03 477 2
->CI
[Table 77] Compound Retention Structure Co Time [M+H] Method No. (m) N N OH -- - N N 0 OH -0366 2.33 473 3 F F o N lkN :r H N N O H H0 1-0367 2.17 485 3 H CI O N) N O H OO ON N OH 1-0368 2.00 475 3 K CI - N N 0 O H CH1-0369 2.24 510 3 CIj F 0 N N OH C1 -0370 1.98 483 3 [Table 781 Retention Structure Compound Time [M+H] Method No. (min) 0 O N N:0 OH H 1-0371 1.88 461 3 C 1 0 N 'k N N N O H 1-0372 2.27 396 2 CI CI 0 CI OH CI N N OH N N O H 1-0373 2.17 443 2 CI CI N N c( N N O 1-0374 2.28 491 2 C1Y C l. N N OH F O N N O Hl Y 1-0375 2.32 473 3 Cl [Table 79] Retention Structure Compound Time [M+H] Method No. (m) O N N OH N N 0 H 1-0376 2.30 453 3 0 H 0 I N OH N N 0 H 1-0377 1.41 446 2 CI 0 N N OH N N 0 H 1-0378 2.02 415 2 CI 0 N N O H -a c -0379 2.11 447 2 0) CI 0 0 N )IN- - 1-0380 2.49 493 2
H
[Table 80] Compound Retention Structure No. Time [M+H] Method F F F N N N- N 1"N N N N 0 1-0381 3.04 440 3 CI CI 0 C ~ NO OH N N N 0 OH H 1-0382 2.09 465 2 0 F AN OH FI F O N N 0 1-0383 2.32 457 3 CI N N F F F N N N O F H 1-0384 2.77 440 2 CI 0 0 N N N N O 1-0385 1.56 463 2 [Table 81] Retention Structure Compound Time [M+HJ Method No. (m) F 0 0T N 'J NA-,N~y2H O N N 0 H C 1-0386 1.81 491 2 F O O N N 0 H H 1-0387 1.86 505 2 F 0 H H C I038N.9N5 9 N N0 H C 1-0388 1.98 519 2 F O ON N 0 H c c 1-0389 1.94 519 2 N ' NN, NyN--WOH N ItKO 0 1-0390 1.77 535 2 Cl1 [Table 82] Retention Structure Compound Time [M+H] Method No. (min) __ 0 F 0 0y N N -I-NNH IN N 0 H 1-0391 1.89 531 2 Cl F 0 0 N N OH H 1-0392 1.77 549 2 7CI CI 0 N N N N N O H 1-0393 2.28 406 2 c1 0 o N H 1-0394 2.30 430 2 Cl 0*" 0 F 0 N N t N O 0- 1-0395 2.77 549 3 ' Cl [Table 83] Retention Structure Compound Time [M+H] Method No. (min) 0 N Nk0 1-0396 1.94 534 2 F H 0N J HNN N - OH N N OH 1-0397 1.69 536 2 CI O HN N O N NO 1-0398 2.51 535 2 F O0 HN N OH 1-0399 1.81 520 2 Cl 0 0 HN N OH ON N OH 1-0400 2.24 521 2 Cl LV0)..L3J [Table 84] CompundRetention Structure Compound Time [M+HJ Method No. (min) 0 0 0 NHN N >r-lla N )N 0- O 1-0401 2.49 527 2 O NHN N O 11 N ' N- 0 cl 1-0402 2.40 519 2 F 0 0 O HN N O N N 0O 1-0403 2.32 499 2 NHN N -OH 1-0404 2.04 485 2 F 0X 0 Ao HN N O N NO0 69 ci 1-0405 2.74 609 2 [Table 85] Retention Structure Compound Time [M+H] Method No. (min) __ CI 0 0 HN N 0' NN N ~ O 1-0406 2.84 625 2 CI0 HN N OH N,1L N 0 1-0407 2.16 501 2 F O0 O N -O a 1-0408 2.13 471 2 F 0 00 SHN N0 N N 0 1-0409 2.09 457 2 F 0 O N HN OH N N 4570 1-0410 2.9 457 2 [Table 861 Structure Retention Structure Compound Time [M+H] Method No. (min) F O -yo HN JN "YO SN 0 1-0411 1.87 443 2 F 0 O NHN N OH IN N 0 F 1-0412 2.10 503 2 -- 0 O N N OH 1-0413 1.63 516 2 0 OH0 HN N OH 1-0414 1.84 528 2 0 OH O HN NOH 1-0415 1.74 500 2 [Table 871 Compound Retention Structure Co Time [M+H] Method No. (m) F O O O HN N OH N N-O N. 1-0416 1.78 514 2 F N O - O NH N ) N " O H N NO0 N- 1-0417 1.79 514 2 F 0 0 O HN N OH N; N O 1-0418 1.78 526 2 HN NOH N' N N- 0 0 1-0419 2.21 519 2 CIC0 O ' N N 0 0 cl 1-0420 2.32 535 2 [Table 881 Retention Structure Compound Time [M+H] Method No. (min) __ 0 O NHN N 0 4 c 1-0421 2.45 531 2 CI 0 0 N N 0 c 1-0422 2.53 547 2 F 0 0 O HN N OH N : N 0 C 1-0423 2.09 503 2 HN N OH O N N 0 C 1-0424 2.20 519 2 HOAX1: HN ) N NH N C 1-0425 1.99 493 2 [Table 89] Retention Structure Compound Time [M+H] Method No. (min) __ NHN N O 1-0426 2.12 496 2 NHN IkN
QO
naN N O 1-0427 1.25 500 2 HO HN N OH N N 0-z 1-0428 1.72 479 2 0 O N x HIN N OH N NO 0 1-0429 1.85 482 2 HN N 0 N N3 .0 Ia 1-0430 2.44 515 2 [Table 90] Retention Structure Compound Time [M+HJ Method No. (min) 0 O HN N OH N' -' N 0 cl 1-0431 2.15 501 2 CIO ON N O 1-0432 2.10 435 1 CI HN F N NLO H N O1-0433 1.79 462 F O OH O < N N O H 1-0434 1.80 449 N N N 0 H 1-0435 1.90 494 1
CI
[Table 911 Retention Structure Compound Time [M+H] Method No. (min) F S 0 W O N N- O H N 1-0436 3.40 590 1 Hc CI F HN ON N O H 1-0437 1.50 448 2 F O OH N N O H 1-0438 1.80 464 2 Cl F HN OH ON N O H 1-0439 1.50 462 2 F O' O- 0H N N 0 H 1-0440 1.70 493 2
CI
[Table 92] Compound Retention Structure Co Time [M+H] Method No. (m ) OH cl 0 N 1-0441 1.88 479 1 CI Cl 0 OH HN>JN o N NX N N o1-0442 2.09 521 1 cl CI 0 Ir~O HN " N OH IN" N OO N0 1-0443 2.06 479 2 'CI CI O H O HN N N%--N N N OO ' C 1-0444 2.21 517 3 CI O H -O HN ) N N, N N-- N OO 1-0445 2.16 492 3
'CI
[Table 931 Retention Structure Compound Time [M+H] Method No. (min) CI 0 H -To HN ),N ' N -'OH
S
1 N NO 0 CI 1-0446 2.03 522 3 CI 0 H 0 -O HN ) N N - NH-2 N N- 00 CI 1-0447 1.98 535 3 F O O O NH N CI 1-0448 2.11 515 3 F O O O HN IkN "kN -yN H2 -6 N N O H 0 C 1-0449 1.87 533 3 CI OCO C 1 0 0 OHN N OkN-,C N N O 1-0450 2.43 521 2
'CI
[Table 941 CompundRetention Structure Compound Time [M+H] Method No. (m ) O O N N O 1-0451 2.23 487 2 'CI F F O O O IkHN N)tO N N 0 1-0452 2.50 509 3 CI F O OA HN N N N NN% O C 0 1-0453 2.61 553 3 F O Nr HN N N : NNk -OH 0 1-0454 2.33 539 3 CI 0 0 O HN Nt tOH N N O CN I-0455 2.31 507 2 [Table 95] Retention Structure Compound Time [M+HI Method No. (min) o o O HN )]%N OH N NA O 1-0456 2.10 473 2 -CI F F 0 O O HN AN OH N N 0 [-0457 2.22 495 2 F 0 0 F HN N N NO 1-0458 2.67 511 2 F O O N%1N I ~C1 1-0459 2.63 553 3 F 0 0 NHN N OH 9CI 1-0460 2.36 539 3 [Table 96] Retention Structure Compound Time [M+H] Method No. (min) __ F 0 0 O HN N O Nc 1-0461 2.29 505 2 F 0 0 NrO- HN N - CA O N 1-0462 2.30 505 2 -CI F O O O
>
1 N HN IkN I O N NO 1-0463 2.74 567 3 F 0 O -YO H N )Ik N>KOH N N O 1-0464 2.22 491 3 F 0 O O HN N OH IN -,"N O 1-0465 2,22 491 3
CN
[Table 971 Retention Structure Compound Time [M+H] Method No. (m ) CI 0 0 N HN N O O N 1-0466 2.41 521 2 '-0 CI O HN N O' 1-0467 2.41 521 2 -CI F 0 O OH -1 0 HN Ak NI O N NO 1-0468 2.38 539 3 N -ci CI O O O HN A N> OH N N O C 1-0469 2.34 507 3 CI O O -N HN N OH N NO47 2 507 3 la i1-0470 2.33 507 3 [Table 981 CompundRetention Structure Compound Time -[M+H] Method No. (min) ___ 0 0 HN N O N N O NC 1-0471 2.33 501 2 0 O H N N >O ZIN N NO 1-0472 2.31 471 2 CI O O H N N O H N NO 1-0473 2.02 457 2 -CI HN N N N NO NC 1-0474 2.06 487 2 CI 00 SHN IkN O-
-
N N O 1-0475 2.41 477 2
CI
[Table 99] Compound Retention Structure Co Time [M+H] Method No. (m ) F F >,0 0 0 HN N AO N 0 1-0476 2.50 527 2 Cl CI O O HN N OH N NO 1-0477 2.29 463 3 CI F F O 0 0 HN N OH N 0 1-0478 2.41 513 3 -CI 0 0 HN ; HN)N tO N ; N O 1-0479 2.15 482 3 IC' F O O FF F 0 0 H N N O' N N 0 1-0480 2.63 511 3 ci LUo AtJ [Table 1001 Retention Structure Compound Time [M+H] Method No. (min) __ CI 00
C
1 Oi~ N OKc C N NO 1-0481 2.75 512 3 'CI O O O N HN N O N NO CI 1-0482 1.78 502 2 F 0 O HNA N O N N-OO 1-0483 2.42 491 3 I F 0 "O HN N OH N N OO 1-0484 2.18 477 3 F HIN N OH N O 1-0485 2.20 497 2 ci [Table 101] Retention Structure Compound Time [M+H] Method No. (min) Cl 0 0 SHN N % fOH CIII N :: NO: 1-0486 2.31 499 2 ICI O 0 HN:; HN N OH N N N O 1-0487 1.71 468 2 CI O 0 HN a 1-0488 2.17 487 2 o o HN N -AO N N O N 1-0489 2.06 473 2 -C' O 0 O HN N>AOX N N O 1-0490 2.22 487 2 [Table 102] Retention Structure Compound Time [M+H] Method No. (min) O 0 O' 0 N HN A.. N- O NN NO 1-0491 1.53 488 2 -CI 0t 0 NOO O HN N 'J - OH N c 1-0492 1.93 473 2 -CI O 0 O HN N>AOH N N O C 1-0493 1.82 459 2 O O O HN N " OH N N O 1-0494 1.98 473 2 -CI O 0 O HN Nk N' "OH N&N N O 1-0495 2.08 487 2
'-CI
[Table 1031 Retention Structure Compound Time [M+H] Method No. (min) CI 0 0 HN N OH 6N- N NO 1-0496 2.03 493 2 -CI o NO HN N 0 N 0N 1-0497 1.98 498 2 . 0 -- CCI o NO HN N O 1-0498 2.28 497 2 '-CI CI 0 0 N
-
NHN N 0 1-0499 1.62 534 2 -CI O 0 0
-
NHN N OH CN I-0500 2.00 483 2 [Table 104] Retention Structure Compound Time [M+H] Method No. (m ) o N O NN 0 1-0501 2.23 510 2 'CI 0 0 N OH NHN )N OH N N kO N C 1-0502 1.96 496 2 -CI NN 0 "10 HN ) N 0 0 CN N 0 1-0503 2.04 498 2 -CI CI 0 0 N - HN N OH -- N lz NO, NC 1-0504 1.43 520 2 O 0 N HN N OH 1-0505 1.75 484 2
-CI
[Table 105] Retention Structure Compound Time [M+H] Method No(mi) 0 0 OO O HN N OH 1-0506 1.74 484 2 Cl O HN N 0-: N N O O 00 ci1-0507 2.50 535 2 o HN NH 1-0508 2.03 401 2 -CI Cl 0 YO HN N -,, OH N N O O NC 1-0509 2.13 507 2 0 NNO N01 N NO 1-0510 1.85 383 2
'CI
[Table 1061 Retention Structure Compound Time [M+H] Method No. (min) 0 OO -,o HN N ON N N O 0 C1 1-0511 2.41 515 2 0 O HN N -,, OH - N N N O o c 1-0512 2.06 487 2 0 O0~ HNA) N ~~i N\,) 'N*NS O o N 1-0513 2.25 497 2 0 0 H OH', N N O a 1-0514 1.89 469 2 0 N 1 0 O O N x N N O N N k0 1-0515 2.44 538 2
'-CI
[Table 107] Compound Retention Structure Co Time [M+H] Method No. (m) o NO 0N 0 N HN IkN -- O N N 01-0516 2.34 524 2 -CI O 0 NOLN N OH N N 01-0517 2.17 524 2 -CI O 0 NHN N OH 1-0518 2.07 510 2 -CI s 0 0 HN N OH N N O 1-0519 2.23 475 3 N 'CI 0- HN IkN' NN 1-0520 2.67 441 3
F
[Table 108] Retention Structure Compound Time [M+H] Method No. (min) F N 0 N NO H 1-0521 2.75 533 3 -CI F N 0 N NO H 1-0522 2.75 533 3 -CI IF O O O N N OH N ),N'-O H N C 1-0523 2.50 519 3 F 0 0 H N ) N 0 0& N N 01-0524 2.40 485 3 Cl 0 O/ HN Nk O 0- N IN O O 1-0525 2.62 516 3 [Table 1091 Compound Retention Structure Co d Time [M+H] Method No. (min) __ yF 0 0 HN N OH SIN N 0 1-0526 2.18 471 3 CI 0 0 -" HN N OH N N 1-0527 2.28 487 3 C1 O, NCI 0 0 / HN N OH N N O O 1-0528 2.25 487 3 0 OO HN N OH N N 0 1-0529 2.00 449 3 0 OO O HN N ON N N O O 1-0530 2.55 495 3 LUdblD [Table 110] Retention Structure Compound Time [M+H] Method No. (min) y CI 0 O 0 HNt NK O N -51N - O N N N0 1-0531 2.64 521 3 'CI F 0 O 0 HNA NKAOA N N O 1-0532 2.53 505 3 CI 0 .0 0 HN NKSOZ N N O 1-0533 2.57 501 3 CI 0 O HN N OH N N N O 1-0534 2.20 467 3 HN N OH N N 01-0535 2.38 507 3
CI
[Table 111] Retention Structure Compound Time [M+H] Method No. (min) __ F HN N OH N N 01-0536 2.26 491 3 '-LC 0 0 0HN N " OH o A N N 0 1-0537 2.30 487 3 CI O O Oa N O H 1-0538 2.18 487 2 -CI O O N O H 1-0539 2.07 473 2 CI OO O N H 1-0540 2.33 501 2
-CI
[Table 112] CompundRetention Structure Compound Time [M+H] Method No. (min) __ oNo N ~ N N N' O N N H 1-0541 2.23 487 2 CIC0 C 1 O 0 N N O H 1-0542 2.29 507 2 'CI O O H N O N 5 N N- O 1-0543 2.16 483 2 -CI O 0 HN N OH aN N'O 1-0544 1.82 459 2 O A HN N OH N N N O 1-0545 1.98 473 2 ItC' [Table 113] Retention Structure Compound Time [M+H] Method No. (min) __ 0 0 -O HN N OH N N NO 1-0546 1.91 473 2 C O O O HN N OH N N O 1-0547 2.09 487 2 C CI 0 0 O N N OH 1-0548 2.03 493 2 -CI O O HN N OH N N N O 1-0549 1.91 469 2 'CI O O HN N OH N 1 N O 1-0550 1.99 487 2
-CI
[Table 1141 Compound Retention Structure Co Time [M+H] Method No. (min) O 0 HN N OH N - N N' -O 1-0551 1.90 473 2 -CI O 0 FyO HN N OH F N N O 1-0552 1.97 495 2 'CI 0 0 HN N OH 1-0553 1.99 475 2
C
F 0 - O N OkN'- 0 0 H L a CI -0554 2.41 533 2 F 0 NNO ' c 1-0555 2.76 547 2 [Table 1151 Compound Retention Structure No. Time [M+H] Method CI 0 O -O HN IkN
-
O N NO 1-0556 2.53 507 2 CI 0 0 ,TO HN N O 1-0557 2.42 493 2 CI O O-1 -Ir O H N J N 0--- N 01-0558 2.65 521 2 CI 0 0 -TO HNN
-
O N 1-0559 2.43 493 2 CI O O HN N OH -0N 60 N23 9O D1-0560 2.23 493 2 [Table 116] Retention Structure Compound Time [M+H] Method No. (min) ___ CI O O - HN N OH N &N NO0 1-0561 2.16 479 2 C 1 O O O HN N OH N NO 1-0562 2.35 507 2 CI O O HO HN N OH N6 N NO- 1-0563 2.12 479 2 0 0 O HN N 1-0564 2.37 473 2 CI 0 = 0 HN N O &N N O 1-0565 2.44 521 2
-CI
[Table 1171 Retention Structure Compound Time [M+H] Method No. (m ) 0 0 'o HN N N- O N N O 1-0566 2.37 501 2 O O 0 HN N SO N NO- 1-0567 2.16 483 2 'Cl 0 0 O HN N OH &N N O 1-0568 2.09 459 2 F O OZ1 -110 HN ) N- O N HN O CI [-0569 2.34 505 2 CI O OC N1 O HNk N '- OH N N O CN 1-0570 2.18 507 2 [Table 118] Compound Retention Structure Co Time [M+H1 Method No. (m) F 0 0 N HN N OH N N O 1-0571 2.28 491 3 0 0 0 HN N OH N N O CI 1-0572 2.32 487 3 N NO 1-0573 2.11 469 3 0 OO HN NO N N 0 1-0574 2.41 477 3 CI N-OH O HN N 01-0575 1.74 478 2
'-CI
[Table 1191 Retention Structure Compound Time [M+H] Method No. mi) Iro 6 H N 1 N N 0 1-0576 2.44 488 2 - C H N N N N O 1-0577 2.04 476 2 -CI HN N N N 0 1-0578 2.21 449 2 -CI O OH CI HN N N N N 1-0579 2.07 477 2 I-Cl N N O 1-0580 2.28 419 2
'-CI
LUOI IJ [Table 120] Compound Retention Structure Co Time [M+H] Method No. (m ) F O OH OHN N I N -N 0 1-0581 1.78 463 2 'CI H F OKN -OH HN 'NO N NO 1-0582 1.62 506 2 -CI H F O N'N' F "Ir ~HN illN N N 0 1-0583 1.72 505 2 -CI H F O N OH O HN N OH N 0 1-0584 1.56 536 2 -CI H F O -, N N HN NO N6 N N O 1-0585 1.40 533 2
CN
[Table 1211 Retention Structure Compound Time [M+H] Method No. (m ) F O t tN OH O NN N N O 1-0586 1.65 520 2 F 0 NH2 ON -YO HNIN0 N O 1-0587 1.66 462 2 F O -O N O N N 01-0588 2.24 491 3 O C I 0 O HN NO N NO 1-0589 2.53 501 3 Cr 1 N HN N O N N O 1-0590 2.50 507 3 Cr 1 [Table 122] Retention Structure Compound Time [M+H] Method No. (min) 0 O~O HN N NNtO 1-0591 2.67 441 3 F F 0 0 )N N N OH N )INO- H 1-0592 2.50 519 3 C1 0 0 0t HN ' N 0 1-0593 2.56 501 3 F 0 O F HN A N)KtOH N N O 1-0594 2.40 497 2 -CI H O N N OH 1-0595 1.49 502 3 [Table 123] Retention Structure Compound Time [M+H] Method No. (m ) F 0 N-N. O HN N N.N N N O H 1-0596 2.08 501 3 -CI 0 O HN N O 1-0597 2.19 510 2 -CI 0 0 Nx HN N OH N i N O 1-0598 1.93 496 2 -CI F 0 OHN N N N OO,0H 1-0599 1.69 477 3 I-CI F HO'N NH 0 / HN N S NOH I N OH 1-0600 1.67 507 3
I-CI
[Table 124] Retention Structure Compound Time [M+H] Method No. (m) 0 HN 9 F O YN TO HN N N6 N N 0 1-0601 2.14 503 3 ci F o O HN N O 1-0602 2.17 491 2 -CI F 0 0 O AA HNH ANOH 1-0603 1.74 492 2 F O HN N 1-0604 2.73 545 3 N NO C1 F 0 0 0- H0N .3N 0 N N N- 0 1-0605 2.32 471 3 [Table 1251 Retention Structure Compound Time [M+H] Method No. (m) 0 o 1-0606 2.33 467 3 a F 0 H TO HN N N O0 N N O O NC 1-0607 2.05 506 2 F 0 0 o HN 1% NA% N tO 6 N -- ,N . O H I N N C 1- 0 6 0 8 2 .1 1 5 2 0 2 F 0 0 O HN N OH Nk 1-0609 1.92 477 2 F 0 0 0
-
HN N OH NAN 1-0610 1,84 457 2 -a [Table 1261 Retention Structure Compound Time [M+H] Method No. (m) 0 0 HN OH N" N 1-0611 1.86 454 2 HO O F 0 O HN N N -N -0612 1.96 489 2 CI F 0 N N Ot HN HNNO N N 01-0613 2.30 606 2 C 1 C CI OI O HN N K N N N OOI 1-0614 2.43 535 2 C F 0 N -o HN kN--/''N 'ilN H H N 0 1-0615 1.96 543 2 - Cl [Table 127] Retention Structure Compound Time [M+H] Method No. (min) rO HN N C OH N N OOH 1-0616 1.91 495 2 -CI F 0 0 O HN N 0 1-0617 2.14 489 2 "F 0 0 N N 01-0618 2.26 471 3 F 0 0 0 N NO 1-0619 2.43 487 3 -CI N HN A N N- O 1-0620 2.71 485 3
-CI
[Table 1281 Retention Structure Compound Time [M+H] Method No. (min) ___ O 0 HN N NIN N O 1-0621 2.57 471 3 -CI F HN O N N 1-0622 2.56 497 3 CI O 0 ON HN N OH -t N IN O 1-0623 2.16 473 3 -CI O 0 HN N OH N 1 N O 1-0624 2.54 471 3 'CI O 0 -o H O'f, HN N'0 1-0625 2.40 485 3
N
[Table 129] StrctreCompound Retention Structure Co Time [M+H] Method ________ (min) _ _ CI 0 0 O HN N O' 1-0626 2.46 505 3 F 0 0 HN N OH N N N' O 1-0627 2.31 457 3 -CI F O6 0 HN N OH NNO 1-0628 2.29 483 3 N 0 0 N H N OH -- N JN O 1-0629 2.14 471 3 N CI 0 0 HN N OH N & N ,N-O 1-0630 2.21 491 3
N
LUOIOJ [Table 130] Compound Retention Structure Co Time [M+H] Method No. (m) 0 0 0A N HNNO N N O 1-0631 2.36 473 2 C1 0 0 N HN N O N N O [-0632 2.29 479 2 C1 O O~ HN N O 0 N 0-0 N OfN 1-0633 2.43 535 2 -C1 F 0 NH H N N"--N NH 2 1-0634 1.60 504 2 F 0 H 0 HN N N NH 2 N N O 1-0635 1.70 477 2
-CI
[Table 131] Retention Structure Compound Time [M+H] Method No. (min) __ F 0 H o HN N N'OH N NO 0 1-0636 1.75 478 2 F 0 0 O HN N OH N -N N'-zO F 1-0637 1.90 475 2 O HNA N"-('OH -- & N N OOH 1 -0638 1.91 495 2 0 0 N N OH 1-0639 2.00 457 3 O HN N N N 01-0640 2.43 521 2 I--
CI
[Table 132] Compound Retention Structure No. Time [M+H] Method No. _(min) F 0 -T OHN N N O N NO NO 1 [-0641 2.34 526 2 'CI F 0 -TO HN )IN 0"c I N NO0 1-0642 2.29 526 2 F 0 O HN N O O N - ON-NH N NO0 1-0643 1.94 503 2 '-CI F 0 0 -O HNA NN">tNNH2 N N -_ H N 1-0644 1.69 491 2 F 0 0y HNA 0 N O 1-0645 1.72 527 2
'-CI
[Table 133] Retention Structure Compound Time [M+H] Method No. (m ) 0 F 0 O4 TO HN N N.NH N N O 1-0646 1.97 517 2 I-ci 0 0 HN N OH N NO 1-0647 2.09 459 2 CI 0 0 O HN N N OH N N O 1-0648 2.01 465 2 F 0 10 H HN N NN N NO NO H 1-0649 1.85 512 2 CI F 0 -1 0HN N -N N A & NH [-0650 1.83 512 2
-CI
[Table 1341 Retention Structure Compound Time [M+H] Method No. (min) CI 0 O HN N N1OH NN NO0 1-0651 2.14 507 2 'CI F 0 HN ) N^,, N Nt N~ O N 1-0652 2.24 592 2 F O H H 0HN N N N, IN i: ,N
--
O N N N N 0 C I 1- 0 6 5 3 1.9 0 5 2 9 2 F 0 O -TO HN ) N^AS NON 1-0654 1.64 513 2 -CI F 0 0 FyO - HNX) -- OIl F NO 1-0655 2.47 513 3
-CI
[0319J [Table 135] CompundRetention Structure Compound Time [M+H] Method No. (min) __ 0 0 0L FIHN ) N ONN N O 1-0656 2.44 501 3 -CI HO HN A 'N! N :IN O 1-0657 1.93 473 3 '-)Cl F 0 0 FO HN kN OH F -6 N 1: N O 1-0658 2.21 499 3 -CI F O H O HN N N NH2 N N O NH C 1-0659 1.49 490 2 CI OI 0 HN N O 1-0660 2.28 493 2
-CI
[Table 1361 Compound Retention Structure No. Time [M+H] Method (mini) _ __ F O O1tN1:1 -- N 1-0661 2.35 606 2 0 N 0 HN fN 0 0 CI O H O-- N 5 NO Nc 1-0663 2.04 562 2 CI 0 H Ia l1-0664 2.06 576 2 CI 0 H 0Y HN % N N -OH -6 N%%0O OH N- c 1-0665 1.79 552 2 [Table 137] Compound Retention Structure Co Time [M+H] Method No. (m ) Cl 0 H N N 00 C I 1-0666 2.13 590 2 C 0O HO HN O H N " N 1-0667 2.34 577 2 -CI O 0 HO H M N OH N 11 N N- O 1-0668 1.67 459 3 'Cl O 0 NHN N OH N N NO 1-0669 1.98 487 2 o 0 H N N N N N O 1-0670 2,28 481 2 [Table 138] Retention Structure Compound Time [M+H] Method No. (m) O 0 HN N 0 N -IkN O 1-0671 2.09 463 2 F 0 HN-N O HNNA HN N N N N 0 1-0672 1.81 500 2 -'-CI CI 0 Nr HN )IN'4 0 C1 Oo NONO 1-0673 2.29 563 2 HO O F 0 HN N 1N N 0 -0674 1.96 489 2 F 0O O HN N' N N 0 1-0675 1.96 489 2
C
[Table 1391 Retention Structure Compound Time [M+H] Method No. (min) CI 0 HO- HN N N N0 N N 0 1-0676 1.94 479 2 I-CI O 0 0 N' HN N O [-0677 2.19 472 3 Q 0 0 H N N N- O 1-0678 2.23 487 2 I- % F 0 SHNl H 1-0679 1.81 486 2 'C1 0 0 N HN N< OH N N O 1-0680 2.04 467 2 LUOLUJ [Table 140] Retention Structure Compound Time [M+H] Method No. (min) OOH N HN N OH N NO 1-0681 1.87 449 2 CI 0 0 O HN N OH 0-- N N 'zO 1-0682 1.99 473 2 F 0 O' 0 HN N N N N 0 1-0683 2.35 526 2 CI 0 HN 1,N,% N N O I-0684 2.51 622 3 CI1 F O O HN N NH N N : NO1 1-0685 1.90 512 2
'-CI
[Table 141] Compound Retention Structure Co Time [M+H] Method No. (m ) O 0 0- HN N OH N ; N N- O 1-0686 1.91 459 3 C CI O H ,O J2YN OH N N- 00 OH 1-0687 1.86 580 2 0 y F ON O HN N o N )N O 1-0688 2.51 622 3 cl& F O O O1 0 HN N N N N NO N 1-0689 1.97 526 2 O 0 0 HN ) N - O N N 0 1-0690 2.31 487 2 cI [Table 142] Retention Structure Compound Time [M+H] Method No. (min) CI 0 0 HN N O 1-0691 2.39 477 2 CCI H 0 0 N HN N O 1-0692 1.96 482 2
A
1 F 0 o N
HNN"-NH
2 ON N 1-0693 1.92 512 2 0 O OFHN J N- O HN N O Nc 1-0694 2.48 527 2 HIN N OH N N O 1-0695 2.05 473 2
-CI
[Table 143] Compound Retention Structure Co Time [M+H] Method No. (m ) CI 0 0 NHN N OH N : N '-O 1-0696 2.12 463 2 CI H 0 0 NHN N OH N NO- N 1-0697 1.73 468 2 0 O 0 HN N OH N N O c 1-0698 2.12 499 2 -0 OHN ) N N O N "O0 1-0699 2.51 628 2 Cl O O CIHN N7 2 5 -- N lNO0 0 N-a c 1-0700 2.34 539 2 [Table 144] Retention Structure Compound Time [M+H] Method No. (min) y O0 0 N I N O [-0701 2.94 557 3 -CI CI 0 0 HN N O N N'0 1-0702 2.16 493 2 -CCI 0 0 o HN N N N O H 1-0703 2.10 512 2 -CI O 0 -1 0 HNANjKNNOH 1-0704 1.94 542 2 C0 O H yO HN ) N 'N -'^'OH & N )"N-- 00 C1 1-0705 1.94 550 2 [Table 1453 Compound Retention Structure Co Time [M+HJ Method No. (min) __ NNo HN NN 1-0706 2.16 499 3 CI O 0 NO HN N O N N O c 1-0707 2.59 501 3 0 O FHN J N -& N ),N O0 1-0708 2.28 614 2 OH 0 O HN N T 1-0709 2.37 515 2 0 O HN
HN
0 7N .0 N 52 Ia 1-0710 2.37 55 2 [Table 1463 Retention Structure Compound Time [M+HJ Method No. (m) O 0 O HN N OH N N O NC 1-0711 2.34 487 3 o 0 O HNk N N \ N N O C1 1-0712 2.28 636 2 o o O 0 X 1 NN N OH O& N N1-0713 1.93 552 2 -O HN 'kN-61 N Nk 1-0714 2.56 636 2 -O 'IHt N1-0715 2.16 552 2 [Table 147] Compound Retention Structure Co Time [M+Hj Method No. (m) 0 OH 0 TO HN N NH N N 0 1-0716 1.58 514 2 CI O OO OU NH O HN HN N N %N O 0 1-0717 2.56 630 2 1 CI 0 0 N N 0 1-0718 2.64 555 2 C] HO O HN N O 1-0719 1.68 489 2 0 O HN N O N N 0 1-0720 2.24 487 2 -aci [Table 148] Compound Retention Structure No. Time [M+H] Method o o 0 N HN N N H O N NON 1-0721 1.98 500 2 -CI 0 N1O HN AN'^'OH N N OH 1-0722 1.86 475 2 0 0 >HN N N-OH ' 'NA N O H 1 1-0723 1.86 530 2 CI 0 0 A0 HN N OH N N- O 1-0724 1.91 479 2 -CI O 0 N I- N H NN NO 1-0725 1.98 508 2
-CI
[Table 149] Retention Structure Compound Time [M+H] Method No. (min) ___ oo O O O~ NHF 1-0726 2.24 568 2 0 0 O N N N 'NO 1-0727 2.53 501 3 c O O HN N O N N 0 1-0728 2.53 501 3 C I 0 S HN N N6 N N O 1-0729 2.57 545 3 ci 0 0 OHN N O N N O 1-0730 2.69 516 3
K
LU IZlJ [Table 150] Retention Structure Compound Time [M+H] Method No. (min) O 0 0 - HN N O N N 0 1-0731 2.68 516 3 0 O H O O NH O HN N -, - OH N NO O 1-0732 2.26 602 2 C 0 0 HO"- O HNk N -, OH 1-0733 1,45 475 2 O O HN N N OH N N O 1-0734 1.95 473 2 I-CLCI F 0 O ,O HN ) N O N N O 1-0735 2.30 548 2
CI
[Table 151] Retention Structure Compound Time [M+H] Method No. (m ) 0 NH 2 NrOx HN N OH N N -- O O NC 1-0736 1.56 502 2 F 0 0 O HN N OH N N N N06 1-0737 1.97 520 2 -CI F 0 0 FtO HN N O N i: N Nz O 1-0738 2.19 523 2 CI 0 CI C O O O HN N HNN CI 0 CN -O HN N N 0 N N 1-0740 2.39 647 2
KCI
[Table 152] Retention Structure Compound Time [M+H] Method No. (min) F 0 0 F O HIN N OH N N O C 1-0741 1.95 509 2 CI 0 rNH _Io H N ) N N,, N NO 0 CI 1-0742 1.56 547 2 CI 0 0 HN N O [-0743 2.66 521 3 0 0 OO O g( HN ) N---O N NO 1-0744 2.13 487 3 -CI 0 0 O yO HN N O -04 -1 5-03 Ia 1-0745 2.13 503 3 [Table 153] Compound Retention Structure No. Time [M+H] Method _________ (min) _ _ O 0 N N O 1-0746 1.86 473 3 0 CI HN N OH ---O- N NO 1-0747 2.40 507 3 O 0 ONO HN N OH -IN " N N- O 1-0748 1.86 489 3 O 0 HN N0 O 1-0749 2.57 501 3 O 0 O HN N OH N N O 1-0750 2.32 487 3
CI
[Table 1541 Compound Retention Structure Co Time [M+H] Method No. (min) __ NNo O H HN N 1-0751 2.17 499 3 CI 0 O 0 HN ' N -- AOH N N O 1-0752 2.43 502 3 CI Y 0 HN N OH N N N 0 1-0753 2.43 502 3 cO A Y 00 HN N OH N 0 1-0754 2.07 487 2 CI 0 0 HN N OH N N 1-0755 2.07 487 2 CI A [Table 155] Compound Retention Structure Co Time [M+H] Method No. (min) OH 0 o -N HN N N N O 1-0756 2.03 516 2 CI O 0 O tJHN N N> N N'O 0 O N 1-0757 2.09 580 2 F 0 0 -1 0 HN AkN' N ) N__ H O N NO C1 1-0758 2.00 501 2 0 00 HN N'O N N 0 1-0759 2.45 549 2 Cl O O -O HN ) N N -,OH N NIO O Cl 1-0760 1.96 566 2 [Table 156] Retention Structure Compound Time [M+H] Method No. (min) __ 0 O HN N N )"NO 0 N 1-0761 2.40 515 2 0 O OH yO HN NO N N 0 1-0762 2.12 521 2 C' CI 0 0 N HN N O 1-0763 2.23 487 2 O 0 0 HN N O N N O 1-0764 2.13 467 2 0 O HN OH 1-0765 2.13 501 2 [Table 157] Compound Retention Structure Co Time [M+HJ Method No. (min) ___ ___ CI 0 0 X HN ) N N NO 1-0766 2.39 502 3 CI O O CI 0 0 HN N Ox N )"NO- N c 1-0767 2.38 537 3 HN N O'N ."&N N O I-a ci -0768 2.49 457 3 -CI O 0 HN N O 1-0769 2.48 469 3 I-ac CI o o HN ) N--A -. N N 0 1-0770 2.13 471 3
-CI
[Table 158] Compound Retention Structure Co Time [M+H] Method No. (min) O 0 HN N OH N N N-O 1-0771 2.20 443 3 CI O 0 N N OH 1-0772 2.20 455 3 ICI o o HN N OH N N O 1-0773 1.86 457 3 'CI 0 0 HNX N N N N 0 1-0774 2.02 513 2 CI O ro O / HN Nq NIN N 01-0775 2.14 485 2
CI
[Table 159] Compound Retention Structure Co Time [M+H] Method No. (m ) O OH O HN N( H N N 0 1-0776 1.84 503 2
CII
0 0 H N )IN O N N O 1-0777 2.56 471 3 CI H O O HN N 0 a I 1-0779 2.42 513 2 0 "T 0HN J N N N N NO N 1-0780 2.18 540 2 [Table 1601 Compound Retention Structure Co Time [M+H] Method No. (min) __ No 00 HNL IN , N N 1-0781 2.24 550 2 rT HN ) N a O NI-0782 2.45 515 2 CI 0 0 7r HO -H O O N N 1-0783 2.45 515 2 'CI 0 CN 1-0784 2.38 554 2 O N &-0781 N2.3570 0 N- c 1-0785 2.37 570 2 [Table 1611 Retention Structure compound Time [M+H] Method No. (m) O H ,,O HIN ' N N, N0N & N I-,N O O ci 1-0786 1.99 500 2 O ~HNXN lN< CI -077 2.05 556 2 O H -O HN N - N-'OH 0 N N OO 1-0788 1.86 530 2 O HN )N OH 1 NN N O N 1-0789 2.11 523 3 O O HN N O 1-0790 1.53 494 3 -acl [Table 1621 Retention Structure Compound Time [M+H] Method No. (min) 0 0 HN N ON N N O 1-0791 2.57 483 3 -CI O O HN N OH N N O 1-0792 2.31 457 3 -CI O O HN ) N OH N N O 1-0793 2.30 469 3 -C O HN N OH 1-0794 1.97 473 2 O O NHN N OH N079 N .2 3O ,-a1-0795 1.92 453 2 [Table 1631 Retention Structure Compound Time [M+H] Method No. (m ) F F O O -%HN N O N N 0 1-0796 2.28 527 2 -CI F F O 'O HN N OH N N O 1-0797 2.04 513 2
-
C O0 0 HN N OH N N O 1-0798 2.19 501 2 -CI 0 O O HN N SOH 1-0799 2.19 501 2 -CI 0 HN) N N0 N NA'O 0~O NOH C1 -0800 1.98 526 2 [Table 164] CompundRetention Structure Compound Time [M+H] Method No. (min) ___ O 0 O HN N OH "'T HN 1-0801 2.04 536 2 0 -rHN YN N N 0 N OH N" 1-0802 2.03 526 2 CI O OH 0 HN N OH N N 0 1-0803 2.04 503 3 o 0 0 HN. N><OA N N 1-0804 2.17 501 2 -CI 0 0K NNO 1-0805 2.54 529 2 N1"C [Table 165] Retention Structure Compound Time [M+H] Method No (min) __ o o O HN N fO N N 00 1-0806 2.22 517 2 -CI O 0 HN N OH N N 0 0 N 1-0807 2.00 503 2 -CI O HN N O IN N 1-0808 2.33 485 3 I-CI 7 o HN N O N NO 1-0809 2.47 515 2 -CI CI 0 O O HN N 04 CN N N O 'NCk 1-0810 2.85 549 3 [Table 166] Compound Retention Structure Co u Time [M+H] Method No. (min) ___ NOAO HN N 0 N N 01-0811 2.69 515 3 I-CI o 0 S HN N O 1-0812 2.53 481 3 O HNA N 1-0813 2.38 467 3 o 0 HN N O N NO- 1-0814 2.58 501 3 o o HN AN N NO 1-0815 2.55 471 3
'--C
[Table 167] Structure Compound Retention Strctre o. Time [M+HJ Method No. (m) O 0 HN N O N -N NOz 1-0816 2.52 481 3 C1 0 O O HN N OH 1-0817 2.45 521 3 O O N N O N N 0I-0818 2.27 457 3 -CI 0 0 O HN N OH I-a cl1-0819 2.32 487 3 N O O N NOH 1-0820 2.27 467 3 [Table 168] Retention Structure Compound Time [M+H] Method No. (min) 0 0I O HN N O0 N N O 'N 1-0821 2.69 515 3 F 0 O O HN N O 'NC 1-0822 2.75 533 3 Y 0 O HN N O N N O 1-0823 2.61 495 3 O 0 OHN IkN O-- l N N O 1-0824 2.47 481 3 'N O HN N OH 'N N O 1-0825 2.20 501 2
'-(-CI
[Table 1691 Retention Structure Compound Time EM+H] Method No. (m) 01 O HN N -OH N N N" O 1-0826 2.19 501 2 O 0 HN N OH aN - NO0 1-0827 2.07 467 2 N OH N N 0 1-0828 1.92 453 2 O 0 HN N OH N N O N 1-0829 2.29 487 3 F O O IrO HN N OH I-8N N N3 0O Ia 1-0830 2,35 505 3 LUJ- UJ [Table 1703 Compound Retention Structure Cou Time [M+H] Method No. (min) ___ O 0 HN N O 1-0831 2.51 515 2 -CI N N ) NO N N 1-0832 2.45 495 2 o No NHN N O 1-0833 2.17 499 2 -C1 o O HN NO O 1-0834 2.12 479 2 -a HN N OH N 2.2N51O N-c 1-0835 2.28 501 2 [Table 171] Retention Structure Compound Time [M+H] Method No (m in) _ _ _ HN N OH N N NO 1-0836 2.22 481 2 O O HN N OH Nc 1-0837 1.94 485 2 O 0 HN N OH aN NO0 1-0838 1.89 465 2 O HN N O N NNO 1-0839 2.56 501 3 CI 0 0 O HN N OH N N O 1-0840 2.33 487 3 [Table 1721 CompundRetention Structure Compound Time [M+H] Method No. (min) F F O HN 'kN O N N O 1-0841 2.44 511 2 - ci 0 0 NNO N N O 1-0842 1.96 485 3 I-ac F O O F F o o H% 1 k N OH N N O 1-0843 2.20 497 3 I-ci O 0 0 HN )N OH N N O 1-0844 1.70 471 3 I-aC' F 0 NN OH NC 1-0845 2,39 519 3 [Table 173] Retention Structure Compound Time [M+H] Method No. (min) F 0 O F " O HN N O 1-0846 2.28 509 3 -C' F 0 0 F "O HN ) N --- O aN N O 1-0847 2.20 489 3 F 0O F' O1 HN J N - OH 1-0848 1.83 495 2 F 0O F' O HN N --- OH 1-0849 1.77 475 2 0 O HN kNOH N N O 1-0850 2.24 527 2
-CI
[Table 174] Retention Structure Compound Time [M+H] Method No. (min) __ 0 O OH -O HN N N N 0 1-0851 2.25 527 2 I-ac CI O 0 HN N OH N N O 1-0852 1.87 489 2 -C' O 0 HN N OH -- & N N 0 1-0853 2.37 481 3 'N O 0 O HN N OH N N O 1-0854 2.21 467 3 0 O O HN N O 'N& N NO F 1-0855 2.39 517 2
'NI
[Table 175] Retention Structure Compound Time [M+H] Method No. (min) CI 0 O O HN N 0 N< , OF F 1-0856 2.32 523 2 O - ~HN N -- OH N N O 1-0857 1.84 489 2 O HN N OH N N O 1-0858 1.70 495 2 HN O H N O N N F 1-0859 2.30 503 2 A N N 0 O O N N 0 1-0860 2.42 465 2 [Table 176] Strctpo d Retention Structure Compound Time [M+H] Method _________ (min) _ _ _ Cl 0 O / HN N O 6N N NO 1-0861 2.44 515 2 NNKN 0 O HN N ON N -1,N -- O O 1-0862 2.29 501 2 O O o HN N 0 'N N N 0 1-0863 1.95 503 2 ICI 0 ' 0 0 HN N OH 'NNN N O 1-0864 1.35 480 3 -CI 0 0 HN N BrN NO 5 Ia r1-0865 2.37 545 2 [Table 177] Retention Structure Compound Time [M+H] Method No. (min) __ CI O O-' O HN N SO N N 1-0866 2.35 501 2 CI 0 0 O- HN I N N N O t 1-0867 2.22 487 2 O 0 O HN N OH N N O 1-0868 2.11 531 2 Br OH O HN N NH N NO O 1-0869 1.83 516 2 -Cl OH 0 | O HN NW NH & N N O 0 1-0870 1.83 516 2 O
CI
[Table 178] Compound Retention Structure Co Time [M+H] Method mNo.n) N O O HIN kIN -1xO H IN IN OF0 1-0871 1.73 475 2 0 0 HN N OH I N N ' O 1-0872 2.17 451 2 CI 0 O HN AN ,,- OH N N O O 1-0873 2.09 487 2 C 1 O O HN k N OH N N N O O Na 1-0874 2.14 473 3 CI 0 0 -,07 HN 3 N 2 O N.NN01-0875 2.36 501 2 [Table 179] Compound Retention Structure Co Time [M+H] Method No. (m ) CI 0 : ,O / HN N O N N 0 1-0876 2.24 487 2 CI 0O O HN AN N O N N O 1-0877 2.39 501 2 CI 0 0 TO HN N OH N -5N N' O 1-0878 2.32 487 3 CI 0 = 0 HN N OH N N NO 1-0879 2.20 473 3 CI 0 = 0 O HN N OH N N NO a 1-0880 2.15 487 2 LUOhq-J [Table 180] Retention Structure Compound Time [M+H] Method No. (min) ___ F 0 0 O 'N HN N O N N- O C I 1-0881 2.37 504 2 CI O O NO ' HN )IK N"S OH N N O 1-0882 1.89 459 2 O O HN O O O HN N 0 N N O 1-0884 2.37 495 2 -- a O O HN N OH N-8 4 N N 1 -0 8 8 4 . 3 7 4 6 5 2 [Table 181] CompundRetention Structure Compound Time EM+H] Method No. (m) O 0 HN N OH 'N NiO 1-0886 2.10 481 2 O 0 H0 N O N NO0 1-0887 2.64 515 3 N~NO -CI O 0 o HIN C " NN NOO 'Nc 1-0888 2.53 501 3 o 0 0 H N OH -- N - NiO la i1-0889 2.36 501 3 O 0 yfHN N I- OH N 0o 1-0890 2.25 487 3
'CI
[Table 1821 Retention Structure Compound Time [M+H] Method No. (m) CI 0 0 -O / HN N O N N O N 1-0891 2.61 501 3 O 0 O-HN N O N NO 1-0892 2.31 493 2 F 0 0 AON HN N OH N N NO, Cl 1-0893 2.11 490 2 0 0 H N N N O 1-0894 2.39 495 2 O - HN A N SOH N N O ,- 1-0895 2.27 473 3 [Table 1831 Retention Structure Compound Time [M+H] Method No. (min) CI 0 0 C1HN O N OH O N N O 1-0896 2.02 473 2 O O O HN N OH N N O 1-0897 2.07 479 2 0 0 HN N OH N N O 1-0898 2.14 481 2 HN N - O N N 1-0899 2.36 501 2 N -0 O H N IkN J- O N N O 1-0900 2.33 513 2
CN
[Table 184] Compound Retention Structure No. Time [M+H] Method Br 0 0 10 HN
C-
N NO 1-0901 2.37 545 2 CI 0 O O HN N X OI [-0902 2.48 527 2 C1 0 0 O HN A NJOn N N O 1-0903 2.38 513 2 CI 0 0 O HN N OH NIN NO, 1-0904 2.34 499 3 CI 0 O O HN-A NQ<OH N N O 1-0905 2.22 485 3 a [Table 1851 Retention Structure Compound Time [M+HI Method No. (min) __ 0 N N OH 1-0906 1.99 501 2 'CI O 0 O HNA N O N NO N N 01-0907 2.33 493 2 0 0 O HNA NO N N --IO N 01-0908 2.39 495 2 Br 0 0 0 - HN N OH N N N- O 1-0909 2.11 531 2 0 0 0 HN N OH N N OH 1-0910 2.09 479 2 [Table 186] Retention Structure Compound Time [M+H] Method No. (min) O 0 O HN N OH -0911 2.15 481 2 o 0 O' HN N Ok N N O 1-0912 2.52 493 3 o 0 oI HN N O' 1-0913 2.49 505 3 00 OO O O HN N OH N N 0 1-0914 2.16 265 3 0 O O1,0 HN N OH N N O 1-0915 2.13 477 3 [Table 1871 Retention Structure compound Time [M+H] Method No. (min) CI 00 -O/ HN N
-
O N 01-0916 2.43 521 2 C CI HNO N NIN -N 0 1-0917 2.54 535 2 -C1 HN N O N N O 1-0918 2.44 533 2 - CI O O HN N Xf O N N 0 1-0919 2.37 513 2 0,0 HN N OH N N O 1-0920 2.09 487 2 [Table 188] Compound Retention Structure Co Time [M+H] Method No. (min) OII1 HN N OH N N O 1-0921 2.06 499 2 CI 0 O HN N OH 0&N NO 1-0922 2.15 507 2 0 CI -TO 0 .0 HN N OH I N NO0 1-0923 2.26 521 2 CI 0 O HN N Z%- OH N N O 1-0924 2.07 505 2 -CI O O N N 0O NC 1-0925 2.01 485 2 [Table 1891 Retention Structure Compound Time [M+H] Method No. (min) __ N 0 O HN N J-:O N N O 1-0926 2.29 481 2 7 -~ HN N 0O N N 0 1-0927 2.40 495 2 CI O O O HN N 0O N N 01-0928 2.46 515 2 O HN ) N OH N N O 1-0929 2.24 467 3 0 0 O HN -NOH N 1-0930 2.34 481 3 LUOLdJJ [Table 1901 Retention Structure Compound Time [M+H] Method No. (min) CI 0 10 rTHN N OH N6 N ; N O 1-0931 2.41 501 3 F HN N OH N N O 1-0932 2.05 527 2 c -CI FV 0O O oo HN N OH N N O 1-0933 2.05 527 2 -CcI 0 0 0- HN ) N - O Ni IN- O1-0934 1.97 497 2 00 0 HN ) N IkH & N N 0 1-0935 2.08 479 2 -a [Table 191] Retention Structure Compound Time [M+H] Method No. (min) N O Oa HN IkN OH N 1-0936 2.23 467 3 O 0 O HN N OH NN N O 1-0937 2.42 481 3 0 =0 O HN ) N O N N1 -0938 2.66 495 3
I
O O 0 HN k N ><O N N O 1-0939 2.51 481 3 O 0 0- HN N AO N N O 1-0940 2.56 525 3
I
[Table 1921 Retention Structure Compound Time [M+HI Method No. (min) O O 0 HN J N0 N NOOK 1-0941 2.64 507 3 F N 0 O N HN N -- O N N O 1-0942 2.30 541 2 C FO O HN N 0 N N 0 1-0943 2.29 541 2 - C O O O)10 HN N O N N O 1-0944 2.75 563 2 Si" O 0 o HN N O N O 1-0945 2.19 491 2 [Table 193] Compound Retention Structure Co d Time [M+H] Method No. (min) __ O 0 O HN N OH -- & N - N-O 1-0946 1.97 477 2 NN O 0 1-0947 2.78 499 3 NN -CI o o HN AN 0 1-0948 2.74 497 3 -CI O 0 HN N OH Y-- N N O Ia 1-0949 2.54 485 3 O 0 -- HN A N OH N NO0 1-0950 2.50 483 3
-CI
[Table 1941 Retention Structure Compound Time [M+H] Method No. (min) __ N 0 0 To HN N O N N O 1-0951 2.13 492 2 0 00 HN N O 1-0952 1.49 514 2 INN -CI N 'o HN 'kN OA N N 0 1-0953 2.21 512 2 I-ci O O NN -a N i" N - -OI-0954 1.52 512 2 -C C1 O Oi CI 0 0 HN N O 1-0955 2.86 517 3
'CI
[Table 195] Retention Structure Compound Time [M+H] Method No. (min) ___ O 0 Br HN N N O 1-0956 2.63 522 3 CI CI 0 0 HN N O N N 0 O 1-0957 2.57 513 3 CI 0 0 HN N O N N O 1-0958 2.55 513 3 HN N OH N NO, 1-0959 2.62 503 3 N I O 0 0 HNA O HN N OH N N O 1-0960 1.98 498 2
'-CCI
[Table 196] CompundRetention Structure Compound Time [M+H] Method No. (min) __ N O 0 O HN N OH N N 0 1-0961 1.90 478 2 O 0 C A HN N OH N N 1-0962 1.34 498 2 N HN N OH I-0962 1.34 508 2 , CI N OH BrHN )N -,O N N O 1-0964 2.34 500 2 -CI OrHN H t G N OH 1-0964 2.36 508 3 2 [Table 197] Compound Retention Structure Co u Time [M+H] Method No. (min) CI 0 O O/ HN ) N - O N N O 1-0966 2.35 501 2 F 0 O OHN N -- O N N 1-0967 2.35 499 2 CI 0 0 O HN N " OH N N N 0 1-0968 2.23 485 3 HN NO O O-6 N N O 1-0969 2.45 527 2 CI 0 O HN N O 0 N N N -z O 1-0970 2.47 539 2 tNI [Table 1981 Retention Structure Compound Time [M+H] Method No. (min) CI 0 0 O HN N OH N N O 1-0971 2.30 499 3 0.0 HN N OH N NO 1-0972 2.19 479 3 CI 0 .0 HN N -OH N N N O 1-0973 2.27 487 3 F 0 ,O N O OH HN N OH N N N O 1-0974 2.28 485 3 ACI 0 EQ A".10 HN ) N '-OH N N N- O Na 1-0975 2.40 513 3 [Table 199] Retention Structure Compound Time [M+H] Method No. (min) AI 0 0 O- HN N OH NN N O 1-0976 2.34 511 3 C O 0 O I 0 -1ro HN N/ 0r N 5 N Nz O 1-0977 2.52 547 2 0 N10 N INO O-& O5 z N 1-0978 2.43 527 2 -CI CI 0 H k N 1-&NO ON NO 1-0979 2.43 527 2 0 N N NO N1-0980 2.37 507 2 LUO'UJ [Table 200] Retention Structure Compound Time [M+H] Method No. (m) CI 0 -0 ~. HNtC N:,ZYOH N N 0 1-0981 2.25 533 2 0 0T H HNAN Thr-OH N N 0 1-0982 2.17 513 2 CI Ol O OH N 5 N NO0 N 1-0983 2.17 513 2 H N NH N 5 N NO- N 1-0984 2.11 493 2 O HN N O-0- N N O N 1-0985 2.81 548 3 [Table 201] Retention Structure Compound Time [M+H] Method No. (m) CI 0 O HN N OH N N N O NC 1-0986 2.45 519 3 0 O ON 1-0987 2.56 5 3 0 O HN N OH 1-0988 2.18 5 3 -CI O O1O N NO O HN N O4 1-0989 2.56 521 3 ICLCI O O HN N 0 Na 1-0990 2.50 501 3 [Table 202] Compound Retention Structure Co u Time [M+H] Method No. (min) ___ O 0 O HAO N OH O HN ''N- OH N N --- 0 1-0991 2.32 507 3 O O O H N OH N N 0 O s 1-0992 2.25 487 3 O O HN N Ox N N OH 2 1-0993 2.25 547 2 Cl O 0 O HN N Ox N N O 1-0994 2.03 503 2 0 0 H N -- A N1-0995 2.41 507 2 [Table 2031 Retention Structure Compound Time [M+H] Method No. (min) ___ o 0 0 HN N C N NO 0 1-0996 2.21 501 2 'C1 O O HN N O N N O 1-0997 2.49 509 2 CI 0 0 o HN N O N N N O 1-0998 2.39 477 2 F F±F 0 0 CI HN N O N N 0 1-0999 2.29 493 2 FN F F 0 0 C1I ::; H N I N C Al :-K 1-1000 2.47 511 2 [Table 204] CompundRetention Structure Compound Time [M+H] Method No. (min) ___ O 0 AHN N OH N N O 1-1001 2.17 493 2 O 0 O HN N OH < N -: N N- O 1-1002 2.03 479 2 F F F 0 0 CI HN N OH C, N N 0 1-1003 2.23 497 2 CI O O C NHN N OH N -N 0 1-1004 2.15 463 2
I
0 O FOI/NHN N O" N N NC 1-1005 2.72 527 3 [Table 2051 Compound Retention Structure Co Time [M+H] Method No. (min) o 0 O HN )N 4 OH N.c 1-1006 2.37 498 3 HN N N N 0 Nc 1-1007 2.73 527 3 HN J N --- OH N N 0 CI 1-1008 2.38 498 3 O O O HN N OH &N N NO 1-1009 1.89 487 2 'CI O HN N OH N N - 1-1010 2.05 521 2
-CI
[Table 206] Retention Structure Compound Time [M+H] Method No. (min) CI O O 0 HN N OH 'N N N~ 1O 1-1011 2.01 535 2 'CI CI 0 O O1 HNA OH N N LOH N N H 1-1012 1.90 553 2 '- Cl CI 0 0 0 HN N OH N N 0 1-1013 2.20 501 2 'N CI O O O, HN N OH N N 0 1-1014 2.21 501 2 'N CI 0 0 O H N O N 1-1015 2.44 515 2 [Table 2071 Compound Retention Structure Cou Time [M+H] Method y" ci o o o HN N O N N N 0 1-1016 2.45 515 2 O O O HN N OH N &N N kO 1-1017 2.24 495 2 0 0 O HN u N >O N N 0O 1-1018 2.51 481 3 O O O HNAN AO N N O S1-1019 2.65 495 3 CI 0 0 O/ HN )N O N N 0O 1-1020 2.70 515 3
N-
[Table 2081 Retention Structure Compound Time [M+H] Method No. (min) F O O O~ i N NO N 1N O -1021 2.24 521 2 CI 0 0 FyO HN N O 1-1022 2.27 509 2 O 0 HN N O NC 1-1023 2.80 511 3 O 0 :N OH N NO, N- 1-1024 2.56 497 3 o N0 o HN N O N N 01-1025 2.40 515 2
CI
[Table 2091 Compound Retention Structure Co u Time [M+H] Method No. (min) ___ O 0 O HN N OH NN NO- S1-1026 2.13 501 2 -CI FF H N )N ci< O N N O -1027 2.52 527 2 0 0 O HN N HyOH S1-1028 2.17 453 3 0 0 0 HNA N AOH N N O S1-1029 2.32 467 3 HN 0 0 O HN 'kN " OH N N 01-1030 2.37 487 3 [Table 2101 Retention Structure Compound Time [M+H] Method No. (m ) F 0O O H HN N- -IOH N :N O -1031 1.93 493 2 CI 0 0 F O - HN N OH F - N ,N O I- 1032 2.04 495 2 CI 0 0 F HN N OH 1-1033 2.29 513 2 O 0 O HN ) N- O N N O I- 1034 2.45 487 3 -CI 0 0 O H N AN -A OH N N O 1-1035 2.19 473 3
CN
[Table 2111 Retention Structure Compound Time [M+HJ Method No. (m) O O O HN N O N N 0 1-1036 2.42 499 3 N NO 1-1037 2.16 485 3 o 0 N IN O- A I- 1038 2.55 501 3 'CI O 0 N IN O" O 1-1039 2.27 487 3 - CI o o H N N O 1-1040 2.64 503 3
-CI
[Table 212] Compound Retention Structure Cou Time [M+H] Method No. (min) __ O 0 HN N O NINO 1-1041 2.74 507 3 -CI AO 0 HN N OH N IN 0 1-1042 2.49 493 3 -CI HN N'N 0 0L N NO-jA 1-1043 2.79 479 3 O 0 HN N OH 1-1044 2.48 465 3 0 -0 O0HN N O -0N N 24 90 N1-1045 2.41 495 2 [Table 213] Compound Retention Structure Co Time [M+HJ Method No. (m ) HN N O 1-1046 2.38 495 2 0 0 O HN IkN - O N 1 N O Na 1-1047 2.37 495 2 O O 0 0 "1I0 N 0N- N N O 1-1048 2.38 495 2 O O 0 O f0 *' 0.. O NHN N
O'-
1-1049 2.40 495 2 o 0 O HN ) N O- 1 I-05N NO 495 2 1-1 050 2.43 495 2 [Table 214] StrutureRetention Structure Compound Time [M+H] Method No. (mi) O Oj O HN N - O N N 0 1-1051 2.45 495 2 o O 0 HN& N -- AO N N O 1-1052 2.39 495 2 O Oj O0 HN ' N- -- O N AN -kO 1-1053 2.40 495 2 O O O HN AN O ANA N 0 [-1054 2.38 495 2 0 O O HN N AO N N O 1-1055 2.43 495 2 tNI [Table 2151 Retention Structure Compound Time [M+H] Method No. (m) O QHN N O N N 0 1-1056 2.46 495 2 -a N O O HN J N O 1 N- I-1057 2.42 495 2 O O O HN 1 N- -O N N 0 I-1058 2.45 495 2 O O O HN N OH I-1059 2.19 481 2 O O l HN N OH N NO6 2 481 2 Na 1-1060 2.15 481 2 [Table 216] Retention Structure Compound Time [M+H] Method No. (min) O 0 HN N OH aN NO- N 1-1061 2.14 481 2 o o O HN IN OH N N 0 1-1062 2.14 481 2 O 0 HN N OH 1-1063 2.16 481 2 O 0 HN N OH N -INO, I-1064 2.21 481 2 0 0 OIN N OH 1-1065 2.19 481 2 [Table 2171 Retention Structure Compound Time [M+H] Method No. (m) o 0 HN N OH N N O 1-1066 2.13 467 2 O O SN N O 1-1067 2.08 467 2 o 0 Oy HN kN YOH N N O 1-1068 2.09 467 2 o 0 OHN ) N " OH N N O I-1069 2.07 467 2 O O N N 0O N 1-1070 2.13 467 2 [Table 218] Compound Retention Structure No. Time [M+H] Method _________ (min) _ __ HNo O O O/ HN ) N OH N N O t . 1-1071 2.15 467 2 o 0 O HN 'it-QNI&N OH N" N O 1-1072 2.15 467 2 O 0 O > HN N O N jNO, N 1-1073 1.90 509 2 o 0 N OH O - O HN N OH 1-1074 1.65 495 2 O 0 0 N H N ' N- NHN N OH 1-1075 1.36 454 2 [Table 219] Compound Retention Structure C o rTime [M+H] Method No. (min) ______ O 0 Br HN N O N N 01-1076 2.18 487 2 N' Br 0 0 N N 0 1-1077 2.23 487 2 N 0 0 HN N O N N 1-1078 2.49 489 2 0 0 -HN N8 2.26 579 N -,IN 0 1-1079 2.49 489 2 0 0 1-1 080 2.26 579 2 LU dzj [Table 220] Compound Retention Structure Cou Time [M+H] Method No. (min) __ 0 0 'Oj HN ) N -AO N 1-1081 2.23 481 2
I
OHN N OH N N 1-1082 1.97 467 2 O 0 HN N O N N N O I-1083 2.42 475 2 N O HN N O N N 0 1-1084 2.39 475 2 NN 0 0 N N C 1-1085 1.79 492 2 [Table 2211 Retention Structure Compound Time [M+H] Method No. (min) ___ O 0 NA HN N O 1-1086 2.06 478 2 I-07I.6 9 O 0 HN N O N N O 0-1087 2.56 491 2 HN N ON Z N N O 1-1088 2.55 491 2 o 0 N N 0 1-1089 2.45 477 2 N NJ N -- AC aaN N W O 1-i 090 2.44 477 2 [Table 222] Retention Structure Compound Time [M+H] Method No. (m) 0 0 NHN N OH 1-1091 1.79 464 2 O 0 O HN N OH 1-1092 2.01 565 2 O 0 N HN N OH 1-1093 1.47 478 2 o 0 N N O 1-1094 2.74 489 3 O 0 HN N O 1-1095 2.72 479 3 [Table 2231 Retention Structure Compound Time [M+H] Method No. (min) O 0 HN N O 1-1096 2.80 491 3 O O HN N fO Cr- N NO ' 1-1097 2.87 511 3 O 0 HNN OH 05: ' N N O 1-1098 2.49 475 3 O 0 HN N OH r~a N -),N 0' I-C c 1-1099 2.56 495 3 N O HN N OH 1-1100 2.56 477 3 [Table 224] Retention Structure Compound Time [M+HJ Method No(mi) O 0 HN N OH r," N N O. 1-1101 2.62 497 3 O O H O l Ca N N 0' 1-1102 2.24 485 3 'CI O 0 HN N OH 1-1103 1.96 471 3 O O NN 1-1104 2.33 467 3 0 0 OHN NY OH N 5 N -- O 1-1105 2.07 453 3 [Table 2251 Compound Retention Structure o Time [M+H] Method No. (min) CI 0 0 O HN N O' N N O 1-1106 2.43 487 3 CI 0 0 O HN A N' %OH N N O 1-1107 2.15 473 3 0 0 HN N OH 1-1108 2.31 477 2 o 0 HN N OH N N O 1-1109 2.32 477 2 O 0 HN N OH N N 0 1-1110 2.20 463 2 [Table 2261 Retention Structure compound Time [M+H] Method No. (m) 0 0 HN N OH 1-1111 2.25 475 2 O O HN N OH N N O 1-1112 2.25 475 2 NH OH HN N OH N - NO, 1-1114 2.15 461 2 O 0 HN N OH N N O 1-1115 2.15 461 2 [Table 2271 Compound Retention Structure No. Time [M+H] Method No._ (min) O 0 Y 0 -N HN DN o N N 01-1116 2.64 456 2
I
HN. HN N O N N N 0 1-1117 2.24 465 2 O o Oa oU H N OH0 N N 0 Na 1-1118 1.84 510 2 O O O- NHN N OH N NO 1-1119 2.35 442 2 -a 0 0 0 N N ) NO , N.1-1120 1.59 496 2 [Table 228] Compound Retention Structure Co Time [M+H] Method No. (min) ___ 0 0 HN N OH H N N N 0 1-1121 1.98 451 2 I-a NN 0 0 - HN N OH N N O 1-1122 1.26 488 2 0 0 O N N OH N N O 1-1123 1.52 488 2 O-O KN 00 O HN N OH N N O 1-1124 1.52 488 2 0 0 t N N O -1125 1.73 502 2 [Table 229] Compound Retention Structure Co Time [M+H] Method No. (m ) N O 0 O HN N O N 1N O -1126 1.72 502 2 N O O O- HN N O N N O 1-1127 1.58 502 2 NN O H 0 0 N& N N 0 1-1128 2.13 483 3 0, 0 0 HN N XO N N 0 1-1129 2.02 497 2
I
0,1: HN
N--IO
N N -rkN 0 - 1-1130 2,27 525 3
N
LUOLUI [Table 230] Compound Retention Structure Co Time [M+H] Method No. (min) O 0 HN N 1-1131 2.13 479 2 0 0 HN N fO & N: N AN kO 1-1132 2.42 465 2 O 0 NHN N O 1-1133 2.23 481 2 OH 0 0 HN N OH N N 0 1-1134 1.68 469 2 -a O' 0 0 HN N OH 1-1135 1.78 483 2 [Table 2311 Retention Structure Compound Time [M+H] Method . (miO) 0 0% 0 HN N OH N N O 1-1136 2.06 511 2 O O HN ) N - OH N 11NO H137 2.18 451 2 O 0 'O'a HN N O 1-1138 2.20 493 2 O 0 HN N OH 1-1139 1.92 465 2 0 0 HN N OH 1-1140 1.99 467 2 [Table 232] Compound Retention Structure Co Time [M+H] Method No. (m) O O HN N O N N "" b1 1-1141 2.25 493 2 O O HN N O 1-1142 2.26 493 2 CI O O N N N O 1-1143 2.16 517 2 O 0 IHN N O 1-1144 2.36 495 2 0 0 O HN N OH 1-1145 1.98 479 2 .. .... . .
[Table 2331 Retention Structure Compound Time [M+H] Method No. (min) __ O 0 O HN A N >O N N O 1-1146 2.37 479 3 O O O- HN ) N- O N N 1-1147 2.43 499 3 -CI o o 0 N HNA N NAOH N 1-1148 2.30 451 3 o 0 O- HN ) N OH N N[O 1-1149 2.08 471 3 -CI 0 0 O HN N OH 1-1150 2.03 479 2 [Table 2341 Compound Retention Structure Time [M+H] Method No. (mi) S 0 0 - HN N O N N O 1-1151 2.19 475 2 -CI o 0 S O OH H N ) N -- O H N N O 1-1152 2.15 461 3 HN J N O N I- 1 3 .1 5 0 0 HN A'N OH N N 1-1154 2.07 441 3 N O NrOx HN N'k O NN N O Cl 1-1155 2.55 501 3 [Table 235] Compound Retention Structure Cou Time [M+H] Method No. (min) ___ O HN N OI N N O 1-1156 2.49 481 3 o 0 0O HN9 N > OH N N O 1-1157 2.22 473 3 -CI O 0 O HN N > OH N N O 1-1158 2.14 453 3 CI O O N CI 0 0 O HN N OH N NO-' 1-1159 1.92 503 2 oO O O HN N OH N 1-1160 2.03 479 2 [Table 236] Compound Retention Structure oo Time [M+H] Method No. (min) ___ 0 0 N OH F N N O 1-1161 1.82 461 2 F O F O HN N OH C 1-1162 1.89 481 2 O 0 O HM " NH OH C 1-1163 2.36 634 2 O = O O HN A N t OH N N O 1-1164 2.13 501 2 -CI 0; 0 0 O HN N- 'N 02 N1-1165 2.66 660 2 [Table 2371 Retention Structure Compound Time [M+H] Method No. (m ) o N 0 FyO HN N 0 1-1166 2.14 495 2 -CI O O HN ) N - OH S1 1-1167 2.13 481 2 Br 0 0 O NHNN O N -),NO 1-1168 2.37 545 2 O O N HN ) N - O 1-1169 1.91 492 2 Oa O N HN rhyN O 1 Na 1-1170 1.53 506 2 [Table 238] Compound Retention Structure Co Time [M+H] Method No. (m ) F 0 0 HN N O N - N N-z O 1-1171 2.68 481 3 CI 0 0 ANHNNO N H kN 0 NII I -,- N N -O 1-1172 1.63 500 2 Br 0 0 HN N O 0-:bN N'O 1-1173 2.23 531 2 F 0 0 .A- HN AN OH 1-1174 2.42 467 3 -N 0 0 O HN N '-OH N N O 1-1175 1.66 474 3 Na [Table 239] Compound Retention Structure Co Time [M+H] Method No. (m ) -N00 OO O HN N '>OH N N 0 1-1176 1.75 494 3 c C-CI CI 0 0 NN NHN N OH N NO" 1-1177 1.40 486 2 Br 0 0 0 -0 HN )I " O O N N O 1-1178 2.04 517 2 Br 0 0 O HN N OH N N kO 1-1179 1.98 517 2 O 0 N HN N OH N NO8 1 478 2 a1-1180 1.58 478 2 LUOUJ [Table 2403 Retention Structure Compound Time [M+H] Method No. (m) O 0 N HN N OH N -1,NO 1-1181 1.43 492 2 N0 0 O o O- HN ) N O N N O 1-1182 1.76 502 2 N O O HN N O N NO K 1-1183 1.86 522 2 -CI O O 00 O NN NOO 1-1184 2.34 508 2 O 0 -1185H N .1N 49402 N N - kN O L- 1-1185 2.19 494 2 [Table 241] Retention Structure Compound Time [M+H] Method No. (min) O O H N 0 N N O 1-1186 2.28 493 2 o NO N 0 O NHN N 0 1-1187 2.32 480 3 O 0 NHN OH N N k,0 1-1188 2.09 494 2 O 0 HN N OH -- N N O 1-1189 2.05 479 2 0 0 O HN N 0O N N O N. 1-1190 2.34 493 2 [Table 242] Retention Structure Compound Time [M+H] Method No. (min) ___ O 0 O HN N O N N NO 1-1191 2.21 479 2 O 0 0 HN A N >KOH N N O 1-1192 2.02 465 2 O 0 HN N O -N iI N--:-O a 1-1193 2.32 475 2 0 0 O HN N OH N N O 1-1194 1.98 465 2 0' 0 0 B N -1 2 5 N N 01-1195 222 517 2 [Table 243] Compound Retention Structure No. Time [M+H] Method ________ (min) _ _ O 0 01N HN,
N
N N 01-1196 1.97 444 2 O 0 HN N 0 -- N N O 0 1-1197 2.44 495 2 0 0 N~O M A HN N 0 N N 1-1198 2.30 481 2 o 0 OT HN ),N -OH N N O 1-1199 2.11 467 2 -a 0 0 HN N OH 1-1200 2.12 461 2 [Table 2441 Retention Structure Compound Time [M+H] Method NO(m) 00 0 NHN NO N NU 1-1201 1.99 439 2 N I-22 .4 7 0 0 HN N O N N NO' 1-1202 2.44 477 2 O O X OHN N O N N O C 1-1203 2.59 479 2 O O O HN N 1 -1 204 2.04 522 3 N0 0 N N O C 1-1205 1.50 522 3 [Table 2451 Retention Structure Compound Time [M+H] Method No. (m ) o 0 N O HN N SOH N N O 1-1206 1.67 494 3 -CI O 0 O HN ) N ' OH NCI N N O I-1207 1.22 494 3 (; N -CI O 0 O HN N O N N O 1208 1.75 516 3 N O O O 1-1209 1.80 516 3 0 0 HN ' N 0 N N N 0 1-1210 2.61 465 3
N
[Table 246] Retention Structure Compound Time [M+H] Method No. (min) ___ -~HN ) N0 N 1-1211 2.67 485 3 'CI o 0 HN N OH 1-1212 2.35 451 3
I
o o HN N OH N 1-1214 2.20 461 3 2 N O HN )N -- OH N N N O 1-1215 2.63 465 3 [Table 247J Compound Retention Structure Cou Time [M+H] Method O 0 HN N 0N N N O 1-1216 2.74 479 3 O O N N 1-1217 2.41 479 3 a O N N 0 1-1218 1.77 481 2 N O O HNHNAO N N 0 1-1219 2.63 507 3 a 0 0 /I - HN N OH 1 A20 1N.9 ,a1-1220 1.96 465 2 [Table 2481 Compound Retention Structure Co Time [M+H] Method No. (min) O 0 HN N OH N NO, [-1221 1.54 467 2 O 0 O HN N OH N 5 N O N 1-1222 2.17 493 2 o o - HNX N SOH N N O 1-1223 2,28 437 3
I
O 0 0 NHN N OH N N O I-1 224 2.41 451 3
I.
O O O NHN Ni lOH 1-1225 1.86 466 2 [Table 249] Retention Structure Compound Time [M+H] Method No. (m ) 0 0 O HN N OH NN N O 1-1226 1.96 480 2 O 0 O- HNANr.QkOH N -N O 11227 1.40 474 2 o 0 O- N N SOH [N N O I-1228 1.17 474 2 NN O O O HN N AO N -O 1-1229 1.76 502 2 NN Y 0 O>% HN IN ,kO N -N O 1-1230 1.35 502 2 [Table 250] Compound Retention Structure Co u Time [M+H] Method No. (min) __ (;NA O O O HN N OH 1-1231 1.34 502 2 N O O HN N OH 1-1232 1.37 502 2 O 0 N HN NO N N1-1233 2.29 526 2 O 0 NQ OI-IN J N - Ox N N 01-1234 2.25 506 2 O 0 N H N A N NN N 01-1235 2.02 512 2 ci [Table 251] Compound Retention Structure No. Time [M+H] Method _________(min) ___ O 0 HN N O N 1-1236 2.30 513 2 -CI O 0 (DNHN) N --- OH NN 0 1-1237 1.98 492 2 N N- O 00 1-1238 1.50 516 2 HO<c 2 HN N N N , ,O O I-1239 1.72 439 2 0 0 O-a HNINiO I-1240 1.35 530 2 [Table 252] Retention Structure Compound Time [M+H] Method No. (min) N 0 0 A HN N O' O OH N N t 1-124 3 1.2 9 4 88 2 O OO 0 r HN Nt O k N IkN O 1-1244 1.24 493 2 NHN A N OH N 1-1245 1.23 522 2 0 00 Br N N"' OH N N 0 C 1-124 4 1.98 5 03 2 [Table 2531 Retention Structure Compound Time [M+H] Method No. (min) __ O 0 O HN N O N N N O 1-1246 2.30 497 3 o 0 0 HN N N N 1-1247 2.58 515 2 -CI Y- O 0 0 HNA N 'AO N- N NO K N N 1-1248 2.37 517 3 HN ) N O Y111-6 N 0I-1249 2.52 495 2 I-C 0 0 HN N O' N N O 1-1250 2.69 485 3
-CI
[Table 2541 Retention Structure Compound Time [M+H] Method No. (min) ___ 0 0 HN N N O clI- 1251 2.80 499 3 F O0 HN N O N N 01-1252 2.74 483 3 O O N N NO I- 1253 2.35 457 3 'CI F 0 0 HN N O N N O I-1254 2.81 503 3 -CI O O N N O N O 1-1255 2.47 471 3
I-:CI
[Table 255] Retention Structure Compound Time [M+H] Method No. (min) F 0 0 HN N OH 1-1256 2.50 469 3
I
F 0 0 HN N OH 1-1257 2.57 489 3 I-- CI F F F 0 0 HN N O N N O I-1258 2.40 491 2 0 N HN OH NIN NO- 'N.l 1-1259 1.28 508 2 o o cO NHN N OH 1-1260 1.25 516 3 N 1N O [Table 256] Structure Compound Retention Strctre o. Time [M+H] Method No. (min) __ O 0 0 HN N OH N N 01-1261 2.28 481 2 N O 0 X HN IkN - OH N N OH 1-1262 1.23 486 3 NOO 0 0 HN N OH N NO'- Cj 1-1263 2.02 499 2 'Y'0' 0 0 0 / HN
N"
t OH N N 0 1-1264 1.95 469 3 a 0' 0 0 HN ) N -- eOH O N N N 0O 1-1265 1.96 517 2
I-CI
[Table 2571 Compound Retention Structure Co u Time [M+H] Method No. (min) ___ y o- o 0 0 HN N">OH N N O 1-1266 1.81 489 2 'CI CI 0 0 HN N OH 1-1267 2.52 471 3 0 0 HN N OH ,- N i: N O 1-1268 1.97 479 2 0 0 0- HN AN -, OH 'NHN)N O H 1-1269 1.22 502 3 0' 0 0 HN N OH N N 01-1270 2.34 501 2
'--CI
[Table 2583 Structure Compound Retention Strctre o. Time [M+H] Method No. (min) F F F 0 0 HN N OH N N O 1-1271 2.13 477 2 N N O1-1272 2.17 511 2 O' 0 0 HN N 0 Nb N ; N 0- 1-1273 2.17 511 2 CI ?O O O1-1274 1.34 516 2 O O N HN N O N N O 1-1275 1.33 474 2 [Table 2591 Structure Compound Retention SrcueNo. Time [M+H] Method O(mn)O >-0 0 0 NN )4Nk I HN N 0 N N N 0 1-1276 1.84 464 2 NN N N 1-1277 2.55 485 2 1 I 0 0 N HN N 0H N N 0 1-1278 1.19 460 2 N-5 0 0 0 HN N OH N N O 1-1278 1.17 460 2 tN r-0' 0 0 H kN OH N N 01-1280 1.87 497 2
N
LVOOLj [Table 2601 Retention Structure Compound Time [M+H] Method No. (min) ___ ___ 0 0 OHN O N 0 N N 01-1281 2.26 499 2 'CI 0 0 HN N AO N N 0 1-1282 2.21 479 2 0 O HNA N t O N N O 1-1283 2.28 499 2 '-CI 0 0 OO O O HN N OH N I NO~) 1-1284 2.01 485 2 O 0 O N N OH 1-1285 1.89 451 2 [Table 261] CompundRetention Structure Compound Time [M+H] Method No. (min) ___ o 0 N NO 1-1286 1.95 471 2 'C1 F F F 0 N1- N ) Nl o N O 1-1287 2.82 453 3 - Cl FF 0 F N' N .kN'" 1-1288 2.83 454 3 F' CI 0 O O F N N O FF N O 1-1290 2.67 526 2 I--ci [Table 262] Retention Structure Compound Time [M+H] Method No. (m) N N -1291 2.07 443 3 -: CI A N 1-1292 2.05 444 3 'CI F 0 N k N N N N 0 1-1293 2.54 419 2 H F O O N N N N 0 1-1294 2.77 447 2 H F 0 N N 0 1-1295 2.65 433 2 H 1 [Table 263] Compound Retention Structure C ou Time [M+H] Method No. (min) ___ F O 0 N OkN N N 0 1-1296 2.45 462 2 -CI F 0 S A / HN N N N N 0 HN-N 1-1297 1.89 487 2 'CI F O O N N O 1-1298 2.76 483 3 F O O HN OH I- 1299 2.44 455 3 0 0 O HN N N 1-1300 2.40 507 2 [Table 264] Retention Structure Compound Time [M+H] Method No. (min) __ O 0 HN N O 1-1301 1.63 464 2 HN N O N 1-1302 2.10 477 2 O O HN N OH N N O 1-1303 2.08 479 2 A O HN N OH 1-1304 1.43 450 2 OO 0 HN AN OH N N1-1305 1.87 463 2
-
[Table 265] Retention Structure Compound Time [M+HJ Method No. (min) __ HN N O N N 01-1306 2.46 501 2 -CI Br 0 O O HN) N O N N 0 1-1307 2.52 561 2 O 0 0 HN N">AO' N N O 1-1308 2.60 515 2 -CI F F F 0 N 6 N N O 1-1309 2.44 491 2 O 0 -O~a HN N O N N O 1-1310 2.27 481 2 [Table 266] Retention Structure Compound Time [M+H] Method No. (min) F o No HN N O N N O 1-1311 2.37 499 2 N O HN N N N N 0 1-1312 2.43 495 2 o o 0~ H N N 0 N N N 01-1313 2.32 481 2 O O HN ) N 0 N N N O 1-1314 2.28 493 2 F o o -T It H N ) N N N 1-1315 2A5 519 2
-CI
[Table 2671 Compound Retention Structure Cou Time [M+H] Method . (m0) HN N O IN N 1-1316 2.34 513 2 -CI F F F 0 O HN N O 6 N N O 1-1317 2.52 511 2 CI O O ( NH N ) N O N N 1-1318 1.57 480 2 'Ci O 0 KNanHN N 0 N 1-1319 1.88 481 2 'CI O O HNN HN ) N 0 N N 0 1-1320 1.95 509 2
CI
[Table 268] CompundRetention Structure Compound Time [M+H] Method No. (min) _ __ O NO HN ) N 0 Sr N N 1-1321 2.02 500 2 N 'N 'CI NHN N O NO N NO [1-1322 1.59 508 2 -CI HN N O N N 0 1-1323 2.33 497 2 -CI HN N -0 N N O 1-1324 1.50 488 2 HN N N N 0 1-1325 2.25 477 2 [Table 2693 Compound Retention Structure Co Time [M+H] Method No. (min) N HN N 0 N N 0 1-1326 2.01 498 2 '-CI 1-1327 2.20 512 2 -CI CI O O HN N O N N 0 1-1328 2.42 513 2 IN NO N N 0- 1-1329 2.51 515 2 CI 0 crolt& HNA N XO N N O 1-1330 2.49 533 2 11 cl L9666j [Table 270] Retention Structure Compound Time [M+H] Method No. (min) ___ OHN ) N OA CtaN :0 N N 0 1-1331 2.46 495 2 CI 0 0 HN NO OH 1-1332 2.09 485 2 N CI 0 0 0 HN N->0OH 1-1333 2.16 505 2 -CI Br 0 T H N OH 1-1334 2.23 547 2 F F F HN NY OH N N O 1-1335 2.15 477 2 [Table 271] Retention Structure Compound Time [M+H] Method No. (min) O 0 HN N OH 1-1336 1.98 467 2
I
CI 0 0 HN N OH 1-1337 2.20 501 2 F 0 0 -O HN N OH 1-1338 2.08 485 2 N y0~ HN N OH 1-1339 2.13 481 2
I
N OH N N O 1-1340 2.03 467 2 [Table 272] Compound Retention Structure Co Time [M+H] Method No. (min) O 0 0 HN N OH < N 5 N zO 1-1341 1.99 479 2 C1 0 0 0-0 HN N OH I-N1342 2.28 521 2 CI F 0 0 HN NYOH 1-1343 2.17 505 2 IC' O = 0 HN N OH 1-1344 2.06 499 2 F F F 0 0 H N OH N N O 1-1345 2.25 497 2 -CLcI [Table 273] Compound Retention Structure Cou Time [M+H] Method No. (min) ___ O 0 HN N OH 1-1346 1.35 466 2 I- CI O 0 N HN J NOH NN N 1-1347 1.62 467 2 CI O 0 NHN N OH 1-1348 1.71 495 2 -CI O 0 HN ) N O H 1-1349 1.75 486 2 010 HN N OH 1-1350 1.37 494 2 '-Cl [Table 2741 Compound Retention Structure No. Time [M+H] Method No'_ (min) -C HN 'N OH (C) N NO0 1-1351 2.04 483 2 CI 0.0 N HN N *OH N N N O I-1352 1.28 474 2 o *o O HN N -OH -CN N N O I-1353 1.96 463 2 O 0 0 HN N OH N N O0 1-1354 2.22 487 2 -CI A-ac O 0 0 HN N NOH N N 01-1355 2.29 487 2
'-CCI
[Table 275] Compound Retention Structure o Time [M+H] Method No. (m ) N 0 0 O N N H I-1356 1.43 488 3 N N 0 CII -NN 0 0 OH N NO 1-1357 1.52 508 3 N NO 0 0 HN JN OH a 1-1358 1.70 536 3 0 0 HN N O 1-1360 2.39 481 2 a [Table 276] Structure Compound Retention Strctre o. Time [M+H] Method O O(m) 0 0 0 -~HN ) "- " N N O 1-1361 2.53 495 2 o' a 0 H N NtOH N N 0 1-1362 2.22 467 2 HN O
I-
o 0 0Q HN N -O N N 01-1363 2.71 529 2 O 0 0 HN N- OH N N 01-1365 2.14 467 2
N
[Table 277] Compound Retention Structure Co Time [M+H] Method No. (min) O 0 QO HN N OH N N 01-1366 2.46 515 2 -CI O 0 O HN N OH N N 01-1367 2.40 495 2 0 0OQHN Y Nh(ON N N NO 1-1368 1.65 536 2 CI O O 0 0 HN1 -- ' N NO 0 Na 1-1369 1.69 530 2 CI 0 0 A HN ) N 0 1-1370 2.93 519 3
ICLCI
[Table 2781 Compound Retention Structure Co Time [M+H] Method No. (min) CI 0 0 HN N O I- 1371 2.86 499 3 a CI1 0 0 HN N OH 1-1372 2.69 505 3 CC 0 0 HN N OH I- 1373 2.62 485 3 0 N 0 C 1-1374 1.43 522 2 O HN N O N 5 N 0 I-1375 1.84 550 2
-CI
[Table 2791 Structure Compound Retention Strctre o. Time [M+H] Method No. (min) 0 '0 0 1-1376 1.84 550 2 ICl N ONHN N'>O NJ N N O 1-1377 1.98 536 2 -C' HN N -O N1-1378 2.40 513 2 I- CI O0 0 11-IN IN N I rJNO 1-1379 2.34 493 2 HN N O N 0 1-1380 1.65 526 2
'CI
LUOc0t [Table 2801 Retention Structure Compound Time [M+H] Method No. (m ) 00 N HN N -'O N N O 1-1381 1.58 506 2
L-
O 0 N HN-f N OH O N N O 1-1382 1.77 484 2 -CI H N O HN N OH HOr N N - O 1-1383 1,51 502 2 C~I 0 0 N HNN OH 0N N 0 C 1-1384 1.94 498 2 H A O N HN ) N OH HO N N O c i 1-1385 1.65 516 2 [Table 281] Retention Structure Compound Time [M+H] Method No. (min) 00 N0 OHN ' N OH OaN N O 1-1386 2.24 501 2 -CI HN )N OH ON N 0 1-1387 2.18 481 2 N O HNA N OH NO 1-1388 1.55 536 2 O 0 NN 1 1 1 :5,HyAN OH N N 0 N. 1-1389 1.56 536 2 N 0 HN N OH crN - kN O' N.c I-1390 1.67 522 2 [Table 282] Compound Retention Structure Co Time [M+HJ Method No. (min) __ O 0Q O] HNN -OH N i N 0 1-1391 2.12 499 2 CI O N Q HN N OH 13N 0'I N WO , a 1-139 3 .0 512 2 O N NO I- 1 39 2 1. 30 4 92 2 OOuQ -19HN N.3 OH N1-1394 1.40 512 2 tN 0 Qn-aNN>3+ -- OH N HN -,INO a1-1395 1.31 492 2 [Table 283] Structure Compound Retention Strctre o. Time [M+I-I Method No. (min) __ 0 N -a N NO N 1-1396 1.51 536 2 0 NOO 1-1397 1.55 530 2 CI 0 N HN IkN 0 N N 01-1398 2.46 514 2 N O CI 0 N 0 )II N 0 N N 01-1399 2.54 534 2 -CI O H N O N N O 1-1400 2.58 493 3 [Table 284] Retention Structure Compound Time [M+H] Method No. (min) ___ ___ o 0 HN N - O N O 1-1401 2.63 513 3 c 00 w HN N N N1-1402 2.69 507 3 o N N 01-1403 2.74 527 3 -CI 0 H HN ) 1NtO NO 0 CI 1-1404 1.30 522 2 0 N kNO O OH - 1-1405 1.24 502 2 [Table 285] Compound Retention Structure Co u Time [M+H1] Method ________ (min) _ _ O 0 0 HN N AOH N N O 1-1406 2.06 465 2 O 0 O HN N -AOH N N O 1-1407 2.11 485 2 'CI 0O O HN NJ OH SN& N N' O 1-1408 2.22 493 2 O HN IkN O~j H I-C LCI-1409 2.28 513 2 I C1 O O HN N OH -4 2.21N N500 a1-1410 2.28 513 2 [Table 286] Compound Retention Structure No. Time [M+H] Method (min) Cl 0 0 c Oi HN N OH 1-1411 2.29 520 2 'CI 0- 0 OHN N- OH N N O 1-1412 1.82 512 2 I-ci NN 0- C HN N 1 OH - NO 1-1413 1.33 522 2 N -acl O CI 0 0 N - NHN N OH H N N 1-1414 2.01 534 3 H0 0 I-41N N 466 3 1-1415 1.79 466 3 [Table 287] Structure Compound Retention Strctre o. Time [Mi-H] Method No. (min) H00 NN H '' N N 1-1416 1.87 502 3 0 0 H HN kN H N5 1-1417 1.63 488 3 o o H N N OH 1-1418 1.55 452 3 H 0 0 -- yN~t H N ) - 04il N N kN 0 1-1419 2.26 528 3 H CI 0 0 -- yN _& H N I O NH N OH 1-1420 2.01 514 3 [Table 288] CompundRetention Structure Compound Time [M+H] Method No. (min) ___ 0 0 0 HN N 0 N N'N 1 O 1-1421 2.19 511 2 ON 0 0 0 HN N O N [N O -1422 2.34 545 2 CI OH O O _O HN N O NNO 1-1423 2.05 531 2 -CI OH O O H N N N N 1-1424 1.91 497 2 Ot 0 0 0 0O HNA N N"0.4 N N1-O -1425 2.17 539 2 N N0 [Table 289] Retention Structure Compound Time [M+H] Method No. (min) __ CI 0 0 N N O NAN O a 1-1426 2.87 499 3 CI 0 0 NH N N OH 1-1427 2.55 471 3 HN AN"N)OH N N O 1-1428 1.86 483 2 -OH O O HN N OH N N ":O 1-1429 1.59 469 2 O 0 HN N OH N N O 1-1430 2.06 531 2 cN [Table 290] Compound Retention Structure No. Time [M+H] Method No. _(min) OH O O o HN N OH N N O 1-1431 1.80 517 2 N -CI N OH O 0 O N N 0 NI 1-1432 1.66 518 2 0 0 O HN ' N' O*' NNO 0 N 1-1433 1.94 483 2 HO N
HN
9
N"
9 O NI N 9 < O 1-1434 1.76 538 2 C1 CIO N N - 0' 1-1435 2.86 533 2
'CI
[Table 291] Compound Retention Structure Co Time [M+H] Method No. (min) CI O N N 1-1436 2.77 513 2 0 O N NkO
H
2 N' NAO I-1437 1.39 333 2 CI 0 0 -~HN IkNY N NON> O I-1438 2.84 533 2 CI CI 0 0 HN YN
NNLQ
1-1439 2.78 513 2 OH 1 0 H N J N --- OH k,1-1440 1.47 504 2 [Table 2921 Retention Structure Compound Time [M+H] Method No. (m) N OH 0 0 O / HN N OH SN NO 1-1441 1.45 510 2 C CIO N N-O OH 1-1442 2.58 519 2 CI CIO N O NJOH NI N -Nt* 1-1443 2.51 499 2 C1 0 0 H N I OH NN 1-1444 2.51 499 2 NH N E OH N N 1-1445 2.62 519 2
-CI
[Table 293] Retention Structure Compound Time [M+H] Method No. (min) ___ ___ o o N N O 0 1-1446 2.23 382 2 CI 0 0 I HN N O y N NANt 1-1447 2.74 513 2 CI 0 0 HN N 0N N5 N-- O N 1-1448 2.75 525 2 CI 0 0 O H N %O -N : N-- -O 1-1449 2.55 519 2 CII A N0L N Z h hI 0 O HN N N Ca N N O- H 0- N"N '0 1-1450 2.64 658 2 [Table 2943 Structure Compound Retention Time [M+H] Method No. (min) ___ Cl 00 HNO OH I-1451 2.45 497 2 O O 1-1452 2.36 513 2 CI ON HN N 0 1-1453 2.32 493 2 O -O o o N HN NY O N N N O 1-1454 1.66 526 2 C1 0 0 CN SNHN NYO N NO 1-1455 1.58 506 2 a [Table 2951 CompundRetention Structure Compound Time [M+H] Method No. (min) ______ O O O HN N OH 1-1456 2.11 499 2 O HN N OH Lf N 1i-1457 2.03 479 2 o o N H N OH 1-1458 1.39 512 2 CI O = 0 N HN N 2 OH N N 01-1459 1.32 492 2 O 0 HN N O 1-1460 2.15 449 2 tN [Table 2961 CompundRetention Structure Compound Time [M+H] Method No. (min) ___ CI 0 0 oN 9k N-<K, O O- HN N OH 1-1461 2.18 491 2 CI 0 0 H N N OH N - N--Nt 1-1462 2.48 499 2 0 0 HN N OH 1-1463 1.88 435 2 N CI 0 0 O O HN N 0 N NANO Y III& N- O1-1464 1.67 500 2 0 0 H N N O H N q Ni:N'<O 1-1465 2.15 497 2
CI
[Table 2971 Retention Structure Co Time [M+H] Method No. (m) O 0 NHN N OH 1-1466 1.76 471 2 '-CCI O 0 N HN N OH NY Nt 1-1467 1.85 500 2 CI 0 0 N HN N OH 1-1468 1.76 480 2
-
N HN ' N l, OH SNN-NOO 1-1469 1.84 500 2 CF N HN ) N "IOH SJ N N -O 1-1470 1.75 480 2 [Table 298] eCompound Retention Structure Co Time [M+H] Method No. (m) f N Y HN N - OH 1-1471 1.99 514 2 Cl 00 HN N OH NXA N* N -O 1-1472 1.86 500 2 C1 o o N HN N OH S a N 1 N -'-:O 1-1473 1.63 466 2 cl NN0 0 Or NH NN "- O I- 1474 2.39 536 2 HNA N 0 O N NO 1-1475 2.56 528 2 [Table 299] Structure Compound Retention Strctre o. Time [M+H] Method No. (min) ___ CI O O HN N OH 1-1476 2.15 522 2 Cl 0 0 HN NOH KY N '. NNO " O H 1-1477 2.31 514 2 O O Lf T' HN N O N Nr~0 1-1478 2.28 494 2 H NO L H N HN N 0 1-1479 2.33 514 2 Cl 0 0 O HN N 'NI N NA 0 0 1-1480 2.18 529 2
'CI
[Table 300] Compound Retention Structure Co Time [M+H] Method No. (min) O 0 O NHN NOH N -NN<O 1-1481 1.94 515 2 CI O 0 HN N OH Cr N-~ % I-1482 2.03 480 2 O 0 O HN N OH 1-1483 2.08 500 2 -C1 O 0 N HN N O 0 ~ N N Ot 1-1484 1.50 512 2 ICl C1 0 0 H N OH N NN> O 1-1485 1.49 486 2
N
[Table 3011 Compound Retention Structure No. Time [M+H] Method (min)____ O 0 O HN N OH NN NA N>N~ 1-1486 1.31 498 2 Cl CI 0 0 HN N O N' 1-1487 2.40 483 2 N o 0 HN N O N 1 N -O 1-1488 2.36 489 2 CI NONO NH N OH 1-1489 2.13 469 2 0 0 HN N OH 1-1490 2.14 475 2 [Table 302] Compound Retention Structure Co Time [M+H] Method No. (min) __ CI 0 0 HN N O I NNO> 1-1491 2.44 483 2
I
CI 0 0 HN N OH N N N I 1-1492 2.19 469 2 HN N O N--1493 2.48 485 2 CI 0 0 HN N OH N O 1-1494 2.25 471 2 N CI 0 0 O HN N OH N19 5 1-1494 2.91 415 2 [Table 303] Compound Retention Structure Co Time [M+H] Method No. (min) __ CI 0 0 .N N OH H N O H 1-1496 2.26 513 2 CI 0 0 CI NHN N 0 NtKN)-O I-1497 2.50 477 2 cI 0 0 HN N 1-1498 2.28 501 2 C1 0 0 C A
-
HN N 0 Nl 6 NAN .<O 1-1499 2.51 521 2 C1 0 0 C N N OH CI 1-1500 2.24 463 2 [Table 304] Structure Compound Retention Strctre o. Time [M+HI Method No. (min) ___ CI 0 0 S NHN N OH C1 N NN-'0 I- 1501 2.29 507 2 I-1502 2.02 487 2 CI 0 0 HN N O N N O1-1503 2.63 511 3 O O HN NA N N N 1-1504 2.56 491 3 S 0 0 NHN I NO N N-1505 2.41 514 3
-CI
[Table 305] Compound Retention Structure Cou Time [M+H] Method No. (min) ___ s 0 0 N / HN N O N N 1-1506 2.32 494 3 O O HN ',N OH1 N N1 -1507 2.30 483 3 I CI 0 0 0 HN N -, OH N N O-1508 2.22 463 3 S O0 N HN N OH N N 1-1509 2.03 486 3 -CI S O Ol -. 0 0 N / FHN AlN - O H N N O 1-1510 1.94 466 3 [Table 306] Compound Retention Structure Co Time [M+H] Method No. (min) CI 0 0 S N N 1-1511 2.49 497 2 NS 0 o N O -1512 1.78 524 2 CI 0 0 HN N OH 1-1513 2.24 483 2 O 0 1-1514 2.00 465 2 0 0 O HN N O 1-1515 2.06 502 2 [Table 3071 Compound Retention Structure Cou Time [M+H1] Method _________ (min) _ _ O 0 O H N OH 1-1516 1.76 451 2 O 0 NHN N OH N 1-1517 1.84 488 2 s0 0 N N~ ~ 1-1518 2.27 500 3 I-acl S O O N N~< 1-1519 2.17 480 3 0 0 N HN N OH N N O 1-1520 1.92 472 3
CI
[Table 308] Compound Retention Structure Co Time [M+H] Method No. (min) 0 0 N HN 'A' N-)< OH NKNkO 1-1521 1.84 452 3 O N 0 0 O1-1522 2.42 532 3 O N N O NN 0 0 N N O I-1523 2.51 552 3 C1 I-1524 1.7 30 0 N NH NN N -1 524 1.67 308 2 N 1-1525 2.05 428 2
I-
[Table 3091 Compound Retention Structure Co Time [M+H] Method No. (min) __ F F F 0 0 :- N N 0 N N 0 1-1526 2.20 496 2 N CI 0 0 HN N 0 OH N NA-- t 1-1527 2.32 515 3 N O O CI 0 0 HN N 0 IF N NNL O 1-1528 2.67 517 3 CI N O 0 N HN N OH N N1O I-1530 2.07 497 3 Cl LVOO I] [Table 310] Retention Structure Compound Time [M+H] Method No. (m) CI 0 0 HN N OH F N 11N -Nt 1-1531 2.41 503 3 CI 0 0 HN N OH OH N NN..I% 1-1532 2.05 501 3 N o o N1 H-1533 1.84 524 2 0c N O- HN N OH 1-1534 1.85 518 2 N I'NN' O OH N 0 0 O)-a |N Nj NN OH 1-1535 1.38 510 2 i-ci [Table 3111 Retention Structure Compound Time [M+H] Method No. (min) ___ OH -N 0 0 O-N OH 1-1536 1.36 504 2 Oa O NHN N 0N SN N "O 1-1537 2.44 526 3 Cl O O O HN N N N --O , c 1-1538 2.78 537 3 O O c 1-1539 2.58 540 3 H N OH N N 1-1540 2.11 506 2 '- CI [Table 312] Retention Structure Compound Time [M+H] Method No. (min) 0 N N 0 S N O O 1-1541 1.84 426 2 CI fl-s 0 Nt H N )N O N N NO 0 I-1542 1.81 528 2 I CI NHN IkN - N N 1 -1543 1.801 485 3 CI SOo 0H N HN IkN OH N N O I-1544 1.75 488 3 -C 00 N OOH N HN N' O S N N O 1-1545 2.34 506 3 [Table 3131 Retention Structure Compound Time [M+H] Method No. (min) 0 0 O', 0HN N N i; N N Ok N 1-1546 2.71 517 3 N HN N 0
-
SA
1-1547 2.49 520 3 H N 0 1-1548 2.07 485 2 CI O 0 HN N OH 1-1549 1.86 471 2 CI 0 N 0 ON N 0 N N O I-1550 2.02 499 2 [Table 3141 Retention Structure Compound Time [M+H] Method No. (min) 0 O N HN N OH N N " O 1-1551 1.99 509 2 C1 0 O N HN N OH N N O 1-1552 1.63 498 2 -CI 0 O N H N' N AOH N N O 1-1553 1.76 512 2 CI 00 N ~jOH Na HN 'kN OH 1-1554 1.57 478 2 O O HN N OH N N O 1-1555 1.92 489 2 [Table 315] Retention Structure Compound Time [M+H] Method No. (m) 00 N H OH 1-1556 1.68 492 2 0 N Nt ON 1-1557 2.14 370 3 CI /s 0 0 N HN N 04 t (N NN O 1-1558 2.42 508 3 S 0 O N HN N O N N-z:O 1-1559 2.38 506 3 /s 0 0 N HN N N>%%OH N N -<N)O 1-1560 2.10 480 3 [Table 316] Retention Structure Compound Time [M+H] Method No. (m ) S 0 N /J HN N OH 1N N O -1561 2.00 478 3 Is 0 0 N HN N - IO N NNO 1-1562 2.49 508 3 s 0 0 N HN N X-AOH N 1N O -1563 2.10 480 3 O o ~ HN N <ON N NNO00 I- 1564 2.49 483 3 I- C CI O0 HN ) N N lF N' NNQ 0 CN 1-1565 2.54 550 3 [Table 3171 Retention Structure Compound Time [M+H] Method No. (min) __ 0 o X
HN
t N N N - O 1-1566 2.22 496 3 'CI O 0 o HN N N F N N O H F F NC 1-1567 2.59 564 3 O O O HN N N)1 C 1-1568 2.25 510 3 o o N~a HN N O S N N O 1-1569 2.37 514 3 CI s0 0 N / N N N N N HI-1570 1.71 465 3 [Table 318] Compound Retention Structure Cou Time [M+H] Method _________ (min) _ _ o 0 N HIN kN O SN 1r N - O 1-1571 2.28 494 3 O 0 N HN N O 5 St9 N N O I-1572 2.52 528 3 'C1 o o N HN NxO N O 1-1573 2.43 508 3 O O HN N O NNO I- 1574 2.73 525 3 C O 0 O HN N O N NLO 1-1575 2.66 505 3 [Table 319] Retention Structure Compound Time [M+H] Method No. (m) N O N H N )IN O H 1-1576 2.06 500 3 -CI o 0 N HN N OH 1-1577 1.98 480 3 NN O 0 N > HN N OH S N N -'-O 1-1578 2.21 514 3 CI 0 HN N OH 1-1579 2.70 471 3 O O N HN N OH S I N :- N - O 1-1580 2.21 494 3 [Table 320] Retention Structure Compound Time [M+H] Method No. (min) O 0 HN N OH N NNO 1-1581 2.45 511 3 '-:Cl O 0 HN N OH N N " O 1-1582 2.38 491 3 CI 00 HN N OH N-ONNANO N, N N - O= -1583 1.24 511 2 CI N 0 0YK ~~N H N kOH NX'AN N H-584 1.15 483 2 I-to 1-1585 1.99 528 2
CI
[Table 3211 Retention Structure Compound Time [M+H] Method No' (min) H N OH CI 1-1586 1.89 526 2 0 0i HN N - OH N N O 1-1587 1.87 510 2 N NO O 1-1588 2.09 517 2 CI O O N H N ' N 1 kO H s N N -O 1-1589 1.66 486 2 CI S HN N -j OH MN N NO 1-1590 1.90 485 2
CI
[Table 322] Compound Retention Structure Co Time [M+H] Method No. (min) ___ NNo N N N NO .O H 1-1591 1.53 469 2 CI NHN Nt O OH NN I: LCI-1592 1.64 483 2 CI N HN N QO N1N N O 1-1593 1.20 483 2 H CI O O N HN N OH N?& N N -O H 1-1594 0.99 455 2 CI o O HN N OH 1-1595 2.02 518 3 N N - ' [Table 323] Retention Structure Compound Time [M+H] Method No. (min) oN 0 O HN NAN'XOH N N N> 'N.O 1-1596 2.04 498 3 N 0 HN OH 1-1597 1.54 494 3 ci NO HN N N'O N N N'O 1-1598 1.27 464 2 O N' HN NAN'X OH N N -' NO 1-1599 1.16 494 2 ,-ct OH NN HNtKNAN'A NH 1-1600 1.49 523 3 -iN' lAc [Table 3241 Compound Retention Structure Co Time [M+H] Method No. (m) OH N HN ) N NA O1-1601 1.48 517 3 -<DN O
S
2 N N - 0 I-1602 2.09 472 3 CI O CI O NkHN
--
<N NO 1-1603 2.29 514 3 -CI 0 O N N O 1-1604 2.67 525 3 CI 0 0 HN ',N N N -Nt a1-1 605 2.07 499 2 [Table 325] Compound Retention Structure Cou Time [M+H] Method No. (min) ___ CI 0 0 HN HAN N Q N 1-1606 2.09 499 2 CI 0 0 H N OH N NN&JO 1-1607 1.85 485 2 0 l 0 O- HN N OH I- NA-- t 1-1608 1.80 471 2 0 o - HNX N , OH N N N O O 1-1609 2.27 469 3 CI 0 f HlN N N OH N N 01-1610 1.84 458 3 C1 [Table 326] eCompound Retention Structure Co Time [M+H] Method No. (m) CI 0 NH -~HN -kN ,N N "N NkQ 0 1-1611 2.56 504 3 NN 0 H N N - 0 1-1612 1.94 499 3 CI o O N / HN N - N-< S N N _tO H c 1-1613 2.00 513 3 CI 0 0
-
N N NNO H N 1-1614 2.61 518 3 0 O O H N IkN ' N HNH F F F C 1-1615 2.15 540 3 [Table 327] Compound Retention Structure Co Time [M+H] Method (min) CI 0 0 N HN N NH 2 1-1616 2.47 484 3 F N o H Fl0fZIJ. HN N* N, F I-1617 2.11 526 3 0 N FI~HN IkN ' H S ~< N N N -OO __.. OH 1-1618 1.72 474 3 S O N HN N 'OH N NO 1-1619 1.56 458 2 CI 0 O HN N' OH F rF /N N- z O F 1-1620 1.83 499 2
'CI
[Table 328] Retention Structure Compound Time [M+H] Method No. (min) N OH 0 O O O-1 HN N N ; N O -1621 1.90 466 3 s 0 N HN N OH N N -:O 1-1622 1.67 472 2 CI 0 HN N"^A OH l N N O I- 1623 2.06 493 2 0 'Cl O- HN ) N ' TOH 1-1624 2.15 485 3 CI 0 O / HN NA- OH \N N 1-1625 1.91 469 2
'CI
[Table 329] Retention Structure Compound Time [M+H] Method No. (min) CI 0 0 O 1 HN N OH N 1-1626 1.96 522 2 CI 0 HN NO N I O 0O N NO 1-1627 2.65 505 3 ('N O O HN A Nt''OH N N O 1-1628 1.37 508 2 I a'ci SO N HN N -1629 2.42 508 3 O 0 0 HNN NOH NNO 1-1630 2.28 477 3
'N
L-f /J [Table 330] Compound Retention Structure Co Time [M+HJ Method No. (min) ___ ___ HN OH N NkO 1-1631 2.01 480 3 N0 O- HN N OH N 4%'NN O 1-1632 1.18 508 2 N 'FAkO NN 1-1633 1.89 455 2 1-1634 1.34 260 2 H N 1-1635 2.00 542 2 L-
CI
[Table 331] Retention Structure Compound Time [M+H] Method No. (min) __ 0 HN N 0 N N-t-O 0
-K
7 I-1636 2.35 553 2 -C CI 0 N HIOH 1-1637 2.24 521 2 '-Cl 0 HN AN0 6N ON00 1-1638 1.51 570 2 0 m 0 HN AN NIO O N N O 1-1639 1.49 556 2 CI 0 Ia 01-1 640 2.35 570 2 [Table 332] Retention Structure Compound Time [M+H] Method No. (m) 0x< O HN N 1 N N O 1641 2.33 556 2 IOcl F F F 0 L-N N O N O O 1-1642 2.10 524 2 CI 0 N N JN OH -c IN N OH 1-1643 1.56 502 2 0 -CI N N O OH 1-1644 1.94 513 2 F F F 0 IN N OH N "O OH 1-1645 1.68 484 2
CI
[Table 333] Structure Compound Retention Strctre o. Time [M+H] Method No. (m) F F &F O F I HN IkN - O N N O 1-1646 2.34 555 2 I-ac CI F 0 0 F' HN N - O N N O 1-1647 2.37 555 2 CI 0 0' N N OH N 1-1648 1.57 556 2 O& N OH I-1649 1.56 542 2 CI O O HN N 0 N N 1-1650 2.12 497 2 Cl [Table 334] Retention Structure compound Time [M+H] Method No. (min) ___ IF F ' 'H N N O H N N O 1-1651 2.02 527 2 - C F O O F HN ) N" OH F N N Ot 1-1652 2.07 527 2 -CI O O O HN N OH N N O 1-1653 1.90 483 2 'CI 0 HN HN N NAN VNNH 1-1654 1.39 470 2 '-CI 0 O NN N H H 1-1655 2.46 422 3
CI
[Table 335] Retention Structure compound Time [M+H] Method No. (m) 0 o A HNX N NH2 0 1-1656 2.15 468 3 11 >Cl 0H 0HN N N N 0 1-1657 2.22 482 3 CI' 0 H H N NOH N N 0 O cl 1-1658 2.10 512 3 0 HN NAN NH2 1-1659 1.72 457 3 '-Cl 0 <N 7 HN X Nfl N 0 1-1660 1.79 471 3 Cl [Table 336] Retention Structure Compound Time [M+H] Method No. (m) <N$/ HN N '---OH sN N 00 Cl 1-1661 1.68 501 3 N OO HN N OH N N N < O 1-1662 2.10 512 3 11 S O N HN N OH N N 1O -1663 1.63 458 2 0 0 O HN ' N-''-O0' N N O 1-1664 2.13 485 3 0m H N~ HN ) N N 1-1665 2.01 513 3
'CI
[Table 337] Retention Structure Compound Time [M+H] Method No. (min) o H N N O 1-1666 2.28 510 3 I O 0 0 O- HN IkNI- 0, o~ N N I- 1667 2.33 441 3 O O H N ' N '-A O' N N 1-1668 2.11 401 3 O O HN N OH N N 1-1669 1.86 387 3 S O O N HN ltN NH 2 N N O 1-1670 1.73 471 3 C1 [Table 3381 Compound Retention Structure Cou Time [M+H] Method 4-s a 0 N HN N NH2 N N 1-1671 1.65 451 3 o o N HN N "'O N N O 1-1672 2.36 452 3 O HH HN N
N
1 NN- O 0 1-1673 2.28 510 3 o oa O O N HN N" OH s N N O 1-1674 2.07 438 3 O O O ~ HN N OH 0 N )N O'A 1-1675 2.31 488 2 0 [Table 3391 Retention Structure Compound Time [M+H] Method No. (min) O O O HN N OH
N
1 N O 1-1676 1.95 388 2 N 0 ~ 1-1677 1.78 457 3 0 O ' N) N O H I 1-1678 1.95 413 3 0 NHN N O N N O 1-1679 1.61 386 2 NIN -CI N O 0 HN N OH N 1-1680 1.95 414 2 N1 [Table 3401 Retention Structure Compound Time [M+H1] Method No. (min) O O HN N . OH N N~ N 0 1-1681 2.51 476 3 Cl HN N OH HN s N ' N O 1-1682 1.13 508 2 'C 01 H NNZY)OH N N 0 uc 1-1683 1.46 497 5 H N , NNH N ) N O H MN K~ctN N~ N I-1684 1.52 501 5 -CI OH O O N N AN S O H I-1685 2.63 545 5 IaCI [Table 341] Retention Structure Compound Time [M+H] Method No. (m) F F N H N OH NN N- O N' 1-1686 1.49 509 5 -CI N HN NtANOH N INI'N 1-1687 1.56 496 5 N NO I-1688 2.46 548 5 00 N N )N O OH SI- 1689 1.57 494 5 CI N N ON -OH N N I-1690 1.43 523 5
CI
[Table 3421 Retention Structure Compound Time [M+H] Method No. (m) N HN N OH HS-JQNA HSSN N - O 1-1691 1.48 480 5 HO N 0H NHN N J"-OH NN N_ N1 N 1-1692 1 34 480 5 O O O\ N HN N O SjN NAN O 1-1693 2.44 482 3 0 0 N HN KN N,)<OI S N N O 1-1694 1.93 402 3 O O
I
O N HN N O SAN N O 1-1695 2.14 468 3
I-
[Table 343] Retention Structure Compound Time [M+H] Method No. (mi) 0 O <N HN N KOH S N N O 1-1696 1.64 388 3 O O N HNA N- & O sN N O 1-1697 2.55 466 3 O O HN N N N 1-1698 2.41 475 3 O O N HN N OH sAN~ NO I- 1699 2.26 452 3 N N O1 I-Cc 1-1700 2,62 511 3
CI
[Table 3441 Retention Structure Compound Time [M+H] Method No. (min) Is 0 N /' HN NO N N O O I-1701 2.39 515 3 CI HN N N N I-1702 2.25 428 3 CI /S 0 NO O HN N O N FN O N N I-1703 2.41 442 3 ac HN NN H 1704 2.37 497 3 lla cl1-1705 2.12 500 3
CI
[Table 345] Retention Structure Compound Time [M+H] Method No. (min) __
N
o o N HN IkN OA / N N NO 1-1706 1.77 479 3
N
o o N HN' NOH ' N N - O 11707 1.55 465 3 'N 1-1 708 2.37 524 3 ,a CI 0 0 H H N N NH N NO 0 1-1710 2.23 496 3
-CI
[Table 3461 Retention Structure Compound Time [M+H] Method No. (m) /s 0 N HN) N NH2 N. N O 01-1711 1.96 499 3 CI HO N N0 O
HN
3 f N , OH N N -NO 1-1712 1.62 482 3 HO N N0 O- -a HN KN OH N N O 1-1713 1.68 496 3 , >Cl HO N O a- N H N OH I-1714 1.26 526 2 10 O NK N-j HN N NH N N OH 1-1715 1.34 437 2 Cl .. Nglg [Table 3471 Retention Structure Compound Time [M+H] Method No (mi) F O O N N 0 1-1716 2.01 479 3 0 0 0 %$THNN V 1-1717 2.23 507 3 o o N HN' N «OA S N N X< O 1-1718 2.77 478. 3 CI 0 0 N HN N O 1N N O-1719 2.94 512 3 O O N HNJ% N - <O I-iN N 2.6 8O a 1-1720 2.56 478 3 [Table 3481 Compound Retention Structure Co Time [M+H] Method No. (m) o 0 CI/ N HN N O o N N 0 N- I-1721 2.83 470 3 CI 0 N H N N"' AOH S N N O 1-1722 2.52 472 3 O O N HNk N "- OH SA N N O 1-1723 2.47 464 3 CI 0 0 N HN N' AOH N N kO 1-1724 2.67 498 3 S' N N 0 0 N HN N OH s N ",N - O 1-1725 2.27 464 3 [Table 349] Retention Structure Compound Time [M+H] Method No. (m) 0 0 CI\ N HNA NN> OH 0 NN O 1-1726 2.57 456 3 F 0 0 O NH N OH 1-1727 1.66 451 3 0 F 0 0 O NHN N" <'" OH IH 1-1728 2.48 501 3 HH F 0 0 H N NrNWOH N N "Nt 1-1729 2.39 475 3 H -0 0 HN' NN>E OH N N ',N Ok
-
1-1730 1.20 464 3 [Table 350] Compound Retention Structure C ou Time [M+H] Method No. (min) HO ,, N 0 o HN N-'<TOH N N kO OH [-1731 1.26 512 2 N. C N N HN N -OH 1-1733 1.90 496 2 lctc N 0 HN kN---OH 1-1733 1.90 510 2 I-ci (N A-- 0 N HN N O | N--4A'H 1-1734 1.72 526 2 N-NcO OH -ac 0 HN_1 NHI ~ 0 N [ N O -1735 1.64 523 2
I-CI
[Table 3511 Retention Structure Compound Time [M+H] Method No. (m) N OH OO N H N N N NN O 1-1736 1.57 452 2 NS O N HN N N N >%N'O 1-1737 1.81 414 2 -C1 S 0 0 N /' HN N N H N N 1-1738 1.97 499 3 lc~ci N O N N N H 1-1740 2.42 504 2
CI
[Table 352] Retention Structure Compound Time [M+H] Method No. (min) N cl 1-1741 1.58 542 2 HN N O -ON 1-1742 1.61 514 2 H 0 N N N O O 1-1743 1.70 469 5 'CI N N N O O H N 1-1744 2.10 511 5 -Cl H HN N OH N:r% N N" O 1-1745 1.30 469 5
CI
[Table 3531 Retention Structure Compound Time [M+H] Method No. N'I ~HN N .0OH b N NN O 1-1746 2.28 500 5 'C1 o u0 HN N OH N -k N NNO -- ?: l I-1747 2.67 537 5 0 .0 O HN N OH NN O-~ HN N OH CN 1-1749 2.26 522 5 lc~Cl N N HN N OH I,-1750 .33 N463 3 1-1750 2.33 463 3 [Table 3541 Compound Retention Structure Co Time [M+H] Method No. (min) ___ HNo F O O -, O N H N Nk VO H N NN Q 1-1751 1.95 474 3 N . 1110 0 N - O" 1-1752 2.26 486 3 Cl O N O P1 1-1753 2.32 524 3 0 NN N K% A 0K C1 1-1754 1.40 508 3 F O O O N H N OH N N 1-1755 1.46 460 3 HN 0 [Table 3551 Compound Retention Structure Co Time [M+HJ Method No. (m ) N0 0O O0 HN kN ,OH kN NNO 1-1756 2.10 470 3 N' NN N- - O H -77 18 0 cl 00 oo o HN NN COH N - NN0 OH 1-1757 1.88 500 3 N -N O 0 0 HN N N 0 0 H HN k N--
O-
'N N N" O 0 1-1760 1.95 452 3 [Table 3561 Compound Retention Structure Co Time [M+H] Method No. (min) o 0 N HN N O S N N O 1-1761 2.42 478 3 O O SHN NOH N N N ANO O 1-1762 1.73 438 3 O O N HN IkN . OH S N N O 1-1763 2.16 464 3 F 0
N
1 A HN ) N - 0\_- 0 Ac c 1-1 764 2.20 622 2 H 0 FI HN 'kN 0 N N 01-1765 2.30 497 2 NC1 [Table 357] Retention Structure Compound Time [M+H] Method No. (m) O 0 HN N OH N N -NtJ 1-1766 2.05 483 2 F 0 HN N Q OH N NNS--O 0 N 1-1767 2.00 502 2 S 0 0 N HN )NKNH2 1-1768 1.91 485 3 CI 0 N HN N N N N O I- 1769 2.21 467 3 CI O .0 HN N = OH 1-1770 2.63 564 5
CI
[Table 3581 Retention Structure Compound Time [M+H] Method No. (m) 0 .0 N HN N OH N- N -'O 1-1771 2.05 496 5 o0 . HN N O OH 1-1772 2.05 511 5 -CI 0 0Q NH N OH 1-1773 2.28 509 5 C 0% N HN N OH N NN O 1-1774 1.92 548 5 -CI O 0C H % N N FN N O OH I-1775 1.56 484 5 Cl [Table 359] Retention Structure Compound Time [M+H] Method No. (m ) O O0 H HN N 0 C 1-1776 2.09 569 5 11:::Cl HO N O O HN 4N8OH a N N " O I i 1-1777 1.87 498 5 N N.HN 'kN 0 o IC 1-1778 1.81 512 5 -CI O .0 O MHN N O o= NNH N O O 1-1779 2.22 526 5 ~C F 0 .0 F N N HN N OH S>% N ;N - O 1-1780 2.24 584 5
CI
[Table 360] Retention Structure Compound Time [M+H] Method No. (m) 00 HA O~aHN IkN 1,O H N N <KO I-1781 1.85 468 5 CI O 0 0 HN HN N OH H NN H N N N-O 0 .1-1782 1.66 513 5 0 0 FF0 HN N OH F F O a N&:-N O0 F C 1-1783 2.68 559 5 O t NO H NO jO H 1-1784 2.13 497 5 Cl HN 'kN l OH N N1O 1-1785 2.82 539 5 Cl [Table 361] Retention Structure Compound Time [M+H] Method No. (m) H0 0 NHN N OH 1-1786 1.69 500 5 C HN N OH O N N N O I-01787 2.41 584 5 0 OH OH 0 0 N -1788 1.51 494 2 CI OH -N N S , 1-1789 1.34 482 2 NONO N N ' N O N IN N-- -O1-1790 1.53 480 5
CI
[Table 362] Retention Structure Compound Time [M+H] Method No. (min) ______ 0 uO HI k INA O N N N OH 1-1791 1.41 511 5 CI HN) N OH ,- Cl1-1792 2.35 528 5 NN HN N OH H N-N NO I-1793 1.82 543 5 F N a NH N ' ' OH I-a cl -1794 1.89 537 5 o 10 N HN N 0 N N N H I- 1795 1.52 497 5
CI
[Table 3631 Retention Structure Compound Time [M+HJ Method ON N OA OH N N1-1796 2.41 483 5 CI 0 (N OH O HN N rOH - N N _O 1-1797 1.25 510 2 c 0 NHN IL N OH 1-1798 2.03 472 3 0 N Q AN kOH -N l 1-1799 2.11 510 3 0 A OH N0 1 494 OH N.1-1800 1.29 494 3 [Table 364] Retention Structure Compound Time [M+H] Method No. (m) 0 0 NHN N N NN NO 1-1801 2.11 440 3 o 0 HN N \N'NA N<0 I-1802 2.50 436 3 o o HN .. JN '-%O' oN N LO 1-1803 1.95 452 3 o a N HN N O N, N N - O 1-1804 2.19 484 3 0 N2 N NH2 SN NO 1-1805 1.87 471 3
CI
[Table 365] Retention Structure Compound Time [M+H] Method No. (min) O 0 N HN NO O N N O 1-1806 2.17 440 3 0H NN 0 1-1807 1.95 485 3 -CI 0 H N NHN ) N -- O H cl 1-1808 1.83 515 3 F O O HN AN N- OH I NAN-O 1-1809 2.33 463 3 O .0 O N NK OH N N' O H 1-1810 1.94 485 5
CN
[Table 3661 Compound Retention Structure Co Time [M+H] Method No. (m) 0 ~0 N N HN IN N N O
H
2 N C 1-1811 1.81 525 5 0 .0 O N HN N OH N NA N0 1-1812 1.57 559 5 N NHN N OH =N N N - O H HNC 1-1813 1.49 485 5 A O N HN N OH N N - O ,-a c 1-1814 2.40 546 5 7 0 ,0 N HN) N" .OH 1-1815 2.44 546 5 Cl [Table 367] Compound Retention Structure No. Time [M+H] Method ______(min) 0 0H N 0 HN N "OH 1-1816 1.90 547 5 O N HNXN 0 N N O N 1-1817 2.81 525 5 i HN N OH HN NN NN<O 0 N 1 1-1818 1.53 513 5 H 0 9 O z:N L N AIkN 2K HN N -OH NC 1-1819 1.63 498 5 rNN A N XOH NAN -O 1-1820 2.03 485 5 C1 [Table 368] Compound Retention Structure Co Time [M+H] Method No. (m) 0 .0 HN N -OH %~CL:: N - N Ok 1-1821 2.41 509 5 -CI O 0 HN N OH O N N: N - O H C 1-1822 1.60 501 5 0 .0 IN N ON OH H - Cl1-1824 1,81 519 5 0 <0 HN N OH O N / N NO O 1 -1823 1.82 510 5 O .0 ONHN N 'j0H N1-1824 1.28 519 5 -cCI [Table 3691 Retention Structure Compound Time [M+H] Method No. (m) OH 0 O b 5-- N kN
-
OH a N I-kN - O 1-1826 2.03 495 5 'Ci 0 .0 O HN N -O IN N O 1-1827 2.86 533 5 I-aCI 0 0 HN N OH [-1828 1.77 512 5 -C1 0 .0 NN YOH 1-1829 2.59 562 5 HN ' 3 NYKOH N N -O 1-1830 2.00 483 5
CI
[Table 370] Retention Structure Compound Time [M+H] Method No. (m) O O HN 'kN .. OH N - N - O o 1-1831 1.92 483 5 CI Br HN N OH C1I-1832 2.63 559 5 N N O N OH 1-1833 1.91 471 5 CI 019 N HN N OH N N O - 1-1834 1.57 480 5 N - CI N 1-1 835 2.05 484 3 Aci [Table 371] Retention Structure Compound Time [M+H] Method No. (min) ___ ___ o 0 N HNNk o N N O 1-1836 1.93 456 3 O O HN N kNAN. OH 1-1837 2.22 422 3 o 0 HN kN N' OH oNA NO 1-1838 2.17 397 3
I'
o 0 N HNA N OH NJ NANAO 1-1839 1.92 470 3 HN 0 0 HN N O -1840 2.66 539 3
CI
[Table 372] Compound Retention Structure Co Time [M+H] Method No. (m) 0 HN IkN 0 N N N 0 -\ CL 1-1841 2.43 527 3 -. 0 HN HNOH 1-1842 2.19 499 3 Cl N ' O0 O N HOOH 1-1843 1.77 540 2 ci OH O HN 1N N N O 1-1844 1,41 480 2 lccl N HN N OH F4-F /NANtO OH F 1-1845 1.85 515 2
CI
[Table 373] Retention Structure Compound Time [M+H] Method No. (min) ___ ___ NN O SNH, 0 O AK N N O 846 1.71 479 2 NI <N 0 oO O HN N NNO 1-1847 2.18 480 2 OH NN N N -1848 1.61 466 2 0 O HN N OH N N H'O OH N: 1-1849 1.98 487 2 O ' N N N O 1-1850 2.10 440 2
CI
[Table 3741 Retention Structure Compound Time [M+H] Method No. (min) 0 OH NH HOI a 1-1851 1.79 544 2 N H N ' N,, 0 kN N N - -- OI-1852 2.06 542 2 -ac CI 0Jt0 0 FN N O 1-1853 1.55 502 2 Cl 0 O11 HN N " -O I-1854 2.46 513 3 HN N OH N N OH 1-1855 1.93 473 3 [Table 3751 Retention Structure Compound Time [M+H] Method No. (m) o 0 N N DZN fNH2 N c -1856 1.96 509 3 00 cl 1-1857 2.03 523 3
N
0 Zr -a NN ~' N---'OO cl I-1858 1.92 553 3 N.-' 0 O H. HN N' N N O I-1859 2.39 481 3 ci F O O -O NH N O I-1860 2.64 489 3 H H [Table 3761 Retention Structure Compound Time [M+H] Method No. (min) F 0 0 -, O N H N N * O H ~ N NrNAK O 1-1861 2.04 451 3 F 0 0 N N O 1-1862 2.25 461 3 HH 0 - N N K#JN NAN O 1-1863 2.07 508 2 ci 0 0 N>~0 I- 1864 2.26 472 5 0 0 N N 0 1-1865 2.28 442 5 [Table 3771 Retention Structure Compound Time [M+H] Method No. (min) ___ o 0 IN ) N 0 N Ila cl-1866 2.31 442 5 'CI O O N N N 0 1-1867 2.29 442 5 -CI 0 0 N N N N O I-1868 2.31 442 5 Cl F 0 1-1869 2.12 476 5 CI 0 H2NN N17 N 0 N- c 1-1870 2.06 492 3 [Table 3781 Retention Structure Compound Time [M+H] Method No. (min) 0 N O N) ~N'a NAN -k H H 1-1871 2.16 506 3 0 07- HN kW <INAN-tO 1-1872 2.42 539 2 CI OCO HN ) N 0 O N- 'O , 1-1873 2.38 515 2 Ny - HNAN'-Q" N2N C OAO H ON 1-1874 2.23 550 3 HN N N N c I-1875 2.05 563 3 [Table 379] Compound Retention Structure Co Time [M+H] Method No. (min) 0 HN N NN' tO 00 1-1876 2.07 556 2 ItCl F 0 0 O / HNtN OH N N 1N O -1877 2.10 511 2 -ac O HN N OH N NN> -0 1-1878 2.11 501 2 O O --- N HN N OH o N N O I-1879 1.69 442 3 O NN 1-1880 2.57 507 3 -ac [Table 380] Retention Structure Compound Time [M+H] Method No. (m) 0 HO 0 0 'WH O t tIt -1 881 2.25 493 3 CI 4F N N OH F 1-1882 1.88 529 2 0 OH 0KK NNH 1-1883 1.26 466 2 _4N F 0 0 O N HNN N0A- O 1-1884 2.23 513 3 F F 0 HO N H HN 1-1885 1.80 494 2 A-ci [Table 381] Retention Structure Compound Time [M+H] Method No. (m) CI 0 HN N 0 N N-N' 0 V\ 1-1886 2.54 535 3 Cl CI O HN N N N O O I-1887 2.56 .521 3 CI N OH O- HN N N N-O I-1888 1.86 467 3 Cl 0 0 O0 HN IN"" N N-ktO 1-1889 2.50 521 3 cl O O HN NO N N N 1-1890 2.22 480 3
HI
[Table 3821 Retention Structure Compound Time [M+H] Method No. (m) o 0 HN IkN - A O- N A 1-1891 1.81 438 3
H
2 N 0 a o 0 H N O NH 1-1892 1.86 452 3 N -A 0 0 HN ) N" O" HN N-N O 1-1893 1.21 489 3 0N HO O 0 O HN N N )N NO 1-1894 2.22 507 3 ci O O HN N A OH N N 1-1895 1.95 466 3
HI
[Table 383] Retention Structure Compound Time [M+H] Method No. (min) ___ No
NH
2 N HN NH 119 N O-1896 1.60 465 2 N NO 0 rN y) N ,,OH H yH N N O 1-1897 1.54 509 2 N NO 0 NN F 0 -YO N HN N O N< O 1-1898 2.02 547 2 ON 1-1899 2.58 529 3 IlaCI N N O-YrO HN N--lrNH2 HO ON c 1-1900 1.43 495 3 [Table 384] Compound Retention Structure Co Time [M+H] Method No. (m) 0 HO NO cl 1-1901 1.49 509 3 0 H NI 0 ~HN NJ--{OH HO N N 0 NZ, 1-1902 1.40 539 3 CI 0 HO O Q O NN N - - 0 cl 1-1903 1.81 510 3 0 07 HN' J N 0 ON O N N N O 1-1904 1.71 508 3 0
N-
0 O HN UN OH O&N HN OH 1-1905 2.11 489 3
CI
[Table 3851 Retention Structure Compound Time [M+H] Method No. (mi) N NHO OH 1-1906 2.04 495 3 C N HOH 0- N N -- O O H I-1907 2.01 481 3 'CI F F 0 0 F0O HN-'N- OH N N O 1908 2.00 513 2 F,,N, F F O HN N OH N N -1909 1.98 497 2 C1 F O O O HN NOH 1-1910 2.04 485 3 F
F
[Table 386] Retention Structure Compound Time [M+H] Method No. (mi) F 0 0 O HN N kO# N 1 N'l"O 1-1911 2.76 505 3 O 0 HN N N N N O H ci 1-1912 2.00 484 3 O O KIi H 1 l C l 1-1913 2.06 484 3 O 0 OHN )N- - NH2 N NtO CI 1-1914 1.94 470 3 O O N N ONNH2 , .1l 1-1915 2.00 470 3 [Table 387] Compound Retention Structure Co Time [M+H] Method No. (min) F O O C ~r HNtkN 'AKH N N O 1-1916 2.41 477 3 0 HN N -OH N N O 1-1917. 2.08 457 3 0 /CNK0 HN N"%NX OH r N N 0 N c 1-1918 2.14 457 3 0
NN
0 H NH1-1 919 2.29 479 3 aci 0 O HN )NOH N N O NH [-1920 1.61 438 3
OI-N
[Table 3881 Retention Structure Compound Time [M+HI Method No. (min) N 0 0 HN N N O 1-1921 1.03 475 3 0 N CI 0 0 N N N O 1-1922 2.57 509 3 N N N - O I 0 HO I-1923 1.96 465 3
-
I 0 0 S HN IN N -- O 1-1924 2.71 501 3 O H2N O I-1925 2.05 492 3
CN
[Table 389] Retention Structure Compound Time [M+H] Method No. (min) 0 'N O a5- HN N % ( NH 2 N:N rx K- NN-L"O o) cl 1-1926 1.18 493 3 0 N 1)" NN NAN'O 0 1-1927 1.21 507 3 0 O 0 HN N O NN O -C 1-1928 1.16 537 3 0 0 -N NO N N 01-1929 2.23 437 3 0 N 0 ~ H N A 'Nc 1-1 930 2.29 471 3 [03451 [Table 390] Compound Retention Structure Co Time [M+H] Method No. (m) O 0 HHN N N Nx O c 1-1931 2.07 496 2 0 HO 0 #"T kHN OH NN .- <N N 1O o 1-1932 1.62 496 3 CI o 0 HN N OH NJN N<N1O 1-1933 2.32 495 3 -C) 0 O OH c 1-1934 1.49 494 3 O H 3 NA- HN N OH N N .O OH 1-1935 1.61 484 2 ACl [Table 391] Retention Structure Compound Time [M+H] Method No. (min) 0 HN N OH N NO o ICLCI i1-1936 2.07 457 3 F O O O/ HN ) N- O N --1N -- O 1-1937 2.46 539 2 0 1 O 0N NO 1-1938 2.21 541 2 CI o H HN N 0H N N OO 1-1939 2.35 471 3 arHN N N NH, N N~ N0O N1-1940 1.93 456 3 [Table 3921 Retention Structure Compound Time [M+H] Method No (mi) 0/ 0 0 ok? 1-1 941 2.17 498 2 N N )-0 lcic 0 H N N 0 N 1-1942 1.99 470 3 CI 0 Oa HNAN-YOH N N 00 1-1943 2.12 457 3 Cl O NH2 1-1944 1.37 493 3 0 N N 0.4 50 3':YN N1-1945 1.42 507 3 [Table 3931 Retention Structure Compound Time [M+H] Method No. (m ) 0 N N0NH2 1-1946 1.98 456 3 NN o N 0 S HN ) N 0- N NN- '0 1-1947 2.47 513 2 Cl 0
LIIY
0 O- HN (NyN 1-1948 2.06 470 3 0 CI H N ~HN NO N IN N O0 1-1949 1.73 454 2 I- CI 0 0 H1j N -~ HN Nr ",AOH N NNO N 1-1950 1.74 468 2
,--CLCI
[Table 3941 Structure Retention Structure Compound Time [M+H] Method No. (m) F O O 0 0 O- HN Jt NrNAOH tN N O 1-1951 2.12 511 2 cI 0 O 0 NHN N OH cl 1-1952 1.54 499 2 F 0 O HN N' OH N N O 1-1953 1.92 479 2 N N OH O H N N OH -1954 1.10 524 2 cl N O N HN NH N N O 1-1955 1.18 436 2 cl [Table 3951 Structure Retention Structure Compound Time [M+HJ Method No. (m) F O O F0 HN IkN " N H, 'a N N <O 1-1956 1.87 512 2 CI F O, O F - O- - HN kNl- N HNH N N O 1-1957 1.91 526 2 ci 0 0 N N O HN F 1-1958 2.15 594 2 F 0 HN N NH 2 ZN N O O 1-1959 1.86 498 2 CI F F 0 f HN N N N N O 1-1960 1.89 512 2
CI
[Table 396] Retention Structure Compound Time [M+HJ Method No. (m) F O H F 0 _,kF ON Ny F Q N N- 0 1-1961 2.14 582 2 aCl HO HN NH o N N -- O 1-1962 1.11 452 2 ci HO 00 O NH NHO I-1962 2.25 527 2 0 N %~O1-1963 1.74 484 2 S: HN J N -- OH Nc c 1-1 964 2.22 499 2 0 HN 0r N- c 1-1 965 2.25 527 2 [Table 3971 Retention Structure Compound Time [M+H] Method No. (m) o 0 N X HN N rN
NH
2 NNO C1 I-1966 1.61 467 2 o 0 H NHN N N CI 1-1967 1.65 481 2 HO N 00 1-1968 1.84 470 2 0 N NO 0 N l 1-1969 2.02 493 2 0 o NHN N OH HO N10 . 4 N-~ c 1-1970 1.57 471 2 [Table 398] Retention Structure Compound Time [M+H] Method No. (m) 0 HN ' N 0- HO N NO1-1971 1.90 513 2 0 O H NH N OH N NNH O H N -1972 2.00 513 2 NNHN C
<
1 1 HNN 1-1973 1.86 516 2 ICI HN N OH N N N- OH 1HN 1-1974 1.81 487 2 N 'J N Nt O H 1- -1975 1.63 448 3 [Table 399] Retention Structure Compound Time [M+H] Method No. (min) __ NNo 0 0 O 11 HN ) N - OH N N[-O 11976 1.38 494 3 HO N NH2 ,- ct 1-1977 1.50 495 3 HO N 0 0 H!JN N N N.- 0 Nc 1-1978 1.56 509 3 0 H HO o OH N H0 - C 1-1979 1.46 539 3 HN N N-'O N N O) 1-1 980 1.32 537 3 LUt''±UJ [Table 400] CompundRetention Structure Compound Time [M+H] Method No. (m) 0 HN NH ON Ot 1-1981 2.05 387 3 -CI -S 0 N HN N N N 1-1982 2.20 554 2 Ci S 0 N~ HN N - OH N N OH 1-1983 1.94 514 3 CI N 1-1984 2.12 545 2 N, 0 0 N N NHN OH 1-1985 1.88 505 3
CN
[Table 401] Retention Structure Compound Time [M+H] Method Structure No. (mi) _______ No HO O 0 O HN N OH N N O 1-1986 1.05 496 2 cl OO HN N OH N N O 1-1987 1.08 510 2 cl 0 O Ofl HN N N N O 1-1988 2.45 507 3 O O O HN N N- N NO I-1989 2.20 459 3 <O O N HN N - O S N N O i -1990 2.43 486 3 [Table 402] Retention Structure Compound Time [M+H] Method No. (m) CI 0 0 N N 1-1991 2.82 508 3 HO O O O HNA N- N N O 1-1992 2.18 493 3 =0. CI
H
2 N SO O H I- 1993 2.10 528 3 aci 0 0 N HN N OH I-1994 2.01 458 3 HO O O-a HN N-OH N N %N' O 1-1995 1.10 510 2 acl [Table 4031 Retention Structure Compound Time [M+H] Method No. (m) 0
H
2 N 0 HN 0 N1-1996 1.67 492 ~-)N N- 0 aci 0
H
2 N HN1-1997 1.47 494 2 ON H ci F F F0 HN IkN' N OH I-N1998 2.01 556 3 C1 F O H 0 HN ) N N -- OH N N O I-1999 1.99 542 3 00 N 1-2000 2.29 559 2 [Table 404] Retention Structure Compound Time [M+H] Method No. (m) 0 O OHN N ON N N O 1-2001 2.15 531 2 I O O
HN
t kN~" N H NOHO 1-2002 2.02 475 3 OH O OK 0 H N KN N 1-2003 1.84 431 3 I Cl O O OHN 1 Ne"f-OH >6N NO OH I-2004 1.84 491 3 0 O HN N N N O cl 1-2005 2.22 545 2 [Table 405] Retention Structure Compound Time [M+H] Method No. (m) O O HN HN N N 01-2006 1.97 461 3 Cl CI 0 0 O HN N OH N "- NN- O 1-2007 2.46 479 3 N O0 HN O N- N 5 N Oz -I -2008 2.29 481 3 ICt H2N O0 O0 HN NAW kN N N - O 1-2009 2.07 492 3 ci 0 o 07? NAN',OH 1-2010 2.10 443 3
CII
[Table 4061 Retention Structure Compound Time [M+H] Method No. (mi) NH cmin NH 0 V1-2011 1.83 493 2 N N-O NH IC O NHN 0H f N1-2013 1.88 473 2 N N a 1-2014 242 499 3 NHN C 0 0 N 1-2015 2.46 521 2 0A 0 [Table 4071 Retention Structure Compound Time [M+H] Method No. (m) OH -N O 1-2016 1.92 467 3 I-cl H HN HO O NN 01 1-2017 2.11 507 2 OH 0 A HN N N N-JO 1-2018 1.34 466 3 CII O N N) N Nt N 1-2019 2.37 492 3 0 l 0A N N N NH2 1-2020 2.30 478 3 [Table 408] Retention Structure Compound Time [M+H] Method No. (min) N HNA' -- N 1-2021 2.02 471 3 C1 N HN3%N~H OHO 00 O N NOH -1N H N O N-02 1.71 468-3 1-2023 2.26 487 3 Is 0 N HN N O O N NI O 4 1-2024 2.31 554 2 HN N O NI NNO 1-2025 2.33 525 2 I C1 [Table 409] CompundRetention Structure Compound Time [M+H] Method No. (min) 7s 0 N / HN N OH t N N' O 1-2026 2.04 470 3 0c OHN N OH N NNO 1-2027 2.05 441 3 CI O ON I NANLO 1-2028 2.48 487 3 0
HN
1 N 1-2029 2.48 487 3 O N N 1-2030 2.35 473 3 N...I9 II [Table 410] Compound Retention Structure Co Time [M+H] Method No. (min) __ NNo. 0 HN 1-2031 2.35 473 3 N N 400 0 HN '< N 1-2032 2.02 508 3 N N- NhQ 00 0s N N>-'>HN 1-2033 2.15 508 3 CI 0 HO 111P 0 [- NN-" -2034 2.14 473 3 nNH HO 0 - HN NI"' 1-2035 2.13 473 3 O-N NAN -K- [Table 4111 Retention Structure Compound Time [M+H] Method No. (min) ___ N OH 0 O O O\0 H N -N N O 12037 2.20 513 2 CI~ 0 H N -N N O 1-2038 2.13 524 2 0 CI H N) NA N>O O< 1-2039 2.08 510 2 CI HN N 00 N N NO 0 CN -2040 1.93 550 2 - - ---- I MIIIII [Table 4121 Structure Retention Structure Compound Time [M+H] Method No. (m) O HO 0-K HN) N kN N N YO [-2041 1.93 499 2 Cl H N HN N OH N N NO 1-2042 1.69 440 2 -CI H N ~ HN O OH4 N 1-2043 1.58 470 2 C1 0 N HN N OH N N1O -2044 1.49 466 2 CI O O CI HN N OH 1-2045 1.97 415 5
N
[Table 4131 Retention Structure Compound Time [M+H] Method No. (min) _ __ O O CHN N" OH 1-2046 2.00 415 5 CI O O 6 HN ) N" OH N N O 1-2047 2.02 415 5 O O O HN N 'J " OH N N-2048 2.02 453 5 VQ N O 1-2049 2.06 457 5 CI O O CHN N "AOH NN N 1-2050 2.30 449 5 a [Table 4141 CompundRetention Structure Compound Time [M+H] Method No. (min) __ CI 0 0 HN Nk N'A OH N IN 1-2051 2.19 429 5 F 0 0 HN N OH 1 N ANO 1-2052 2.09 461 5 O O - O q FHN N " OH N N O F 1-2053 2.10 461 5 CI 0 0 FH N N'O t OH N NO [-2054 2.15 433 5 0 O HN' N OH N NO -2055 2.45 507 5 F F
F
[Table 415] Retention Structure Compound Time [M+H] Method No. (m) OH 0 Ol HN N 0 KN N O 1-2056 1.26 446 3 0 0 F N IJk N-.' 1-2057 2.32 525 2 O- HN N 1-2058 2.42 493 3 N NN.I-h
N
0 N 0 -~ja HNNl 1-2059 2.42 493 3 ac O 0C0 K0 $HN O 1-2060 2.01 459 3 <IN
N
[Table 416] Retention Structure Compound Time [M+H] Method No. (m) HO 0 N0 O HN N 1-2061 1.99 459 3 N NO 1-2062 1.84 494 3 -ACI HO 0 1-2063 2.08 479 3 Z-C1 HN 0" HO O O HIN 'iN^ N -N O 12065 2.19 479 3 CI- - [Table 4171 Retention Structure Compound Time [M+H] Method No. (m) O 0 HO H N 'N l 1-2066 2.02 511 2 ci 0 0 1-2067 2.38 508 3 ICI HN NO 00 0 N 9 ON O 1-2068 2.61 545 3 0 00 H N N N N~' 0 [-2069 2.16 511 2 CI 0 O HN N OH N N "N O OH 1-2070 1.72 471 2
CI
[Table 418] Compound Retention Structure C ou eTime [M+H] Method StrutureNo. (mi) 0 HN N 0 N N O I' 1-2071 2.27 525 2 CI 0 $ HN N OH N N tO OH 1-2072 1.80 485 2 I-ac CI O~ HN N O~Q N N N 1-2073 2.45 539 2 CI 0 HN N ' OH N N 1-2074 2.17 455 3 N OH O HN N' N N - O 1-2075 1.60 480 2 ,>Cl [Table 419] Retention Structure Compound Time [M+H] Method No. (m) 0 0 HN 1-2076 1.99 488 2 N ' OH 0 o D-2077 1.69 580 2 CI N OHO 0 NOH HN N 1-2078 1.71 474 2 NN OH 0 N z-01-2079 1.26 496 2 F F F 0 0 N A<N -tO 1-2080 2.48 527 5 Br LU34b [Table 420] CompundRetention Structure Compound Time [M+H] Method No. (m) F F F 0 0 z HN N* O OH NENIO 1-2081 2.54 517 5 F F F F F 0 0 HN N OH N N "-O 1-2082 2.28 463 5 F F F 0 0 HNk N*' OH N KN O 1-2083 2.29 467 5 F F F F 0 0 HN N A OH N N O 1-2084 2.44 483 5 CIN IF F F 0 0 HN N OH N NO 1-2085 2.30 463 5 N N O [Table 421] Retention Structure Compound Time [M+H] Method No. (m) F F F 0 0 FHN N OH N N O 1-2086 2.26 467 5 F F F 0 O NCHN N -AO H N N O 1-2087 2.39 483 5 IF FF O O BHN ) N 'AO H N N O -2088 2.42 529 5 IF F F 0 0 N HN C!NN "TOH N N N-'-O 1-2089 2.48 497 3 F F F 0 0 N HN) N OH loN N O 1-2090 2.57 497 5
CI
[Table 4221 Retention Structure Compound Time [M+H] Method No. (m) HN Nt OH N NO 1-2091 1.21 482 5 0 0 Or HN N-%>OH N N O0 1-2092 1.25 496 5 N O HN IkN OH ) N N O 1-2093 1.19 508 5 F C 0 N O HN N OH N N O 1-2094 1.26 500 5 0.. HO N NA 0 0N 1-2095 2.17 494 3
N
[Table 4233 Retention Structure Compound Time [M+H] Method No. (m) ON N N O O' HN IkN- N N O 1-2096 2.30 481 3 cl N / HN N OH N N O OH 1-2097 1.82 460 3 V-s0 N HN N OH IN NN N O 1-2098 1.97 430 3 0 N OH 0 NKLNNO1-2099 1.38 480 2 -a N--'-A '-OH 0H k II1-2100 1.29 460 2 [Table 424] Retention Structure Compound Time [M+H] Method No. (min) O NHO F N N O1-2101 1.86 497 2 Cl N OH O O N OH 1-2102 1.4 446 2 N OH O 0 O NH I-2103 1.65 480 2 NH IC 00 N HN ' NH 1-2104 1.64 457 2 ON NO NN A 0 O HN IN 1-2105 2.00 508 2 10ci [Table 4251 Compound Retention Structure Co Time [M+H] Method No (mi) 0 o N 0 O ) N- ' - 2 1 6 1 9 0 4 8 8 2 0 0 N NH2 0 0 N NO -- 1-2107 1.79 483 2 o N NH OH N N O HN N N N O 2108 1.84 467 3 F 0 O O yN N > ,O 1-2109 2.47 592 3 cl N1 N 1-2110 2.05 491 3
F
[Table 4261 Compound Retention Structure Co Time [M+H] Method No. (min) O NN 0 0 O HN N N ~ >O1-2111 2.16 492 3 N NO F N OH 0 HN N ) N 1-2112 1.85 478 3 ICF 0 -C( N 0 00 00 1213 27 598 2 N N O g NN CI HO N 11 NIk - 1-2114 1,62 480 2 HO 0 NN 0 H IL, -- 1-2115 1.78 494 2 O-a N--'-N - [Table 427] Retention Structure Compound Time [M+H] Method No. (m) HO N 0 0 HN < N- 1-2116 1.70 474 2 N-O OH 00 - N N _OH 1-2117 1.38 500 2 N NA-'-t HO N 00 O OH 1-2118 1.52 486 2 C-aI H2N O NN -A 0 O 1-2119 1.84 493 2 N NN'-O A CCl NN NH 2 O A N NAN 1-2120 1.73 477 3 NN
F
[Table 4281 Compound Retention Structure Co Time [M+H] Method No. (min) 0 NN OH O O HN1H N 1-2121 1.57 460 2 F H NyO HN N ,N%%%'OH N ~t N IIN 0k" c 1-2122 1.49 492 3 -s HN N 1-2123 2.25 494 3 N OH N N &O 1-2124 1.84 466 3 N O HN NA N tN O 1-2125 2.34 481 3
C
[Table 429] Retention Structure Compound Time [M+H] Method No. (m) 0 0 HO HN N "
O
T H N -: N "O 1-2126 1.40 397 5 0 0 0 NHN>Nk N IOH 1-2127 1.37 478 2 O O O NHN N"^ OH s -N N - O 1-2128 1.56 462 3 0 O HO 5,N HN N- AOH ZNAN 'C - N N '%O [-2129 1.35 448 5 O O HN N OH N - N N Ok 1-2130 2.17 475 5 [Table 430] Retention Structure Compound Time [M+H] Method No. (m) O 0 HN AN -AOH HO N NAN#O 1-2131 1.74 447 5 O 0 ON HN N ,N>OH N N A O 1-2132 1.54 476 5 O O N HN A N ^ OH sN N -- O N0 1-2133 1.52 454 5 O 0 HN AillN AOH NN NtO H 1-2134 1.81 434 5 O O N HN ) N OH N N O 1-2135 1.62 432 5 [Table 431] Retention Structure Compound Time [M+H] Method No. (min) 0 0 HN IkN" OH N N N N O 1-2136 2.11 432 5 0 0 O-0 rN 14zHN N 'J " OH S -N N O 1-2137 1.96 462 3 0 0 NH 0 S HN IN' 1-2138 2.04 512 3 ci H N N N N 1-2139 2.19 506 3 ci OH 0 0 HN flNH 1-2140 1.19 446 2
N-
[Table 4321 Retention Structure Compound Time [M+H] Method No. (min) __ 0 No OH OH 0 N1-2141 1.41 484 2 ci s 0 N / HN N OsN- ' I N N NANO 0 1-2142 2.20 500 3 Cl -S N H N )N O N N O O 1-2143 1.92 486 3 0 0 0~ 0 N HN N' N N O I-2144 2.14 508 3 H 2 N " N 0 NN- 1-2145 2.05 493 3 I-ci [Table 4331 Retention Structure Compound Time [M+H] Method No. (m) 0 HO O 0 N, N )N O N N% 1-2146 1.93 494 3
FC
0 N S y HN H 1-2147 2.53 542 2 N )N N> -O I-cI 0 MJ0 N S N 1-2148 2.41 528 2 ON NO N N ) O 1-2149 2.25 497 3 0 No d 0 0 - N N'' - 1-2150 2.23 497 2 O\N N- O
CI
[Table 434] Compound Retention Structure Co Time [M+H] Method No. (min) 0 OH N S HN N - - 1-2151 2.04 514 2 0 OH 0 A H II 1-2152 1.94 483 2 N< N NO 0 r_ OH NH 1-2153 1.96 500 2 O N NO O N ac 0 Na / HN N O' N
N
0 0 Nt- H N N 0O v1-2155 1.99 494 2 [Table 435] Compound Retention Structure No. Time [M+H] Method (min) s'O N HN N -O N IlN O' 1-2156 2.13 508 2 N 0 0 4NHNkNI 1-2157 2.15 522 2 ci 0 0 0 N / HN ) N -OH N N O 1-2158 1.90 480 3 N HN IkN -OH N N O 1-2159 2.06 494 3 0 f 0 0 0 HN N 'N N )N-'<O 1-2160 2.32 522 3 aci [Table 4361 Retention Structure Compound Time [M+H] Method No. (min) O OH NI 0 OH 0 O HN N 0 N N N O 1-2162 1.93 508 3 c S H N / HN N * N OH N% N Ot 1-2163 1.28 487 3 I-:C CI 0 NN OH 0 N 1-2164 1.75 495 3 'q CI O HN x
H
2 N N O 1-2165 1.75 493 3
I-CI
[Table 4371 Retention Structure Compound Time [M+H] Method No. 0 N- NH2 k O N HNIN -N N O 1-2166 1.45 465 2 I-CI SA O F F F 0 N HN N -,OH x N N LN O 1-2167 2.16 498 2 CI F F F S O NN HN N OH N N t<N O OH I-2168 1.99 528 2 FN F F Is 0 N HN N OH N N"O OH 1-2169 2.02 542 2 0 O HNA N NN* N O HO O CI 1-2170 2.06 469 3 HO I c [Table 438] Compound Retention Structure Copne [MTm+H] Method No. (min) __ 0 o HN N N N> O 1-2171 2.09 455 3 HO CI No N NN NNO 0 1-2172 2.16 495 2 O O, Oa HN'N 0 N ON Jg NO N N 01-2173 2.25 506 2 O O OO 0 NN 1-2174 2.11 506 2 0 N O- HN ) N N N O 1-2175 1.95 492 2 HO 0 [Table 4391 Retention Structure Compound Time [M+H] Method No. (min) ___ 0 O / FHN Ol N N N - N "O 1-2176 2.02 491 2
H
2 N 0 0 OHN 'kN-^ N -T N 5 N- O HO O 1-2177 1.64 492 2 0 N 0 ~~~ HN A N-'N N O >NAN-O
H
2 N 1-2178 1.84 491 2 N O HNN N 0 N IN- O <I 1-2179 2.24 473 2 N 0
N
0 0 0 -- aZIi~ NAN 1-2180 2.28 488 3 LVOUVJ [Table 440 Retention Structure Compound Time [M+H] Method No. (m) 0 HO N O 1-2181 2.06 474 3 N CI 00 X N'J N 01 1-2182 2.66 535 3 s0 0 HN N ON N N N O 1-2183 2.45 528 3 C
-
N OH 1-2184 2.39 521 3 N N O 1-2185 2.15 514 3 Cl [Table 441] Retention Structure Compound Time [M+H] Method No. (min) 0 N C HN NrN- 1-2186 1.93 509 3 - NA Nt 0 N'% 0 N O HN0 N N N-, 1-2187 2.27 512 2 0 r_ O ON 0~ HN N ON N -' 1-2188 2.25 512 2 CI OH N 0 S HN 1-2189 1.84 484 2 N N N'O lcCl 0 OH O N N N NA N-tO 1-2190 1.92 484 2 NH N
CI
[Table 4421 Retention Structure Compound Time [M+H] Method No. (min) 0 0 S N o K )H N- 1-2191 2.32 528 2 NO HN 00 0 H 1-2192 2.09 511 2 ci OH S N 0 2 HN N-O 1-2193 1.97 500 2 Z-1 I lcic 0 -OH HN 0 HN 'fN--N. 1-2194 1.74 483 2 o N N c <c o o HN N N N O 1-2195 2.64 524 5 I-cl [Table 443] Structure Compound Retention Strctre o. Time EM-iH] Method No. (min) H N CI 0 O HN N-N N 1 N O 1-2196 2.41 523 5 cI OHN
N
O NA1-2197 1.81 472 5 IOcl HO O N N HN ' " N N 1-2198 1.58 441 2 cN N, N 0 OHN ) N-' N N -O 1-2199 1.89 469 5 I-ci ON N 0 N N O 1-2200 2.04 469 5 ci [Table 444] Compound Retention Structure Co Time [M+H] Method No. (m) N 0 H N 1-2201 1.54 478 5 N :, -220 1.9 483 5 N~ O~ H I N- -2203 2.198 507 3 CI 0 H N 0 ON a HN IN 1-2204 2.59 508 3 O NH O 0 0 N1N 1-2204 2.19 507 3 0 NN cK -, 0 HN I NA -'-- 1-220 5 2.44 508 3 0 -- N -- [Table 4451 Compound Retention Structure Co Time LM+H] Method No. (min) __ 0 0 HNo O ANtKN"tO 1-2206 2.22 509 3 N O -O 0 NN OH OH 0 %AN N kN..t 1-2207 2.27 494 3 0 Nl OH AC1 O CI O O HNAN O 1-2209 2.4 494 3 0 CI 0 HN NA0 HN) -- '1-2210 2A0 545 3 C NyNk 0 0- c [Table 446] Compound Retention Structure Co Time [M+H] Method No. (min) 0 OH 0 0o KN )k NH 1-2211 1.43 495 3 ZN -1 7N 0 0 0 HN 1-2212 2.03 509 2 ci H H N N - 0 0 HN N N1 O 1-2213 1.68 548 2 C l
NH
2 NO 0 N HN ' 1-2214 1.45 465 2 aci ON 0 HO 0 F 1-2215 1.87 530 2 N c [Table 447] Compound Retention Structure Co Time [M+H] Method H No. (min) _ __ S0 N N NO CI - 0 0 NHN N ON Cl 0 F 0 0N 'k N NO OC 1-2218 2.40 525 2 0 FO o1-2219 2.47 525 2 0 O N O HN N NyN N N O ON C 1-2220 2.09 512 2 [Table 448] Compound Retention Structure Co Time [M+H] Method No. (m) 0 HO / HN N N N 1-2221 1.62 373 2 C 0 HO NyO N HN.N N N N AN OH NC 1-2222 1.61 484 2 O F O / FHN 'iN N N O HO 0 1-2223 2.15 511 2 0
N
0 A N 0 t NH N -'tO 1-2224 2.62 533 3 0
N
0 N aci NH1-2225 2.57 535 3 [Table 449] Compound Retention Structure Co Time [M+H] Method No. (m) 0 FO :r" HN
JN---
HO N-tO c 1-2226 2.07 511 2 NN O N HN N NAN O 1-2227 2.37 475 3 HN N-N N N NO 0 -2228 2.20 540 3 NN C 0 N N : OH NOH -2229 1.86 500 3 N NAN~O -2230 2.48 489 3 ci LU60.1 [Table 450] Retention Structure Compound Time [M+H] Method No. (min) 0 HO 0 0 ANHN&O 1-2231 2.30 519 3 CI 0 HO N 0 HOO N I A L22 -2232 2.28 521 3 Or HN N IF 0<0 N N O
H
2 N QC 1-2233 2.12 510 2 0
H
2 N O N 1-2234 2.07 510 2 0 0
H
2 N NO N 1-2235 2.07 510 2 [Table 4511 CompundRetention Structure Compound Time [M+H] Method No. (m) 0 N N H 2 O 0 o NHO S H1-2236 1.64 494 3 Z-C1 CN 0
NH
2 v--- 0 0 NI ,N -1-2237 1.81 494 3 eNH N CI 0 N 0 0 0 N N ' - 1-2238 2.11 509 3 NC 0 OH 0 NN'O 1-2239 1.90 495 3 N a, C 0 N 0 N 1-2240 1,84 494 3 N a [Table 452] Compound Retention Structure Co Time [M+H] Method No' (min) 0 HNK 1 HN N' 1-2241 1.87 507 2 N NN HN 0 HN N 1-2242 1.97 521 2 HN HN O NN 0 o HN N- 1-2243 1.95 548 2 N IC N N N0 A HNA N S N -N O 12244 1.34 507 2 NN O HN
N
XIN -tkN 1-2245 1.35 493 2 C1 [Table 453] Retention Structure Compound Time [M+H] Method No. (mi) 0 NH NHN 0 N F 1-2246 1.92 513 3 0 s IC S1-2247 2.48 514 5 <:N NN -0 0 N HO N CI 0 OH s 1 0 0 4NHNAN N 1-2249 2.21 500 3 NN '-0 0 HO " K#-a NA)N-^- 1-2250 2.11 494 3 N N -A~c [Table 4541 Compound Retention Structure No. Time [M+H] Method (min) 0 NH IC 0~~ 0N I N -- -2251 2.26 537 3 I-ci HN O HN YN N N O 1-2252 1.92 536 3 C l 0 HN N 1-2253 2.92 445 3 N ICI H N N % O N N 1-2254 2.84 445 3 sN ',N IkN 01-2255 2.58 445 3 01' [Table 4551 Retention Structure Compound Time [M+H] Method No. (min) ______ S HN NN 1-2256 3.08 461 3 -Cl CI S ON N N NO 1-2257 3.00 479 3 CI HO O HNiN-N cl 1-2258 2.15 482 3 CI NH O IN Nt 1-2259 1.80 476 3 NH O N N 1-2260 1.73 442 3
-CI
[Table 456] Retention Structure Compound Time [M+H] Method No. (min) NH O N NO 1-2261 1.65 428 3 N O -CI 0 NN cK OH os N OF-N QLNI.N O-2262 2.59 524 3 0 HN NV- 1-2265 2.46 600 3 NO CI 0 KL Kt1-2264 2.28 510 3 0 o- N 0 HN) '-1-2264 2.79 538 3
N
[Table 4571 Compound Retention Structure Co Time [M+H] Method No, (m) 0
N
0 0 Oo 0 O N NO 1-2266 2.13 474 3 O 0 \ N HN IkNI /N ) N N>O 1-2267 1.80 457 2 'C 0 HO H 0< N )N 1-2268 1.92 460 3 N N 0" O HN 1-2269 2.18 509 3 0 N O N O N N -- C 1-2270 2.30 509 3 N-kN -O [Table 4583 Compound Retention Structure Co Time [M+H] Method No. (min) 0 O O 1 HN 0 N N hO 1-2271 2.25 494 3 OH 0K%51 N 'k N O 1-2272 2 03 480 3 NN ci O OH O N O 1-2274 1.93 479 3 CI 0
-
N N 0 N N1-22 75 1.98 509 3 N -N -Nt NN N
CI
[Table 4591 Compound Retention Structure Co Time [M+H] Method No. (min) N N 1-2276 2.65 413 3 H 00 A HN N 1-2277 1.38 500 3 O OH N 1 N 1-2278 1.75 495 3 O NH2 N O N 0 ON.J XN N- 1-2279 1.81 494 3 CI NN NI-28N 8 462 1-2280 1.86 469 2 [Table 460] eOompound Retention Structure Co Time [M+H] Method No. N NN y 0 1-2281 2.35 476 3 Ci 0 N OH K-N 0 HN 1-2282 2.09 495 3 CI 0 NH2 NN N O 0 HN k '-128 1.9 494 C1 0 NN NH 2 1-2284 1.96 494 3 CI O OH NX N O HNN 1-2285 1.90 495 3 N - NN'-< [Table 461] Compound Retention Structure Co Time [M+H] Method No. (min) A NMN O- HN kNA N N 1O -2286 2.24 456 2 CI 9 0 r# HN N 0 N N %O 0 Aj 1-2287 2.16 540 2 N, C S090 0-a:-,HN A N'" 0 LZN ... N.'<0 1-2288 2.24 540 2 CI~ N MN A )N>NN'Y0O 07<- 1-2289 2.19 526 2 s N N 5 N-N-tO o 7 Q/- 1-2290 2.27 542 2
CI
[Table 462] Retention Structure Compound Time [M+H] Method No. (min) N, O HN 'kN " O H O H OH 1-2291 1.71 500 2 N " N NO O HN XJ N OH N N O 1-2292 1.80 456 2 I-CI 0? N 0 HN N OH N ;ILN Ot OH 1-2293 1.68 486 2 Cl S N oHN N -- OH N N NO OH 1-2294 1.77 502 2 Cl k OH 0 HN1-2295 1.68 524 2 t4 N- [Table 4631 Compound Retention Structure Co Time [M+H] Method No. (min) OH N O HN IkN"-2296 1.97 495 2 00 OH O HN N-I--2297 1.42 500 2 N NO 00 N1-OI2298 1.34 472 3 I-cl HO HO - NH 0 -N kN'-- 1-2299 1.42 486 2 <IN 1), N-A [Table 4641 Compound Retention Structure dNo. Time [M+H] Method NN NN H 1-2300 2.28 455 3 IH N N N N O 1-2301 2.54 459 3 CI NN N O NH 1-2302 2.35 475 3 C1 0 HO N O HN N 1-2303 2.02 474 3 N N O
N
[Table 465] CompounRetention Structure dmpoun Time [M+H] Method d No.) Ot 0 NH HN 1-2304 2.17 565 2 0 H N N-,L N - O N 0 N 1-2305 2.49 474 3 CI N N /0 HN NrN 1-2306 2.34 475 3 N NO CI~ ry0 NN H N %N 1-2307 2.2 509 3
CI
[Table 4661 Retention Structure Compoun Time [M+H] Method d No. 0 N 0 A HN N 1-2308 2.09 520 2 '-CI 0 NH 0 NQ%- H N N 1-2309 1.99 519 2 IN O N 1-2310 2.28 476 3 N'- CI 0 N NH 2 N N 0 NH 1-2311 1.94 494 3 'C
CI
[Table 467] Retention Structure Compoun Time [M+H] Method d(mNo. 0 O HN N O N N dIN#-O O>1-2312 2.38 525 2 N CI 0 HN N OH N N O OH 1-2313 1.95 485 2 CI - 0 HN NO N N& O 1-2314 2.42 511 2 CI - 0 HN AN
--
r\OH N N O OH 1-2315 2.01 471 3
CI
[Table 468] Compou Reteniion Structure Compoun Time [M+H] Method F 0 O N N NH N N1-2316 1.59 476 3 ICI F 0 0 O 1-2317 2.21 518 3 CI HN 1-2318 2.04 476 3 N N Nci 0 S OH N N a H 1-2319 2.01 495 3
'CI
[Table 469] Compound Retention Structure d No. Time [M+H] Method O OH N HN N 1-2320 2.16 494 3 OC N N O Cl 0 N N 1-2321 2.40 448 2 CI Nt-N A o1/ HN N-2322 2.25 509 3 N N Oz 'Cl HO 0 N rN O O-/ H N 1-2323 2.03 495 3 N N O
'-CI
LU6036J [Table 4701 Structure Compou Time [M+H] Method d(mNo. 0 N HN ) N-^ -o 1-2324 2.25 502 2 CI 0 N H N ) k '' HO-7 1-2325 1.90 430 2 CI 0 N HN 'kN-^ 1-2326 1.96 488 2 >CI 0
O
0 O OHN N 1-2327 2.52 513 3 N NO (Table 4711 Retention Structure Compoun Time [M+H] Method 0 0o 1
-
N 0 OHN N 1-2328 2.40 499 3 N Nt 0N 0 N0 ON H N 1-2329 2.49 519 3 Cl 0 N OH 0 HN N 1-2330 1.52 506 2 OrN N "Nz0 C 0 HO HO O HN N 1-2331 1.82 506 2
CI
[Table 4721 Retention Structure Compoun Time [M+H] Method 0 N 0 o A I HN N 1-2332 2.04 536 2 CI N F 0 o /HN N 1-2333 2.26 554 2 CI NN F 0 HN N 1 OH N N O OH 1-2334 1.84 514 3 CI NHN N O N N O 1-2335 2.56 539 2
CI
[Table 473] Detention Structure Compoun Time [M+H] Method 0 0 HN N OH N O 1-2336 2.09 455 2 CI 0 N HN N 0-N SL NANt 1-2337 2.40 471 2 CI 0 N HN N N% N 1-2338 2.35 471 2 CI 0 N - 5e H N ) N-' N-~S N N O 1-2339 2.35 439 2 C I [Table 474] Retention Structure Compoun Time [M+H] Method AN N 0 HN N 1-2340 2.13 441 3 AN N N HN N 1-2341 2.22 461 3 N CI 0 N
NH
2 HN Q H A N 1-2342 1.70 459 3 N N O 0 OH N OH HN N 1-2343 1.86 460 3 N N O [Table 4751 CompounRetention Structure Compoun Time [M+H] Method 0 HO N 0 ONHN O 1-2344 2.2 0 4 99 3 NN- O N HN N N O 1-2345 2.30 475 3 CI 0 OH N S O HN N 1-2346 2.25 500 2 O<IN N - O OH N yS 0 O-/ H1N N -2347 2.17 486 2 N N "O [Table 476] Retention Structure Compoun Time [M+H] Method OH S yN O HN N 1-2348 2.17 486 2 N N O 0 OH S Io N HN N- 1-2349 2.40 486 3 N N" ,O s HN N N 4 O 1-2350 2.48 442 3 o OH N O O / N 'kN 1-2351 2.15 480 3 O"I' N -:N - O [Table 477]
..
Retention Structure Compoun Time [M+H] Method 0 HO N 0 HN N 1-2352 2.05 480 2 0 NN OH 00 Oa NH N ) N OH 1-2353 1.80 514 2 1 -C O HO O 0 HN N- 1-2354 2.28 479 2 N N O -N 0OyN 0 HN N NO 1-2355 1.87 441 2
CI
[Table 478] Retention Structure Compoun Time [M+H] Method d No. ia N 0 1-2356 2.00 426 2 CI H 0 1-2357 2.22 440 3 CI 0 N? 0 HN N OH N -O 1-2358 1.91 470 3 CI CC N 0 HN N 1-2359 2.02 492 3
NF
[Table 479 Retention Structure dmpoun Time [M+H] Method 0 N OH N0 OH HN N 1-2360 1.54 478 3 F 0 N
NH
2 0 HN LN 1-2361 1.91 477 3 N HNAN0 N" vN N - O 1-2362 2.08 451 3 CI 0 HO HO N HN N 1-2363 2.08 485 3 N N O Lt O'I [Table 480] Retention Structure Compoun Time [M+H] Method 0 HO - I 0 OaHN ' NA 1-2364 2.15 505 3 NN CI
H
2 N N O 0 0--a HN ' N-- 1-2365 1.93 493 3 CI N HO N O N N 1-2366 1.98 494 3 N-N II CI ,N 1C [Table 481] Compoun Retention Structure d No. Time [M+H] Method N 1-2368 2__ __minL.2
N
I ,NHN N 4 O~1-2368 2.24 553 3 NN N H1-2379 1.72 5 4 3 CI N0 NN 00 HN-- N ' OH 0 ~ZIIIN~A% ~ OH 1-2370 1.75 486 3 IC N-0 1-2371 1.72 513 3 N N NNOO0H C I [Table 482] Retention Structure Compoun Time [M+H] Method d No. N ,N 0 HN Nr 1-2372 2.07 476 3 N CI1 N N O RN NX 1-2373 2.12 476 3 N 'N 0 HN A 1-2374 2.21 461 3 ON~a N N O N N HN) '-,1-2375 2.09 476 3 N -: N N 1 [Table 483] Retention Structure Compoun Time EM+H Method d(mNo. 0
H
2 N N 0 Oa H N 1-2376 1.80 479 3 -ac CI 0 H2NN N OHN N .- 2377 2.03 494 3 -ac 0
H
2 N N N 1-2378 1.92 479 3 0N 1 NNA NN N 0 HN ) N 1-2379 1.84 480 3 N N [Table 484] Compound Hetention Structure Co. Time [M+H] Method d No. (in 0 NH2 N NH HN 1N -2380 1.8 480 3 N NO 'CI O OH NO HN N 1-2381 1.88 481 3 N NtO 'CI O OH N N O O HN N 1-2382 1.78 461 3 N N O O 0H N O N 0 HN N-"'N 1-2383 1.92 475 3 N NO [Table 485] CompounHetention Structure Co. Time [M+H] Method d No. (mn O OH N N O S--a H N A I-2384 1.82 475 2 N N ' O O OH N fN O HN'A N 1-2385 1.69 461 2 N N O O OH N O N O O r-ijHN k N 1-2386 1.79 481 2 N N - O NO NN '0c HN NN 1-2387 2.26 505 2
CI
[Table 4861 CompounRetention Structure Compoun Time [M+H] Method O NH2 N lN0 HN N 1-2388 1.95 494 2 N N t:O '- CI O N H2 N kN0 HN N 1-2389 1.82 480 2 N N O NN
CI
01 N I N -2390 2,15 491 2 C' 0 OH N OH HN N 1-2391 1.96 480 3 N N O
CI
[Table 487] Compound Retention Structure CNo. Time [M+H] Method N N / HN N 1-2392 2.19 461 3 N N O NN -CI N O H N 1-2393 2.10 441 3 0<'N : N Ok NN HN N O N N "O 1-2394 2.17 538 2 F N N /0 HN N' - 1-2395 2.24 455 3 N N O a LTable 488] CompounRete-ntion Structure Compoun Time [M+H] Method 0O N N S / HN N ON N N O O 1-2396 2.14 538 2 NN F NN N 1-2397 1.78 454 3
H
2 N 0 O N 0 N1-2398 1.87 473 3 N -: N - O Nv Ox /AN OH N N O OH 1-2399 1.78 498 3
F
[Table 489] RCompoun detention Structure CNo. Time [M+H] Method HO 0 N / HN N- 1-2400 2.06 474 3 N N O II HO 0 N/O A HN N 1-2401 1.92 460 3 QaNl N O N 0 HN N 1-2402 2.06 494 3 N NO CI 0 OH N TN O o HN N 1-2403 1.75 461 3 N N tO LU UL!JUJ [Table 4901 Retention Structure Compoun Time [M+H] Method 0 OH N N O HN N'N 1-2404 1.89 475 3 N N O 0 OH N N0 N I N -2405 1.84 481 3 NH2 N 0 HN N 1-2406 1.88 479 3 N N O CI
H
2 N O HN N 1-2407 1.83 479 3 N N -kO
CI
[Table 491] Retention Structure Compoun Time [M+H] Method d No.) Oa / HN N 0 OH O H 1-2408 1.71 486 2 I ci OH 00 N S O o HN N 1-2409 1.92 486 2 N N O CI OH S N O O-/ HN N 1-2410 1.93 486 2 N N O 0 OH
N
HN / O /a HN N 1-2411 1.73 469 2 N N O
'-:CI
[Table 4921 Retention Structure Compoun Time [M+H] Method d No. :N IC N 0o- HN N OH N1 N O 1-2413 1.76 483 2 'CI
NH
2 NN S1 O-^ o/ HN N 1-2414 1.80 485 2 N N O0 CI
NH
2 SN Oa HN N 1-2415 1.82 485 2 N N N O NCI I-aCI [Table 4931 Retention Structure Compoun Time [M+H] Method 0
NH
2 HN H~y 0 O-/a HN N 1-2416 1.64 468 2 N N O C1 0
NNH
2 HNO HN~ 0 o HN N 1-2417 1.77 482 2 N N O 'C1 0 N O HNA N N OH -N N 1-KN O OH 1-2418 1.62 497 3 1-2419 2.22 467 3 NCI
CI
[Table 494] Retention Structure Compoun Time [M+H] Method d(mNo. NN FO 0 HN N OH N N O 1-2420 1.90 484 3 N Cl 0 NyO HN N O NN N N O 1-2421 2.32 481 3 Cl 0 (N N OH 00 OHN ) N- 1-2422 1.83 480 3 N NOO Ox OH -N O O 0, HN N-N 1-2423 2.09 524 2 N I N NNLO C1 [Table 495] Retention Structure Compoun Time [M+H] Method d No. (1min) 0 OH KOHNO HN AtN 1-2424 1.97 510 2 N N -C1 H H N N N N 0- 0 IN NAN 1-2425 1.70 522 2 CI 0 HN NH N 0 O HN 1-2426 1.96 522 2 N N O N N N O NON HN N 1-2427 2.22 476 2 N N O
I--CI
[Table 496] Retention Structure Compoun Time [M+H] Method d No. N N <N O HN N 1-2428 2.09 462 2 N N O IC' 0 HN N 0 O N 1-2429 1.82 493 2 N N O I CI H N N O O- A N N O 1-2430 1.49 479 2 CI H N O 0 HN N 1-2431 1.60 493 2
C'
[Table 497] Retention Structure Compoun Time [M+H] Method 0 dNo N N NN H F 0 HN 1-2432 2.34 525 3 N NN HA N F O HN N 1-2433 2.19 511 3 N N XO CI NO 0 0 0 I N~HN 'JN Nt t-Kt-N N N O 1-2434 2.28 512 3 C1 N?\, O O /a HN N OH N NNO 1-2435 1.91 484 3
CI
[Table 498] Retention Structure Compoun Time [M+H] Method d No. F H N OH OH 1-2436 514 3 C S yN O NaN HOLNH 1-2437 1.89 516 3 N N ""O OH CI 0 N HN Nr OH N N< )O 2438 1.94 474 2 NN NHH1-2439 1.84 518 2 CI 0 N F 0 1-2439 1.84 518 2 N N kO O H N 'C I [Table 499] StrutureCompoun Rettion Structure d No. Time [M+H] Method N(mFnO 00 NN 0 HN 'kN' OH I N N O OH 1-2440 1.80 504 2 CI CI O HN 1-2441 2.50 484 3 CI HO $ N /0 O- / HN N 1-2442 2.01 480 3 N N O CI NO O / HN N NH 2 N N ) NNO 1-2443 1.77 483 3
-CI
[Table 500] Retention Structure Compoun Time [M+H] Method d No. 0 OH 1H N 1-2444 1.9 475 3 N 0NO 0 O 0--aH N ) N 1-2445 1.75 461 3 N N "O N HN 1-2446 2.35 447 3 ON I0H N>C HN N1-2446 2.3 447 3 [Table 5011 Compound Retention Structure dNo. Time [M+H] Method _____ ____ _____ ____ ____ _____ ____ _ . (m in)i _ _ S yN O o- HN N OH N N ' O OH 1-2448 1.78 502 2 N -- V. 0 HN INN OH 1-2449 1.39 505 2 I-C 0 OH S yN 0 0Qa HN N 1-2450 2.16 514 2 N N O CI OH SyN 0 HN N 1-2451 2.12 500 3 N N LO
'CI
[Table 502] Retention Structure Compoun Time [M+H] Method dNo.
N
HN ? 0 HN N OH N N O 1-2452 1.74 469 3 C1 N? O-' H N N - OH N 1-2453 1.59 485 3 CI
N
IC H N ?- 0 0--' H N) NOH 1-2454 1.57 499 2 CI
N
0 )s ''k' 1-2455 1.94 439 2 C I [Table 503] Retention Structure Compoun Time [M+H] Method d No.) SN SH N N OH 1-2456 1.91 516 2 oHN N OH 0""'N N -- O 1-2457 2.13 486 3 C1 S N NHN kN OH 1-2458 2.03 530 3 C1 N 0 O h HN N OH 0N N O O -2459 2.11 498 2
CI
[Table 504] Retention Structure ompoun Time [M+H] Method N , O0 O /- HN N OIk 1-2460 2.10 498 2 CI 0 HO NN F 0 O / HN N 1-2461 1.69 498 3 N O C1 0 HO N F NN O 1-2462 1.83 512 3 N NO CI
H
2 N N HN N 1-2463 2.05 465 3 N N "O [Table 505] Retention Structure dmpoun Time [M+H] Method
H
2 N N 0 HN N 1-2464 1.74 459 3 N N O HO 0 HO N HN N 1-2465 2.14 466 3 N N -O N N O HN <N N 1-2466 2.18 459 3 F 0 NN 0 If N 0 Oa H N1-2467 2.2 489 3 N N [Table 506] Retention Structure Compoun Time [M+H] Method d(No. 0 N O lyN O HN N 1-2468 2.05 475 3 N N O 0 IN 0 -- a HN ) N 1-2469 2.14 495 3 N C1 N? 0 O O 1-2470 2.48 472 3 C I 0 N NH 2 1-fN O HN N 1-2471 1.81 480 3 N N O -: CI [Table 507] pRetention Structure Compoun Time [M+H] Method d(No. 0 N
NH
2 'fN O HN N 1-2472 1.87 474 3 N N O 0 N
NH
2 -rN O HN N 1-2473 1.74 460 3 N N O 0 NN OH K-N O HN N 1-2474 1.98 475 3 N N " O 9NN 0 NN OH K-fN 0 HN N 1-2475 1.84 461 3 N N"O [Table 5081 CompounRetention Structure Compoun Time [M+H] Method d No.) 0 OH N OH 9N O 0N N 1-2476 1.94 481 3 N Nt-' 11::LCI S-N N 0 QHN N7OH 1-2477 1.92 473 2 CI S-N H N ' N O H N N OH 1-2478 1.82 517 2 CI S-N O HN N HN ) 4 *'"OH N N O OH 1-2479 1.79 503 2
CI
[Table 509] Compound Retention Structure dNo. Time [M+H] Method 0 N N OH O N N N ""O 1-2480 1.98 522 3 0 N OH 0 HN N 1-2481 2.29 522 3 cI 0 N OH HN 1-2482 1.96 522 3 'Ci 0 NN OH 0 N HN N 1-2483 2.27 522 3 N O O llaCl LUtU I I [Table 5101 Retention Structure Compoun Time [M+H] Method d No. .(2i)~ _ _ 0 N I OH 00 N N 1O -2484 1.90 520 3 -CCI 0 N OH -A 0 O I HN N 1-2485 2.23 520 3 Ol N Nt 'CI 0 ? N = O/ HN ) N OH N N O O 1-2486 1.94 484 3 CI NN HN ' N OH N N O O 1-2487 1.94 484 3
CI
[Table 511] Hetention Structure Compoun Time [M+H] Method 0 /?N\ O 1-2488 1.99 470 3 C1 N0 OJ OH 1NH N O 1-2489 1.99 470 3 CI 0 NO O / HN N O O NH0 tNANXO -40 18 0 CI HO / NO 0 H N N 1-2491 1.96 497 3 N ;N O
CI
[Table 512] Retention Structure dmpoun Time [M+H] Method d(mNo. N NF 0 0 HN NrN 1-2492 2.47 493 3 N Nt C1 N IN F 0 HN N 1-2493 2.34 479 3 0 N N t HN NF H N1-2494 2.49 461 3 0
H
2 N N N 0 H %.J~WN N. 1-2495 1.89 47/7 3 N N -':
,---
[Table 5131 Retention Structure dmpoun Time [M+H] Method d No. (min).__ 0 HO N N HN Nk 1-2496 1.99 478 3 F 0
H
2 N O HN N 1-2497 2.20 479 3 0 N OH F 0 HN N--N 1-2498 2.34 512 3
-
N N -O 'C1 0 HO N 0'Za H N NANS O 1-2499 2.29 480 3 N : N - O [Table 5141 Retention Structure Compoun Time [M+H] Method d(mNo. 9 N ", O0 O/a HN N NH2 N1N O 1-2500 1.77 483 2 CI NNH N N O O1-2501 1.77 483 2 CI 0 OH F 0 HN N 1-2502 2.21 498 3 N N -O CI F ' OHn )<%NH Oa N5N
-
1-2503 2.13 440 3 C1 [Table 5151 CompounHetention Structure Compoun Time [M+H] Method d No. 0 ?0 N, O N 7 1-2504 1.83 470 2 CI S yN O HN N OH N N< O 1-2505 1.89 472 2 C1 S yN O NH OH 1-2506 1.77 502 2 CI S N O oX / HN NOH 1N N O -2507 1.80 470 2
F
[Table 516] Retention Structure Compoun Time [M+H] Method S N. W~F S-N 0HN N OH OH 1-2509 1.80 502 2 N, O O HN NO OH N N H 1-2510 1.62 466 2 N S H OH 1-2511 1.73 517 2
CI
[Table 5171 Retention Structure Compoun Time [M+H] Method d No.) N 0 O /H/N NH 2 N N1 O O -2512 1.70 469 2 CI H yNN O N NNO OH 1-2513 1.90 516 2 'C I S N I ?9 0 O HN N OH ON O OH 1-2514 1.78 502 2 NI , P I HN=N H N yN O O / N ) N' N N O1-2515 1.84 441 2
CI
[Table 518] CompounHetention Structure Compoun Time [M+H] Method d No. ____ FO HN N N N 1 Nt1-2516 2.09 484 3 CI N S O A FN N OH NHKN O H 1-2517 1.76 531 2 C S N0 N N OH 1-2518 1.75 517 2 O~ I N Nt Cl SN o/ HN N "-f OH N N O OH 1-2519 1.70 503 2
CI
[Table 519] StrutureCompoun R~Hietnion Structure d No. Time [M+H] Method S N S N O N N O OH I-2521 1.89 5317 3 CI SN O H~ O / NN 0 0 1-2522 2.24 555 2 CI N N0 O HCI 1-2523 1.37 455 2
CI
LUOcJOJ [Table 520] Detention Structure Compoun Time [M+H] Method d No. (min) Ns O 9 HN N N NkO 0 1-2524 1.75 497 2 Ci F N0 -NN OH 1-2525 1.96 514 3 'C1 F N OH a N N O H 1-2526 1.98 526 3 N ?N ~0 0 O0.%-a KHN NAN' tz H 1-2527 1. 83 497 3 N N .
'CI
[Table 521] petention Structure dmpoun Time [M+H] Method N N F HN~ NA-O 0 N N 4 O 1-2528 2.19 486 3 C1 0 OH N, F O0 O O HN N OH IN N O 1-2529 1.88 504 3 C1 NsO O /- HN N -' OH N N '-O OH 1-2530 1.86 502 3 C NsO N N N O'OH 1-2531 2.02 530 3
CI
[Table 522] Compound Hetention Structure CmNo. Time [M+H] Method 0 dNo Na
NH
2 'N O HN IN 1-2532 1.94 494 3 I-CI H 0 N, N N O O N 1N -2533 1.97 508 2 O''a N: N - O C 0 O H O HN N 1N N O-2534 1.80 497 2 C I 0 ?0 N0 HN N N N O O 1-2535 1.81 497 2 Ci [Table 523] Retention Structure Compoun Time [M+H] Method d No. 0 N 0 HN N 1-2536 1.96 538 2 N N - O C1 0 N O HN N 1-2537 2.07 538 2 N N O IC' N N A HN N O 1-2538 2.13 505 2 N HN N 1-2539 1.82 477 2 IN
N
[Table 524] Compound Retention Structure dNo. Time [M+H] Method pN yOx 0 0 O0/ HN N 1-2540 2.68 651 2 N N O I CI S N OH O HN N O ON N O 1-2541 1.84 502 3 CI NO O-- OH -NH N O 1-2542 1.74 486 3 CI 00 OH N N N O O -217HN9481 NN 1-2543 1.79 481 3 [Table 525] Retention Structure Compoun Time [M+H] Method d(mNo. N N ON O HN NOH HN N OH O 1-2544 1.66 511 3 N N O OH C1 N ICI N0 HNA hN.AH 1-2545 2.13 490 3 0 N H2 0 Oa H N IkNJ H1-2546 1.60 538 3 NN OH 00 O-a HN ) W- 1-2547 1.82 524 2 N Nt Nl c [Table 5261 Retention Structure Compoun Time [M+H] Method 0 N O H KNH HN N 1-2548 1.98 524 2 N N O lCI N NH NH 0 HN ) N1-2549 1.60 551 3 N N "Nt 0-55 206 52 NN C I NN N 0 0 1-255 1 1.95 489 3
N
[Table 527] Retention Structure Compoun Time [M+H] Method 0 dNo OH 0 HN N 1-2552 1.55 524 2 N N O CI 0 OH ( llN 0 HN N- 1-2553 1.62 496 2 N NNO NH2 0 jI
NH
2 N NH O HN 1-2554 1.39 522 2 N N O -ac CI 0 N j NH / HN N 1-2555 1.40 536 2 N N O IaCI [Table 5281 Retention Structure Compoun Time [M+H] Method di No. _ _ N N OH NH HN 1-2556 1.50 523 2 N N O N N O O o/ HN 'kN "AO H N N O 1-2557 1.79 495 3 C1 N N O O oN/HN "N NOH 0N 1N -2558 1.71 475 3 N N0 O NH2 0 0 / HN N - OH -1-2559 1.72 508 3 N N O
CI
[Table 5291 Retention Structure Compoun Time [M+H] Method d(mNo. *N 0 HN NjX'%%OH 1-2560 2.03 520 3 N N O OH NN 9CO 1N OH -2561 1.62 510 3 CI F I'N 0 HNN N N O o 1-2562 2.43 526 3 C I N, ON 1-2563 2 472 3
CI
LU6OVjJ [Table 530] Retention Structure dmpoun Time [M+H] Method F 0 0~H ~ O 0- N N~O H 1-2564 2.11 498 3 N N -O O 'C I N-yN 00 H HN N" NH2 N 1-2565 1.66 494 3 C I Kcm N N 0 O o / HN N NH 2 1-2566 1.57 474 3 0 OH NNS o o HN N1 -2567 2.02 484 3 N NAO
N
[Table 5311 Retention Structure Compoun Time [M+H] Method d(mNo. OH 0< S N O HN N 1-2568 2.01 484 3 N N ' O F N O HN HN NA N N NO 1-2569 1.26 429 3
N-K
S N 1-2570 2.24 529 2 N CI SN HNy N OH H OH 1-2571 1,78 529 2
W~F
[Table 5321 CompounRetention Structure Compoun Time [M+H] Method dNo. O N / H A N N 1-2572 1.45 443 2 O OHN NX' t1 [-2573 1.42 430 2 N N O 0 N? F 0 O HN N OH IN NO OH 1-2574 1.94 516 3 F NO HN )k N> OH NI N O01-2575 2.01 487 3 Ci [Table 533] Retention Structure Compoun Time [M+H] Method N S yN0 NH KN N OH 1-2576 1.92 545 2 N-N SN 0 O / HN OH N | N )P N O OH 1-2577 1.77 517 2 ci 'CI 0 F 0 0 HNXXk N' OX N N N O O 1-2578 2.29 516 2 CI S N N OH 1-2579 1.91 501 2 KNci [Table 534] Retention Structure Compoun Time [M+H] Method d No. 00 N s F O O HN N O N NNtOO 1-2580 1.97 488 2 N I4 C I Hici SyN 0 H NNO 1-2581 1.83 514 2 e H -28 201 52 CI F N0 1-2582 2.01 528 3 C NF I'N 0 N H HN N H1-2583 1.88 512 3 N Nr - O 0H
N
[Table 535] Compound Hetention Structure d No. Time [M+H] Method F 0 HN; 0.~ H N NH2 1-2584 1.97 497 3 N ,1-2585 2.04 511 3 N N N 2 0 N CI 0 F 0 ZHNA N H ' Nd'K N A o 1-258 1.84 487 2 CI 00 Ni H 0H N )' N -O O H 1-2587 1.90 501 2 NZ C I [Table 5361 Retention Structure Compoun Time [M+H] Method d No. OH N NH N0 O~%HNA HN N 1-2588 1.43 509 2 N NO CI
N
S yN HN0l N N H NH2 1-2589 1.77 500 2 C1 N 0 H N kN O O 1-2590 1.75 483 2 -1 CI N 0 H H N ) N'-- 1-2591 2.41 475 3 N N O C
I
[Table 537] Compound Retention Structure dNo. Time [M+H] Method HO 0 N O 0 -t HN A, N 1-2592 2.24 494 3 N N O NN aCI N N H 1C N N H N 1-2595 2.18 541 2 CI 0 N N - -a HN N OH 1-2595 2.27 541 2 N NIONO N1::C [Table 538] Detention Structure ompoun Time [M+H] Method d No. 0 N yN O HN N '-f\OH 1-2596 1.85 527 2 a N N ' <O OH CI 00 HN N 1-2597 2.78 523 3 N N O -CI HN N <N N N 1-2598 2.04 456 3 CI N 0 HN1-2599 1.84 431 3 "IaN ; N .
[Table 539] Structure Compoun He [M+H] Method d No. 0 N HNK N N N kO 1-2600 1.93 451 3 K1 CI N NN N N I CN N. K-N H N 0 O~~%.,HN~r 1-2602 2.09 518 2 O OH S- H )I - 1-2603 2.43 509 3 N N O IID
CI
LU3tUJ [Table 5401 Compound Retention Structure CNo. Time [M+H] Method ( o min N O H HN N N 1-2604 1.80 494 2 C1 NO H OH 1-2605 1.67 515 2 F
N
S N O H N NOH 1-2606 1.80 485 2 F S N I O H 1-2607 1.74 501 3
F
[Table 5411 Retention Structure Compoun Time [M+H] Method
NH
2 S yN O HN NN. 1-2608 2.05 499 3 0aN N O c 0 NH 2 N S 0 o-/a HN N 1-2609 2.01 499 3 N N O C1I 1-2610 1.99 524 3 -N N 21O H 4 C I NQ OlN N"O1-2611 2.07 451 3 N C I [Table 542] pRetention Structure Compoun Time [M+H] Method C1~n Nd No. 9NH NN O HN 1-2612 1.79 55 3 N NOH N: IC N HN N1-2613 2.36 475 3 I CI
NN
0 0 HN 1 N'- 1-2614 1.93 551 2 0 1-2615 2.39 541 2 C1 [Table 5431 Retention Structure Compoun Time [M+H] Method d No.) A 0 HN )N OH N N -O OH 1-2616 2.10 501 3 Cl 0 AI O HNK "- OH N HN OH 1-2617 1.96 485 3 F N yS O HN N N'O" N - N - O O 1-2618 2.28 514 5 CI N S 1-2619 2.42 528 5 C1 [Table 544] Compound Retention Structure CmNo. Time [M+H] Method O
NH
2 N0 O N HN N'N 1-2620 1.92 493 3 N N NO CI O OH O N HN N-N 1-2621 2.11 494 3 N N O -CI HN ,, OH N O 00 O/ HN 'kN- 1-2622 1.61 523 2 N NO -C1 N S O /a HN %N OH 1-2623 1.93 486 5
CII
[Table 5451 RoHetention Structure Compoun Time [M+H] Method d No. N yS O H N O 1-2624 2.07 500 5 CI HN NH2 NO0 0 HN NO 1-2625 1.53 522 2 N- N -'kO HN NH NO0 HN N- 1-2626 1.59 536 2 N N O N S N O' O 1-2627 2.19 498 5 C I [Table 546] pRetention Structure Compoun Time [M+H] Method NNSO N ~ H N O N N O O 1-2628 2.22 515 5 N 1 CI N-S N N 1-2629 2.32 515 5 0 NH O N N O on 1-2630 2.28 554 2 CI o OH 00 O6 / HN )N 1-2631 2.00 525 3 S<'N N O0 llaCl [Table 547] Retention Structure Compoun Time [M+H] Method o OH 0 O HN NN 1-2632 2.21 541 3 N N O -CI N N O O HN 'N - ' 1-2633 2.21 513 3 NN N O O o HN N OH LZN N 4 O 1-2634 1.97 499 3 NN N 0 O HN IN N OH 1-2635 1.96 499 3 N N O [Table 5481 Structure Compoun Time [M+H] Method d(No. N HN N 1-2636 2.20 513 3 N NO NN ICI S 0 0 N NN N N 1-2637 2.45 456 3 IC1 CI 1-2638 2.29 .465 3 NN C I [Table 549] Retention Structure Compoun Time [M+H] Method d(mNo. N N0 N OH 1-2640 1.98 485 3 N O O N HN N OH 1-2641 2.08 540 3 N N ''O O H N N O H N ' N 1-2642 2.08 451 2 CI N-S N 1-2643 1.96 487 5
CI
[Table 550] Retention Structure Compoun Time [M+H] Method d No. N S HN ( N H2 N N o 1-2644 1.80 485 5 CI N yS O H N Ny
NN
N N O O 1-2645 1.87 499 5 CI N S ON O- 0 0H 1-2646 1.75 529 5 CH N S0 N )NH2 1-2647 1.95 499 5
CI
[Table 551] Retention Structure Compoun Time [M+H] Method r={ HN No N yS O H 1-2648 2.01 513 5 CI N yS O H O' J ~ N OH -2649 1.90 543 5 C1 O O FOHN ' N O' 1-2650 2.37 526 5 CI O O N OHN ) N ' O N'S 0"N N " O 1-2651 2.27 529 5
CI
[Table 552] Detention Structure Compoun Time [M+H] Method di No. (wn o 0 < N O HN .kN'1
O
N 'S N"J- N - O 1-2652 2.20 515 5 CI o 0 F N N HN N ' OH 1-2653 2.14 512 5 CI o 0 F N HN N"N kNH 2 1-2654 1.98 511 5 C1 o 0 F N NH N NH 1-2655 2.03 525 5 NCI
CI
[Table 553] Structure Compoun Teten n [M+H] Method H H NN N 0 0 HN N 1-2656 1.51 508 2 N N O HN N ON O~a N . N 0 O 1-2657 2.05 509 5 CI NO NH 0 0 1-2658 2.03 509 5 C1 NN N yS O OI HNN>OH N N OO 1-2659 1.85 487 5 N N CI 740 [Table 554] Structure Compoun Retention [M+H Method d No. Time (mO) N HN N NAN N0 0 HN N 0 1-2660 2.23 513 3 N N O " O N N 0 0 HN N O OH 1-2661 1.99 499 3 N I N N LO NH N OH0 N N . O H -2662 1.68 481 5 C I II 0
HN
t N OH N N OO 1-2663 1.68 481 5 N CI 741 [Table 5551 Structure Compoun te ntn [M+H] Method N.N I N YOO 1-2664 1.88 509 5 -Cl N N O OH 1-2665 1.52 481 5 NO N N O 0N 1N -2666 2.29 533 3 N N -- V N>C N N N O OH 1-2667 2.04 519 3 I-a CI 742 [Table 556] Structure Compoun Tete n [M+H] Method 0 N OH N / O O HN N OH 1-2671 1.74 518 3 N N-<O 0 O O OH [-2672 2.04 484 5 CI NS N yS O H ON/' HN A NH Q 1-2673 1.79 500 5 CI fN N S O H N N Nt O1-2674 1.68 530 5 CI 743 [Table 557] Structure Compoun te ntn [M+H] Method N-S <N 0--a HN N ""NH2 N 0 1-2675 1.82 486 5 CI N-S 0N N O O-2676 1.89 500 5 CI N-S N O N OH 1-2677 1.79 530 5 NN CI -N N S Y 0i H 0 HN~ Nh N ~OH N N N O O -2678 1.75 544 5 IN N" CI 744 [Table 5581 Structure Compoun Teten n [M+H] Method 7F O H K-N 0H 0 HNA N(N OH N-K A o O1-2679 1.86 541 5 CI N1O-I2680 1.66 513 5 C 0 H ') N KN 0 O -26801.6 5513 5 O- F F0 -2F 1 2.06 CF H2N" N / O 0 / H NKN&O 0 F F 1-2682 1.93 531 3 N N O 745 [Table 5591 Structure Compoun te nti [M+H] Method 0
H
2 N " IN / O0 HN 1NOH 1-2683 1.72 517 3 Nl-- N --- O O~A 0
H
2 N N0 0 HN N O 1-2684 2 551 3 N N NO OH 0 HN O ONN H 1-2685 1.65 526 3 CI N N 0 N N O O -2686 1.55 480 5 CI 746 LUUUJ [Table 560] Structure Compoun Retention M+H Method d No. Time (min)[+] Mto N yN O Y H O /HN~ N ><N N N kO O 1-2687 1.61 494 5 N N CI N yN O H O1 O -2688 1.52 524 5 CI N IC N-N 1-2689 1.562 49 5 N0 C I N N ~0H N-- HN )- N O o I- 1-2690 1.629 0 5 C1 747 [Table 5611 Structure Oompoun te ntn [M+H] Method O H ONO N N N N N O O 1-2691 1.53 524 5 CI NO AN0 O - N HN N OH 1-2692 1.67 511 3 OOH 'C1 0
H
2 N N / O HN N OH [-2693 1.79 537 3 NN HN N NH H N N O O OH -2694 1.76 512 5 CI 748 [Table 5621 Structure Compoun te ntn [M+H] Method '% , 0 O N N N NH2 1-2695 1.41 480 5 Cl y ~0H o H N N ) 0 [-2696 1.47 494 5 N IN '-:Cl O O N O H N . OH N IN O 1-2697 2.03 515 5 Cl 0 O <N O N N rAOH N-S N N O 1-2698 1.96 501 5 C7I 749 [Table 563] Structure Cdmpoun te ntn [M+H] Method 0 N NHO N H 1-2699 1.79 479 5 O F O O N 0 HN N-N 1-2700 2.25 494 5 N N 26O N N0 0 'HN N 1-2701 2.26 495 5 N N - O N N -a N I N - -2702 2.5 461 5 750 [Table 564] Structure Compoun te nti [M+H] Method N 0 O / N HN N'-X 1-2703 2.79 475 3 N N' N"O I CI N Cl N IF 0 IH N N OH 1-2705 1.8 528 2 CI NF N 0a H NN OH IN N OH1-2706 1.88 528 2 CI 751 [Table 565] Compoun Retention Structure d No. Time (mn) [M+H] Method
N
SyN F 0 o HNNO S N N KO OH H 1-2707 1.8 519 2 F N-/ SyN F 0 I N NAN OH 1-2708 2.06 535 3 -NN N0 O O N~N N OH1-70 183 52 CI N N N O 0NHN N 'iN O OH 1-2709 1.83 525 3 Nz Cl 70 NN) NO 1-2710 1.76 511 3 752 [Table 566] Structure (intermediate) Compound No. Retention Time [M+H] Method (min) _ _ 0 N N N N JN O 11-1 2.04 312 3 O 0 N N NN O 11-2 1.73 333 3 N CI 0 N N N N "O 11-3 2.1 332 3 CI 0 N ) N N N O 11-4 1.93 317 3 CI 0 N N N N O -5 1.88 297 3 753 [Table 567] Structure (intermediate) Compound No. Retention Time [M+H] Method o -= 0 N N OY NN , PN N O2I1 .88 316 3 0 N N ON 0 N N 11-13 1.01 266 2 N NZO N )N''o" N NO ,N N Ok- O 11-14 2.07 390 2 CI o 0 N N ON N N 'JO 11-15 1.92 370 2 754 [Table 568] Structure (intermediate) Compound No. Retention Time [M+H] Method 0 0 II I-16 0.86 266 3 /, 'N N " O ~ H [0363] Test Examples Test Example 1 Evaluation of human P2X 3 receptor inhibitory activity Stably expressing cell line (C6BU-1 cell transfected with human P2Xs receptor gene (GenBank accession number Y07683) was used. The cells were seeded in a 96-well microtiter plate at a concentration of 8000 cells/well and cultured in the medium (8.3% fetal bovine serum, 8.3% horse serum, 1% antibiotic and antifungal in DMEM) for one day at 37 *C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 iM Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 10% BSA, and 0.08% Pluronic F-127, pH 7.5) and incubated at 37*C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 40 iL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 pL of DMSO solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 iL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 3 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC 5 0 ) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC 5 0 was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.) The data of the compounds of the present invention are as shown in the following Tables. [0364] 755 [Table 569] Compound P2X3 Compound P2X3 Compound P2X3 Aln J(fA/1M i ln 1( 50/ M( i ln J1c5iu i L01 0A29L 1q7 J - 0n L 151 n 02 i- nn0c0 2 1 n. -& L 159 n1J25 L A11 A ARL UD L1 im 05 L 012L 03L L00 A1L 1L 13 i-nii A n23 AP9Q A1nn L1 7 Q n 12 LU12 17 n17 1.. ng12 L 116 ngi L0123g QA |1 - 091A n oA L 1,76 n n i- ~ 71i A 1. -01 An A7i L- 1-rR7A nnq LU126.i a89 1 - 9n.-) n n? I-1~ rfA n nv L02& QA 2R 9L J L 157 1J i- l~s n 8n |- ng17 n A10 L- 1,W7Rn L A217 1.. L000 JL 1& 01 L-ninnfl& nn n~j LU91f I- L1,r9R nDnUU L n141 nR r) Jf 017 L 157n nQnn& i- ~ QAQg n17i i-nc n02 1i - 1.SR1 n A LU162 a70 1- L022 v01 1.R2 n nns L- n QB5 nL0~s i914 nn74A L 1573 nAQ4 L~if2 2QA L1- 5 L 1RRR~i L0200 A nii Jl Ai -Qis L 1575 A1J02 L2 nn 0 25& 1-fl27 n n1 L 157 n Li- g 26& LUn 917 0014 1& rUR nU6n L021& r.r i0505 nf92 n4L 11577 n nn7 LU2 11R r9L- n02 L 1,Rq a 1nR |- 02A AA7 |i- ?021 n 129 1-1A8 n nn7 L0 22 n 97 - 092 n nQ.9 12 n n21 L023.'4 n29 Jfl92 005 -1~ n00qnn14 LA2A 1..D nfls2L Aq2R L 15S7 nni L023A 0J'i n|99- Aq? n L 198 nJ i- nig n QQAR i -n m mernslA I- 1eRem mnmam L2A4 A04 JA 1..n I-5 L1A59 1.9s L024 n16& n JQ95 grzi&~ Ji59 - -Q n4) i O5-nci on0241 n447i9 nJI9M3r5 rno n L 0254 n- 0QA1i n n.5 I- 01nn5 i- n?29 An 144 1- AgQA4L n A5 17n 10296 2716 1-0940 0008 21JL 010 L02n.70 n Rs? 1. Lq4 n 21 L1R19 n L2 nRR nU21 1- L041 n ng2 L 1f1 A 25 i- . T n2Z5g i nclci n9Q95 I-a L1R9 n nns 1..2 A52 A7A1 1S15 a75 756 [Table 570] Compound P2X3 Compound P2X3 Compound P2X3 Nn 1.190 (I M Nn 50 I M Nn 1.190 I M ~3& l5 AG2 2 Li 1 Z 1-07 ~0 31i 10994 0 023 1-617 0 027 1-0281i 01?~ 1h0956 ~0 139 I-1619 000 L~2 2 L05 2a Li 81a LfJ2&Lq nf197 LL195&7 n ngr% L1I nn4 I- ~ 0227 0 _~ I08 - A8007 1-12? 00 MiMM4 nnIa - n I9 - L1 R9M1MMM MM 1- 02 0 277 M0inL 0074 114 0l00 L~L ~222 LA2 91 L11R2R MiMM9R n 9 1-nq nM nMiiMM I-I MMMnnn i- nggL nAA L 12 7 MMi- n nos ?AA MM ng n non 1-1FP AsMMMi Li 4 n17 n n-n L 1R2 n i-MMM E nMgna i-nA n nia MMi-in nonis i- gg n17R 1_-0n71 nn i I nc nr i- nM M n n2.9 1- noZ n n.io -M R n nn2 ~inL nl7i - -na79 n m i I-I M non i-n~9 nf4A LL-1974 n n~121 L1638 n n vi Ri nnoii n ins i n infgi 1 JMi non L O n /IR _ -2577 n nirZ I- L I11 Rini nn nM n nn 1-n1R4 n nni Mi .il n 14, 1-nasla MiMMMMMMMnni L-n-i 09 n inA i - 0q 17 L- 1 07 n F77 -nmv 78 1-n, i n nnZ 1-MM R4M nimio 'll3A n rrr i - n A 1 L /1u n qRr -nai9 n 9i-n ni M1 1 inM nilinn i72 i nad Lni M -n.'117 nn17 1 -nEM n nir; E IIM.1 M L0312 A OJL9 L0982M WJ UL LL1315 nl? i nqB& nL98 n.912 1 5 F9R n nOq n112 JR iiI nn 1 n IMnM LA22 Ofl 1_ 2001 OM Lim7 OO6 Ri-nO nna 1.naa n nLn O - MiM n nii9 i 2 n.,r n 19A5 i 2- L I 7R I oa n i nO n n I- M ii nn11 Mi nin nc saa 1- naa nRr I Miln11 ~ln LL 22 n ni& i - 19n n14 1 aflnoin Lnm4 nnaa iL)OL n ?a2 1-610M n nnM Mi mM n nq, M iMM ni.i iMMq IMMMR7.3 MM1 L- nqi0 n 77-c i- inA nns I 07 71 Mii- l niusi MiMM n n n.,i M- iliMMn sMM R in4 n 14a i-inn n11s 1- R7 nn17 757 [Table 571] Compound P2X3 Compound P2X3 Compound P2X3 nf 1('90 (11 M 1 In 1('50 (1 M f In 1('0 (1 M i-o Jf5O n ni 1-nng J5iui I-o JC5O nu L~ A2 A21 ~ & L 190~ 1-034 ~0198 1f109 Ogg 11680 10730 0A4 251 Ai n21 1 A1 & w1Al L-nA A1i L 1012 n l I 118 r i- n249 n 11v 1- 1f1 OO n nIn 2 i- mri nin iu nAn17 I- LAEi nA22 1. ARcG2 Anr 1-1A1-; nn7 I- A12 -~ L Aqc DW Lnl 117 n L 17n1 n L0-n.3524 nOO36 J11~ O17 q L -1700 nOO124 i- nq;-c; ngn -iniq n nn7 1. 17A2i n n L A3R3 0& JfL 0L 17W0 1-0,116 00lf19 110900 O~M 1-1704 001l5 L05L A =7 AA7 LZ 1 n1 L 17ARc5 nn1A i- nirg oo55A 1- 1022 n On14 1- 170& nn1I i- 0qc59 An 1 1 n-O,- wJinZO9 i- 1.±6ZJ LO n LAR 1- 19 n L 171 n 07 i- n,3 n n7& 1- 1 n9A n 14 L1711 nA03 i- nqln n 1. 1 A127 nog 1.1719 n02L i- .- d nnin 1.1A2Q A nAn 1. 1718 A nA21, L- nw OnO4DR 1. 1 1 nOA 1 71725 n Qn3 L029 ~OO L J1f3 A OO62 L 1720~OO i- 43 n ~n 1. 1 A.iR n M 1.-1791 5, i-nR nnl 1 L -,n I 1792 ~ L 0370 14 1 1034 L00f 1 1739 0011 1- 0L372 0964 1103 000 L 173A 0005 LL 0 7 i 1L 1n17 L 171c n005 1.3z AZL7A ~fl L 1739 D L A379 A 13 L 1f12 JA L 174L 7 1. n'77 n 755 1-1 L 179 n n5 iA L ,32A7 L- 1 A1 L 17n 1. n'17() A 99 1. 1 AA2 L AR I 17A1 n n55 i- ig n qR 1.1 AA L q I 17A2' n 19i L0283R.i O532g J~1 45 n A59 1-1744 n 949~ i- 03)8L o 1-104 n=O~ 0J13& 1174 n o23 i- n Ofn3A69 1-1AA9 L n17AA nA2A I- 006721-10A7 o 1 A L 17A7 i4 niql n43 |- 10 AQ 1& L 175L nfn12 i- ~ nl4 n 159 1.- 1 n.5 2 1 17,5 Ai L5 An L 17R; n L03 A9 n LOO44 11 OO43 n17R7 n A1 JJL59ARG L 1780 Dm n401 n441 1- 1 Agn nO7c L 17RI& nOOO6 L-n0 005 L0 179 003 S75817 L 17In 758 [Table 572] Compound P2X3 Compound P2X3 Compound P2X3 Nn I(,.i (ln J1 6±M9 (ln ICn MI] 1 MinMnA n owi Mi 1ngM n isq 1-171 ni in il nino i- Q4 n95 1-1 7E7 n927 Mi-n noo7 Ei 1n, n_ namI-1T n oqoo Li- o aiL in iiAB n 042 1-m74 no25 MInn ni q ili- in7 on Mn -i77 nonai Mii-n e mmnn4 -ing n111 1-177( now., i- Ml9 no() i Minin nA71 I- 17A1 nrson Mi M 1~inn -10n71 n aang 1_ 179,' n17 M I nl nnA |_ain7 nos 9 ri EI R n o-ro Mi nir n n.asr |_inTI n n E 1179 n 69i Mi Ml nn.v; i in n mP I_ 17AR n n 1-0417 no00 1_ 1n76 017 1|_ 8 0030 MinilAn onao Ii n7 nn 1-17) no no Eingn nni( il!M n nng I_ 17() n san 1-0499 0n04 1109 n 1- _17% 0587 Li2 MlAO i2 n 0c 1i7W n LiM49 nnI- L1JOit 9 _ 170 n w MiniMr; n Mii i 1ng nn.1 1-1a)( ME M nigg 1-0494 0679 1-09 09flZ2 1-~ Li7n 0.51 Minn n77) -in7 n nzl I MMM nRA 1-0430 0004 1107 0.54 178&) 0169 Min n ioi n qR iin nia AR 1E1PiMM nnn 1-h0439l nQo0O |_10()0 I-E7 L1M7 06 I-04,QA 007()3 ff1107& 0Q1 17() 13n 000B4 Mi Mi noo |_ inog n Mni oma- (() w. 1-0420 0(4.1 -1() LilB OQ Li190 069 MInin1 n naaA |_ inoA n i EnI- A9n Ri M i-nA, n An7 |_ inos n iOA I- M Mr n ooo7 1-0444 0006 i_1n0W n141 11816 0300 LI QAMr, Mi-A284 n nA I_ JA7 n noO 1-0426 0006 1i-li on07 Li1 n An2 1-04472 00 1-110 0llB 0432 118 0873A R I inA noss i_ 11ni n |_, 1- j91 n aqn 1-0442) 0055 1-1109 0148 1-121 049(L Minirn n i 1- 11Enim m i n y11-s1 w.i LIB3 n1n7 1|_0 lflB In- L199 n7f4 1n Minrg n 7 E1-in 1 s -1J90 no()v 1- 0,52 017 1 L11 OR 0007 1199 00f19 Min,r_ n nn aln7 o nxi i ipniM nAR 1-i045 00E0 1-inn L11 0.1 MIninS n97() 1-11no) ini 1.y -na op19 n u Minno7 wgg nfin n 20(7 I|- 1n P111 rg HiniMn nn 1-1111 n171 I 1 MV n nn I- 04R 00043 1111. 019.1 1-LIA 0797 Ldi- I-im nf4 9A I-i2 n ar I- 042. 004 1 115 O0JA4 I L1fli 0007 MinR nonvai 1-111A ns'iR EI- P1n nn 1-04i5 000n 1-1190 n o053 1-18O4 00i hOi4i mifiME I-im~l milili'1o2Ei MM 29 LI04RR 001 11199 0OM I 1fl22 00-2 I- n nnAQ L1111 n L I- L1PA n 75 L~d6 DQJ LiJ2 OB ~L13~ ~759& [Table 573] Compound P2X3 Compound P2X3 Compound P2X3 Jb IQD(IIA No JD(IILA No 112A A JG2M) I-a 04RP 0016 1-3 1 ~ ~ 19 00 1146 0011 J~~Od69 aw 1.. 125 LO~L~E ai Snn L 1 12R L 19 I- I PA7 n 1.0471 ..4 1-1127 0Q M& 1-1848 0014 L 0473 01..7 1129 LOfifi 1- 1 RS1 0004 1..48 0A7A 1..1136 L94 - 1 98 00 L 47 1 11'17 n .iia L 33 J~1852 n i-Z n4R9 osWvi 1- 1 11-) nn ~ 1 ~ i- n4A Ani7 1.. 11g nnA 1-1PI9n2c L 047 0015 L-119 080 L 185 A 1 i- n4RR n nr;R I- I.. 11 nnA I-IAR; '-; 1-0487 0f692q 1-1144 ~0 74 - ffi1B5 0fl09 L 0A7Q 019 11147 0010 L 187 05 I-049 012. 1-1 R 0R 1873 0009 i-8 n l35 n q~ L11A n A fl 1-EA 1 n 2 LO~8h AR719 L11A1 0E~fiB9~l2 I-dB 042 JP4 0WLg1111 04 1187 0013 J~ aL2 11A&2 A J 927 I-04921 0049~ 1 U1A,9 0110 1- 1 8ZR 0 011.1 I-04P7 0194 J50 01,t 1-18Z8 001 J~~ A12 L 11AR L 1 JA972~3 L AAQ2 1. 11A CV L 17Q n19 I-04PP9 0~46 I U156g ongL 18 Ag 0 1.1 L AORO~2 Li11L 0A L 188 7A O& LO~f A W1QA 1..1151 LO ~ ff1B8 7 flh L AAQ 1.. 11W 2 A AR 1-001 010 1115 0 063 L 1 79 012 L- qQ n I.. 1 AIR-1 n 1 nn LO~5 A A27 Li112 029 L887003 J~05 A W2 L J112 LL9 L&3 2 1-05904 0192 -J1Z 0148 1-1AR 010A L05 A 1250 AiZ 70Z 19 M4 1-.0,96 048 1-13 0J823 1-Z 1 PU972 0003 1- 0.0137 1-A 1ZZ 0004 11A A003 A A1. 5, 1171 L J Z1 1 JJ90 n 11 I-iL 01J L1179 0AOP7 1 L 0A27 .L A512 1. 117A 0 JJ~ 0.0 L 0519 0.S9 1..1174 5 0097 L 1A7 0014 L A1A 0015 L 117. 0 1 0094 L- n-c1 A 27Qg I.. 117 n 279 I-IPQR n i I- 0S21 00.97P 1-1177 ~0 973 1 1fi1P5 0004 i- ~ ~ n2c1 L n 1117R nn1 -iq ng L-0.17 A.51i1 1..1 17PQ01 -io 11 i-ncl Rr2q L- 1 1R2 L r) 1 Qqn2 L- A1Q PI..P 1 111 L04 1 03 00 L- Ar2A n 19 -I P , -IOn n L A.527 0L00 111 7 0L15 1A 7 0005 760 [0365] [Table 574] Compound P2X3 Compound P2X3 Compound P2X3 Ah I17ni \ Aln JGSOIIMA An 1Cn 6i Mi L052 A12 WU A 1Jt L9 aZ A0529 0liO 11139 1iO - i1911 0253 -new- iiin n nA 1-1 in o I-19n iniog Li2 L0o9 110i2 L 11 019 -nemg nini - g nm ni n Ii- a IA~ non I O 1 060 1 1OE WU ),9& 0040D 1 15 009. I-J , 054 1- 1 V4 00,11 JJ1- 1c1R 0 95 L 5 AR2R Ln 11 22 1 1 17 A2 105,6 A0033 1-1 1q7 0O 1 i1B 0019 L- AR7 L 110 - IR L -,r 11 AI 21iA I-J RP 099 1 1J2 iWU99 0L0,11& 1 1 93 0 084 Ji- n n no J2nn lnO uA95 11n 1L940 010 JJ2 n 1 10A92L D Mi n!Mi nooo u-ong ino uoon I-IQ7 1-0,94 0010J 1-19031 0Q5,219 2 8 M 00Q5 MiniifniMg u-inA n nm i- i cn nilim! noniA n irMoni nnoirn nng nI R nonno 1- ,95 0046 -1 n nID 00d&i 13 1 -9 n 1-,97 01 1-~i W1908 0091t 1 35 0 QQ9 i-nrA n7 i igL n 12- I R on I- 0920 7 1 0 0 037 1- 1 38 0312 1- 591 0601 1211 L070 1- 013)9 0 WC JE I alio9 um~i iLiMMML iin no55 J~2 A 172 L 1219 JL D Mi !r oiln o a1- 9 -1Qan nnii 1-0,56 00l11A L121 R OM I 1.w 000 I-5 9 |-1219 7) 1 4 151 Qi2 n A 12 1213 RQ29L L IQR n A25 J~in!WiliM u210 DilDi uoa2 oZB Ri! nr oom 1-m9 n 17 1 iqmin noso Mini mifno um, 119 n n17 Mi cM n nqQ 19 13g 1-122 L9 1- 2 a 781 i.~ aw L 122L L~ ~~ 105z i- nrc M iio aosI 19 n 199 1- 1 64 inino i- n-rR n Q 12297 L 102 I IQ7 Ri !rEg noo uma I- 19an n - 7 noogg I- 0,9 007~ 1130 0004W 1- N58 0016 1071 027 I- 12-2 OM A1O A0054 I -057Z9 00405 W1213.1 5 i4 13 qgl 01 1- 074 05& 1- 9,1 0914 1 4,, 001.1 Mi n ili n umR -19 n nvi 1- 1iMMd in 97 1-0,977 04l30 1137 0I I-&3 1.C)65 003 MiM~ll! n-e mn e oa M -IqR nii a2 L 1 23& A A2 A~J 277 I ~ ~ -A I5 c 01- 1971c 0I3 - 1 0ss 000 J~O5A9 2RA L1232 03 L 10RR oa 1 0-1 038 1 19249 0158 1 9 WO 008 Mi -,Ani -ik i mo9,- n nig MiigM~iln o A 2A4 L 12A 2 JZL71 761 [Table 575] Compound P2X3 Compound P2X3 Conpound P2X3 NNo 1 1 (i Mi No I50(II Mi No ICM(II M i- rAq nii L-19AA nAA71 LiG1 79 nAqAi J~ D200 I..2 4Z 1107 24 i- 5 nLq 1-99 19J4.5 n nrn I -W ,Z& n nn i-n q n g L 19AR 1 1Q7A2n i- n n cn1.4 1-247 n & 1.. 107R AA17 i- r~i nnrLI 19AR L nr. 11077 nnc i-~ n5DZ n -1.. D .94 1 W n 94 i- -rAq n ni L 19-M n n17 1 ~ i0nn9 ~~ ~ 1. 125A~ L 1QAJA i- nci n wil L1.. 2 19-2 L19Bi n 3 Ji D~ L 09 251-19A L0- 1QR Lom2 Aflfl2OR L 19557 n OOA 1 1 lflhAL i- n4 001 . 1-256 0018 L 1QA5 001 Lom A 19rl L- 19ic7 AO 1- 1 CARO7i J~L ~fJ2 JJL2 1WL A Rio LOi- n~i) oOO I.. 1951 n nos 1$n & J~if DA A J2 L 1949 Li01L L i- cLD3ZA A127 6 An25 L 12 A 2A J~i2 JJ A A21 L iQQA i- 6IL 0031 11961 0018 L 1acil00 i-61 ngvi nn 1- 196O Lngg i107 1-0617l 00f67 11969 nO f ong ~ I- fl2A003 1-0618 01912 1-1970 00O19 - J (A9 009l8 Ji- ngi Q nA 1-2tL1971 n J-i n LO~~O ~~flfl~~1. 19272 O 7 Lm On5 1- 0620 0044 1-1979 0007 1- . 000 1- 029 013. 1274 n 08 A4 0013 i- n~-,i nn~n L 197-c r, i qnr n, 1- 064 00lf49 1-1976 00O78 1-m flfl 036 Ji 5 1977 n Air2 i- J r2 7 A1i7 J~D~6 A A22 1..127A cD3 ~f~& ao i- r~R n1..I 197R n A,)i i nR nn7 i- n9A A 127 1..1981 L 20 i gi11 n i i- n Dn nnL L 19R9 L Jd2m9 n42 i- ~n nnin I-2a 19R 2Z n ~ W nn -gn.i n n i- ~n 00.9 1..1989 L51 2-017 04 J~D~9 0122 LI2 A Ais L 2A1A ci i- nnR o1..I 12AR L 201n A 0n R n 2g i- A13i n fQ I. 12Q L J 2D17 aon a J~2 D1.. 1201 A A222A i- 21Rq 1. .- 19A7 nfl51D i L 201 n 9A LO~3& Of 1.. 1296QA 9 L 2022 fl6 1-0640 0005 1199L 0026 L 9029 00 D~2L JJ22 ~5L LJ2A2A O Oi 42 nm aOI5n J311901 n nciA L 902 n n iA 1 A2 1.. 19 L 2A27 A A17 762 [Table 576] Compound P2X3 Compound P2X3 Compound P2X3 Nn 1('son(1 M1 Nn K1('son1 M3 Nn IC.0 u fI-OwA 0Q336~ 1f1306 O&L h290Q30 000l6 i- nrA n ni |_ 19n n7_ I-nnii n Aqq I ffi5 00902 1fi1308 02Oq 290Q31 000l4 M Oi- I n oo7 i Dnn n non I- nL A6 M i img n ing i_ vin n ng I M A n nn M i ggE n n.o1 1i_ 11 n i_., 1-n11. nonvo i- ngs nng I-no 1.19 n 4r; I-Wgg n n M i M |_g. na n6 nnci -911 non M ilinR n 471 1i_11. ni n= I_ 9nno n n M i mA n ino I-|_ R na;4 E M i n non M i gg n im I_ .11 jig E M i nM ni M i M |_nnni I-ii nond M M i n non M ilimF; n on7 |_ ig mam Mi n. n nog I- Dff2 000 1193 001 12904 01 38 i- nRR nnaR 1_1395 n omi g n o85 OiM n I_ Li o9 nO 9(A9 n aA M i M |_n nn nn I q9 qIli0 noon LD-5 n671 ntl. nOD9 I-Q3 1,1q n 34-0(FR LiMM 7 nlO ii n mi L2Q3& nQi2 M iMM oRI ne |_aI- no96 M I MM) nonn7 LD n74 1i2 L31 1-X,1 n2~ n.4 -9fl2 n9 M i m n mq I|_qq mra M M i Mg n non MiMM oA7 ne 7q I|_q~ n n-,4) i MM M ng i-~ n678 nIif nng 112111 n a02&gR4 n ~ M iM- |_nnng -,1,1 mag o n iln non M i- Fi nnQ I.11Qn oon iE qMRM iMM M I-Oii 0on 1- aW 0 004i 1-nz 9i9200 ii-LOP3 nnA n I-iM9M n n- L2nin non hiO naa 1325 n hnfA9 n naflB i- n~q nnI93 fI-32 CUR Z n ~~ gigQ-g952 n M i n n ovo i_ vn n ng i_ on77 n no Mim- i_.l n i 11,19 nsi E m i MM nn M i FM nv I -ns VIS n1g- gn7o n o M iiinF n igg n-s nMi I () nawvi M inA7 r7 I 1S nos |_nsa M M I MM n Asq M i m iP na ng n17 1 9 MR nowu M M i- n c n -7I_-1 -qq nAA i- i'iin on nns i-E o~n na |_ -V,9 nsa9 MiliMEg n, L n01 n_ IVSA n L 2 I- L2i n jJ MiME~n nin7 M I- ,1.9 n79 1 nc) n 1-073 0015 11202 OOI 9(2.) 000 L062 AD0O& Li30 OH LE a2 763 [Table 577] Compound P2X3 Compound P2X3 Compound P2X3 Nn 1('90 (1 M 1 Nn K('50 (1 M Nn BC9 1 i- nO5q nAniJ I- 12629 - r-A i-2 gini n n9 1-i0706 0014~ 1fi1363 00.96 1h9109 0Qfl34A 1-070 A A0O 1165 OO L21 0040 1 IJ.L 1267 nQ14 L 21A& n00 L n711 n025 1126 O L 21na &7 L- n719 n A2s L- 19qq n r - ig L 071& QI L 1270 1- L 210 0 Q11n L A71A n nO3D L 1171 n L211iA A i2 L 0715 03 L 1272 L & 2111 a~ LO ni 1jf2 Ln197 L v12112 n4Z L 0717 n n21 L1274 n 017 L2112 n Q L0Z1& A02 LI 17.L nI211A nOOL L n71) n 115 L176 n L 2115 nnig LO-i A12 LI 1 077 L 21 Ani1 i- 799 nni L 1q7A L nq 19117 n Agq 1-i0723 009l4~ 1- 137q 00f10~ 19118 00f35 i-O~ A n O2A LJ 1q74 L nL2-11A Q nniR fi- n72 Qfi4 I- 199 n 9r7 L9191 A Ag1 1-0727 0012 1-1384 L0.90 2122 0 OM9 LO~& aW 286 OO~ L 212& a00 S722 nn7 I1-8.17 n L 2124 a n27 L~lO A0 A2& ~ L 2125 aOO L~z A 012 L 12AQ OQ1 0 2 12& 0287 L072 a4L L 1220 0 L 213 00 L~f& 08L L 192L O L 21l7 012A L075 a07 L 12220A L 213L 0A32 L~f A 0A10 Li2190O3 L 21AA 0J L073 A20~ L219608 ~ L 21A1~aO L07A0 221 L 1907 LO m .21A2 ao L A71~a5 L128 A O5 L 21A& A A23 L.Q7A2 L 1&JA944 L. J21AR QlQ LA7A5 A 125 L 1AA2 A A3 L 21AQ A 701i L07& 040 L 1AA WRL L 215D O0 L A7A7 AA12 A A4 02A L 211 A A12 W07& 0205 L 1AAR OD L 2152 a4 L A7AQ A A27 iO L 215& DO& L075 0f22 L 1AA7 O L 215A A 12& L 0751 aO A212 ~ L 215& 00 L 075 Q11 WIAIXI Wn& L2157 n 987 -n719 n 1A1i 1O L 215& A A22 L 0755 n9A L 1A12 L 12150 n i4L L 0717 n in L- 1A1A n44 L211 O54g 1-0749 0087 L9 1A1 000 Sn 1 L1I-A17 n 207 I27 i-nAS n1 .; i-jnLnigi LI-n1A Q1 i- n4R i ~ i-14ni nq i-91.;n7644 [Table 578] Compound P2X3 Compound P2X3 Compound P2X3 An IJnOr Mi M Aln 1C.06i M Aln I QO, M L0Z63 f 1..1WA2A 60 L21AR~flfl 7R4 n24 1-1A21 n L2167 n54 i- nR-c; n1.. 1-A22 L 2cg I 1R A nARC7 L0Z5A0lA L- A2Z 5 OA L-21AQ Ofl51 h0 n766 n4A3 . 1A2A3 n4l L217 916 nn50 S076q 27 1- 1A25 005 L2171 0 29A J- n A5 1-1A2 n- J.212 n nQ i- ~ n7 n A77 1.. 1A27 L mI 217I ni n773 00 1- 1A2- n L 2174 00& Sn774 n I. 19A2a 292 L2 17c fn1 i n775 0 |- 1A3 n1 L217A n04 LO~A 11JR W1ZA 2A2 i.L h 8 nQl77| 1-1A2 n 94 1-217A nnl 1-0780 0O0 15 1..1A35 00A 1 L21091 0011 LO- L 1fl02 n I1..ARi L 21 LO- n 0A9 1-1,1A& nQ L 21A2 nfl i- nZ3 I-6 14Aa nJI L2IS 1-983 n LO A 0A22 JW0 O~L 21AA 0f~ i- nQ1J nn 1-14 1 no1 L 21AR n01 LO~ 0fJ5 11A2 O L 21A&RJ h0 787 Ql4 1-14A43 n nog 1h9187 nQl4 LO-& n2A 1-144 n1AAA 1- 21AS 7 ~ nt nis . 1AA745 n L 218A n A4Z LD~L D2~6 WIA4 012 L 2101 00 L2 n 0 170 1-147 1 nnQ L21Q2 n00 LO~4 OJ1..W1A5A A AA L 219& f LD-5 7n2A 1-1A51 n n L21 02 i- ~ ~ l i~q I14A n LnI 91A9 n n i- ~ 701A 1- 1 Asn 1 4 1- 921 AA n AAA i-A 2~)5 91 1- 1A.5 L ag I 21QQ n nr1 h0 7qZ QZnE 1-14A53 nQfn13~ 1-2196 n4A46 - A 21t 1..1A55 n 01AI- L f 05ri i- pjl|- 1A57 n 1A-9) A2 L-n~aIL 01 - AA 0214 L- 00n2 JA 1m a2 1.1A6n 92 1- aQnQ LQ 0022 MWi O72 L24 M 0il2 hiA A1A2 I1A1 nQ22 A2r5 A12lO9i i n O.OJ201 1-1A2469 nO2 1-990 n i-A 2p0sI 1 1AR.1 n R,2 I- A12 ni h~m ~Ql1 1..f1AR2 QJ1 2L 221A9 LQ& AAn3 1-1AA7 n 0192 L2911 2 La 003 1 1-1A4 nn0 1-2219 2 LQ~f i OfJ l_4B iA7 L 221f Ol LQB1L 047 I- 1A71 nJ2L L221 n14 i- ~ n8A42n7 1.. 1A79 n A12) L-91 n217 1-08i a Q I- 1A7A 00l1A 221S 0 10813f A03 1.14. 1 0017 L221 0 0. i-A nsR I- 1A7SA i 1 9 A nn97 L1 nl n n.-, n 1A77 n n L2222 nOn nr L081S 01.. 1A74 J2 L 222S 0 765 [Table 579] Compound P2X3 Compound P2X3 Compound P2X3 Nn I 10(11 M No n I5 (1G M Nnw I 1c5u0(1 M 1-0230_ 1A7 L02 1- A 0 A 1i 1- O824 00l18 1-14A 0 00012 1- 2225 0061 L2 n 0D1S n 1_ W1AR1 n L 222R AnA Sn,26i 1- 1a82 A 1- 2227 n005 n,2,9 n n?.r 1.1A-84 nn L 222q n02R J-,2q 0n?R |1AR5 |-? ???O nnn? i-n~n nniR |-1JARR nn -9-q n, L~a3O a089 WIAB& OQ~& L 223L 1~ 1-0831 0077 1-1AR7 011- 2232 001IL i- n g n1 ni |- 1ARR nRd -9111 n i-n~r)I nA 1- 1Aq 0,16 L- ?922R n I-3 2cA ; I - 1 AB& QA L 22 79 I- 7 0 017 1- 1AqA 0.571 1-? R 01AR i- n Ofl A5i 1- 1AqR n n54q L 2224 n nA2 ffiO&3 nOD7B~ I-1AqR L nO6 122A <n nn2 Lan6A 017 |- 1A07nn -q4 21- n020 fI-Ow 0 011.5 11.f1A94 0L11 122A2 J500 L~a~a O2A M A45~ 90 L 22AA A A4Q i- nR4 n 2 1. 1 2 n L 22AR A 702 109419 0061-1 % 00? - 2247 0003 I- Q1-1AA& Q721 L22A1 01 m4 I-Z a0 01- 1505 |1- 22Aq 000 i-nri n n?A | rn n - ??.rO n n LO~ ~O1.O W1507 OO L 2241 MOO i- ~ n i n vi i-rn nI- 22.r nZ7q LoaI 0l2 1 1 aLAQ L 225A ao iB54 a A12 0 1.11 L 22nI 7 a 11 i- na0 2 1.g I Q11 L 22R2 17 1059 0017 1- 151A 0 & 1- 22R1 0004 1-06 0 06 1-15 5 17 - 264 055R JiQ- nPR I I- 1517 Q4 I- 9nn i-nPF- nAvRI 1.c81R L 22 I 9R7 A 991 L- nggr) 017 I- 151 n 2 I- aR n 4 L~ a05 1. 1 O2A L 22RO~ L~~E aQ~~2 I1521 02 L29 a~ iLn 7 n2I 15? 12 n n22 L 2271 <n nn4 - na 574 1- 1527 n|3 - 2272 a o12 i-n97n mrZn -53 L1,52 n~O nm 12?3 nni2 1- 0,972 0091 _ 1529 LOO? 02275 0010 i- R~q I A A7 1_ 1 r0 L n22n 1 9 7R n 77R 1-OB74 0086 1 - .1531 0O025 1- 2277 0 107 I-n? |R., Q J - 16 -??0 09c1- 780 1-,F LfJB7nE?.i -f2 L1511.1 n~l Li -227q naoaa I-U77 00921_ 1 MA 0005 192B A 12 I1 1 ()7 L 2283 'I -Q 766 [0366] [Table 580] Compound P2X3 Compomd P2X3 Compound P2X3 Nn C06 Nn i uq Nn 1(i0 M i-ng 127 1. 1n9 17 L2R I- O89 0100 1.. 153& L00 1.22A5 nOnO4r ~i-.O883 A an2 A W -2 L. 22nR 0005 I-I.. 142 L 0022A7 I- I..R 1Q LR 220201 ~I- OP 0076 1.. 1.9" 002 1-O18 L 2287 0 I OPU97 0093 1 -1 J5 45 00(.1 0 004 I-O8B aoaog 0053& 1-57 0003 1-.22 0019 I O9 00&13~ W1 154q OM I- 1 0909 1 1 5.5 1L 0 OM I- 005 I -0 Rq5 004 55& 3 011l i- .B9 nn.W, JnJ5A +~ 767 [Table 581] Compound P2X3 Compound P2X3 Compound P2X3 No. IC50 (i I No. IC50 (uj M No. IC50 (uM 1-2300 n QflO& 1W351 nQl9 W-4QtilO & W2 t n 437 1..92h W352 n 1.. Ln- 9 LO -l29n nWB 1n nW L 74.9 Q 1W2305 nO 1.9356 n -2 .40. i i - 9.1..9ng n n19 1-93..n i i-94n7 n nc L-0 002 1-9358 0f 1-2408 Q 11T -D I ilB n 0I- 1..9Q& n n2i .. n -l0 i 9,ic)n ngi1 .9ign nn11 1..9410 W3 -0D03 n1.9,11 n n1i 1..911 n 1 1..921111 n 1..9,19 n i 1..9419 1-9119 0005 1-9363 000t 1-2413 03 1 1. n1Ans 19,116 n 211 194 14 n nm 1..9211 n n17 1- .. 5 n9 1 1..941. n nnca 191 ~nn91 1..9367 n 19 1.9417 J 1-2317 00&3 1-9368 021 1-2418 C 19231m n0Q I-ZB1.6A n0DQ9, 1..9413 C n3& 1. 91n nn17 1..937n nan11 1.949n n -23n n 006 1.9371 n ing 1.991 0 0 1.2991 nn11 1..9379 n n2 1..9499 nQ t 1-9399 0U 1-2373 0 t033 1-2493 n 122.. 2QflO6 1..9374 n 42 19A9A 1..9,19A n11.9 1..93779 n n2 1.9.9 119.99 n n47 1..99776 n1..9A21 9 n1 I-911Rn n 1- .. 177 n n1vi 1..997 n n 1-23297 0 1-9378 000 1-W9498 00 1..22 n 10Q WB.in n n2 f t.n nQ 1-2330 nD il 1..9381 n0DQ f 1..9431 A00 1.. 9,1,1 n n 1..9,19 n .9 1..94,9 9 1-2339 0913 1-9383 005 1-2433 000C 1-1. 1 2n9 nn 19,18 n n 1.9 194,11 n n 1L913C1 nD0 WBB& 1-9D1.5 n i 1L94319 nQ37 1.233 9 Qfl& WZ & 19l8l n n1vi 1..94 i 1-91111 n in1..9387 n n 1..9437 1-ff3 960 1-93RR 0003 1-9438 Q 1.. 9M n na vi1. .ig0 n 1..i -944n 1-2341 n16 1..991 n I 1940 I-9S9i WI- 93.9 0 nLn 1..91 I- 9S001 1-939t 0.010 1-2443 0 I- S44n n1..I-93qA n n21 1..94 I- S47n n1..-93W7 n ni 1..9447 nni -238 024 W1-9398 0 t003 1-2448 I-h234U n -1I JZ239li nlQIOn fI44i nlQ2C L..9900 000 1..940 0 768 [Table 582] Compound P2X3 Compound P2X3 Compound P2X3 No. IC50(u iW No. IC50 (u M No. IC50 (uL 1. 2451 n n25 1 -25Q1 n n57 .25 I -255 1.. 2A42 n ... 2802 .?L J258 n 1.2453 nJAM 1. 2503 n 1-I.25 1.244 n n.2514 1.sna n 7n 1.. 2555 nn 1.249s n 1.. 29n9 n5n17 1.. 255 124.6 n Q 1..25 -nR nn1A 1..2557 n ni c 1..24.7 n n1 v -2 O7 n n.21& 1.9. nn 1-2458 n-i 1-9508 0013 1-2559 aom 1.. 9A9c n. L2n0 -. 29gn 09 996n . -246n n n 1.9 i25in n 1.251 01 1.2461 n nn7 1.2911 n 9. 1..2562 1-9Q 1..46 n2 Q0 1..219 n 11 1.. 2569 n n. 1-2463 n0 03 1-2513 0 1-2564 096c9) 1..464 Qi 1..2i1A n011i 1..2586 nn17 1..46. n4 1..2515 1& wA 1. 2566 nn17 1..466 l 1 9251 R n nq 1..2567 n ais 1..2467 n L 1..251 0 167 .25 1 09 |-9468 02090 |-2518 0004 1 |9569 016 I. 246 nn1c 1-.. C251 04 1..9297n n 1.. 247n n 1..2 2O n 2 1.92571 n 1.2471 n 5 1..221 n 1..9 1257 1..2472 n.0i 1.222 0 211 1..27A4 1-2473 000 1-9593 016 i-9575 0006 1.42A74 n 1.2n2A a 1..976 7 . 1..2475 nQ0i2 1.2525 n 1..277 0 1.2476 n n1 1 1..2-26 n 1.. 2578 1.2477 n n12 1 297 n 2n7g I9,7 |-2478 n0n5 |- 959A 0.073 |-25Bqn n-2o4 I. 247q n 1. -253 ln n8 1 91 1 B -0 1.29,11 n 1..282 0.103 1.241 n nns 1. 29,9 n nnQ5 1.2899 19. 1.42 011 1-.2511 n 1. 2584 n 1-2483 00 1-9534 0-105 1-9585 O0 1.244 n 1. 25n n 1..25986 n n 1..24R n 1.2596 n 1- ..997 n nn .. 9486 n 381 |.9537 n n|..51-9J588 nO 1 1..AR R n n37 |..909 n |..9 00 6 |-2489 n0050 |-9539 0078 |-9590 1.4.n in 1. 294 n104 I. 291 1 I. W4i n n74 1.241 nJ 11 9.292 wiqn I. 242 4M 1..242 n 1, 1.. 9.9q3 I4g1 Q.A05 1.2-& 4 1 29A 1-24c4 000 1-2544 0-011 1-95C ) I. 9A.5 n n21 1-..5 n J .. 2096 n n 1 1..4R 2.on 1..Q94 n 259 1.21 124(7 n nni 1.2547 n ns 1.29& (19 1..49n QA.i 1-..9 19 |.I 9.9 00 0 |- 249 0005n |-954c) 0012 2 n On4 L0 1.. n255 n 004 L260l n0i2 1..251 n 4 .202 -. 0n 769 [Table 583] Compound P2X3 Compomd P2X3 Compound P2X3 No. IC50 (u IW No. IC50 (u M) No. IC50 (u M) i - 6n.i n 12865 16.5. 27nQ n1OOR I- ~ 2f21ng 1..65 2An I.. 271 n L2605 A A1A~ 1..2A5&RR X 1-26n62 014 1.2657 nn i -260& nfQ L2; -65c) n 9T -2610 012 1-2661 n 0n1 1.2611 nJn14 1.2R663 n a2 1-9619 n2 nn 12664 n nD 1..2614 n-n27 1.. 266ARnRn 1- 2615 n-007 1- 2667 n n 1. 21 n ni2 1. 9671 1.2617 49 1.2672 0QJ1 1-2618 n-nnOL 1. 9673 .2n7 1961. 2QF 1..6Z4 7A 1-62n 0110 1-2675 n n1M 12R21 n 25 I.. 27 1676 n1n 1..2622 n n6 1 2677 n n I 2R29.11 i12678 n &I. 7 1..64 A I-& 1..9 2n7n 1-2625 O-Oni i 268n n 12 1.. 26 I.. 219 1 12R2 n 27 1. 2682 1.2-2A nn4 1. 268.1 n 12 1..6 2264 n n 1- 23n 00n.3 1-2685 n n12 ..2R1 A A75 1..686 I..2Ra 2RnI2 26A7 n A.L 1- 2n34 nl1 1688 00 I-.3.5 0 1.. 968 022A 1- 236 0009~ 21-2690 nn .. 2R17 n 177 1. 2621 n 1-2& a015 1.2692 n 1..2R39 nn2&R I.2693 01 19640 0009 1..294 00 1-2641 0012 1-2695 I- 2FA 0011 1.2696 1- 96434l 1.267 nnia 194 n nn17 I. 29&A 0 025 I-L2F1. 2001 119 d 1-2646 0008 1-2700 0,11, I. 2d7 1..6 12-7n1 n 19648 lnniA .27n2 nn 1. 29c . FL27-04 00 I- 9R500.11 1-90.5 27n 1- 2&51 0002 1-2706 00 .2R652 10.2 1707 00 1.. 2 3 .9 .2-70A nn [0 367] Test Example 2 Evaluation of rat P2X3 receptor inhibitory activity 770 Rat P2X3 receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The cells stably expressing rat P2X 3 were seeded in a 96-well microtiter plate at a concentration of 8000 cells/well and cultured in the medium (8.3% fetal bovine serum, 8.3% horse serum, 1% antibiotic and antifungal in DMEM) for one day at 37 'C under 5 % carbon dioxide atmosphere. In transiently expressing system, the C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium for one day at 37 'C under 5 % carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Roche). The transfected cells were cultured in the medium for one day at 37 'C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 pM Fluo-3-AM solution (pH7.5) containing 20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 10% BSA, and 0.08% Pluronic F-127, and incubated at 37'C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 40 pL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 PL of DMSO solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 pL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 3 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC 50 ) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC5o was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.). The data of the compounds of the present invention are as shown in the following Table. [Table 584] Compound rat ,P2X3 No. IC50 (p M) 1- 0837 0.019 1-2291 0.003 1- 1788 0.005 1- 1679 0.006 [0368] Test Example 3 Evaluation of rat P2X 3 receptor inhibitory activity in the presence of rat serum albumin (RSA) 771 Rat P2X3 receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The cells stably expressing rat P2X 3 were seeded in a 96-well microtiter plate at a concentration of 8000 cells/well and cultured in the medium (8.3% fetal bovine serum, 8.3% horse serum, 1% antibiotic and antifungal in DMEM) for one day at 37 'C under 5 % carbon dioxide atmosphere. In transiently expressing system, the C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium for one day at 37 'C under 5 % carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Roche). The transfected cells were cultured in the medium for one day at 37 'C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 pM Fluo-3-AM solution (pH7.5) containing 20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 10% BSA, and 0.08% Pluronic F-127, and incubated at 37'C under 5% carbon dioxide atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 40 pL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 PL of DMSO solutions containing 1% RSA (final concentrations) and different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% Pluronic F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 PL) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 3 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC 5 0 ) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC5o was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.). The data of the compounds of the present invention are as shown in the following Table. [Table 585] Compo rat P2X3 (+ RSA) und No. IC50 (p M) I- 0837 0.044 1- 2291 0.020 1- 1788 0.059 I- 1679 0.023 [0369] Test Example 4: Evaluation of the urinary function in a rat model of cystitis 772 Surgery for cystometry A rat was fixed in the supine position after being given anesthesia through the inhalation of 2% isoflurane (Anesthetic background; Nitrous oxide: Oxygen = 7:3). A midline incision was made in its abdomen to expose the bladder. A cannula (made by processing a polyethylene tube (PE-50: Becton Dickinson)) was inserted through a small incision on top of the bladder and fixed to create a bladder fistula. The other end of the cannula was led through the hypodermal tissue to the back, and the muscular coat and skin were sutured. The cannula, which was led to the back, was protected with a stainless spring in the middle and connected to the cannula swivel. Acetic acid infusion Two days after the surgery, 0.3% acetic acid was infused into the bladder through the indwelled cannula at a rate of 4 mL/hr for 30 minutes to induce cystitis. The animals, where acetic acid was not infused, were used as normal animals. Cystometry measurement Three days after the acetic acid infusion, the other end of the cannula inserted into the bladder was connected to a T shape stopcock and then the intravesical pressure was recorded continuously using a pressure amplifier while infusing warmed normal saline solution at a rate of 3.0 mL/hr from one side and through a pressure transducer on the other side. The baseline of the intravesical pressure was measured (for approximately 40 minutes) after a measurement for stable duration (for approximately 20 minutes). After that, a vehicle, positive control compound or test compound were administered, and the value after administration was measured for approximately 120 minutes. At the same time, the voided urine was received on scales under the cage to measure the variation in weight simultaneously. Data adoption criteria Based on the voiding interval, normal animals whose voiding interval was 10 minutes or longer were adopted and those whose voiding interval was shorter than that were excluded. In the case of the animals into which acetic acid was infused, those whose voiding interval was less than half the average value of the normal animals were adopted as animals with cystitis and those whose voiding interval was longer than that were excluded. Collection of residual urine After the completion of the measurement, the infusion of normal saline solution was stopped immediately after urination to collect the residual urine under pentobarbital sodium anesthesia. The collected residual urine was transferred to the voided urine receiver and recorded on the chart. Analysis items Intravesical pressure one to two hours after the start of the measurement (pressure during rest and pressure during urination), voiding interval, voided volume per urination, and residual urine volume The following value was used as an indicator of the effect on the voiding interval: Improvement rate of the urinary function = (Voiding interval of an animal with cystitis after drug treatment - Voiding interval of an animal with cystitis before drug treatment) / (Mean voiding interval of normal animals before drug treatment - Voiding interval of an animal with cystitis before drug treatment) The following value was used as an indicator of the effect on the voided volume per urination: 773 Improvement rate of the voided volume per urination (Voided volume per urination of a rat with cystitis after drug treatment - Voided volume per urination of an animal with cystitis before drug treatment) / (Mean voided volume per urination of normal animals before drug treatment - Voided volume per urination of an animal with cystitis before drug treatment) In the above-mentioned test, the compound 1-0364 showed improvements in the urinary function in the voiding interval of 74.8% and in the voided volume per urination of 88% after oral administration of 30 mg/kg. [0370] Test Example 5 Analgesic Effect in a Seltzer model Preparation of Partial Sciatic Nerve Ligation model in Rats Rats were anaesthetized using isoflurane/02 inhalation anaesthesia. After induction of anesthesia, the left thigh was shaved. An incision was made in the skin just below the hip bone. The muscle was bluntly dissected to expose the sciatic nerve. One third (1/3) to one half (1/2) of the sciatic nerve thickness was tightly ligated and the wound was closed. The right thigh is used as a sham-operated control. The right thigh undergoes an identical procedure with the left hind limb, however, the sciatic nerve is not manipulated or ligated. Evaluation (1) Two weeks after nerve ligation, the effect on mechanical allodynia was assessed using a series of von Frey filaments. For habituation, the rats were placed into a plastic cage on a wire mesh bottom. The mechanical sensitivity (mechanical threshold) of the hind paws was estimated with a series of von Frey filaments (0.4 - 26 g). The measurement of mechanical sensitivity of the right and left hind paws was performed to obtain predose mechanical sensitivity. The rats showing the threshold change from 0.6 to 2 g (in nerve ligated side) and 8 to 15 g (in sham operated side) were used in the experiments. On the day before the experiment, the rats were evaluated with a series of von Frey filaments to familiarize them with the test procedure. The adopted animal was administrated with the test compounds. The test compounds were homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.1 - 2.0 mg/mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose mechanical sensitivities of the right and left hind paws were measured at approximately 1 to 5 hours after drug administration. Percent reversal of mechanical allodynia for each rat was calculated using the following formula. The analgesic effects of the compounds were compared. Logio (Postdose mechanical sensitivity in nerve ligated side) - Logio (Predose mechanical sensitivity in nerve ligated side) 0 Reversal = Logio (Predose mechanical sensitivity in sham operated side) - Logia (Pre dose mechanical sensitivity in nerve ligated side) In the above examination, the analgesic effect of the oral administration of compound 1-0364 at dose of 10 mg/kg was 41.2% reversal at 3 hours. The analgesic effects of the compounds of the present invention after single administration of 3 mg/kg at 3 hours are as shown in the following Table. [Table 586] 774 Compound No. analgesic effects ( reversal) 1-0837 23.7 1-1788 29.8 1-1679 40.6 Oral administration of 1-0826, 1-0931, 1-1373, 1-1849, i-2291, I-2292, I-2293, I-17 57, 1-2153, 1-2272, 1-2283, 1-2369 and 1-2428 at dose of 3mg/kg produced analges ic effect more than 30%reversal. Evaluation (2) Mechanical hyperalgesia was eavaluated using an analgesy meter. Two weeks after nerve ligation, the paw pressure test was performed using an analgesy meter (stimulus pressure increased 16g per second) to obtain paw withdrawal thresholds (PWT). Measurements were made on both sides of the hind paw and to obtain pre-dose PWT. The rats showing the threshold change from 60 to 90 g (in nerve ligated side) and 100 to 175 g (in sham operated side) were used in the experiments. On the day before the experiment, the rats have their hind paws set on the apparatus to familiarize them with the test procedure. The adopted animal was administrated with the test compounds. The test compounds were homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.03 - 100 mg/2mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose PWT of the right and left hind paws were measured at approximately 1 to 5 hours after drug administration. Percent reversal of mechanical hyperalgesia for each rat was calculated using the following formula. The analgesic effects of the compounds were compared. % Reversal =Postdose PWT in nerve ligated side - Predose PWT in nerve ligated side Predose PWT in sham operated side - Predose PWT in nerve ligated side In the above examination, the analgesic effect of the oral administration of compound 1-0364 at dose of 10 mg/kg was 56.7% reversal at 3 hours. [0371] Test Example 6 CYP3A4 fluorescent MBI test The CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction, and the test was performed using, as CYP3A4 enzyme expressed in Escherichia coli and employing, as an index, a reaction in which 7-benzyloxytrifluoromethylchmarin (BFC) is debenzylated by the CYP3A4 enzyme to produce a metabolite, 7-hydroxytrifluoromethylchmarin (HFC) emitting fluorescent light. [0372] The reaction conditions were as follows: substrate, 5.6 kmol/L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25'C (room temperature); CYP3A4 content (expressed in Escherichia coil), at pre-reaction 62.5 pmol/mL, at reaction 6.25 pmol/mL (at 10-fold dilution); test drug concentration, 1.5625, 3.125, 6.25, 12.5, 25, 50 kmol/L (six points). [0373] An enzyme in a K-Pi buffer (pH 7.4) and a test drug solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction, a part of 775 it was transferred to another 96-well plate so that it was 1/10 diluted by a substrate in a K-Pi buffer, NADPH as a co-factor was added to initiate a reaction as an index (without preincubation) and, after a predetermined time of a reaction, acetonitrile:0.5 mol/L Tris (trishydroxyaminomethane) = 4:1 was added to stop the reaction. In addition, NADPH was added to a remaining preincubation solution to initiate a preincubation (with preincubation) and, after a predetermined time of a preincubation, a part was transferred to another plate so that it was 1/10 diluted with a substrate and 775A a K-Pi buffer to initiate a reaction as an index. After a predetermined time of a reaction, acetonitrile:0.5 mol/L Tris (trishydroxyaminomethane) = 4:1 was added to stop the reaction. For the plate on which each index reaction had been performed, a fluorescent value of 7-HFC which is a metabolite was measured with a fluorescent plate reader. (Ex = 420 nm, Em = 535 nm). [0374] Addition of only DMSO which is a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution, and IC5o was calculated by reverse-presumption by a logistic model using a concentration and an inhibition rate. When a difference between IC5o values is 5 kM or more, this was defined as (+) and, when the difference is 3 kM or less, this was defined as (-). (Result) Compound No. 1-0837: (-) [0375] Test Example 7 CYP inhibition test Using commercially available pooled human hepatic microsome, and employing, as markers, 7-ethoxyresorufin O-deethylation (CYP1A2), tolbutamide methyl-hydroxylation (CYP2C9), mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), and terfenedine hydroxylation as typical substrate metabolism reactions of human main five CYP enzyme forms (CYP1A2, 2C9, 2C19, 2D6, 3A4), an inhibitory degree of each metabolite production amount by a test compound was assessed . [0376] The reaction conditions were as follows: substrate, 0.5 kmol/L ethoxyresorufin (CYP1A2), 100 kmol/L tolbutamide (CYP2C9), 50 kmol/L S-mephenitoin (CYP2C19), 5 kmol/L dextromethorphan (CYP2D6), 1 kmol/L terfenedine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37'C; enzyme, pooled human hepatic microsome 0.2 mg protein/mL; test drug concentration, 1.0, 5.0, 10, 20 kmol/L (four points). [0377] Each five kinds of substrates, human hepatic microsome, or a test drug in 50 mmol/L Hepes buffer as a reaction solution was added to a 96-well plate at the composition as described above, NADPH, as a cofactor was added to initiate metabolism reactions as markers and, after the incubation at 37'C for 15 minutes, a methanol/acetonitrile = 1/1 (v/v) solution was added to stop the reaction. After the centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant was quantified by a fluorescent multilabel counter and tributamide hydroxide (CYP2CP metabolite), mephenytoin 4' hydroxide (CYP2C19 metabolite), dextromethorphan (CYP2D6 metabolite), and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC/MS/MS. [0378] Addition of only DMSO being a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution and IC5o was calculated by reverse presumption by a logistic model using a concentration and an inhibition rate. (Results) Compound No. 1-0837: five kinds>20 pmol/L Compound No.1-2291: five kinds>20 pmol/L 776 Compound No.1-1788: five kinds>20 pmol/L Compound No.1-1679: five kinds>20 pmol/L [0379] Test Example 8 FAT Test 20 pL of freezing-stored rat typhoid bacillus (Salmonella typhimurium TA98 strain, TA100 strain) is inoculated on 10 mL of a liquid nutrient medium (2.5% Oxoid nutrient broth No.2), and this is cultured before shaking at 37'C for 10 hours. 9 mL of a bacterial solution of the TA98 strain is centrifuged (2000 x g, 10 minutes) to remove a culturing solution, the bacteria is suspended in 9 mL of a Micro F buffer (K 2 HPO4: 3.5 g/L, KH 2
PO
4 : 1 g/L, (NH 4
)
2
SO
4 : 1 g/L, trisodium citrate dehydrate: 0.25 g/L, MgSO4 7H 2 0: 0.1 g/L), the suspension is added to 110 mL of an Exposure medium (Micro F buffer containing Biotin: 8 ig/mL, histidine: 0.2 ig/mL, glucose: 8 mg/mL), and the TA100 strain is added to 120 mL of the Exposure medium relative to 3.16 mL of the bacterial solution to prepare a test bacterial solution. Each 12 kL of a test substance DMSO solution (8 stage dilution from maximum dose 50 mg/mL at 2-fold ratio), DMSO as a negative control, 50 pg/mL of 4-nitroquinoline-1-oxide DMSO solution for the TA98 strain, 0.25 ig/mL of 2-(furyl)-3-(5-nitro-2-furyl)acrylamide DMSO solution for the TA100 strain under the non-metabolism activating condition, 40 Ig/mL of 2-aminoanthracene DMSO solution for the TA98 strain, 20 ig/mL of 2-aminoanthracene DMSO solution for the TA100 strain under the metabolism activating condition as a positive control, and 588 kL of the test bacterial solution (a mixed solution of 498 k 1 of the test bacterial solution and 90 kL of S9 mix under the metabolism activating condition) are mixed, and this is shaking-cultured at 37'C for 90 minutes. 460 kL of the bacterial solution exposed to the test substance is mixed with 2300 kL of an Indicator medium (Micro F buffer containing biotin: 8 ig/mL, histidine: 0.2 ig/mL, glucose: 8 mg/mL, Bromo Cresol Purple: 37.5 ig/mL), each 50 kL is dispensed into microplate 48 wells/dose, and this is subjected to stationary culturing at 37'C for 3 days. Since a well containing a bacterium which has obtained the proliferation ability by mutation of an amino acid (histidine) synthesizing enzyme gene turns from purple to yellow due to a pH change, the bacterium proliferation well which has turned to yellow in 48 wells per dose is counted, and is assessed by comparing with a negative control group. (-) means that mutagenicity is negative and (+) is positive. [0380] Test Example 9 Solubility test The solubility of a compound was determined under a condition in which 1% DMSO was added. 10 mmol/L compound solution was prepared using DMSO, and then 6 pL of the compound solution was added to 594 pL of artificial intestinal juice in pH 6.8 (to 250 mL of 0.2 mol/L potassium dihydrogen phosphate reagent solution was added 118 mL of 0.2 mol/L NaOH reagent solution and water to provide a final volume of 1000 mL). After standing at 25 degrees Celsius for 16 hours, the mixed solution was filtrated with suction. The filtrate was diluted twice with methanol/water (1/1), and then a concentration in the filtration was measured with HPLC or LC/MS/MS by the absolute calibration method. (Results) Compound No. I-0837:>50 pmol/L Compound No. I-2291:>50 pmol/L Compound No. I-1788:>50 pmol/L Compound No. I-1679:>50 pmol/L 777 [0381] Test Example 10 Metabolism Stability Test Using commercially available pooled human hepatic microsomes, a test compound is reacted for a constant time, a remaining rate is calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver is assessed. [0382] A reaction was performed (oxidative reaction) at 37'C for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L tris-HC1 pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes. After the reaction, 50 kL of the reaction solution was added to 100 kL of a methanol/acetonitrile = 1/1 (v/v), mixed and centrifuged at 3000 rpm for 15 minutes. The test compound in the supernatant was quantified by LC/MS/MS, and a remaining amount of the test compound after the reaction was calculated, letting a compound amount at 0 minute reaction time to be 100%. (Results) The remaining rate at the compound concentration 0.5 kmol/L are shown below. Compound No. 1-0837: 99% Compound No. 1-2291: 94% Compound No. 1-1788: >99.9% [0383] Test Example 11 hERG Test For the purpose of assessing risk of an electrocardiogram QT interval prolongation, effects on delayed rectifier K+ current (IKr), which plays an important role in the ventricular repolarization process, is studied using HEK293 cells expressing human ether-a-go-go related gene (hERG) channel. After a cell was retained at a membrane potential of -80 mV by whole cell patch clamp method using an automated patch clamp system (PatchXpress 7000A, Axon Instruments Inc.), IKr induced by depolarization pulse stimulation at +50 mV for 2 seconds and, further, repolarization pulse stimulation at -50 mV for 2 seconds is recorded. After the generated current is stabilized, extracellular solution (NaCl: 137 mmol/L, KCl: 4 mmol/L, CaCl2 -2H 2 0: 1.8 mmol/L, MgCl2 - 6H 2 0: 1 mmol/L, glucose: 10 mmol/L, HEPES (4- (2-hydroxyethyl)- 1-piperazineethanesulfonic acid): 10 mmol/L, pH=7.4) in which the test compound had been dissolved at an objective concentration (1.0 pmol/L) is applied to the cell under the room temperature condition for 10 minutes. From the recording IKr, an absolute value of the tail peak current is measured based on the current value at the resting membrane potential using an analysis software (DataXpress ver.1, Molecular Devices Corporation). Further, the % inhibition relative to the tail peak current before application of the test substance is calculated, and compared with the vehicle-applied group (0.1% dimethyl sulfoxide solution) to assess influence of the test substance on IKr. [0384] Test Example 12: Metabolic stability test The test compound is reacted for a given period of time using cryopreserved rat hepatocytes that are prepared and the residual ratio is calculated based on the comparison between reacted and unreacted samples to evaluate the degree of hepatic metabolism. 778 [0385] The compound is reacted in the Williams E medium containing 1.0 x 106 cells/mL of cryopreserved rat hepatocytes at a temperature of 37oC for 0, 1 or 2 hours. After reaction, 50 tL of reaction solution is added to and mixed with 100 tL of a solution containing methanol and acetonitrile in the proportion of one to one (v/v) and the mixture is centrifuged at 3000 rpm for 15 minutes. The test compound contained in the centrifugal supernatant is quantitated using a LC/MS/MS system and the residual ratio of the test compound after reaction is calculated regarding the amount of compound after the reaction for 0 minute as 100%. [0386] Test Example 13: Protein binding test The unbound fraction of the present compound in serum was measured using serum of various species. [0387] The reactive conditions are as follows: Evaluation method, Equilibrium dialysis; Reaction time, 24 hours; Reaction temperature, 37oC; Concentration of the present compound, 2 pg/mL [0388] The test solution was added to each serum and the mixture was agitated to prepare the serum samples at the concentration mentioned above. Each serum sample was added into one side of the cell and phosphate buffered saline (PBS) was added into the other side to perform equilibrium dialysis at 37oC for 24 hours. Then, the concentration of the compounds in the samples that were obtained from both sides was measured by LC/MS/MS. (Result) The ratio of PBS concentration to serum concentration is expressed as unbound fraction. Compound No. 1-0837: 2.1% Compound No. 1-2291: 4.5% Compound No. 1-1679: 1.8% Compound No. 1-2011: 0.5% [0389] Test Example 14 Bioavailability (BA) test Materials and Methods for experiment of BA (1) Animals: Mice or SD rats were used (2) Breeding conditions: Mice or SD rats were allowed to freely take solid food and sterilized tap water. (3) Dose and grouping: orally or intravenously administered at a predetermined dose; grouping was as follows (Dose depends on the compound) Oral administration: 0.3 to 30 mg/kg (n=2 to 3) Intravenous administration: 0.5 to 10 mg/kg (n=2 to 3) (4) Preparation of dosing solution: for oral administration, in a solution or a suspension state; for intravenous administration, in a solubilized state (5) Administration method: in oral administration, forcedly administer into ventriculus with oral probe; in intravenous administration, administer from caudal vein with a needle-equipped syringe (6) Evaluation items: blood was collected over time, and the plasma concentration of drug was measured by LC/MS/MS (7) Statistical analysis: regarding the transition of the plasma concentration of the 779 present compound, the area under the plasma concentration-time curve (AUC) was calculated by non-linear least squares program WinNonlin (Registered trade name), and the bioavailability (BA) was calculated from the AUCs of the oral administration group and intravenous administration group (Results) Compound No. 1-0837: 46% Compound No. 1-2291: 83% Compound No. 1-1788: 31% Compound No. 1-1679: >99.9% Preparation Example 1 A granule containing the following ingredient is prepared. Ingredient Compound of the formula (I) 10 mg Lactose 700 mg Corn starch 274 mg HPC-L 16 mg The compound of the formula (I) and lactose are passed through a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve. These are mixed with a V-type mixing machine. An aqueous solution of HPC-L (low viscosity hydroxypropylcellulose) is added to a mixture powder, and this is kneaded, granulated (extrusion granulation, pore diameter 0.5 to 1 mm), and dried. The resulting dry granule is sieved with a vibration sieve (12/60 mesh) to obtain a granule. Preparation Example 2 A powder for filling into a capsule containing the following ingredients is prepared. Ingredient Compound of the formula (I) 15 mg Lactose 90 mg Corn starch 42 mg HPC-L 3 mg The compound of the formula (I), and lactose are passed through a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve. These are mixed, a HPC-L solution is added to the mixed powder, this is kneaded, granulated, and dried. The resulting dry granule is adjusted in a size, and 150 mg of it is filled into a No.4 hard gelatin capsule. Preparation Example 3 A tablet containing the following ingredients is prepared. Ingredient Compound of the formula (I) 10 mg Lactose 90 mg Microcrystaline cellulose 30 mg CMC-Na 15 mg 780 Magnesium stearate 5 mg The compound of the formula (Ia), lactose, microcrystalline cellulose, CMC-Na (carboxymethylcellulose sodium salt) are passed through a 60 mesh sieve, and mixed. Magnesium stearate is mixed into a mixture powder to obtain a mixture powder for tabletting. The present mixed powder is directly compressed to obtain a 150 mg tablet. Formulation Example 4 The following ingredients are warmed, mixed, and sterilized to obtain an injectable. Ingredient Compound of the formula (I) 3 mg Nonionic surfactant 15 mg Purified water for injection 1 ml Formulation Example 5 A cataplasm containing the following ingredients is prepared. Ingredient Compound of the formula (I) 50 mg aqueous-based (5% ethanol/5% butylene glycol/90% purified water) 950 mg glycerin kaoline aqueous polyvinyl alcohol The compound of the formula (I) is added to aqueous-based. The mixture is irradiated by ultrasonic for 15 minutes and then is sufficiently stirred to obtain a solution. 5 part of glycerin, 1 part of kaoline and 5 part of aqueous polyvinyl alcohol are homogeneously mixed and 1 part of the resulting solution is added to the above solution including the compound of the formula (I). The obtained solution is mixed and to give a paste form and the resulting paste is applied to an non-woven fabric. The resulting composition is covered by polyester film to give a cataplasm. [0390] As shown, the compounds described in the present specification showed inhibiting activity on P2X3 receptor and analgesic activity and treating effect on overactive bladder. Furthermore, as the compounds of the invention are effective on P2X3 subtype, the compounds are also considered to have inhibiting activity on P2X2/3 receptor, which comprises P2X3 subtype. [Industrial Applicability] [0391] The compounds of the general formula (I), the general formula (II), the general formula (III), the general formula (IV), the general formula (VII), the general formula (VIII) and the general formula (IX) have an antagonistic effect on P2X3 and/or P2X2/3 receptor and are useful in the treatment of diseases or conditions associated with a P2X3 and/or P2X2/3 receptor, such as chronic pain, urination disorder, etc. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information 781 derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. 781A

Claims (65)

1. A compound of the formula (VIII): (R 9 )s Z 1 (R 9 )s' ILN N R e B C N N' b X N Z 2 (VIII) (CR 4 aR 4 bf R2 wherein Z1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R 5 )- or -(CR5aR5b)-; -L- is -0-, -S-, -N(R5')- or -(CR5a'R5b')-; R 5 and R 5 ' are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R5a, R5b, R5a' and R5b' are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy or substituted or unsubstituted alkenyloxy; ring D is a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; carbon atom a and carbon atom b are carbon atoms which constitute ring D; ring B is an aromatic carbocyclic ring, a non-aromatic carbocyclic ring, an aromatic heterocyclic ring or a non-aromatic heterocyclic ring; s and s' are each independently an integer of 0 to 3; and R 9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or ,7'70 unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy; provided that s' is an integer of 1 to 3 when ring B is a cyclopentane ring, a benzene ring, a tetrahydropyran ring or a piperidine ring, or its pharmaceutically acceptable salt or a solvate thereof.
2. The compound according to claim 1, wherein -L- is -0-, or its pharmaceutically acceptable salt or a solvate thereof.
3. The compound according to claim 1 or 2, wherein ring B is an aromatic heterocyclic ring, or its pharmaceutically acceptable salt or a solvate thereof.
4. The compound according to any one of claims 1 to 3, wherein ring B is a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a pyrazole ring, an imidazole ring, a triazole ring, a furan ring, a thiophene ring, a thiadiazole ring, an oxadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a triazine ring or a benzoxazole ring, or its pharmaceutically acceptable salt or a solvate thereof.
5. The compound according to any one of claims 1 to 4, wherein ring B is a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a thiadiazole ring, an oxadiazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, or its pharmaceutically acceptable salt or a solvate thereof.
6. The compound according to any one of claims 1 to 5, wherein s' is an integer of 1 to 2, and at least one of R 9 ' is hydroxy, carboxy, cyano, substituted alkyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof.
7. The compound according to any one of claims 1 to 6, wherein s' is 1, and R 9 ' is carboxy or substituted or unsubstituted carbamoyl, or its pharmaceutically acceptable salt or a solvate thereof.
8. A compound of the formula (IX): (R 9 ')s' (R 9 )s Z 1 C N N' R 13 a R1 3 b D X N Z2 ) (CR 4 aR 4 bf wherein Z1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -X- is -0-, -S-, -N(R 5 )- or -(CR5aR5b)-; R 5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R 5 a and R5b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; ring D is a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring; carbon atom a and carbon atom b are carbon atoms which constitute ring D; Ri3a and Ri3b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy, or Ri 3 a and Ri3b attached to the same carbon atom are taken together to form oxo or thioxo; ring E is a cycloalkane ring or a cycloalkene ring; s and s' are each independently an integer of 0 to 3; and R 9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted hetero aryloxy, 7 Q A or its pharmaceutically acceptable salt or a solvate thereof.
9. The compound according to claim 8, wherein Ri3a and Ri3b are both hydrogen atoms, or its pharmaceutically acceptable salt or a solvate thereof.
10. The compound according to claim 8 or 9, wherein ring E is a cyclopropane ring, or its pharmaceutically acceptable salt or a solvate thereof.
11. The compound according to any one of claims 1 to 10, wherein ring D is a benzene ring, or its pharmaceutically acceptable salt or a solvate thereof.
12. The compound according to any one of claims 1 to 11, wherein carbon atom a is positioned on ring D in a 1,4 relationship with respect to carbon atom b, or its pharmaceutically acceptable salt or a solvate thereof.
13. The compound according to any one of claims 1 to 12, wherein s and s' are each independently an integer of 0 to 2; and R 9 and R 9 ' are each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof.
14. A compound of the formula (VII): Zi (R 9 )s ''I sX lN IZ2 (VII) (CR 4 aR 4 b)f R 2 wherein Z1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; '70- -X- is -0-, -S-, -N(R 5 )- or -(CR5aR5b)-; R 5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; R 5 a and R5b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; s is an integer of 0 to 3; and R 9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof.
15. The compound according to claim 14, wherein s is an integer of 0 to 2; and R 9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof.
16. The compound according to any one of claims 1 to 15, wherein Z1 and Z2 are both oxygen atoms or both sulfur atoms, or its pharmaceutically acceptable salt or a solvate thereof.
17. The compound according to any one of claims 1 to 16, wherein Z' and Z2 are both oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof.
18. The compound according to any one of claims 1 to 17, wherein Rc is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted 7 Q9 or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group A, unsubstituted alkynyl or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof.
19. The compound according to any one of claims 1 to 18, wherein Rc is unsubstituted alkyl, alkyl substituted with one or more substituents selected from Substituent Group B" (Substituent Group B": hydroxy, carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), unsubstituted alkenyl, alkenyl substituted with one or more substituents selected from Substituent Group B", unsubstituted alkynyl or alkynyl substituted with one or more substituents selected from Substituent Group B", or its pharmaceutically acceptable salt or a solvate thereof.
20. The compound according to any one of claims 1 to 19, wherein Rc is unsubstituted alkyl, or its pharmaceutically acceptable salt or a solvate thereof.
21. The compound according to any one of claims 1 to 19, wherein Rc is (CR11aR11b)m-OH; Ria and R11b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or Ria and R11b together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non-aromatic heterocyclic ring; and m is an integer of 2 to 4, or its pharmaceutically acceptable salt or a solvate thereof.
22. The compound according to any one of claims 1 to 19 and 21, wherein Rc is -(CR11aR11b)m-OH; Rua is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R11b is -(CR12aR12b)u-OH; R1 2 a and R12b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; u is an integer of 0 to 2; and m is an integer of 2 to 4, or its pharmaceutically acceptable salt or a solvate thereof.
23. The compound according to any one of claims 1 to 19, 21 and 22, wherein Rc is a group of the formula: 7 Q 7 OHOH OH OH OH OH OH OH 0 OH OH OH OH OH OH- 55O OH OH k Z OH 'OH or OH or its pharmaceutically acceptable salt or a solvate thereof.
24. The compound according to any one of claims 1 to 19, wherein Rc is (CR14aR14b)t-N(R15a)(R15b); R1 4 a and R14b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, or R1 4 a and R14b together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non aromatic heterocyclic ring; t is an integer of 2 to 4; and R1 5 a and R15b are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl; or -(CR14a'R14b')t'-C(=O)N(R5a')(R15b'); R1 4 a' and R14b' are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl or R1 4 a' and R14b' together with the carbon atom to which they are attached form a substituted or unsubstituted cycloalkane ring, a substituted or unsubstituted cycloalkene ring, or a substituted or unsubstituted non aromatic heterocyclic ring; t' is an integer of 1 to 4; and R1 5 a' and R15b' are each independently a hydrogen atom, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted acyl, substituted sulfonyl or substituted sulfinyl, or its pharmaceutically acceptable salt or a solvate thereof.
25. The compound according to any one of claims 1 to 19, and 24, wherein Rc is a group of the formula: '7QQ N(R1 5 a)(R1 5 b) N(R1 5 a)(R1 5 b ) N(R1 5 a)(R1 5 b) N(R'a)(R5b)N(R15a)(R15b) N(R15a)(R15b) N(R15a)(R15b) ,,N(R15a)(R15b) N(R15a)(R15b) 0 0 N(R1 5 a')(R1 5 b N(Rl 5 a')(Rl 5 b) N(R1 5 a)(R 5 b') ." NN(R15a)(R15b) N(1a(R5)(R5 0 0 N(R15a)(R15b " 0 0 or 0 N(Rl 5 a)(Rl 5 b) wherein R1 5 a, R15b, R1 5 a' and R15b' are as defined in claim 24, or its pharmaceutically acceptable salt or a solvate thereof.
26. The compound according to any one of claims 1 to 25, wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof.
27. The compound according to any one of claims 1 to 26, wherein R 4 a and R4b are both hydrogen atoms, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof.
28. The compound according to any one of claims 1 to 27, wherein n is 1, and R 4 a and R4b are both hydrogen atoms, or its pharmaceutically acceptable salt or a solvate thereof.
29. The compound according to any one of claims 1 to 28, wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof.
30. The compound according to any one of claims 1 to 29, wherein R 2 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof.
31. The compound according to any one of claims 1 to 30, wherein -X- is N(R 5 )-, and R 5 is as defined in claim 1, or its pharmaceutically acceptable salt or a solvate thereof.
32. The compound according to any one of claims 1 to 31, wherein -X- is NH-, or its pharmaceutically acceptable salt or a solvate thereof.
33. A pharmaceutical composition comprising the compound according to 7Q0 any one of claims 1 to 32, or its pharmaceutically acceptable salt, or a solvate thereof.
34. The pharmaceutical composition according to claim 33, wherein the composition has a P2X3 and/or P2X2/3 receptor antagonistic effect.
35. Use of a compound according to any one of claims 1 to 32, or its pharmaceutically acceptable salt, or a solvate thereof in the manufacture of a medicament for the treatment or prevention of a disease related to P2X3 and/or P2X2/3 receptor.
36. A method for treating and/or preventing a disease related to P2X3 and/or P2X2/3 receptor comprising administering the compound according to any one of claims 1 to 32, or its pharmaceutically acceptable salt, or a solvate thereof.
37. A pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder comprising a compound of the formula (I): Ra Rb R 1 N N R Rh N Re R9 IR Rf wherein (i) Rh and Ri are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo, thioxo or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Rf is -(CR 4 aR 4 b)n-R 2 ; R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; -R9 is -X-R 3 ; -X- is -0-, -S-, -N(R5)-or -(CR5aR5b)-; R 3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl; and R 5 a and R5b are each independently a hydrogen atom, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or 70n unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkynyloxy, or substituted or unsubstituted alkenyloxy; or (ii) Rh and Ri are taken together to form a bond; Ra is a group of -Y-Rla; Ria is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Y- is -0-, -S-, -N(RT)- or -C(R8aR8b)-; R 7 is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted acyl; R8a and R8b are each independently a hydrogen atom, halogen or substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rb and Rc are taken together to form a bond; Rd and Re are taken together to form oxo or thioxo; and Rf and R9 are as defined above (i); or (iii) Ra and Rb, Rd and Re, and/or R9 and Rh are taken together to form oxo or thioxo; Rc is unsubstituted alkyl, unsubstituted alkynyl, alkyl substituted with one or more substituents selected from Substituent Group B (Substituent Group B: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, and nitro ), alkenyl substituted with one or more substituents selected from Substituent Group B, or alkynyl substituted with one or more substituents selected from Substituent Group B; Rf is -(CR4aR4b)-R6; Ri is -(CR 4 a'R 4 b')-R 6 '; R 6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 6 ' is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 4 a, R4b, R 4 a' and R4b' are each independently a hydrogen atom, or substituted or '70 1 unsubstituted alkyl; or (iv) Ri and Rb are taken together to form a bond; Ra is a group of -Y-Rla; -Y- is -0-, -S-, -N(R7)- or -C(R8aR8b)-; Ria is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rc is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rd and Re are taken together to form oxo, thioxo or =N-Rx; Rx is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -Rf is -(CR 4 aR 4 b)n-R 2 ; R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R9 and Rh are taken together to form =N-R 3 ; and R 3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that 1) a compound wherein, in (i), -X- is -NH-, and R 3 is cyclohexyl substituted with guanidyl, and 2) a compound wherein, in (ii), Ra is substituted phenyl, Rd and Re are taken together to form thioxo, R 4 a and R4b are taken together to form oxo, and R 3 is unsubstituted cyclohexyl, are excluded, or its pharmaceutically acceptable salt, or a solvate thereof.
38. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to claim 37, comprising the compound of the formula (II): '700) Zi N NRC R X N IZ2(II) (CR 4 aR 4 b)fn R 2 wherein Z1 and Z 2 are each independently an oxygen atom, a sulfur atom or =N-Rx; Rx, R 4 a, R4b, n, R 2 , X, and R 3 are as defined in claim 37; and Rei is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof.
39. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to claim 38, comprising the compound wherein Z1 and Z 2 are both oxygen atoms or both sulfur atoms, or its pharmaceutically acceptable salt or a solvate thereof.
40. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder, according to claim 38 or 39, comprising the compound wherein Z1 and Z 2 are both oxygen atoms or its pharmaceutically acceptable salt or a solvate thereof.
41. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 40, comprising the compound wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof.
42. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 41, '70 Q comprising the compound wherein Rci is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof.
43. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to claim 37, comprising the compound of the formula (III): RR3 N N R X ilN 'Z2 III (C R 4 aR 4 b) n R 2 wherein Z 2 is an oxygen atom, a sulfur atom or =N-Rx; and Rx, -Y-, Ria, R 4 a, R4b, n, R 2 , -X- and R 3 are as defined in claim 37, or its pharmaceutically acceptable salt or a solvate thereof.
44. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to claim 43, comprising the compound wherein Z 2 is an oxygen atom or a sulfur atom, or its pharmaceutically acceptable salt or a solvate thereof.
45. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to claim 43 or 44, comprising the compound wherein -Y- is -0-, or its pharmaceutically acceptable salt or a solvate thereof.
46. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 43 to 45, comprising the compound wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group A (Substituent Group A: halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted '70 A cycloalkenyloxycarbonyl, substituted or unsubstituted non-aromatic heterocycyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, nitro, oxo, and thioxo), alkenyl substituted with one or more substituents selected from Substituent Group A, or alkynyl substituted with one or more substituents selected from Substituent Group A, or its pharmaceutically acceptable salt or a solvate thereof.
47. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 43 to 46, comprising the compound wherein Ria is alkyl substituted with one or more substituents selected from Substituent Group B' (Substituent Group B': carboxy, sulfo, a substituted or unsubstituted non-aromatic heterocyclic group, tetrazolyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, and substituted or unsubstituted guanidyl), alkenyl substituted with one or more substituents selected from Substituent Group B', or alkynyl substituted with one or more substituents selected from Substituent Group B', or its pharmaceutically acceptable salt or a solvate thereof.
48. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 47, comprising the compound wherein n is 1, or its pharmaceutically acceptable salt or a solvate thereof.
49. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 48, comprising the compound wherein R 4 a and R4b are both hydrogen atoms, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo, or its pharmaceutically acceptable salt or a solvate thereof.
50. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 49, comprising the compound wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof.
51. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 50, comprising the compound wherein R 2 is cycloalkyl optionally substituted with one or more substituents selected from Substituent Group C (Substituent Group C: halogen, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, and alkylsilylalkynyl), aryl optionally substituted with one or more substituents selected from Substituent Group C, or heteroaryl optionally substituted with one or more substituents selected from Substituent Group C, or its pharmaceutically acceptable salt or a solvate thereof.
52. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 51, comprising the compound wherein -X- is -N(R 5 )-, and R 5 is as defined in claim 37, or its pharmaceutically acceptable salt or a solvate thereof.
53. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 52, comprising the compound wherein -X- is -NH-, or its pharmaceutically acceptable salt or a solvate thereof. '70 F
54. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 53, comprising the compound wherein R 3 is a group of the formula: (R 9 ) S A wherein ring A is an aromatic carbocyclic ring or an aromatic heterocyclic ring; s is an integer of 0 to 3; and R 9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy, or its pharmaceutically acceptable salt or a solvate thereof.
55. The pharmaceutical composition having an analgesic effect or an improving effect on a urination disorder according to any one of claims 38 to 54, comprising the compound wherein R 3 is aryl optionally substituted with one or more substituents selected from Substituent Group D (Substituent Group D: halogen; hydroxy; alkyl optionally substituted with halogen, hydroxy, cyano, alkyloxyimino, dialkylamino, alkyloxy, cycloalkyl, or heteroaryl; alkenyl optionally substituted with cycloalkyl; alkynyl optionally substituted with cycloalkyl; alkyloxy optionally substituted with halogen, alkyloxy, cycloalkyl, aryl or a non-aromatic heterocyclic group optionally substituted with alkyl; alkylthio; cycloalkyl; cycloalkenyl; cycloalkyloxy; aryloxy; heteroaryloxy optionally substituted with alkyl; a non aromatic heterocyclic group; and alkylamino), or heteroaryl optionally substituted with one or more substituents selected from Substituent Group D, or its pharmaceutically acceptable salt or a solvate thereof.
56. A method of producing a compound of the formula (XI): Zi N AlN IRc1 R3 X il, N kIZ2(X1) wherein Z1 and Z 2 are each independently an oxygen atom or a sulfur atom, Rfl is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or 7oc unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rei is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R 3 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X is -N(R) R 5 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl, or its pharmaceutically acceptable salt or a solvate thereof, characterized by reacting a compound of the formula (X): Zi N N Rc1 N 2X (R 2 7 )n' wherein Z1, Z 2 ,Rfl and Rei are as defined above; R 2 7 is substituted or unsubstituted alkyl; and n' is an integer of 0 to 3, or its salt, with a compound of the formula: R 3 -X' wherein R 3 is as defined above; -X' is -NH(Rt); and R 5 is as defined above.
57. The method of producing according to claim 56, wherein Z1 and Z 2 are oxygen atoms.
58. The method of producing according to claim 56 or 57, wherein Rf 1 is a group of -(CR4aR4b)n-R2; wherein R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; and R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
59. The method of producing according to any one of claims 56 to 58, wherein Rci is substituted or unsubstituted alkyl.
60. The method of producing according to any one of claims 56 to 59, wherein R 5 is a hydrogen atom.
61. The method of producing according to any one of claims 56 to 60, wherein R 3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
62. A compound of the formula (XII): 707 Zi N N Rcl N ilNZ2 (XII) (R 27 )n' wherein Z1 and Z 2 are each independently an oxygen atom or a sulfur atom; Rfl is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Rei is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; provided that Rei is not unsubstituted alkyl, unsubstituted alkenyl or unsubstituted cycloalkyl when Rfl is a hydrogen atom; R 2 7 is substituted or unsubstituted alkyl; and n' is an integer of 0 to 3, or its pharmaceutically acceptable salt or a solvate thereof.
63. The compound according to claim 62, wherein Z1 and Z 2 are oxygen atoms, or its pharmaceutically acceptable salt or a solvate thereof.
64. The compound according to claim 62 or 63, wherein Rfl is a group of (CR 4 aR4b)n-R2; wherein R 4 a and R4b are each independently a hydrogen atom or substituted or unsubstituted alkyl, or R 4 a and R4b attached to the same carbon atom are taken together to form oxo or thioxo; n is an integer of 1 to 4; and R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or its pharmaceutically acceptable salt or a solvate thereof.
65. The compound according to any one of claims 62 to 64, wherein Rci is substituted or unsubstituted alkyl, or its pharmaceutically acceptable salt or a solvate thereof. o70Q
AU2011290261A 2010-08-10 2011-08-09 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity Ceased AU2011290261B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2010-179350 2010-08-10
JP2010179350 2010-08-10
JP2010-182803 2010-08-18
JP2010182803 2010-08-18
JP2011-074763 2011-03-30
JP2011074763 2011-03-30
PCT/JP2011/068113 WO2012020749A1 (en) 2010-08-10 2011-08-09 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity

Publications (2)

Publication Number Publication Date
AU2011290261A1 AU2011290261A1 (en) 2013-03-07
AU2011290261B2 true AU2011290261B2 (en) 2014-11-06

Family

ID=45567712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011290261A Ceased AU2011290261B2 (en) 2010-08-10 2011-08-09 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity

Country Status (16)

Country Link
US (1) US9718790B2 (en)
EP (1) EP2604595B1 (en)
JP (2) JP5594706B2 (en)
KR (1) KR101867110B1 (en)
CN (1) CN103153968B (en)
AU (1) AU2011290261B2 (en)
BR (1) BR112013002984B1 (en)
CA (1) CA2807947C (en)
DK (1) DK2604595T3 (en)
ES (1) ES2572481T3 (en)
MX (1) MX346367B (en)
PL (1) PL2604595T3 (en)
RU (1) RU2565073C2 (en)
TW (2) TW201542210A (en)
WO (1) WO2012020749A1 (en)
ZA (1) ZA201300920B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2399910T3 (en) 2009-02-13 2014-09-30 Shionogi & Co Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them
WO2012006004A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
RU2565073C2 (en) 2010-08-10 2015-10-20 Сионоги Энд Ко., Лтд. Triazine derivative and pharmaceutical composition including it, possessing analgesic activity
TW201331188A (en) * 2011-12-15 2013-08-01 Shionogi & Co Substituted triazine derivative and pharmaceutical composition comprising the same
JP6124351B2 (en) * 2012-02-09 2017-05-10 塩野義製薬株式会社 Heterocyclic and carbocyclic derivatives
NZ626112A (en) * 2012-03-30 2016-04-29 Nissan Chemical Ind Ltd Triazinone compound and t-type calcium channel inhibitor
TWI637949B (en) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 Aminotriazine derivative and pharmaceutical composition comprising the same
EP3670496A3 (en) * 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
JPWO2016084922A1 (en) * 2014-11-28 2017-09-07 塩野義製薬株式会社 1,2,4-Triazine derivative and pharmaceutical composition thereof
BR112017022654A2 (en) 2015-04-24 2018-07-10 Shionogi & Co., Ltd. 6-membered heterocyclic derivative and pharmaceutical composition comprising the same
KR102528627B1 (en) 2016-10-17 2023-05-03 시오노기 앤드 컴파니, 리미티드 Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical compositions containing them
GB201810669D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
JP6725188B1 (en) 2018-10-05 2020-07-15 塩野義製薬株式会社 Medicine for the treatment of chronic cough
AU2020348089A1 (en) * 2019-09-19 2022-03-31 Shionogi & Co., Ltd. Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same
JP6813717B1 (en) 2019-10-02 2021-01-13 あすか製薬株式会社 Urination disorder improving agent
WO2021065027A1 (en) 2019-10-02 2021-04-08 あすか製薬株式会社 Dysuria-alleviating agent
TW202203929A (en) 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 Medicament for the treatment of pain
TW202241452A (en) 2020-12-18 2022-11-01 日商Ａｓｋａ製藥股份有限公司 Solid preparation
KR102494188B1 (en) * 2021-04-14 2023-01-31 시오노기 앤드 컴파니, 리미티드 Triazine derivatives having virus growth inhibitory activity and pharmaceutical compositions containing them
EP4349816A1 (en) * 2021-06-04 2024-04-10 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof
CN113620888B (en) * 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 Dihydropyrimidine compound and preparation method and application thereof
CN113773300B (en) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 Sulfonamide compound, preparation method and application thereof
CN113801097B (en) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 Dihydropyrimidine compound, preparation method and application thereof
MX2024003600A (en) 2021-09-28 2024-04-09 Shionogi & Co Pharmaceutical composition containing triazine derivative.
TW202320793A (en) 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 Pharmaceutical composition comprising triazine derivative
JP7261529B1 (en) 2021-11-24 2023-04-20 塩野義製薬株式会社 Method for producing triazine derivative having virus growth inhibitory action
AU2022333823A1 (en) 2021-11-24 2024-05-02 Shionogi & Co., Ltd. Preparation for oral administration containing triazine derivative
WO2023095860A1 (en) * 2021-11-26 2023-06-01 塩野義製薬株式会社 Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
TW202339757A (en) 2022-01-19 2023-10-16 日商塩野義製藥股份有限公司 Medicament for treating novel coronavirus infection
WO2023169572A1 (en) * 2022-03-10 2023-09-14 湖北九康通生物医药有限公司 Triazine compound, intermediate thereof, preparation method therefor and use thereof
CN116284133B (en) * 2022-03-24 2024-03-29 南京知和医药科技有限公司 Novel six-membered heterocyclic derivative, and pharmaceutical composition and application thereof
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
WO2023184482A1 (en) * 2022-04-01 2023-10-05 湖南南新制药股份有限公司 Aminotriazinone compound, preparation method therefor and pharmaceutical use thereof
CN116891459A (en) * 2022-04-08 2023-10-17 湖北九康通生物医药有限公司 Synthesis method of polysubstituted triazinane compound
CN114805314B (en) * 2022-04-20 2023-12-15 杭州国瑞生物科技有限公司 Synthesis method of Entecavir
CN114751894A (en) * 2022-04-29 2022-07-15 苏州立新制药有限公司 Preparation method of oral medicine for treating neocoronary pneumonia
CN115650959B (en) * 2022-05-20 2023-10-20 南京济群医药科技股份有限公司 Process for the preparation or purification of compounds
CN114773282B (en) * 2022-05-27 2024-07-02 杭州布朗生物医药科技有限公司 Preparation method of 3-tert-butyl-6-ethylthio-1, 3, 5-triazine-2, 4 (1H, 3H) -dione
CN115504968B (en) 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 Triazine derivatives
WO2024114665A1 (en) * 2022-11-30 2024-06-06 上海海雁医药科技有限公司 Substituted triazine-2,4-dione derivative intermediate and preparation method therefor
WO2024114663A1 (en) * 2022-11-30 2024-06-06 上海海雁医药科技有限公司 Crystal form of triazinyl methyl cycloalkyl carboxylic acid derivative and use thereof
WO2024169781A1 (en) * 2023-02-15 2024-08-22 南京明德新药研发有限公司 Pyrimidinone derivative and pharmaceutical application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598815A (en) * 1968-10-25 1971-08-10 Goodrich Co B F Bis-(hydroxyphenylalkylene) alkyl isocyanurates
US4021249A (en) * 1974-09-12 1977-05-03 Fuji Photo Film Co., Ltd. Heat developable light-sensitive material incorporating a substituted s-triazine-2,4,6-(1H, 3H, 5H)-trione reducing agent
US4127718A (en) * 1976-10-18 1978-11-28 Ciba-Geigy Corporation Tris-tetrazoles as chemical blowing agents
US4317911A (en) * 1976-07-08 1982-03-02 Ciba-Geigy Corporation Piperidine containing cyanuric acid derivatives
US4518688A (en) * 1982-11-26 1985-05-21 Ciba-Geigy Ag Color-photographic recording material
JPS62156110A (en) * 1985-12-27 1987-07-11 Res Inst For Prod Dev Polymer containing isocyanurate structure in side chain and having adsorption capability

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158724A (en) * 1976-10-18 1979-06-19 Ciba-Geigy Corporation Tris-tetrazoles as chemical blowing agents
GB1599518A (en) * 1977-02-21 1981-10-07 Ici Ltd 1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof
DE2962124D1 (en) 1978-05-26 1982-03-25 Ici Plc Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture
JPS57144269A (en) 1981-03-03 1982-09-06 Taiho Yakuhin Kogyo Kk Triazine derivative and its preparation
EP0401707B1 (en) 1989-06-05 1994-09-21 Daiichi Pharmaceutical Co., Ltd. Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity
RU2057754C1 (en) 1989-06-05 1996-04-10 Дайити Фармасьютикал Ко., Лтд. Heterocyclic compounds or their acid-additive salts
DE4141721A1 (en) * 1991-12-18 1993-06-24 Bayer Ag SUBSTITUTED HETEROCYCLYLTRIAZINDIONE
JP3542482B2 (en) 1997-12-25 2004-07-14 日研化学株式会社 3-anilino-2-cycloalkenone derivatives
WO1999052881A1 (en) 1998-04-15 1999-10-21 Sagami Chemical Research Center 2-anilinopyrimidinone derivatives, intermediates in the production thereof, process for producing the same and pesticides containing the same as the active ingredient
JP2995293B1 (en) 1998-08-25 1999-12-27 工業技術院長 Method for producing 1,6-disubstituted-1,3,5-triazine-2,4 (1H, 3H) -dione compound
US6177437B1 (en) 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6713486B1 (en) 1999-03-04 2004-03-30 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
DE10027514A1 (en) * 2000-06-06 2002-01-03 Basf Ag Ligands of integrin receptors
JP4674676B2 (en) 1999-11-08 2011-04-20 公益財団法人相模中央化学研究所 2-Substituted aminopyrimidinone derivatives, methods for producing them, and insecticides and acaricides containing them as active ingredients
WO2001055093A1 (en) 2000-01-25 2001-08-02 Japan Tobacco Inc. N-arylhydrazide compounds and use thereof as drugs
US20020049320A1 (en) 2000-04-27 2002-04-25 American Cyanamid Company 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof
JP2005508288A (en) 2001-05-18 2005-03-31 アボット・ラボラトリーズ Tri-substituted-N-[(1S) -1,2,3,4-tetrahydro-1-naphthalenyl] benzamides that inhibit P2X3 and P2X2 / 3-containing receptors
WO2004054617A1 (en) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
JP2006528640A (en) 2003-07-22 2006-12-21 ニューロジェン・コーポレーション Substituted pyridin-2-ylamine analogues
KR100822530B1 (en) 2004-03-05 2008-04-16 에프. 호프만-라 로슈 아게 Diaminopyrimidines as p2x3 and p2x2/3 antagonists
AU2005266887B2 (en) 2004-07-22 2011-08-18 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
ATE519759T1 (en) 2004-12-30 2011-08-15 Exelixis Inc PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHODS OF APPLICATION
CN101326168A (en) 2005-03-24 2008-12-17 詹森药业有限公司 Prokineticin 1 receptor antagonists
KR20070116915A (en) 2005-03-24 2007-12-11 얀센 파마슈티카 엔.브이. Pyrimidindione derivatives as prokineticin 2 receptor antagonists
JP2008537548A (en) 2005-03-24 2008-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Prokineticin 1 receptor
US8507415B2 (en) 2005-05-03 2013-08-13 Southwest Research Institute Lubricant oils and greases containing nanoparticle additives
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
JP4987871B2 (en) 2005-08-15 2012-07-25 エフ．ホフマン−ラ ロシュ アーゲー Piperidine and piperazine derivatives as P2X3 antagonists
CN101253159B (en) 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 Diaminopyrimidines as P2X3 and P2X2/3 modulators
DK1924264T5 (en) 2005-09-01 2014-03-24 Hoffmann La Roche Diaminopyrimidines as P2X3- and P2X2 / 3 modulators
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP4850913B2 (en) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Diaminopyridines as P2X3 and P2X2 / 3 regulators
CA2635845A1 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
US7902358B2 (en) 2005-12-29 2011-03-08 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2044037A2 (en) 2006-07-24 2009-04-08 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
CL2008000065A1 (en) 2007-01-12 2008-09-22 Smithkline Beecham Corp COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA.
CN101679445A (en) 2007-04-13 2010-03-24 先灵公司 Pyrimidinedione derivative and application thereof
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2009007258A (en) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd 3-anilino-2-cycloalkenone derivative having inhibitory action on production of pai-1
CA2704185C (en) 2007-10-30 2016-02-16 Janssen Pharmaceutica N.V. Amino-heteroaryl-containing prokineticin 1 receptor antagonists
JPWO2009101917A1 (en) 2008-02-13 2011-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Bicycloamine derivatives
JP5608655B2 (en) 2008-09-18 2014-10-15 エヴォテック アーゲー Modulator of P2X3 receptor activity
MX2011004570A (en) * 2008-10-31 2011-06-17 Merck Sharp & Dohme P2x3, receptor antagonists for treatment of pain.
PL2399910T3 (en) 2009-02-13 2014-09-30 Shionogi & Co Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them
SG177308A1 (en) 2009-06-22 2012-02-28 Hoffmann La Roche Novel biphenyl and phenyl-pyridine amides
IN2012DN00838A (en) 2009-08-05 2015-06-26 Du Pont
CA2806572C (en) 2010-07-30 2018-10-30 Expression Pathology, Inc. C-src selected reaction monitoring assay
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
RU2565073C2 (en) 2010-08-10 2015-10-20 Сионоги Энд Ко., Лтд. Triazine derivative and pharmaceutical composition including it, possessing analgesic activity
JP5849246B2 (en) 2010-09-03 2016-01-27 パナソニックＩｐマネジメント株式会社 Scroll compressor
EP2693881B1 (en) 2011-04-01 2019-09-04 University of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
TW201331188A (en) 2011-12-15 2013-08-01 Shionogi & Co Substituted triazine derivative and pharmaceutical composition comprising the same
JP6124351B2 (en) 2012-02-09 2017-05-10 塩野義製薬株式会社 Heterocyclic and carbocyclic derivatives
TWI637949B (en) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 Aminotriazine derivative and pharmaceutical composition comprising the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598815A (en) * 1968-10-25 1971-08-10 Goodrich Co B F Bis-(hydroxyphenylalkylene) alkyl isocyanurates
US4021249A (en) * 1974-09-12 1977-05-03 Fuji Photo Film Co., Ltd. Heat developable light-sensitive material incorporating a substituted s-triazine-2,4,6-(1H, 3H, 5H)-trione reducing agent
US4317911A (en) * 1976-07-08 1982-03-02 Ciba-Geigy Corporation Piperidine containing cyanuric acid derivatives
US4127718A (en) * 1976-10-18 1978-11-28 Ciba-Geigy Corporation Tris-tetrazoles as chemical blowing agents
US4518688A (en) * 1982-11-26 1985-05-21 Ciba-Geigy Ag Color-photographic recording material
JPS62156110A (en) * 1985-12-27 1987-07-11 Res Inst For Prod Dev Polymer containing isocyanurate structure in side chain and having adsorption capability

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Esayan, G. T. et al, "Synthesis and sulphuric acid hydrolysis gamma-chlorocrotylbenzyl(alkyl)isocyanurates", Armyanskii Khimicheskii Zhurnal, 1975, Vol.28, No.4, pp 332-337 *
Lerchova, J. & Pospisil, J., Angewandte Makromolekulare Chemie, 1974, Vol.39, No.1, pp 107-118 *
Shao, X-B. et al, "Strapped porphyrin rosettes based on the melamine-cyanuric acid motif. Selfassembly and supramolecular recognition", Tetrahedron, 2004, Vol.60, No.41, pp 9155-9162 *
Zuen, H. & Gandini, A., "Crystalline furanic polyisocyanates", Polymer Bulletin, 1991, Vol.26, No.4, pp 383-390 *

Also Published As

Publication number Publication date
EP2604595B1 (en) 2016-03-16
ES2572481T3 (en) 2016-05-31
US9718790B2 (en) 2017-08-01
PL2604595T3 (en) 2016-09-30
KR101867110B1 (en) 2018-06-12
WO2012020749A1 (en) 2012-02-16
RU2565073C2 (en) 2015-10-20
JP5594706B2 (en) 2014-09-24
TWI505829B (en) 2015-11-01
MX2013001542A (en) 2013-03-18
CA2807947C (en) 2018-06-19
KR20130138734A (en) 2013-12-19
CN103153968A (en) 2013-06-12
EP2604595A4 (en) 2014-04-23
US20130172317A1 (en) 2013-07-04
JP2014198738A (en) 2014-10-23
TW201542210A (en) 2015-11-16
RU2013110068A (en) 2014-09-20
JP5765753B2 (en) 2015-08-19
BR112013002984A2 (en) 2016-06-07
ZA201300920B (en) 2014-04-30
CA2807947A1 (en) 2012-02-16
CN103153968B (en) 2016-02-03
JPWO2012020749A1 (en) 2013-10-28
TW201210600A (en) 2012-03-16
DK2604595T3 (en) 2016-05-23
MX346367B (en) 2017-03-16
AU2011290261A1 (en) 2013-03-07
BR112013002984B1 (en) 2021-10-26
EP2604595A1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
AU2011290261B2 (en) Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
CN110352188B (en) Fluoroallylamine derivatives and use thereof
CA2915325C (en) Amino-triazine derivatives and pharmaceutical composition containing said derivative
JP6124351B2 (en) Heterocyclic and carbocyclic derivatives
CN102245597B (en) Compounds useful for inhibiting CHK1
SG173647A1 (en) Novel triazine derivative and pharmaceutical composition containing same
CZ299836B6 (en) Aryl- and heteroaryl-substituted heterocyclic ureas, their use and pharmaceutical compositions in which the ureas are comprised
WO2011078143A1 (en) Pyrimidine derivatives and pharmaceutical composition containing same
CA2738563A1 (en) 8-substituted isoquinoline derivatives and the use thereof
AU2009266756B2 (en) Triazole derivative or salt thereof
CA2647423C (en) Triazolone derivative
WO2011024987A1 (en) Aromatic fused heterocyclic derivative and pharmaceutical composition containing same
CA2991168C (en) Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
CN102066328A (en) Iminopyridine derivative and use thereof
AU2018236530B2 (en) Deuterated benzimidazole compound and medicinal use thereof
AU2019218150B2 (en) Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor
CN109563073B (en) For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired